药促会官方微信

WeChat Official Account of PhIRDA

创投大会微信服务号

WeChat Official Account of the CBIIC

会长寄语 | Message from Chairman of PhIRDA

肩负使命，砥砺前行

刘殿波

Forging Ahead with Our Mission

Liu Dianbo

今天，伴随着大数据和智能时代的到来以及交叉学科的兴起，全球医药创新正在发生着日新月异的革命性进步。未来医药研发将进一步发生价值链重构和资源的全球配置。从实验室到临床研究，从药企到研发外包，从资本孵化到上市，将形成多方融合的创新生态系统。在中国，近几年政府出台了一系列鼓励医药创新的改革政策，推动行业深刻转型、加速与国际市场接轨。随着人口老龄化、居住城市化、人们健康意识增强以及疾病谱变化，医药需求将持续增长，今后5-10年将是行业发展的关键时期，也是大有可为的战略机遇期。

新时代给医药创新带来前所未有的机遇和空间，也赋予新的使命和课题。与国际主流相比，中国医药行业的差距与挑战依然存在。随着中国加入ICH以及市场开放的不断深入，市场竞争会变得愈发激烈。我们必须以前瞻的眼光和国际的标准，不断提升研发能力和国际竞争力，在竞争中成长和成熟。包括政府和行业在内的利益各方，将需要更紧密协作，共同创造更好的创新环境，携手不断提高创新药的可及性，以更好满足患者日益增长的需求，我对此充满信心。

中国医药创新促进会自成立以来，秉承“创新、产业化、国际化”的宗旨，以临床需求为导向，肩负推进中国医药创新发展的使命，通过搭建国内外交流平台，提供政策建议、技术咨询、推动产业界的交流合作，已成为具有国际影响力的专业社团。在接下来的一年，我愿与各位同仁一起努力，为提高中国医药产业创新水平，让更多的中国创新药走向全球市场造福患者，做出应有的贡献。

Nowadays, as we are entering into the age of big data and intelligence, and with the emerging of interdisciplinary subjects, global pharmaceutical innovation is experiencing a revolutionary development. Pharmaceutical R & D is expected to have supply chain restructure and global resource allocation in the future; the industry will form a multiple integrated innovative ecosystem from pharmaceutical companies to CRO, from capital incubation to IPO. Chinese government has issued a number of reform policies for the purpose of encouraging pharmaceutical innovation, promoting profound transformation, and to keep pace with international market. Pharmaceutical products demand will have sustainable growth due to aging population, urbanization, development of health awareness, and change of disease spectrum. The next 5-10 years will be a key period for industrial development; it is also a period of strategic opportunity for a promising future.

The new era has brought unprecedented opportunity and potential for pharmaceutical innovation, it has also given us new missions and tasks. Chinese pharmaceutical industry is facing gap and challenges in comparison with international mainstream market. As China is joining in ICH and constant in-depth development of market opening, market competition is getting even fierce. We need to have visionary mindset and international standards; we need continuous improvement of R & D capabilities and international competitiveness to get stronger in competitions. Stakeholders including government and industry players need closer collaboration to jointly create a better environment for innovation, to improve accessibility innovative drugs in order to meet patients' growing demands. I'm fully confident with our future.

China Pharmaceutical Innovation and Research Development Association (PhIRDA) will exert great effort on “academia-industry collaboration”, which centers on the principle of “innovation, industrialization, internationalization”, persists in innovation to achieve unmet clinical requirements. Our mission is to promote the development of pharmaceutical innovation in China; we have become an influential organization by establishing platform for domestic and international communication, offering policy advice and technical consultation, and promoting industrial collaboration. I hope to work with all of you for the aim of improving Chinese pharmaceutical innovation, and to bring more Chinese innovative drugs to global market benefiting patients all over the world.

目 录

Contents

中国医药创新促进会简介
Brief Introduction of PhIRDA 003

中国医药创新促进会章程
Constitution of PhIRDA 005

机构设置
Organizational Structure of PhIRDA 013

会领导介绍
Introduction of PhIRDA Leadership 014

第九届会员大会以来历任会长
Chairmen of PhIRDA since the 9th General Assembly 014

现任会领导
Current Leadership of PhIRDA 016

第十届会员大会第五次会议
The Fifth Meeting of the 10th PhIRDA General Assembly 019

工作报告摘要
Summary of PhIRDA Annual Work Report 019

会议纪要
Summary of the Meeting 037

专业委员会介绍
Introduction of Specialty Committees 039

第二届药物研发专业委员会
The 2nd Drug R&D Specialty Committee 040

第二届药物临床研究专业委员会
The 2nd Clinical Research Specialty Committee 041

第二届医药政策专业委员会
The 2nd Medicinal Policy Specialty Committee 042

第二届医药创新投资专业委员会
The 2nd Pharmaceutical Innovation Investment Specialty Committee 043

第一届创新研发服务专业委员会
The 1st Innovation Research Service Specialty Committee 044

重要活动
Important Events 045

会员单位及其代表
PhIRDA Members & Representatives 070

会员单位简介
Brief Introduction of PhIRDA Members 076

大事记(2017年11月-2018年9月)
Remarkable Events (November, 2017-September, 2018) 215

中国医药创新促进会

中国医药创新促进会，英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA），成立于1988年，是经国家民政部登记注册的非营利性全国性一级社会团体组织。

中国医药创新促进会（简称“中国药促会”），原名“中国医药工业科研开发促进会”，2014年10月23日经国家民政部批准更名。中国药促会秉承“创新、产业化、国际化”的宗旨，以临床需求为导向，长期致力于“产学研用”紧密结合，促进医药行业创新发展。目前，中国药促会有会员单位140家，主要由六个方面成员构成：一是，专注于药品自主创新的在国内医药创新领域处于领先地位的医药企业；二是，专注于医药创新研发的初创型研发企业；三是，专注于医药创新研发服务的机构；四是，从事医药创新研发的国内一流高等院校和科研院所；五是，在新药临床研究领域具有较高水平的临床医疗机构；六是，致力于医药创新投资的金融、投资机构。中国药促会成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会和创新研发服务专业委员会，形成了以创新为核心，以促进创新为目标的涵盖药物研发、生产、使用、投资以及资本市场的全链条组织构架，并作为国际药品制造商协会联合会（IFPMA）的成员继续拓展国际交流渠道。

中国药促会工作内容主要包括：一是，通过举办各种论坛、发布会、大型会议等活动，促进会员单位乃至整个医药产业的相互交流、创新发展；二是，通过与国内外医药行业协会、企业、科研机构和外国驻华使馆合作，推动国际医药产业的多方位、多维度合作交流，为会员单位搭建国际交流平台；三是，开展医药政策研究，为我国医改事业、完善药物政策和医药产业发展建言献策；四是，为会员单位提供医药信息搜集、整理、评价服务，包括编辑每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》等内部电子刊物以及中国药促会官方网站、微信公众号等服务平台；五是，践行国家创新驱动发展战略指导精神，为会员单位拓宽医药创新投融资渠道、搭建合作平台，推动社会资本加大对初创及研发型企业自主创新项目的投入，营造更有吸引力的医药创新投资环境。

中国药促会将围绕办会宗旨，不断拓展服务内涵和外延，做好政府与会员企业的桥梁和纽带，维护会员合法权益，加强行业自律，推动我国医药产业的创新和可持续发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献！

Brief Introduction of PhIRDA

Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level.

Formerly named China Pharmaceutical Industry Research and Development Association, the association was approved to rename into PhIRDA by the Ministry of Civil Affairs on October 23, 2014. PhIRDA will exert great effort on "academia-industry collaboration", which centers on the principle of "innovation, industrialization, internationalization", persists in innovation to achieve unmet clinical requirements. At current stage, PhIRDA has 140 members, mainly consisting of six major categories: first, top leading pharmaceutical enterprises focusing on innovation of pharmaceutical products in China, second, start-up and R&D enterprises focusing on innovation of pharmaceutical products; third, institutions focusing on pharmaceutical innovation research and development services; fourth, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development; fifth, clinical institutions featuring high skills in applicable research on new drugs; sixth, financial and investment institutions committing to pharmaceutical innovation. Moreover, PhIRDA has established Drug R&D Specialty Committee, Clinical Research Specialty Committee, Medicinal Policy Specialty Committee, Pharmaceutical Innovation Investment Specialty Committee and Innovation R&D Services Specialty Committee in order to form a fully functional organization structure focusing on innovation, aiming to promote the development of innovation, covering the whole industrial chain, including drug R&D, manufacturing, using, investment and capital market. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.

Major work of PhIRDA includes: first, to promote communication and innovative development of our members and even the whole pharmaceutical industry through forums, press-conferences, summits, etc.; second, to make efforts to establish an international exchange platform for our members through cooperation with foreign embassies and foreign associations to stimulate comprehensive communication between China and foreign countries in pharmaceutical field; third, to conduct policy researches, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry; fourth, to improve the website and WeChat official account of PhIRDA and provide collecting, arranging, revising service of pharmaceutical information, which includes the following internal e-magazines such as the daily *Pharmaceutical Information Brief*, the weekly *International Pharmaceutical Development Tendency and Research Information Brief*; fifth, to practice the guiding spirits of national innovation-driven development strategy, to broaden the investment and financing channels of pharmaceutical innovation, to build the cooperation platform for our members, and to promote social capitals to pay more attention on investment in innovative projects of start-up and R&D enterprises to create a more attractive environment of pharmaceutical innovation and investment.

PhIRDA will center on our principle, continuously expand services, build a bridge between the government and our members, maintain legitimate rights and interests of members, strengthen self-discipline, promote healthy development of Chinese pharmaceutical industry, making constant contributions to the greater economic development of the country and public health.

中国医药创新促进会章程

第一章 总 则

第一条 本团体的名称：中国医药创新促进会，英文名称：China Pharmaceutical Innovation and Research Development Association；缩写：PhIRDA。

第二条 本团体是由国内医药创新型生产企业、专注于医药创新的研发型企业、从事医药创新研发的高等院校和科研院所、在新药临床研究领域具有较高水平的药物临床研究机构和致力于医药创新投资的金融机构自愿结成的全国性、专业性、非营利性社会组织。

第三条 本团体的宗旨：高举中国特色社会主义伟大旗帜，以邓小平理论、三个代表重要思想、科学发展观为指导，贯彻国家有关方针、政策和改革精神，提高中国医药工业的科研创新能力，加强医药科研与生产的紧密结合，推动中国医药创新的国际步伐，加快中国医药及相关行业的技术进步，提高经济效益，维护会员单位的合法权益，为医药卫生事业、经济社会发展做出更大的贡献。本团体遵守宪法、法律、法规和国家政策，遵守社会道德风尚。

第四条 本团体接受业务主管单位国务院国有资产监督管理委员会和社团登记管理机关民政部的业务指导和监督管理。

第五条 本团体的住所：北京市。

第二章 业务范围

第六条 本团体的业务范围：

（一）认真贯彻执行党中央、国务院有关中国医药创新各项政策，深入研究新药研发政策和中国医药体系创新的相关问题，科学预测新药研发的走向，及时提出中国医药创新发展的政策建议，切实反映会员单位合理的愿望和要求，协助会员单位解决实际问题；

（二）组织和参加有关医药行业发展的交流活动，增强中国医药行业的创新能力。组织和参加有关学术交流，组建中国医药行业发展、创新智库，推动医药行业产学研的结合，积极开展新药科研和技术协作及科技成果的推广，组织技术转让与协作，促进医药高科技的产业化、专业化；

（三）发挥自身优势、充分利用现代化手段，搜集、整理、研究、传递医药科技研发信息，聚焦医药行业重点问题，并开展咨询服务；

（四）推动中国医药行业的国际交流，组织开展各种形式的中外医药行业信息、技术、人员的交流与合作；

（五）践行国家创新驱动发展战略指导精神，为会员单位拓宽医药创新投融资渠道、搭建合作平台，推动社会资本加大对医药创新项目的投入。

第三章 会 员

第七条 本团体的会员为单位会员。

第八条 申请加入本团体的会员，必须具备下列条件：

（一）拥护本团体的章程；

（二）有加入本团体的意愿；

（三）在本团体的业务领域内具有一定的影响。

第九条 会员入会的程序是：

（一）提交入会申请书；

（二）经会员大会讨论通过；

（三）由会员大会或会员大会授权的机构发给会员证。

第十条 会员享有下列权利：

（一）本团体的选举权、被选举权和表决权；

（二）参加本团体的活动；

（三）获得本团体服务的优先权；

（四）对本团体工作的批评建议权和监督权；

（五）按规定有获得本团体发出的信息资料和刊物权；

（六）有对本团体提出保护合法权益不受侵害的权利；

（七）入会自愿，退会自由。

第十一条 会员履行下列义务：

（一）遵守本团体章程，执行本团体决议；

（二）维护本团体合法权益；

（三）完成本团体交办的工作；

（四）按规定交纳会费；

（五）向本团体反映情况，提供有关资料。

第十二条 会员退会应书面通知本团体，并交回会员证。会员如果2年不履行义务，视为自动退会。

第十三条 会员如有严重违反本章程的行为，经会员大会表决通过，予以除名。

第四章 组织机构和负责人产生、罢免

第十四条 本团体的最高权力机构是会员大会。会员大会的职权是：

（一）制定和修改章程；

（二）选举和罢免会长、副会长和秘书长；（三）审议本团体的工作报告和财务报告；

（四）制定并修改会费标准；

（五）决定名誉职务的设立和人选；

（六）决定办事机构、分支机构、代表机构和实体机构的设立、变更和注销；

（七）决定副秘书长、各机构主要负责人的聘任；

（八）决定本团体终止事宜；

（九）决定其他重大事宜。

第十五条 会员大会须有2 / 3以上的会员出席方能召开，其决议须经到会会员半数以上表决通过方能生效。

第十六条 会员大会每届5年，因特殊情况需提前或延期换届的，须经会员大会表决通过，报业务主管单位审查并经社团登记管理机关批准同意。但延期换届最长不超过1年。会员大会每两年至少召开1次。

第十七条 秘书处是会员大会的执行机构，在闭会期间领导本团体开展日常工作，对会员大会负责。

第十八条 本团体的会长、副会长、秘书长必须具备下列条件：

（一）坚持党的路线、方针、政策、政治素质好；

（二）在本团体业务领域内有较大影响；

（三）会长、副会长最高任职年龄不超过70周岁，秘书长最高任职年龄不超过60周岁且为专职；

（四）身体健康，能坚持正常工作；

（五）未受过剥夺政治权利的刑事处罚；

（六）具有完全民事行为能力。

第十九条 本团体会长、副会长、秘书长如超过最高任职年龄的，应当办理离职手续。

第二十条 本团体实行年度轮值会长制度；会长从会员中经选举产生，任期1年。

副会长、秘书长每届任期5年，连任不超过两届。

第二十一条 会长为本团体法定代表人。因特殊情况，经会长委托，会员大会同意，报业务主管单位审查、社团登记管理机关批准后，可以指定一名副会长或秘书长担任法定代表人。

法定代表人代表本团体签署有关重要文件。

本团体法定代表人不兼任其他团体的法定代表人。

本团体会长、副会长、单位会员代表离开所属单位的，自动失去会长、副会长、单位会员代表资格，由原单位会员推荐新的人选，报会员大会选举备案。

第二十二条 本团体会长行使下列职权：

（一）召集和主持会员大会；

（二）检查会员大会决议的落实情况；

（三）代表本团体签署有关重要文件；

（四）会长可委托副会长或秘书长代行会长的部分职权。

第二十三条 本团体设立秘书处，秘书长行使下列职权：

（一）主持办事机构开展日常工作，组织实施年度工作计划；

（二）协调各分支机构、代表机构、实体机构开展工作；

（三）提名副秘书长以及各机构主要负责人，交会员大会决定；

（四）决定办事机构、代表机构、实体机构专职工作人员的聘用；

（五）处理其他日常事务。

第五章 资产管理、使用原则

第二十四条 本团体经费来源：

（一）会费；

（二）捐赠；

（三）政府资助；

（四）在核准的业务范围内开展活动和服务的收入；

（五）利息；

（六）其他合法收入。

第二十五条 本团体按照国家有关规定收取会员会费。

会费由秘书处负责管理，并在会员大会期间向全体会员单位公布经费使用情况。

第二十六条 本团体经费必须用于本章程规定的业务范围和事业的发展，不得在会员中分配。

第二十七条 本团体建立严格的财务管理制度，保证会计资料合法、真实、准确、完整。

第二十八条 本团体配备具有专业资格的会计人员。会计不得兼任出纳。会计人员必须进行会计核算，实行会计监督。会计人员调动工作或离职时，必须与接管人员办清交接手续。

第二十九条 本团体的资产管理必须执行国家规定的财务管理制度，接受会员大会和财政部门的监督。资产来源属于国家拨款或者社会捐赠、资助的，必须接受审计机关的监督，并将有关情况以适当方式向社会公布。第三十条 本团体换届或更换法定代表人之前必须接受财务审计。

第三十一条 本团体的资产，任何单位、个人不得侵占、私分和挪用。

第三十二条 本团体专职工作人员的工资和保险、福利待遇，参照国家和本团体的有关规定执行。

第六章 章程的修改程序

第三十三条 对本团体章程的修改，须经会员大会审议。

第三十四条 本团体修改的章程，须在会员大会通过后15日内，报业务主管单位审查，经同意，报社团登记管理机关核准后生效。

第七章 终止程序及终止后的财产处理

第三十五条 本团体完成宗旨或自行解散或由于分立、合并等原因需要注销的，由会员大会提出终止动议。

第三十六条 本团体终止动议须经会员大会表决通过，并报业务主管单位审查同意。

第三十七条 本团体终止前，须在业务主管单位及有关机关指导下成立清算组织，清理债权债务，处理善后事宜。清算期间，不开展清算以外的活动。

第三十八条 本团体经社团登记管理机关办理注销登记手续后即为终止。

第三十九条 本团体终止后的剩余财产，在业务主管单位和社团登记管理机关的监督下，按照国家有关规定，用于发展与本团体宗旨相关的事业。

第八章 附 则

第四十条 本章程经2017年10月29日第十届会员大会第四次会议表决通过。

第四十一条 本章程的解释权属本团体的会员大会。

第四十二条 本章程自社团登记管理机关核准之日起生效。

Constitution of PhIRDA

Chapter One: General Principle

Article 1. Name of the Association: China Pharmaceutical Innovation and Research Development Association (the abbreviated name is PhIRDA).

Article 2. The Association is a nationwide, professional, non-government and non-profit industrial organization, which consists of national pharmaceutical enterprises excelling at innovation, start-up and R&D enterprises focusing on independent innovation of pharmaceutical products, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development, clinical institutions featuring high skills in applicable research on new drugs, especially those undertake “major new drug innovation” technological platform for good clinical practice and investment institutions committing to pharmaceutical innovation.

Article 3. The objectives of the Association include:
Holding the great banner of Socialism with Chinese characteristics, taking Deng Xiaoping Theory, Three Represents and Scientific Outlook of Development as our guide, to implement the relevant general and specific policies and the reform spirit of the government, enhance research and innovation capacity of China's pharmaceutical industry, strengthen the combination between the scientific research institutions and pharmaceutical enterprises, promote international cooperation on research and development of China’s pharmaceutical industry, expedite the technological development in pharmaceutical industry, enhance the economic efficiency in enterprises and provide better service for healthcare and economic developments.
The Association follows the China’s related constitution, laws, regulations and policies, as well as the ethical code of the society.

Article 4. The Association undertakes administration by Ministry of Civil Affairs and State-owned Assets Supervision and Administration Commission of the State Council.

Article 5. The Association’s residence is in Beijing.

Chapter Two: Business Range

Article 6. Business range of the Association
(1) To carry out and implement relevant general and specific policies on Chinese pharmaceutical industry development made by the Central Committee of CPC and the State Council, perform in-depth research on new drug development and Chinese pharmaceutical innovation system, scientifically forecast the direction of new drug development, timely propose the recommendations for development of Chinese pharmaceutical industry, reflect members’ reasonable wishes and demands, and assists members to solve practical problems.
(2) To organize and participate in the relevant exchange programs to enhance Chinese pharmaceutical industry development. To organize and participate in the relevant academic exchanges, set up a think tank for Chinese pharmaceutical industry development and innovation, promote the pharmaceutical industry combination of scientific research and practices, operate the relevant research cooperation and academic-achieve promotion, and assist to industrialization and specification of the high technology.
(3) Using our advantages and modern technologies to collect, study and publish the medical information, to focus on the key issues of industry and provide consultancy.
(4) To promote the international communication of Chinese pharmaceutical industry, and organize different kinds of cooperation and exchanges on information, technologies and personnels.
(5) To implement national innovation-driven development strategy to guide the members to broaden the channels of pharmaceutical innovation and investment, build a platform for cooperation, and promote social capital for the newly independent innovation projects of those R&D enterprises.

Chapter Three: Members

Article 7. Members of the Association: Institutional members.

Article 8. Applicant members should fulfill the following requirements:

(1) Upholding the constitution of the Association;

(2) Be willing to join the Association;

(3) Possessing certain influences in the professional (industrial, academic) realm of our Association.

Article 9. Procedure of joining the Association

(1) Submitting application;

(2) Being approved through discussion on PhIRDA General Assembly;

(3) PhIRDA General Assembly or authorized agency issuing certificate to approved members.

Article 10. Rights and duties of members

(1) The rights of election, being elected and vote;

(2) Participate in the Association activities;

(3) The priorities of obtaining services from Association;

(4) The rights of supervision, suggestion and criticizing the issues of Association;

(5) The rights of obtaining the information and publications by Association;

(6) The right of protecting legitimate rights and interests.

(7) Enjoying freedom of joining and quitting the Association;

Article 11. Duties of the members

(1) Follow the Constitution of PhIRDA, implement the decision of the Association;

(2) Protect the legal rights and interests of the Association;

(3) Complete the work entrusted by the Association;

(4) Pay membership dues on time as per the stipulation;

(5) Provide various information requested by the Association.

Article 12. Quitted members should notify the Association with a written statement and return the membership certificates. If members don't carry out their duties for 2 years, they are regarded as withdrawing from the Association automatically.

Article 13. Members with serious breach of the Constitution will be cancelled with their membership by vote of the PhIRDA General Assembly on the basis of consensus.

Chapter Four: Generation and Recall of Organization Leadership

Article 14. The PhIRDA General Assembly is the highest powerful organization of the Association. Functions of the PhIRDA General Assembly include:

(1) Composing and revising the Constitution of the association;

(2) Electing and recalling of the Chairman, Vice-President and Secretary-General;

(3) Reviewing working report and financial report of this association;

(4) Establishing and modifying the membership fee standard;

(5) Making decision on the establishment and nomination of honorary position;

(6) Deciding the establishment, alteration and cancellation of offices, branches, agencies and entities of the Association;

(7) Appointing Deputy Secretary-General and other major responsible persons;

(8) Deciding termination of the Association;

(9) Deciding other important issues.

Article 15. The PhIRDA General Assembly should require a participation of more than two thirds of all members. The effectiveness of its decision should require acquire approval vote of more than half members.

Article 16. The PhIRDA General Assembly lasts 5 years each term. Approval from Members General Assembly, subject to the review and approval from the related registration and administration authority, Members General Assembly can be convened in advance or later under special circumstances. Members General Assembly shall not postpone one year in maximum. The PhIRDA General Assembly shall be convened at least once every two years.

Article 17. Secretariat shall conduct routine work of the association during the inter-sessional period.

Article 18. The Chairman, Vice-Presidents and Secretary-General of the association must meet the following requirements:

(1) Persist in the CCP political direction, decisions, policies and good political qualities.

(2) Strong influence in the professional work field.
(3) An age of no more than 70 for the Chairman, Vice-President. An age of no more than 60 for the Secretary-General. The Secretary-General should be in full-time position.
(4) Being healthy enough to do normal daily work.
(5) Never deprived of political rights for criminal punishment.
(6) With ability of complete civil behavior.

Article 19. The Chairman, Vice-Presidents and Secretary-General of the association exceeds the maximum age shall conduct demission procedures.

Article 20. The Association applies system of annual Chairman rotation; the Chairman shall be elected from association members, and the term lasts for 1 year.
The Vice-President and Secretary-General are in position for a 5-year term, while their maximum tenure in office shall not surpass 2 terms.

Article 21. The Chairman is the legal representative of the Association. Under special circumstances, with the Chairman's commission and approval from Members General Assembly, subject to the review and approval from the related registration and administration authority, a Vice-President or the Secretary-General can be appointed as the legal representative.
The legal representative will represent PhIRDA to sign the relevant documents.
The legal representative is not allowed to hold a concurrent post in other associations.
The Chairman, Vice-President and members of the Association will automatically lose their representative qualification when leaving their member units, and new election from candidates for their posts will be invoked.

Article 22. Function and powers executed by the President:
(1) Calling for and hosting the General Assembly.
(2) Examining the implementation of decisions made by General Assembly.
(3) In the case of being authorized by the Chairman, Vice-Presidents and Secretary- General can perform parts of Chairman's responsibilities.

Article 23. The PhIRDA General Assembly establishes the Secretariat, and functions executed by the Secretary-General include:
(1)In charge and to organize administrative sectors to do routine work and implement annual work plan.
(2) To coordinate the work of sub-branches, representatives and entities.
(3) To nominate the Deputy Secretary-General and representatives of sub-branches for the General Assembly's approval.
(4) To manage the employment of full-time staffs for the Association.
(5) In charge of other routine affairs.

Chapter Five: Principle of Assets Management and Utilization

Article 24. Funds resources of the Association:
(1) Member annual fee;
(2) Donation;
(3) Government subsidies;
(4) Income from approved business activities and services;
(5) Interests;
(6) Other income from legitimate sources.

Article 25. Members pay fees to the Association according to the relevant state regulation.
The secretariat is responsible to manage the dues and the financial revenue and expenditure will be reported to all members during the General Assembly.

Article 26. The funds of the Association shall be used in the business range and career development regulated in the constitution and shall not be distributed among members.

Article 27. The Association sets up strict financial management rules and regulations, in order to ensure that the accounting data is legitimate, true, accurate and complete.

Article 28. The Association employs accounting staff with professional qualifications. An accountant cannot be a cashier at the same time. Accountants must perform accounting and accounting supervision. If accountants leave the posts or are transferred to other work, they must go through connecting procedures with the managing staff and shifting persons.

Article 29. Management of assets of the Association shall be executed according to the financial regulations stipulated by the state, and shall accept supervision of the members' Conference and the financial department. The assets that come from the government subsidies and social contribution shall be subjected to supervision by the audit organ, and shall be also promulgated to the public by the proper means.

Article 30. Before the legal person of the Association is replaced or is at the expiration of his term of office, he must be subjected to the financial audit by the relevant registration administration organ and the professional administration unit.

Article 31. The assets of the Association cannot be embezzled, diverted and distributed in private by any unit or any person.

Article 32. The wages, insurance and welfare of full-time staffs should comply with relevant regulations for government institutions in China.

Chapter Six: Revision Procedure of the Constitution

Article 33. The right of interpreting this Constitution belongs to the General Assembly.

Article 34. The Constitution comes into force on the date when it is ratified by social registration administration organ.

Chapter Seven: Procedure of disbanding the Association and handling the Assets

Article 35. Association cancelled due to organization structure changes or other reasons will be firstly proposed by the General Assembly.

Article 36. The proposal needs to be submitted and passed by the General Assembly and approved by administration department.

Article 37. Before disbanding the Association a clearing group shall be formed, under the direction of the professional administrative unit and the relevant organ, settle claims and debts, and to deal with the aftermath. During the clearing period any activities except clearing work will not be in progress.

Article 38. The Association is terminated after cancelling its registration in Social Organization Registration Administration.

Article 39. The left assets, after the Association is terminated, will be used to develop the business concerned about the Association's aim under the supervision of the professional administrative unit and the mass organization registration administration, in accordance with the relevant state regulations.

Chapter Eight: Appendix

Article 40. This Constitution was approved by the 4th Meeting of 10th PhIRDA General Assembly on October 29th, 2017.

Article 41. The right of interpreting this Constitution belongs to PhIRDA General Assembly.

Article 42. The Constitution comes into force on the date when it is approved by the authority of social organization registration & administration.

机构设置

Organizational Structure of Association



会领导介绍 | Introduction of PhIRDA Leadership

第九届会员大会以来历任会长照片
Chairmen of PhIRDA Since the 9th General Assembly

桑国卫

中国药促会会长(2009-2012) 中国药促会荣誉会长(2012-2014)

十一届全国人大常委会副委员长 中国工程院院士

Sang Guowei

Chairman of PhIRDA (2009-2012) Honorary Chairman of PhIRDA (2012-2014)
Vice Chairman of the Standing Committee of Eleventh National People's Congress
Academician of Chinese Academy of Engineering

陈启宇

2012-2013年度会长
上海复星医药（集团）股份有限公司
执行董事、董事长

Chen Qiyu

Annual Chairman 2012-2013
Executive Director, Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

闫希军

2013-2014年度会长
天士力控股集团董事局主席

Yan Xijun

Annual Chairman 2013-2014
Chairman of the Board, Tasly Holding Group

孙飘扬

2014-2015年度会长
江苏恒瑞医药股份有限公司董事长

Sun Piaoyang

Annual Chairman 2014-2015
Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.

蒋华良

2015-2016年度会长

中国科学院院士 中国科学院上海药物研究所所长

Jiang Hualiang

Annual Chairman 2015-2016
Academician, Chinese Academy of Sciences
Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

丁列明

2016-2017年度会长

贝达药业股份有限公司董事长兼CEO

Ding Lieming

Annual Chairman 2016-2017
Chairman of the Board & CEO, Betta Pharmaceutical Co., Ltd.

蒋建东

2017-2018年度会长

中国医学科学院药物研究所所长

Jiang Jiandong

Annual Chairman 2017-2018
Director, Institute of Materia Medica, Chinese Academy of Medical Sciences

刘殿波

2018-2019年度会长

绿叶制药集团有限公司董事长

Liu Dianbo

Annual Chairman 2018-2019
Chairman of the Board, Luye Pharma Group Co., Ltd.

现任会领导
Current Leadership of PhIRDA

会长　刘殿波
绿叶制药集团有限公司董事长
Liu Dianbo, Chairman of PhIRDA
Chairman of the Board, Luye Pharma Group Co., Ltd.

执行会长　宋瑞霖
中国医药创新促进会
Song Ruilin, Executive President
China Pharmaceutical Innovation and Research Development Association

副会长 陈启宇

上海复星医药（集团）股份有限公司
执行董事、董事长

Chen Qiyu, Vice President
Executive Director, Chairman of the Board,
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

副会长 闫希军

天士力控股集团董事局主席

Yan Xijun, Vice President
Chairman of the Board, Tasly Holding Group

副会长 孙飘扬

江苏恒瑞医药股份有限公司董事长

Sun Piaoyang, Vice President
Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.

副会长 蒋华良

中国科学院院士
中国科学院上海药物研究所所长

Jiang Hualiang, Vice President
Academician, Chinese Academy of Sciences
Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

副会长 丁列明

贝达药业股份有限公司董事长兼CEO

Ding Lieming, Vice President
Chairman of the Board & CEO, Betta Pharmaceutical Co., Ltd.

副会长 蒋建东

中国医学科学院药物研究所所长

Jiang Jiandong, Vice President
Director, Institute of Materia Medica, Chinese Academy of Medical Sciences

副会长 张伯礼

中国工程院院士 天津中医药大学校长

Zhang Boli, Vice President
Academician, Chinese Academy of Engineering
President, Tianjin University of Traditional Chinese Medicine

副会长 蔡东晨

石药控股集团有限公司董事长

Cai Dongchen, Vice President
Chairman of the Board, CSPC Holdings Co., Ltd.

副会长 任晋生

先声药业有限公司董事长

Ren Jinsheng, Vice President
Chairman of the Board, Simcere Pharmaceutical Group

副会长 舒 畅

上海医药集团股份有限公司副总裁

Shu Chang, Vice President
Vice President, Shanghai Pharmaceuticals Holding Co., Ltd.

副会长 柯尊洪

成都康弘药业集团股份有限公司董事长

Ke Zunhong, Vice President
Chairman of the Board, Chengdu Kanghong Pharmaceutical Group Co., Ltd.

秘书长 冯 岚

中国医药创新促进会

Feng Lan, Secretary-General
China Pharmaceutical Innovation and Research Development Association

中国医药创新促进会工作报告

2018年9月17日第十届会员大会第五次会议

（摘要）

执行会长 宋瑞霖

第一部分 2017-2018年度的主要工作回顾

自2017年10月29日我会召开第十届四次会员大会，并在2018年1月5日会长会议扩大会议上明确2018年度工作重点以来，我会始终围绕“创新、产业化、国际化”宗旨，为新组建各政府机构提供反映行业呼声、促进改革落地的政策建议，在提高会员及行业服务能力方面向国际接轨，不断创新服务领域、拓展服务内涵，为促进医药产业创新与国际化发展做出了一些开创性工作，取得了行业瞩目的成果。2017-2018年度完成的主要工作体现在以下六个方面：

一、围绕行业密切关注的政策痛点开展深入研究，继续为政府新机构发挥新职能提供决策建议

（一）聚焦完善新型医疗保障体系建设组织研讨并建言献策

1、为在我国建立基本医保目录动态调整机制提供建议

2017年11月，我会接受原人力资源与社会保障部医疗保险司委托，对在我国建立基本医保药品目录动态调整机制进行研究并提出建议。建议获得相关部门领导的重点关注和认可，委托我会继续开展药品监管与医保及医保药品使用具体衔接政策措施研究。

2、为配合抗癌药国家医保谈判工作组织座谈会听取企业意见

为配合国家医保部门尽快开展谈判工作，2018年7月11日，我会针对抗癌药品医保准入谈判工作原则、材料要求、流程安排等问题组织召开了企业座谈会（8家内资/10家外资企业），向到会的国家医疗保障局（以下简称“医保局”）相关负责同志提出意见建议。此次座谈会的召开，为医保局接下来加快工作进度，尽快遴选出谈判品种范围奠定了基础，也是医保局探索动态谈判准入工作加强企业沟通原则的重要体现。

3、针对国家药品集中采购试点工作组织企业座谈反馈意见

我会两次组织部分企业代表对医保局拟定的针对高价抗癌药及已有通过仿制药质量一致性评价品种的国家药品集中采购试点工作方案（以下简称“集采试点方案”）进行研讨，并围绕集采试点原则、试点品种范围、招标方式、供货方式、落实采购量方式及医保支付标准的制定等形成了建议稿递交医保局，为形成正式集采试点方案发挥了重要作用。

4、受邀参与医保局“全面建立中国特色医疗保障制度”专题研究

我会宋瑞霖执行会长作为专家受邀参加医保局组织召开的关于“全面建立中国特色医疗保障制度专题研究”座谈会，发表的意见受到医保局高度认可；国家医保局负责人在会员大会之后与会员企业代表围绕“建立中国特色医疗保障制度”主题举办研讨会，重点讨论：现行医疗保障制度面临的问题和挑战；如何构建医疗保险制度评价指标和动态调整体系，实现基金管理的成本、质量、效率平衡目标；医保药品招标采购科学管理与合理定价机制的形成路径；医疗保险基金如何发挥国家战略购买与支付杠杆作用，引导药品供给结构优化；如何通过建立和完善医疗保障制度促进激励创新、优胜劣汰、公平有序、规范运营的市场机制的建立与健全等问题。

（二）接受我国药监部门委托不断探索完善我国药品知识产权保护制度

我会接受原中国食品药品监督管理总局（CFDA）药品化妆品注册管理司委托，对在我国建立药品专利链接制度及开展药品专利期补偿试行工作方案进行了研究（包括对我会创新型会员企业的在研及上市新药开展专利情况调研），形成了工作方案建议稿，获得国家药品监督管理部门相关领导的高度认可。

（三）赴日本开展政策交流访谈活动，为我会深入开展药品监管及医保相关政策研究获取一手资料

2017年11月28日，我会代表团参加了 “第九届中日制药交流会”。会议围绕中日双方药品监管体系动态改革展开，来自国家药品监督管理总局药品审评中心、审查核验中心、评价中心的领导和专家就中国近期监管改革做了简要介绍，日本厚生省和大阪府的专家分享了日本在药品审评审批方面的经验。

我会代表团还访问了强生日本分公司，就中日医保目录调整及医保支付标准（价格）形成机制进行了深入交流。

2018年4月12日，我会代表团访问日本制药工业协会（JPMA），与JPMA知识产权委员会就日本药品知识产权保护制度、医药监管政策等进行了深入研讨，并与日本医疗和全球政策学会（HPGI）就日本医疗保障体系进行了交流。

访日活动对充分借鉴日本医药创新发展成功经验，促进我会与JPMA在行业重大政策问题研究等方面的合作，以及推动我会与日本及亚洲相关机构在医药创新领域的合作，奠定了坚实基础。

（四）听取企业反映《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》落地困难的呼声并对其进行研究

我会围绕如何解决我国临床试验瓶颈问题组织部分创新型会员单位代表开展深入研讨。我会在会后不断收集汇总会员单位意见，正在研究解决方案，撰写提高我国临床试验质量和管理水平的意见建议稿，拟上报相关部委。

（五）为完善我国基本药物制度组织企业座谈研讨

我会组织部分会员单位召开座谈会，围绕国家卫生健康委员会药政司起草的《关于进一步完善国家基本药物制度的意见（征求意见稿）》（以下简称“意见稿”）中关于采购配送、优先使用激励机制中的“结余留用”问题、基本药物制度与仿制药一致性评价的关系、原料药供应等条款形成了建议。

（六）组织专家参与国际药品注册指南ICH的制修订及培训等工作

1、在京召开ICH药物警戒相关二级指南研讨会

我会于2018年3月17日主办了在我国实施ICH药物警戒相关二级指南研讨会，邀请药监机构及企业药物警戒专家全方位解读了实施ICH相关二级指导原则的监管要求、应用策略与企业操作实践。为促进业界对ICH二级指导原则和监管思路的全面理解，推动ICH相关二级指南在中国的全面转化与落地实施奠定了基础。

2、推荐、组织专家参加ICH相关工作组及指南修订工作

我会受国际药品制造商协会联合会（IFPMA）委托，先后推荐了多名专家进入ICH指南相关工作组，参与指南制修订工作。同时，我会还组织对药审中心关于ICH E17国际多中心临床、M4通用技术文件、E2F药物研发期间安全性更新报告以及其他指南的中英译文提出修改意见，为推动ICH指南在我国顺利转化实施发挥了积极作用。

二、采用多种方式宣传我国医药创新研发成果

（一）组织撰写并在《Nature》发表的展示中国医药创新重大成果系列文章获评“2017年度中国十大医学科技新闻”

我会在《Nature》杂志上刊发的系统介绍近年中国医药创新领域取得成果的文章（以下简称“系列文章”），在由《健康报社》联合中华医学会、中国医学科学院、国家卫生计生委科技发展中心等单位共同主办的“中国卫生与健康科技创新发展高峰论坛”暨“2017年度中国、国际十大医学科技新闻发布仪式”上，获评“2017年度中国十大医学科技新闻”；这是对我会向世界宣传我国医药创新成果，并长期致力于促进医药创新发展工作的褒奖，同时更是对

中国医药创新发展的肯定。

（二）与《医药经济报》合作开展“向创新高端致敬——改革开放四十年中国医药创新企业系列宣传”报道计划

2018年9月起，我会与南方所《医药经济报》合作开展“向创新高端致敬——改革开放四十年中国医药创新企业系列宣传”报道计划，在《医药经济报》开设专栏/专版给予刊载，在回顾改革开放以来企业创新故事的同时，展望中国新药创制工业崭新的未来。

（三）改革医药创新品牌评选模式，继续打造权威高端的医药创新品牌评选活动

为继续打造更加权威、公正并具有广泛国际影响力的新型医药创新品牌评选活动，我会与苏州工业园区、人民网共同主办了医药创新品牌评选活动，并将评选名称确定为“‘独墅湖杯’医药创新品牌评选”（以下简称“品牌评选”）。

2018年品牌评选主要有以下几大亮点：1、改革评选规则，采用国际科学奖项评选通行参评项目专家推荐制（不接受自主申报）；2、评选流程设计严格遵循国际创新标准和国际科学奖项的同行评议制度；3、秉承公益、公开、公正原则。

品牌评选终审会议及颁奖典礼于9月17日下午及晚上在苏州文化艺术中心举办，全国政协副主席、农工党中央常务副主席何维等重量级嘉宾出席颁奖典礼并为获奖项目颁奖，人民网和苏州电视台进行了网络直播。品牌评选活动的开展，将为推动我国医药创新品牌文化建设，向国内外推广宣传中国医药创新活动、创新品种，树立中国医药创新品牌良好形象，助推我国医药行业创新能力提升，增强我国医药创新国际竞争力贡献力量。

三、与国内外各创新与投资相关机构鼎力合作，搭建医药创新与投融资界零距离交流对话平台，推动我国医药创新研发能力不断提高，与国际接轨

（一）开展两岸四地创新与投资交流合作

1、协办“2017亚太生技投资论坛”并组团交流

我会作为支持单位组织十余家企业参加了“2017亚太生技投资论坛”（2017 Asia Pacific Biotech Investment Forum）。会议使海峡两岸与会医药企业深入了解了大陆在药品监管政策方面的重大改革理念及措施，增加了两岸投资公司对我国大陆医药创新产品的投资兴趣与信心。

2、与台、港、澳三家协会在台湾共同主办“第一届中华医药创新与投资大会”

我会与台湾-生技医疗产业策进会、香港生物医药创新协会、澳门国际中药质量研究会和香港交易所共同主办的“第一届中华生物医药创新与投资大会”是我会搭建的除中国医药创新与投资大会以外的又一个多元化的交流平台。来自两岸四地的专家和企业从不同角度分析了四地在医药创新方面的优势及各自在推进医药创新进程中所起的作用，并围绕“医药创新与投资合作”主题进行了热烈讨论。

（二）支持举办“2018香港生物科技峰会”，与香港交易所、招商局集团健康产业事业部建立协作机制，共同推动社会资本与医药创新结合

我会作为“2018香港生物科技峰会”（以下称“峰会”）的支持方，组织二十余家会员企业赴港参会，旨在为生物科技公司提供与投资者、市场参与者以及资本市场专家互相交流的渠道，共同建构香港生物科技的投融生态系统。宋瑞霖执行会长在会上对我国内地医药监管政策变革及已经取得的创新成果、正在完善的投融资环境进行了全面分析，获得与会者高度关注和好评。

在峰会召开期间，我会分别与招商局集团健康产业事业部、香港交易所签订合作备忘录，拟通过多种合作模式共同推进我国医药行业创新能力提升。

（三）医药创新投资专业委员会切实推进创新与投资对接

我会医药创新投资专业委员会（以下称“投资专委会”）自2016年成立以来，紧紧围绕“医药创新和资本高效对接”的工作宗旨，充分发挥投资专委会资源优势，助力香港交易及结算所有限公司（以下称“港交所”）完成25年来上市制度最大改革、筹划并创办了“中国医药创新与投资大会”和“中国生物医药创新投资人论坛”等多项专业活动。

1、牵头助力港交所完成25年来上市制度最大改革

在港交所对《上市规则》修订公开征询意见阶段，我会与投资专委会多次受邀组团赴港，代表创新型生物科技公司与香港交易所交流，对《上市规则》提出建议，在协助港交所完成《上市规则》改革的过程中发出内地生物医药创新企业的声音。

2018年6月12日，香港联合交易所有限公司（以下称“联交所”）宣布，聘任我会执行会长宋瑞霖先生和投资专委会主任委员田源博士为联交所生物科技咨询小组成员。至此，在联交所公布的生物科技咨询小组15人名单中，已有5位来自我会或我会相关专业委员会专家。截止目前我会会员歌礼生物、百济神州和华领药业已先后成功登陆香港交易所，成为新《上市规则》实施后第一批赴港上市的未有收益生物科技公司。

2、召开专委会换届大会，筹划未来工作蓝图

根据《中国医药创新促进会专业委员会管理办法》的相关规定，投资专委会换届大会暨第二届第一次工作会议审议通过了投资专委会第二届委员候选人名单（68人，其中主委1人、副主委10人）。元明资本创始合伙人田源当选为投资专委会第二届主任委员。投资专委会在新任领导班子的带领下，将继续发挥医药领域专业投资人的优势，探索新的业务模式，定制小型投资活动，使投资专委会的业务更有针对性、更加丰富多彩。

3、创办首届“中国生物医药创新投资人论坛”

投资专委会创办的首届“中国生物医药创新投资人论坛”（以下简称“论坛”）受到了香港生物医药创新协会、香港交易所以及礼来亚洲基金、平安创投等知名机构的关注和支持。首届论坛的成功召开，为提高投资人分析项目、把握机遇能力，降低投资风险，促进医药企业与投资机构的深入交流与合作发挥了积极引导作用，同时也是我会通过定制小规模精品专业活动的方式，积极探索促进医药创新与投资界高效对接融合迈出的坚实一步。

（四）成功举办第二届中国医药创新与投资大会，并积极筹备第三届中国医药创新与投资大会

1、第二届中国医药创新与投资大会较首届在规模上再创新高

由我会会同中国证券业协会、中国医疗器械行业协会和香港交易所共同举办的第二届“中国医药创新与投资大会”（以下简称“大会”）于2017年10月29日-31日在苏州盛大召开。大会设置了逾18场特色活动，来自国内外共135个在研新药、医疗器械项目及相关公司在大会上进行了展示；吸引了1318家相关企业/机构逾2000位代表参会，会议规模空前；受到业界高度好评，已经成为向世界宣传展示我国医药创新政策与成果、促进创新项目投资合作的高端平台。

2、第三届中国医药创新投资大会筹备顺利，力争将大会打造成为亚太地区促进医药创新交流与发展的重要活动品牌

第三届大会由我会会同中国医疗器械行业协会、中国医院协会、香港交易所共同主办，于2018年9月18-20日在苏州工业园区召开。与前两届大会相比本届大会新增设了人工智能（AI）智慧医疗创新项目、罕见病治疗药物路演专场和跨境并购论坛、香港交易所与医药创新企业闭门座谈会和《Nature Reviews Drug Discovery》主编与国际顶级科学家闭门座谈会等活动。17家国内外组织、机构作为创投大会支持方给予大会全方位鼎力支持；美国摩根大通集团作为独家国际投行支持本届大会。此外，施普林格·自然集团旗下的国际顶级学术杂志《Nature》，人民健康网、医药经济报、米内网作为支持媒体，健康报、经济参考报、21世纪经济报道、中国科协《科技创新与品牌》等20余家传统媒体，药时代、研发客、知识分子、正奇投研等10余家新媒体作为合作媒体对本届创投大会做全方位的报道。全国政协副主席、农工党中央常务副主席何维博士、美国耶鲁大学肿瘤中心免疫学主任陈列平教授、香港交易所行政总裁李小加、泰康保险股份有限公司董事长兼CEO陈东升和麦肯锡伦敦办公室高级合伙人Martin Dewhurst受邀到会围绕全球医药创新及亚洲医药创新活力发表独特见解。

四、通过国际交流发出我国医药创新行业声音、贡献中国力量，提高创新研发能力

（一）出席第36届J.P.摩根健康产业大会并首次在亚洲论坛上代表中国发表演讲

我会宋瑞霖执行会长出席了在美国旧金山举行的第36届J.P.摩根健康产业大会（J.P. Morgan Healthcare Conference），并应邀在亚洲论坛上发表了题为《2017中国药品监管重大变革》的演讲。本届大会的亚洲论坛安排专门介绍中国的药品监管改革尚属首次。

（二）作为重要成员之一出席第七届亚洲制药组织合作会议（APAC），为推动亚洲创新发展做出努力

2017年9月30日，我会正式成为亚洲制药组织合作会议（APAC,Asia Partnership Conference of Pharmaceutical Associations）成员，成为APAC中代表中国医药行业的唯一成员。2018年4月10日，中国药促会组团参加第七届APAC会议。来自亚洲主要经济体的药品监管机构、医药行业协会和知名创新医药机构代表，围绕营造亚洲医药创新良好生态环境、增强创新药品可及性等重要话题展开研讨。为促进亚洲主要经济体药品监管理念创新融合及创新机构合作发挥了重要作用。

（三）推动中美肿瘤药创新研究领域深度合作，提高我国肿瘤药研发水平

1、中国脑癌攻关圆桌会工作组会议研讨建立脑癌临床药物研发平台，攻关脑癌治疗药物研发

我会与消除癌症计划组织（Eliminate Cancer Initiative, ECI）和美国癌症研究基金会（National Foundation for Cancer Research, NFCR）共同主办，首都医科大学附属北京天坛医院承办的“中国脑癌攻关圆桌会工作组会议”于2018年4月13日在北京天坛医院新院召开。会议一致认同：各方将携手组建包括基础研究、临床试验、标本库与大数据处理、投资开发等脑瘤攻关工作组。我会与美国癌症研究基金会将共同在北京天坛医院建立脑癌临床药物研发平台。

2、中美肿瘤专家圆桌会议共话国内外肿瘤药研发趋势

我会与苏州工业园区管委会共同主办，美国华裔血液及肿瘤专家学会(Chinese American Hematologist and Oncologist Network,CAHON)协办的“中美肿瘤专家圆桌会议” 2018年7月6日上午在苏州举行。由美国食品药品监督管理局（FDA）肿瘤卓越中心主任Richard Pazdur博士、生物医学评估与研究中心肿瘤科主任Ke Liu博士率领的美国FDA肿瘤专家代表团与国内创新企业的领军人物分别围绕国际肿瘤药研发趋势、新药审批及国内企业最新研发进展等相关议题展开讨论。

五、通过组织年度论坛及学术交流活动、发起成立研发服务专业委员会、建立企业商业伦理准则等多种方式提高协会服务水平

（一）第九届医院药学论坛为药学服务在临床研究中发挥的作用指明方向

2018年7月20日，由我会与中国药师协会、中国医院协会和北京大学人民医院共同主办的第九届中国医院药学政策论坛在北京顺利召开，各地医保、药政相关领导及医院药学相关领域代表共计400余人出席论坛。本届论坛以中国医院改革和医院药学政策为主题，围绕临床试验机构管理制度改革、全面发展药学服务、发挥药师在医保支付方式改革/医保控费及医院合理用药中的作用等议题进行专家解读与讨论。

（二）第三届中国临床研究质量管理（GCP）暨ICH大会推动我国国际多中心临床研究开展

2018年5月24日，由我会与中国心血管健康联盟、中国抗血栓药物治疗联盟、杭州市投资促进局和杭州经济技术开发区管委会共同主办的“第三届中国临床研究质量管理（GCP）暨ICH大会”在浙江省杭州市召开。

来自国家药品监督管理局药品审评中心、国内知名医疗机构临床研究中心和相关医药企业的多位专家，围绕国家药品监督管理局监管改革、我国药物临床研究现状与存在的问题展开深入探讨。大会的成功举办，加深了临床研究相关业界对我国已实施ICH指南的理解，为促进ICH相关指导原则在中国更好地转化实施，推动国际多中心临床研究特别是早期临床研究在我国的开展，提高我国药物临床研究水平，提升我国医药产业创新和国际竞争力贡献了力量。

（三）为整合研发资源、提高研发质量和效率，发起成立“创新研发服务专业委员会”

为了提高我国创新研发合同组织的服务水平，2018年3月17日，我会成立了创新研发服务专业委员会。专委会囊括了国内优秀的CRO、CDMO机构和专家，将为充分利用和整合国内外研发资源、减少药物研发成本、提高研发效率，推动和提高国内药物研发整体水平做出贡献。

（四）借鉴国际经验，推动我国医药企业商业伦理准则建设工作，为规范我国医药市场秩序发挥作用

1、出席APEC中小企业商业伦理论坛，学习国际先进商业伦理建设经验

受亚太经合组织（APEC）邀请，2018年7月18-20日，我会代表出席了在日本东京举办的“2018亚太经合组织中小企业商业伦理论坛（2018 APEC Business Ethics for SMEs Forum）。论坛围绕推动亚太地区医药行业伦理

准则建设与制度创新等热点话题展开讨论。有助我会会员企业全面了解亚太地区医药伦理合规进程和伦理合规对营造良好生态环境的重要性，推动我国医药行业伦理建设的发展。

2、成立医药企业伦理准则工作组、制定“中国药促会行业伦理准则”，规范中国医药产业的市场环境

为进一步推动我国医药行业伦理准则与国际标准的对接，促进会员企业接轨国际，我会参照《医药代表登记备案管理办法（试行）（征求意见稿）》、《墨西哥城原则》以及IFPMA医药行业准则的相关内容，制定了《中国药促会医药企业伦理准则》（以下简称“伦理准则），成为业内首个制订伦理准则的国内医药行业组织。今后，我会将积极推进会员企业按照我会准则建立完善企业伦理准则与风险管理合规体系，并督促会员单位切实落实实施。

六、不断调整会员结构、开放纳入新鲜血液

在会员大会闭会期间，我会通过召开会长会议及通讯表决等方式，新吸纳会员38家，会员单位达到142家（其中，会长单位1家，副会长单位11家）。通过各会员单位和专业委员会的共同努力，我会正在搭建覆盖医药创新全产业链的会员组织架构，从医药产业链各环节、医药创新环境各方面为切入点，积极整合各医药创新要素，成为政府有关机构倚重并信赖，代表医药创新重要力量，致力推动我国医药创新政策与生态环境不断完善的行业组织；同时，我会会员单位的研发、投资活动已成为我国医药创新发展不可或缺的重要力量，使我会正在成长为国内外创新产业界与投资界交流合作的重要纽带与平台。

第二部分 2019年度重点工作建议

中共第十九次代表大会正式宣告中国特色社会主义进入了新时代。中办、国办颁布的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》（以下简称“两办《意见》”）和中国药品监管部门加入国际人用药品注册技术协调会议（ICH）这两大举措，开启了中国药品注册审批标准与国际接轨的征程。香港交易所实施零利润生物技术企业上市政策，8月底中国证监会明确表示将进一步完善配套制度和监管规则，支持符合条件的未盈利生物制药企业在A股创业板上市，进一步助推生物医药创新发展，实现创新与资本的紧密对接；这些无不昭示着中国医药创新的春天已经到来。

今年中共中央对国家监管机构进行了改革，医药相关政府机构监管职能被重构。我会作为国内促进医药创新的代表性行业组织，将继续发挥会员单位和专委会专家的作用，汇集各方资源，协助新的政府机构不断深入研究贯彻落实两办《意见》的具体执行政策与措施，以促进医药行业创新发展环境的持续改善；同时，我会将不断创新为会员单位和医药行业服务的渠道和方式，通过搭平台、强宣传、促交流，提高服务业务水平，努力成长为全方位、强有力促进医药行业创新、国际化发展的社会团体。为此，2019年度将着重开展以下几项工作：

一、继续发挥行业智库作用，开展各项医药政策研究

1、协助医保局开展“全面建立中国特色医疗保障制度”研究

医保局希望我会对“全面建立中国特色医疗保障制度”开展专题研究，特别是研究药品审批、医保支付和医院使用三者联接的具体方案建议。

2、配合药监部门工作，为完成两办《意见》配套政策文件提出具体建议，推动改革措施尽快落地，稳妥实施

两办印发《意见》，全面阐明了我国药品审评审批制度改革和鼓励医药创新的方向、目标和措施。我会将积极配合国家药品监督管理局，进一步深入开展药品专利链接、专利期补偿等知识产权保护具体政策措施的研究；全面提高我国临床试验水平和质量的路径和方式研究，通过吸纳国际先进经验，结合我国国情，提出切实、可行的具体建议。

3、继续推荐、组织专家参与ICH相关指南修订及指南转化实施工作

我会将继续按照IFPMA的ICH秘书处和CDE的需求，推荐相关专业领域的权威专家参与ICH技术指南的制修订工作，做好ICH相关指导原则在中国转化实施的培训工作，为推动我国药品研发和风险管理水平与国际接轨，提升我国医药企业创新能力和国际竞争力贡献力量。

4、开展中美贸易摩擦对我国生物医药产业影响研究

随着中美贸易摩擦的不断升级，美国加强了对中国在美投资生物医药与引进技术的限制。如何避开美国政策限制，快速提升中国医药生物研发生

产水平和国际竞争力，已经成为政府有关部门和行业关注的重点。为此，我会受工信部委托，将深入开展中美贸易摩擦背景下中国生物医药产业实现快速创新发展的路径研究，以有效推动我国生物医药产业向全球产业链高端转移。

二、发起成立医药创新发展基金，推动创新活动开展

为了继续扩大企业和科研机构作为医药产业创新主体所发挥的积极作用，引导社会资本投资生物医药产业，调动科研人员自主创新的积极性，营造大众创业、万众创新的环境，我会拟发起设立“医药创新发展（苏州）基金会”（以下简称“基金会”）。基金会致力于支持中国医药创新监管体制改革、协助解决药品监管领域优秀人才引进问题、支持医药创新早期研发项目、助力罕见病患者及弱势群体的用药保障（推动药物研发、政策完善、慈善赠药等相关工作），为医药产业各创新主体提供资金和技术支持，激发我国医药产业的创新活力和创造潜能，提高医药创新和科技成果转化的效率，提升创新药可及性。

三、继续搭建创新与资本对话交流平台，办好第三届和第四届“中国医药创新与投资大会”

为了践行习总书记关于资本服务实体经济的指示精神、促进建设世界科技强国目标的实现，我会已成功举办了三届“中国医药创新与投资大会”。通过搭建创新与资本对话交流平台，强化科技同经济对接、创新成果同产业对接，促进了资本市场对科技成果转化的支持，获得业界积极响应。为此，我会将继续争取各方支持，办好第四届 “中国医药创新与投资大会”（2019年9月21-23日召开）。努力将大会打造成为涵盖药物研发、生产、使用、流通、投资五位一体的多元化国际交流平台，成为亚洲独具特色的医药创新与投资人年度品牌盛会。

四、不断改进医药创新品牌评选模式，继续办好2019“独墅湖杯”医药创新品牌评选活动

我会曾成功举办两届“最具价值创新品牌”评选活动，在业界获得不俗反响。为了使品牌评选活动更具权威、公平、公正性，我会改革了2018“独墅湖杯”医药创新品牌评选活动方式，使第三届品牌评选较前两届更具权威性和公信力，颁奖典礼规模也更高端，获得了医药业界和权威专家的高度认可。

2019年我会将继续完善品牌评选流程，吸引专家推荐更多真正具有创新价值品种及更具创新性的研究者、机构参加评选，力争将该品牌评选活动本身打造成为亚太地区权威创新评选盛典。

五、在与香港交易所的合作备忘录框架下，继续推动更多内地创新医药企业赴港IPO

我会将在与香港交易所已有的合作基础上，继续为更多内地创新医药企业赴港IPO向香港交易所提供咨询，推动我国医药创新企业在国际资本支持下进一步发展和壮大。

六、与国内外相关机构建立创新研发协作机制，共同推动我国药物创新水平提高及与国际接轨

1、继续与台湾-生技医疗产业策进会、香港生物医药创新协会、澳门国际中药质量研究会开展两岸四地创新交流合作

我会将继续在两岸四地医药创新合作协议及工作方案框架下，与我国台湾-生技医疗产业策进会、香港生物医药创新协会、澳门国际中药质量研究会开展四方医药创新交流合作，汇集两岸四地医药创新领域专家及产业界代表，就新药研发趋势、医药卫生领域合作等热点问题进行交流，为中国及全球生物医药界华人提供创新合作的平台与纽带。

2、与中国医院协会、北京协和医院共同牵头发起成立“中国罕见病联盟”

为了解决我国乃至全世界罕见病患者急迫的临床需求，推动孤儿药研发及相关政策制度建立，我会与中国医院协会、北京协和医院共同牵头发起成立“中国罕见病联盟”（以下简称“联盟”），已经国家卫健委医政医管局批复同意，秘书处设在协和医院。联盟旨在整合我国罕见病研发资源，实现在罕见病研究方面的重大突破，提升罕见病诊断和治疗水平；建立全国罕见病临床协作诊疗网络、落实国家罕见病注册系统，加快基础医学研究和孤儿药研发成果转化等工作，促进罕见病临床、科研与孤儿药开发的协同创新。

七、不断丰富会员架构，汇聚医药创新产业链各环节力量

为了使我会真正成为覆盖医药创新产业全链条、汇集各方力量共同促进我国医药创新发展的行业组织，我会将对入会标准进行调整，接纳国内顶尖

临床研究机构，高端精准智慧医疗技术、器械等公司，港澳台地区以及外资医药研发型企业加入（暂不接纳外资生产型企业）。

八、继续办好各种论坛及学术交流活动，服务医药创新关键环节

创新药品能够成功上市的关键在于临床试验研究环节，而创新药品是否能够被合理使用、惠及患者则离不开医院药学人员的技术服务；因此，我会将与中国医院协会等机构开展合作，继续办好每年一届的中国临床研究质量管理（GCP）大会和医院药学政策论坛，为提高我国临床研究水平，充分发挥医院药学工作者在医保支付方式改革与控费、保障合理用药方面的作用作出应有贡献。

当前医药领域监管改革不断深化。新的医疗保障局组建推动医保动态调整及抗癌药谈判准入、药品集中采购试点等政策接连出台，医药行业正迎来史上前所未有的转型发展时期。只有坚持以创新引领发展，以交流带动合作，才能把握机遇、面对挑战。中国药促会将不断保持自身创新意识，紧紧依靠会员单位的支持与参与，为会员单位提供更创新、多元化的服务；做好企业与政府的桥梁，促进医药创新政策环境的持续改善；搭建更高层次的国内外合作交流平台，为医药行业的创新、可持续发展和保障人民的健康，为实现医药强国的伟大目标而不懈奋斗！

PhIRDA Annual Work Report of 2017-2018

The Fifth Meeting of the 10th General Assembly on September 17th, 2018

(Abstract)

SONG Ruilin, Executive President of PhIRDA

Section One. Review of Major Work in 2017-2018

The Fourth Meeting of 10th General Assembly on October 29, 2017 and the President Board Meeting on January 5, 2018, pointed out the key works of 2018, PhIRDA has always focused on the purpose of "Innovation, Industrialization and Internationalization", and continued to play an important role in offering suggestions for new government sectors in response to industry invoice and implementation of reform, align our service ability for members and the industry to the international standards, and make efforts to innovate service areas and expand service connotations. PhIRDA have made some groundbreaking works and obtained some industry-focused achievements in promoting innovation and internationalization development of pharmaceutical industry. Our main work completed in 2017-2018 involved six aspects:

I. PhIRDA conducted in-depth researches by focusing on the closely-watched policies and kept providing suggestions for new sectors in government to exert their new functions

(I) PhIRDA organized seminars and offered suggestions for improving new medical insurance system construction

1) PhIRDA offered suggestions on dynamic adjustment of National Reimbursement Drug List

In November 2017, upon the entrustment of the former Medical Insurance Division of the Ministry of Human Resources and Social Security of the People's Republic of China, PhIRDA conducted researches and made suggestions on the dynamic adjustment mechanisms of National Reimbursement Drug List. PhIRDA's suggestions were highly recognized by the leadership of relevant departments, and were entrusted to keep researching on policy and detailed measures of medical insurance and drug supervision.

2) PhIRDA organized seminars to listen to enterprises' opinions in order to coordinate with the national medical insurance negotiation working group on anti-cancer drugs

For coordinating with national medical insurance departments on negotiation, PhIRDA organized the enterprise seminar on July 11, 2018 for negotiation of reimbursement anti-drug list, involving regulations, requirements, procedures, etc. The enterprises attending the meeting (8 domestic enterprises/10 foreign enterprises) made suggestions to relevant principals of the National Healthcare Security Administration (NHSA). The seminar accelerated work efficiency and the selection of varieties for negotiation, and also substantially reflected the NHSA's efforts into the dynamic negotiation and enterprise communication.

3) PhIRDA organized the enterprise seminars to make feedback about the pilot work of national concentrated drug procurement

PhIRDA organized some enterprise representatives twice for discussion of the programs for pilot work of national concentrated drug procurement drafted by NHSA for high-priced anti-cancer drugs and varieties passing through the quality consistency evaluation of generic drugs (hereinafter referred to as "Pilot Program for Concentrated Procurement"). Participants drafted a proposal regarding the principles of concentrated pilot procurement, scope of pilot varieties, way of bidding, way of supply, way

of implementation of procurement volume, and formulation of medical insurance payout standards, and submitted it to NHSA, which played an important role in enacting the formal Pilot Program for Concentrated Procurement.

4) PhIRDA was invited by NHSA to participate in research on "Comprehensively Building the Medical Security System with the Chinese Characteristics"

SONG Ruilin, Executive President of PhIRDA, as an expert, was invited to attend the seminar of "Special Study on Comprehensively Building the Medical Security System with the Chinese Characteristics" held by NHSA. His opinions were highly recognized by NHSA; after the General Assembly, the principals of NHSA and member representatives held a seminar themed "Building the Medical Security System with the Chinese Characteristics", holding a discussion on the following questions: problems and challenges in existing medical security system; evaluation standard on the system of medical insurance and the system of dynamic adjustment for the balance between cost, quality and efficiency; scientific control over bidding & procurement and reasonable pricing mechanism for medical insurance drugs; the leverage role of medical insurance fund in the aspect of national strategic purchase and payment, and the optimization of drugs supply; means to promote the establishment and perfection of market mechanism featuring innovation, high-quality, justice and standard through establishing and perfecting the medical insurance system, etc.

(II) PhIRDA continued to improve drug intellectual property protection system upon the entrustment of drug administration authorities

Entrusted by the former Department of Drug and Cosmetics Registration of China Food and Drug Administration (CFDA), PhIRDA discussed the pilot work on drug patent link and patent term restoration system (including the patent survey of drugs under development and drugs listed in the market of PhIRDA's innovative member enterprises). The proposal drafted by PhIRDA was highly appraised by the leadership of the CFDA.

(III) PhIRDA visited relevant organizations in Japan for exchanging opinions and obtaining a series of first-hand material for drug regulations and medical insurance

On November 28, 2017, PhIRDA delegation attended the "9th China-Japan Pharmaceutical Exchange Meeting". Focusing on the dynamic reforms of drug administration system of China and Japan, the leaders and experts from the Center for Drug Evaluation, Center for Food and Drug Inspection, and Evaluation Center of China Food and Drug Administration (CFDA) briefly introduced the recent regulatory reforms of China. At the meeting, experts from the Ministry of Health, Labor and Welfare and Osaka Prefecture shared the experience on drug evaluation and approval system in Japan.

PhIRDA delegation also visited Japan Branch of Johnson & Johnson, and made in-depth exchange about the adjustments of reimbursement drug list and National Reimbursement Drug List dynamic adjustment mechanism in China and Japan.

On April 12, 2018, PhIRDA delegation visited Japan Pharmaceutical Manufacturers Association (JPMA), discussed the drug IPR protection systems, pharmaceutical regulatory policies, and communicated with Japan Medical and Global Policy Academy (HPGI) in terms of the medical insurance system in Japan.

By learning from the success of the pharmaceutical innovation in Japan, the visit has promoted cooperation with JPMA in research of major industrial policy, and the cooperation with other relevant pharmaceutical institutions in Japan and Asia.

(IV) PhIRDA listened to and discussed enterprise's difficulties in implementing the Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices

PhIRDA organized the representatives of some innovative members for the discussion on how to resolve the bottleneck of clinical trials in China. By collecting the member's opinions and researching solutions, PhIRDA drafted a proposed for promoting the quality and management of clinical trials. The draft is to be submitted to relevant ministries and commissions.

(V) PhIRDA organized enterprise seminars to improve the essential drug system of China

PhIRDA organized some members to join a seminar. Some suggestions were proposed for the following issues involved in Opinions on Further Perfecting the National essential drug system (Draft for Comments) drafted by the Department of Drug Policy and Essential of the National Health Commission of the People's Republic of China: procurement and distribution, preferential use of "retained balance" in the incentive

dmechanisms, relationship between essential drug system and generic drug consistency evaluation, supply of raw material medicines, and other issues.

(VI) PhIRDA recommended experts to participate in the formulation, revision, training and other work of the international drug registration guidelines for ICH

1) PhIRDA convened the seminar of ICH Pharmacovigilance related secondary guidelines in BeijingPhIRDA hosted the seminar for China's implementation of ICH Pharmacovigilance Related Secondary Guidelines on March 17, 2018. Regulatory authorities and enterprise experts in pharmacovigilance were invited to comprehensively interpret the regulatory requirements, application policies and enterprise operation practice for implementation of ICH related secondary guidelines. This seminar laid a foundation for procuring the industry to comprehensively understand the ICH related secondary guidelines and administration ideas, and promoting the all-round transformation and implementation of ICH related secondary guidelines.

2) PhIRDA recommended experts to participate in ICH working group and revise the guidelines

Entrusted by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), PhIRDA successively recommended a number of experts to join in relevant working groups of ICH Guidelines, and to participate in revisions. Meanwhile, PhIRDA also organized members to make suggestions for revisions to the Chinese and English versions of the guidance, such as ICH E17 international multicenter clinical guideline, M4 general technical documents, E2F safety update reports for drug development periods, etc., playing an active role in promoting the smooth transformation and implementation of ICH Guidelines in China.

II. PhIRDA publicized China's pharmaceutical innovative achievements

(I) Series of articles about China's pharmaceutical innovative achievements wrote by PhIRDA published in *Nature* were honored as the "China Top 10 Medical Science and Technology News in 2017"

PhIRDA published articlesfor systematic introduction of China's pharmaceutical innovation achievements in recent years in the magazine Nature (hereinafter referred to as "Series Articles"). At the "China Technological Innovation Development Summit Forum for Hygiene and Health" and "China and World Top 10 Medical Science and Technology News Release in 2017" jointly sponsored by *Health News* in collaboration with the Chinese Medical Association, Chinese Academy of Medical Sciences, Science and Technology Development Center of the National Health and Family Planning Commission and other units, the articles were honored with "China Top 10 Medical Science and Technology News in 2017", which is not only a praise for PhIRDA's work in publicizing China's pharmaceutical innovation achievements to the world and in promoting the innovative pharmaceutical development, but a recognition China's development in innovative pharmaceuticals.

(II) PhIRDA cooperated with the Medical Economic News on the report program titled "Salute to High-end Innovation - Series Publicity of China's Innovative Pharmaceutical Enterprises over the Past Forty Years after China's Reform and Opening up"

Since September 2018, PhIRDA has carried out the report program titled "Salute to High-end Innovation - Series Publicity of China's Innovative Pharmaceutical Enterprises over the Past Forty Years after China's Reform and Opening up" in partnership with *Medical Economic News* of Southern Medicine Economic Research Institute at CFDA. Through a special column/page in the *Medical Economic News*, it reviewed the stories of enterprise innovation since China's reform and opening up, and looked into the new future of China's new drug creation and manufacture industry.

(III) PhIRDA reformed the mode of pharmaceutical innovation brand selection and continued to build an authoritative and high-end event

To make the pharmaceutical innovation brand selection more authoritative, fair and extensively influential globally, PhIRDA co-hosted the activity with Suzhou Industrial Park and People.cn, and named the selection as "Dushu Lake Prize" (hereinafter referred to as "Brand Selection").

The 2018 version featured the following highlights: 1. New rules adopted expert recommendation system in the selection for international science prizes (self-assessment rejected); 2. New rating process designed strictly by the system of peer evaluation used in the international innovation standards and international science awards; 3.Sticking to the principles of non-profit, transparence and fairness.

The final meeting and awarding ceremony of brand selection were unveiled in Suzhou Culture and Arts Centre on the afternoon and evening of September 17 respectively. Heavyweights such as HE Wei, Vice Chairperson of the Chinese People's Political Consultative Conference (CPPCC) National Committee, Executive Vice Chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party attended the event and presented prizes for winning programs. People's Daily and Suzhou TV

station aired the event online. The brand selection activity promoted the cultural construction of China's pharmaceutical innovation brands, publicized the activities and innovation varieties at home and abroad positively, and advanced China's innovation ability and international competitiveness.

III. PhIRDA collaborated with domestic and foreign institutions of innovation and investment, to establish the direct exchange and dialogue platform for pharmaceutical innovation and investment & financing, and constantly advanced R&D ability of pharmaceutical innovation at an international level

(I) PhIRDA made exchange and cooperation of innovation and investment between four Regions across the Straits in China

1) PhIRDA supported the "2017 Asia Pacific Biotech Investment Forum" and organized a delegation for exchange

PhIRDA, as the supporter, organized more than ten enterprises to participate in 2017 Asia Pacific Biotech Investment Forum, which enables the pharmaceutical enterprises in Four Regions across the Straits in China to deeply understand the significant reform concepts and measures of Chinese Mainland in terms of drug administration policies. This increased the interest and confidence of investment enterprises to invest in innovative pharmaceuticals in the Chinese mainland.

2) PhIRDA co-hosted the "1st Chinese BioMed Innovation and Investment Conference" with associations in Chinese Taipei, Hong Kong and Macau

PhIRDA co-hosted the "1st Chinese BioMed Innovation and Investment Conference" in collaboration with Chinese Taipei's Institute for Biotechnology and Medicine Industry, Hong Kong Bio-Med InnotechAssociation, Macao International Association for Quality Research in Chinese Medicines and HKEX. It is another diversified exchange platform of PhIRDA in addition to Chinese BioMed Innovation and Investment Conference. Experts and enterprises from four regions across the straits analyzed each's advantages in pharmaceutical innovation and respective roles in promoting pharmaceutical innovation from different perspectives, and made heated discussion around the theme of "Hong Kong Pharmaceutical Innovation and Investment Cooperation".

(II) PhIRDA supported the "2018 Hong Kong Biotechnology Summit", and established the collaborative mechanisms with HKEX and Health Industry Division of China Merchants Group to jointly promote the combination of social capital and pharmaceutical innovation

To support the "2018 Hong Kong Biotech Summit" (hereinafter referred to as the "Summit"), PhIRDA invited more than 20 members to attend the event in Hong Kong, aiming to provide the exchange channels for biotechnology enterprises to exchange with investors, market participants and capital market experts and to jointly establish the investment and financing eco-system for Hong Kong biotechnology. At the meeting, SONG Ruilin, Executive President of PhIRDA, comprehensively analyzed the reforms of pharmaceutical administration policies, existing innovation achievements and perfected investment & financing environment in China, winning the great attention and appraisal of attendees.

During the Summit, PhIRDA signed a memorandum of cooperation respectively with the Healthcare & Pharmaceutical Industry Development Department of China Merchants Group and HKEX, to enhance the innovative ability of China's pharmaceutical industry by various modes of cooperation.

(III) Pharmaceutical Innovation Investment Specialty Committee boosted the combination between innovation and investment effectively

Since its establishment in 2016, Pharmaceutical Innovation Investment Specialty Committee (hereinafter referred to as "Investment Specialty Committee"), PhIRDA has assisted HKEX in completing the largest reform of listing system over the past 25 years, planned and initiated a number of professional activities such as "China BioMed Innovation and Investment Conference", "China Biotechnology Innovation Investors Forum", etc. by closing focusing on its mission of "effective alignment between pharmaceutical innovation and capital" and giving full play to the advantages of the Investment Specialty Committee.

1) PhIRDA took the lead to assist HKEX in the largest reform of listing system over the past 25 years

At the stage of HKEX collecting information for public comments on revisions to the *Listing Rules*, PhIRDA and the Investment Specialty Committee were invited to visit Hong Kong for several times. PhIRDA offered suggestions on the *Listing Rules*, and shared opinions of the innovative biotechnology companies in Chinese mainland with HKSX.

On June 12, 2018, HKEX announced that SONG Ruilin, Executive President of PhIRDA, and Tian Yuan, Chairman of PhIRDA Pharmaceutical Innovation Investment Specialty Committee were appointed as the members of the Biotech Advisory Group.

So far, 5 of 15 Biotech Advisory Group published by HKEX are experts from PhIRDA or specialty committees. PhIRDA's members, Ascletis BioScience, BeiGene and Hua Medicine have been successfully listed on HKEX in succession, becoming the first biotechnology companies without profits listed in Hong Kong after the implementation of the new *Listing Rules*.

2) PhIRDA held meetings for reelection of specialty committees for future working plan

In accordance with the provisions of the *Administrative Measures for Specialty Committees of China Pharmaceutical Innovation and Research Development Association*, the Reelection Meeting of the Investment Specialty Committee & the First Work Conference of the 2nd Investment Specialty Committee adopted the name list of members to the 2nd Investment Specialty Committee (68 members, including one Chairman and ten Vice-Chairmen). TIAN Yuan, Founding Partner of Yuanming Capital, was elected as the Chairman of the 2nd Investment Specialty Committee. Led by the new leadership, the Investment Specialty Committee will continue to exert the advantages of professional investors in the pharmaceutical fields, explore new business modes, customize small-sized investment activities, so as to make its business more target-oriented and colorful.

3) PhIRDA initiated the 1st "China Biotechnology Innovation Investors Forum"

The 1st "China Biotechnology Innovation Investors Forum" (hereinafter referred to as "Forum") initiated by the Investment Specialty Committee won the attention and support of well-known institutions such as HK Bio-Med Innotech Association (HKBMIA), Hong Kong Stock Exchange, Lilly Asia Ventures, Ping An Ventures, etc. The success of the first session played a positive guiding role in enhancing the ability of investors to analyze projects and grasp opportunities, reducing investment risks, promoting the in-depth exchange and cooperation between pharmaceutical enterprises and investment institutions. Meanwhile, this event also represented a solid step of PhIRDA to actively explore and promote the efficient alignment between pharmaceutical innovation and investment circle through the customization of small-sized, boutique, professional activities.

(IV) PhIRDA held the 2nd China BioMed Innovation and Investment Conference successfully and is preparing for the 3rd session actively

1) The 2nd China BioMed Innovation and Investment Conference created a new record high in the size of activity

PhIRDA co-hosted the 2ndChina BioMed Innovation and Investment Conference (hereinafter referred to as "Conference") with the Securities Association of China, China Association for Medical Devices Industry and HKEX in Suzhou on October 29-31, 2017. Featuring 18 special activities and 135 exhibits in new drugs under development, medical devices and relevant companies at home and abroad, the event attracted 1,318 relevant enterprises/institutions, over 2,000 representatives. With an unprecedented scale, the event was highly appraised among the industry as a high-end platform for China to display its pharmaceutical innovation policies and achievements and to promote the cooperative investment in the innovation projects.

2) The 3rd China BioMed Innovation and Investment Conference was well prepared. PhIRDA is striving to build the Conference into an important activity brand for exchange and development of pharmaceutical innovation in Asia-Pacific Region

PhIRDA held the 3rd China BioMed Innovation and Investment Conference (2018 CBIIC) in collaboration with China Association for Medical Devices Industry, Chinese Hospital Association and HKEX, in Suzhou Industrial Park, on September 18-20, 2018. Compared with the previous two sessions, 2018 CBIIC included Artificial Intelligence Roadshow, Rare Diseases and Orphan Drugs Roadshow, Cross-Border M&A Forum, closed door meeting between innovative pharmaceutical enterprises and HKEX and the Chief Editor of *Nature Reviews Drug Discovery* and international top scientists, etc. 17 domestic and foreign organizations and institutions provided the all-round, strong support to the event. J.P. Morgan supported the event as the exclusive international investment bank. Besides, this event was fully reported by the supporting media, including *Nature*, the international top academic magazine under *Springer Nature*, *health.people.cn*, *Medical Economic News* and *MENET*, more than 20 traditional media such as *Health News*, *Economic Information*, *21st Century Economy Report*, *Technology Innovation and Brand of CAST*, etc., as well as more than 10 new media such as *Drug Times*, *DrugRNDer, Media Intellectuals*, *Zhengqi Investment Research*, etc. as the cooperative media. Dr. HE

Wei, Vice Chairperson of the Chinese People's Political Consultative Conference (CPPCC) National Committee, Executive Vice Chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party, Professor CHEN Lieping, Director of the Cancer Immunology Program at the Yale Cancer Center, Charles LI, Chief Executive of HKEX, CHEN Dongsheng, Chairman and Chief Executive Officer of Taikang Insurance Group, and Martin Dewhurst, Senior Partner of McKinsey's London Office were invited to express their unique insight into the global and Asian pharmaceutical innovation.

IV. PhIRDA expressed the opinions of pharmaceutical innovation industry in China, made contribution in our own way and advanced the innovative R&D ability through international exchange

(I) PhIRDA attended the 36th J.P. Morgan Annual Healthcare Conference and delivered a speech at the Asian Forum on behalf of China for the first time

SONG Ruilin, Executive President of PhIRDA attended the 36th J.P. Morgan Annual Healthcare Conference held in San Francisco, USA, and delivered a speech titled Significant Reform of China Drug Administration in 2017 at the Asian Forum upon invitation. It is the first time for the Asian Forum to make special arrangement for introduction of China's reform of drug administration.

(II) PhIRDA attended the 7th Asia Partnership Conference of Pharmaceutical Associations (APAC) as an important member to promote the Asian innovative development

On September 30, 2017, PhIRDA formally became a member of Asia Partnership Conference of Pharmaceutical Associations, the only member from the Chinese pharmaceutical industry. On April 10, 2018, PhIRDA organized a delegation for the 7th APAC Conference. Drug administration institutions, medical industry associations and representatives of well-known innovative pharmaceutical institutions from major economies of Asia presented workshops on creating the favorable ecological environment of pharmaceutical innovation, strengthening the availability of innovative pharmaceuticals, and other important topics. This event played an important role in promoting the innovative fusion of drug administration concepts of major economies in Asia and cooperation among innovative institutions.

(III) PhIRDA deepened the Sino-U.S. cooperation on oncology innovative research and strengthened oncology R&D ability in China

1) China Brain Cancer Mission-Working Group Meeting was held to discuss the establishment of clinical drugs research platform for brain cancer, to tackle problems in R&D for brain cancer drug

Co-hosted by PhIRDA, Eliminate Cancer Initiative (ECI) and National Foundation for Cancer Research (NFCR) and organized by Beijing Tian Tan Hospital of Capital Medical University, "China Brain Cancer Mission-Working Group Meeting" was held in the new headquarter of Beijing Tian Tan Hospital, on April 13, 2018. The consensus was reached at the meeting: all parties would bring joint efforts to set upworking groups that focus on fundamental research, clinical trials, Biobank and big data process and funding. PhIRDA and NFCR would cooperate to establish a clinical drugs research platform for brain cancer in the Beijing Tian Tan Hospital of Capital Medical University.

2) PhIRDA held the SINO-U.S. Oncology Experts Roundtable to discuss the cancer drugs R&D trends at home and abroad

Co-hosted by PhIRDA and Suzhou Industrial Park Administrative Office (SIPAC) and co-organized by Chinese American Hematologist and Oncologist Network (CAHON), "SINO-U.S. Oncology Experts Roundtable" was held in Suzhou on the morning of July 6, 2018. Led by Dr. Richard Pazdur, Director of U.S. FDA Oncology Center of Excellence and Dr. Ke Liu, Chief of Oncology of Center for Biologics Evaluation and Research, the U.S. Delegation had a fruitful discussion with chairmen and senior management from pharmaceutical enterprises on the global trend of cancer drugs R&D, approval system for new drug and the latest pharmaceutical R&D status in China in this event.

V. PhIRDA improved its services by multiple means including organizing annual forums and academic exchange activity, establishing R&D service specialty committees, establishing the enterprises code of business ethics, etc.

(I) PhIRDA co-hosted the 9th China Hospital Pharmacy Policy Forum to define the roles of pharmaceutical services playing in the clinical research

Co-hosted by PhIRDA, Chinese Pharmacists Association, Chinese Hospital Association and Peking University People's Hospital, the 9th China Hospital Pharmacy Policy Forum was held in Beijing, on July 20, 2018. Over 400 participants, including leaders from medical insurance and drug administration departments and representatives in the relevant fields of hospital pharmacy attended the event. Themed with the hospital reform and hospital pharmacy

policy of China, the forum was dedicated to expert interpretation and discussion on topics including management system reform of clinical trial institutions, all-round development of pharmaceutical services, roles of pharmacists in the reform of medical insurance payment mode/medical insurance expense control and rational drug use of hospitals, etc.

(II) PhIRDA held the 3rd China Cadiovascular Disease Clinical Research Quality Management Standard Conference (GCP) and ICH Conference to promote international multicenter clinical research in China

Co-hosted by PhIRDA, China Cardiovascular Association, China Anti-thrombotic Drug Treatment Association, Hangzhou Investment Promotion Bureau and Hangzhou Economic and Technological Development Zone Management Office, the "3rd GCP and ICH Conference" was held in Hangzhou, Zhejiang Province, on May 24, 2018.

A number of experts from the Center for Drug Evaluation,CFDA, clinical research centers of domestic well-known medical institutions and relevant pharmaceutical enterprises made an in-depth discussion on the regulatory reform of the CFDA, current status of clinical research of drugs and existing issues of China. The success of the event deepened the understanding of clinical research industry to ICH Guidelines, and made contribution to promoting the better transformation and implementation of ICH guidelines in China, pushing ahead with the international multicenter clinical research in China, especially the translational research, enhancing China's clinical research levels of drugs, and boosting the innovation ability and international competitiveness of China's pharmaceutical industry.

(III) PhIRDA established the "Innovation R&D Services Specialty Committee" for the purpose of R&D resource integration and enhancement of R&D quality and efficiency

To enhance the service level of innovation R&D contract organizations of China, PhIRDA established the Innovation R&D Services Specialty Committee on March 17, 2018. Consisting of domestic excellent CRO, CDMO institutions and experts, the Specialty Committee will make its contribution to domestic and foreign R&D resource integration, drug R&Dcost reduction, R&D efficiency enhancement, and all-round improvement of domestic drug R&D level.

(IV) PhIRDA urged the code of business ethics for Chinese pharmaceutical enterprises by adapting international experience, playing a role in regulating the pharmaceutical market order of China

1) PhIRDA attended the APEC Business Ethics for SMEs Forum for advanced experience in international business ethics

Invited by Asia-Pacific Economic Cooperation (APEC), PhIRDA representatives attended the "2018 APEC Business Ethics for SMEs Forum" in Tokyo, Japan on July 18-20, 2018. The forum focused on the hot topics including construction of ethical codes of the pharmaceutical industry in Asia-Pacific region, system innovation, and so forth. This event not only helped PhIRDA members comprehensively understand the progress of pharmaceutical ethics compliance in the Asia-Pacific region and the importance of ethics compliance for creation of favorable ecological environment, but also promoted the development of ethics construction of pharmaceutical industry in China.

2) PhIRDA established the Ethical Codes Working Group for Pharmaceutical Enterprises, formulating the PhIRDA Codes of Ethics and regulating pharmaceutical market in China

To further bring the ethical codes of China's pharmaceutical industry in line with international standards and gear members to international practice, PhIRDA formulated the PhIRDA Code of Ethics in accordance with relevant contents of the *Administrative Measures for Recordation and Registration of Medical Representatives (Trial) (Draft for Comments), Principles of Mexico* and IFPMA, becoming China's first pharmaceutical organization which have formulated the Code of Ethics in China. In the future, PhIRDA will actively promote members to establish and improve the compliance system of ethical principles and risk management compliance, and urge members to put it implementation effectively.

VI. PhIRDA kept adjusting the structure of membership and recruiting new members

During the intersessions of General Assembly, PhIRDA accepted 38 new members approved at Chairman Board Meeting and voting by correspondence, increasing the number of members up to 142 (including one Chairman and 11 Vice- Chairmen). With the joint efforts of members and specialty committees, PhIRDA is establishing the membership structure covering the full industry chain of pharmaceutical innovation. Through breakthroughs in all links of pharmaceutical industry and from all aspects of pharmaceutical innovation environment, PhIRDA actively integrated all elements of pharmaceutical innovation, becoming an important force of pharmaceutical innovation on which government agencies will rely and represent pharmaceutical innovation and also an industry organization that is able to promote the constant improvement in pharmaceutical innovation policies and ecological environment; meanwhile, R&D and

investment of PhIRDA's members have become indispensable force for the development of China's pharmaceutical innovation, and enable PhIRDA to develop into the important link and platform through which domestic and foreign innovation industry can exchange and cooperate with the investment circle.

Section II Suggestions on Key Works in 2019

The 19th National Congress of the Communist Party of China formally declared that the socialism with Chinese characteristics has entered a new era. The *Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices* issued by the General Office of the CPC Central Committee and the General Office of the State Council (hereinafter referred to as the "Opinions") and CFDA's joining in ICH unveiled a new journey for China to bring its drug registration approval standards in line with international practice. HKEX implemented the listing rules for zero-profit biotechnology enterprises. In late August, China Securities Regulatory Commission (CSRC) made it clear that it would further improve the systems and regulatory rules in support of the eligible, unprofitable biotechnology enterprises to be listed on GEM A-share market, which further promoted the development of biotechnology innovation and realized the close combination between innovation and capital; these measures show that China has embraced the spring of pharmaceutical innovation.

The CPC Central Committee reformed the national regulatory bodies, and the regulatory functions of government sectors for pharmaceuticals were restructured. As a domestic industry organization typical of promoting pharmaceutical innovation, PhIRDA will continue to play the role of members and specialty committees, gather all resources, assist the new government sectors in deeply researching and implementing the specific policies and measures for the Opinions, in furtherance of continuous improvement of innovative development environment for pharmaceutical industry; at the same time, PhIRDA will continue to promote innovations inservice channels and ways for members and pharmaceutical industry, and strive to become a comprehensive and internationally developed social organization that strongly promotes the innovation of pharmaceutical industry through building platforms, promoting exchanges and improving the service business level. PhIRDA will focus on the following work in 2019:

I.PhIRDA will continue to play the role of industrial think tank and conduct pharmaceutical policies researches

1) PhIRDA will assist NHSA on "Comprehensively Building the Medical Insurance System with the Chinese Characteristics"

NHSA hope that PhIRDA could conduct study on "Comprehensively Building the Medical Insurance System with the Chinese Characteristics", especially focus on the proposal suggestions for linkage among drug approval, medical insurance payment and hospital use.

2) PhIRDA will cooperate with NMPA, to offer advice and suggestions for drafting and completing supporting policy documents of Opinions by the General Office of Central Committee of CPC and the General Office of the State Council, and urge the implementation of reform measures effectively

The Opinions fully clarified the reform of China's drug evaluation and approval system, and the direction, target and measure of encouraged pharmaceutical innovation. PhIRDA will, in collaboration with NMPA, actively make in-depth research on policies and measures for IPR protection, including drug patent links, patent period compensation, etc., conduct researches on the paths and ways of comprehensively enhancing the level and quality of China's clinical trials. Through drawing lessons from the international advanced experience, PhIRDA will put forward the practicable and feasible suggestions in combination with China's actuality.

3) PhIRDA will recommend and organize experts for ICH experts working groups and guidelines revision works

PhIRDA will, according to the requirements of ICH Secretariat and CDE of IFPMA, continue to recommend the authoritative experts of relevant fields to participate in formulating and revising ICH Technical Guidance and properly perform training for transformation and implementation of ICH Guiding Principles in China, so as to make contribution to keeping China's drug R&D and risk management levels in line with international practice and enhancing the innovation ability and international competitiveness of China's pharmaceutical enterprises.

4) PhIRDA will conduct research on the impacts of Sino-U.S. trade conflicts on China's pharmaceutical industry

Along with the escalation of Sino-U.S. trade war, the U.S. has strengthened its restrictions on China's investment into pharmaceutical and technology import. It has become the major concern of the government and the industry about how to avoid the restriction of U.S. policy and how to swiftly enhance pharmaceutical R&D level and international competitiveness

of China's pharmaceutical industry. On that, as entrusted by the Ministry of Industry and Information Technology of the People Republic of China, PhIRDA will deeply research the solution of innovative development of China's pharmaceutical industry under the background of Sino-U.S. trade war, in order to effectively build China's pharmaceutical industry as high-end industry chain globally.

II. PhIRDA established the Pharmaceutical Innovation and Research Development Foundation to promote related events

The Pharmaceutical Innovation and Research Development Foundation (PhIRDF) was proposed by PhIRDA to constantly boost the active roles of enterprises and scientific research institutions as the innovation subjects of pharmaceutical industry, guide social capital to flow into pharmaceutical industry, mobilize the independent innovation enthusiasm of scientific research personnel, and create the environment for mass entrepreneurship and innovation. PhIRDF is dedicated to regulation reform of pharmaceutical innovation in China, solving the problems of excellent talent introduction in drug administration, supporting new R&D projects about pharmaceutical innovation, safeguarding the medication of rare disease patients and disadvantaged groups (promoting pharmaceutical development, policy perfection, charitable drug donation, etc.). PhIRDF is intent on funding financially and supporting technically all innovative subjects, simulating the innovative vitality and creativity of pharmaceutical industry in China, enhancing the efficiency of pharmaceutical innovation and transformation of achievements in science and technology, and increasing the access of innovative pharmaceuticals.

III. PhIRDA will continue to build the dialogue and exchange platform for pharmaceutical innovation and investment and prepare for the 3rd and 4th China BioMed Innovation and Investment Conference

Under General Secretary Xi's spirit of making capital serve for the real economyand building China into a powerful nation of science and technology, PhIRDA has successfully held three sessions of "China BioMed Innovation and Investment Conference". Through building the dialogue and exchange platforms between pharmaceutical innovation and investment, PhIRDA has promoted the connection between technology and economy, and the correlation between innovation and the industry, thereby transforming the capital market support into achievements in science and technology. PhIRDA's efforts have won active response among the industry. Thus, PhIRDA will continue to strive for the support from industry, and prepare for the 4th China BioMed Innovation and Investment Conference (September 21-23, 2019), continue to build it a five-in-one diversified international exchange platform covering Drug R&D, production, using, circulation and investment and build the it an unique professional pharmaceutical innovation and investors annual brand meeting in Asia.

IV. PhIRDA will continue improving the mode of pharmaceutical innovation brand selection and prepare for the 2019 session

PhIRDA has successfully held two selections activities of China Pharmaceutical Innovation Brand which aroused positive response among the industry. To increase its authority and fairness, PhIRDA reformed the selection mode of 2018 session. Compared with the previous two sessions, the event this year, more credible and transparent with high-level award ceremony, was highly appraised by the pharmaceutical industry and authoritative experts.

As to the 2019 session, PhIRDA will continue to improve the procedure and have experts recommend more innovative brands, researchers and institutions for the selection, building it a influential selection feast in Asian-Pacific region.

V. PhIRDA will facilitate more innovative domestic pharmaceutical enterprises to IPO in Hong Kong, under the Memorandum of Understanding with HKEX

Based on the previous cooperation with HKEX, PhIRDA will continue to provide consultancy services for more domestic pharmaceutical enterprises about their IPO in HKEX, so as to promote the further development of China's innovative pharmaceutical enterprises under the support of international capital.

VI. PhIRDA will establish an innovation R&D collaboration mechanism with domestic and foreign relevant organizations, jointly promoting the improvement of pharmaceutical innovation in China and in line with the international practices

1) PhIRDA will continue the innovation exchange and cooperation with Chinese Taipei Institute for Biotechnology and Medicine Industry, Hong Kong Bio-Med Innotech Association, Macao International Association for Quality Research in Chinese Medicines in Four Regions across the Straits
Under the cooperation agreement signed by Chinese Taipei Institute for Biotechnology and Medicine Industry, Hong Kong Bio-Med Innotech Association, Macao International Association for Quality Research in Chinese Medicines, PhIRDA will continue to establish a four-party pharmaceutical innovation and cooperation mechanism, gather experts and industrial representatives in pharmaceutical innovation industry from four regions, make exchanges for new drug R&D trend, pharmaceutical and healthcare industry cooperation and other hot issues and provide a platform and link of innovation and cooperation for Chinese power in bio-pharmaceutical industry in China and in the world.
2) PhIRDA co-found the "China Alliance for Rare Disease" (CARD) with Chinese Hospital Association and Peking Union Medical College Hospital
In order to address the imperative clinical needs of rare disease patients at home and abroad and formulate relevant policies and systems of orphan drug R&D, PhIRDA took the initiative to establish "China Alliance for Rare Disease" (CARD) in partnership with Chinese Hospital Association and Peking Union Medical College Hospital. Upon the approval of the Medial Authority of the National Health Commission of the People's Republic of China, the secretariat was set up in Peking Union Medical College Hospital. CARD aims to integrate China's R&D resources for rare diseases, make great breakthroughs in the research of rare diseases, enhance the diagnosis and treatment levels, establish the national clinical cooperative diagnosis & treatment network of rare diseases, put into effect the national rare disease registration system, step up the basic medical research and transformation of orphan drug R&D achievements, and boost the coordinated innovation of clinical trials, scientific research and orphan drug R&D for rare diseases.

VII. PhIRDA is improving membership structure and assembling the power of entire pharmaceutical chain

For forming an association with members covering the entire pharmaceutical chain and promoting the development of pharmaceutical innovation in China, PhIRDA will adjust the access standards for accepting domestic top clinical research institutions, high-end, precise and enterprises engaging in smart medical technologies and devices, as well as the enterprises in Hong Kong, Macao and Chinese Taipei and foreign-funded pharmaceutical R&D enterprises (foreign-funded production enterprises excluded).

VIII. PhIRDA will continue to hold various forums and academic exchange activities, to serve the key links of pharmaceutical innovation

Research of clinical trials is a key link that matters the success of marketing of an innovative drug. However, innovative drugs cannot be used reasonably and bring benefits for patients without technical services of hospital pharmacy personnel. Thus, PhIRDA will continue to hold the annual "China Cardiovascular Disease Clinical Research Quality Management Standard (GCP) Conference" and Hospital and Pharmacy Policy Forum, to make due contributions of industrial association to improving quality and level of clinical research in China, improving rational drug use and other capabilities improvement in key fields of pharmaceutical innovation of hospital pharmacy personnel and assistant doctors.
The current regulatory reform in the pharmaceutical sector is deepened constantly. The new-established NHSA successively is promoting dynamic adjustments of medical insurance and negotiation-based access of anti-cancer drugs, concentrated pilot drug procurement, and other policies. The pharmaceutical industry is embarking on its unprecedented stage of transformation. As long as we stick to innovative development and promote cooperation through exchange, we can grasp opportunities and face challenges. PhIRDA will continue to keep its own sense of innovation, provide more innovative and more diversified services for members, be a good bridge between enterprises and governments, promote the improvement of policy environment for pharmaceutical innovation and build a higher level of domestic and foreign cooperation and exchange platform, to make struggles for innovation and sustainable development of pharmaceutical industry, thus protecting people's health and realizing the great goal of a powerful country in pharmaceutical innovation.

中国医药创新促进会
第十届会员大会第五次会议纪要

2018年9月17日，中国医药创新促进会（以下称“中国药促会”）在苏州召开了第十届会员大会第五次会议（以下称“大会”）。大会应到会员单位142家，实到会员单位124家，符合章程关于“会员大会须有2/3以上会员出席方能召开”的规定。

大会由中国药促会2017-2018年度会长、中国医学科学院药物研究所所长蒋建东主持。中国药促会124家会员单位共250余位代表参加了会议。

会议内容如下：

1、大会审议通过了中国药促会执行会长宋瑞霖所做的《中国医药创新促进会2017-2018年度工作报告》。

2、大会审议通过了《中国药促会2017-2018年度会费收支情况报告》。

3、大会审议通过了《关于发展中国医药创新促进会会员单位的议案》。本次会议审议通过了4家单位的入会申请，并追认了会员大会闭会期间会长会议表决通过的34家单位的入会申请。由此，中国药促会会员单位增加至142家，形成了药品制造、研发、临床、政策、投资、研发服务全链条多元化的会员组织架构。

4、大会审议通过了《中国医药创新促进会医药企业伦理准则》。

5、大会审议通过了《关于成立换届选举筹备工作组的议案》。

6、以无记名投票方式表决通过了《关于追认会费标准的议案》。

新任会长刘殿波对中国药促会上一年度的工作予以肯定，并提出了下一年度工作的设想和要求。他表示，在接下来的一年中，将与各位同行一道，寻求机遇迎接挑战，把医药产业做得更好。

本次会员大会内容丰富，安排紧凑，圆满完成了各项议程。通过了追认会费标准、制定伦理准则及成立换届选举工作组等各项议程，完善了内部治理结构，为下一年度发展方向确定和主要任务的开展实施奠定了基础；同时新会员的加入为中国药促会推动医药创新和发展注入了新的血液和动力，彰显了中国药促会在医药创新领域的拓展和凝聚力的进一步增强。

二〇一八年九月十七日

Summary of the Fifth Meeting of the 10th PhIRDA General Assembly

On September 17, 2018, China Pharmaceutical Innovation and Research Development Association (PhIRDA) held the Fifth Meeting of the 10th PhIRDA General Assembly (hereinafter referred to as the meeting) in Suzhou. The number of members supposed to attend is 142 and the actual attendance is 124, which met the "2/3 member participation requirement" of PhIRDA Constitution.

The meeting was chaired by Jiang Jiandong, 2017-2018 Annual Chairman of PhIRDA and Director of the Institute of Materia Medica, Chinese Academy of Medical Sciences. 250 representatives from 124 PhIRDA members attended the meeting.

The content of the meeting are as follows:

1. The meeting approved 2017-2018 Annul Work Report & 2017-2018 PhIRDA's Work Plan presented by Song Ruilin, Executive President of PhIRDA.

2. The meeting approved PhIRDA's Annual Financial Report for Year 2017-2018.

3. The meeting approved the Proposal on Recruiting Members of PhIRDA. The meeting has approved 4 new member applications and confirmed 34 new members approved by the Presidents' meeting during intersessional meetings. So far, the number of members of PhIRDA has increased to 142, covering the whole chain from pharmaceutical manufacturing, R&D, clinical, policy, investment to R&D service.

4. The meeting approved the PhIRDA Code of Ethics.

5. The meeting approved the Proposal on Establishing Preparation Working Group for General Election.

6. The meeting approved the Proposal on Revision the Membership Fees Standard by secret ballot.

Liu Dianbo, 2018-2019 Annual Chairman, gave high praises of PhIRDA's work in last term and proposed plans and requirements for the next year. He said, in the coming year, he would seek opportunities to meet challenges, making a better pharmaceutical industry with each and every colleague.

The meeting successfully completed all contents. All items on agenda have been completed successfully. The revision of membership fees, PhIRDA Code of Ethics and establishing preparation working group for General Election were approved, having improved the internal governance structure and laid a solid foundation for setting the development direction and implementing the major tasks in the upcoming year. Meanwhile, PhIRDA has been injected with fresh blood and impetus by recruiting new members, manifesting that the expansion and cohesive power of PhIRDA has been further enhanced in the field of pharmaceutical innovation.

September 17, 2018

专业委员会简介

Introduction of Specialty Committees

根据工作需要，经中国医药创新促进会（以下简称“中国药促会”）第十届一次、二次、四次会员大会审议通过，批准成立药物研发、药物临床研究、医药政策、医药创新投资和创新研发服务五个专业委员会。

药物研发专业委员会旨在通过强化药物研发交流，促进中国药促会会员单位创新研发能力的提升；参与ICH及国内外相关技术指南修订，为促进行业药物研发规范性及与国际接轨提出意见和建议。

药物临床研究专业委员会旨在通过为中国药促会会员单位的临床研究活动提供指导和建议，促进会员单位临床研究能力与水平的提升。

医药政策专业委员会旨在研究国内外医药政策领域的重大理论与实践问题，为政府提供决策参考。

医药创新投资专业委员会旨在吸纳对于医药创新有经验、有实力的投资界代表加入，激发中国药促会会员单位与投资界的密切合作，提升医药创新的效率和效益，在医药领域推动投资早期介入创新的政策和生态环境的形成。

创新研发服务专业委员会包含合同研究组织（CRO）和合同开发与生产组织（CDMO），旨在通过为会员单位及国内外企业提供符合国际标准的新药研发服务，形成具有国际竞争力的新药研发核心服务商集群，助力创新成果的转化。

各专业委员会允许吸纳相关专家以个人身份加入，为中国药促会会员单位在政策、研发、技术创新、临床试验及研发服务等方面提供指导与咨询，为会员单位创新活动的开展提供切实服务。

According to the First, Second and Fourth Meeting of 10th PhIRDA General Assembly, China Pharmaceutical Innovation and Research Development Association (PhIRDA) approved the establishment of five Specialty Committees: Medicinal Policy, Drug R&D, Clinical Research Pharmaceutical Innovation Investment and Innovation R&D Services.

Drug R&D Specialty Committee aims to enhance the innovative R&D capability of PhIRDA's members through providing suggestions and comments on their innovative R&D activities, participating in the revision of ICH and relevant technical guidelines both at home and abroad, and providing opinions and suggestions for promoting the standardization and international harmonization of drug R&D of pharmaceutical industry.

Clinical Research Specialty Committee aims to promote clinical research capability through providing guidance and suggestions, as well as other aspects of clinical research activities of PhIRDA's members.

Medicinal Policy Specialty Committee aims to research major theoretical and practical issues in medicinal policies, providing references for government.

Pharmaceutical Innovation Investment Specialty Committee aims to attract representatives from investment communities with rich experience in pharmaceutical innovation, in order to stimulate the close cooperation between investment institutions and members, enhance the efficiency and effectiveness of innovation, promote the policy environment and ecological environment of innovation investment in early intervention.

Innovation R&D Services Specialty Committee includes Contract Research Organizations (CRO) and Contract Development and Manufacturing Organizations (CDMO), aiming to providing the new drug R&D services to members with international standardization, to create an international competiveness new drug R&D service group, to enhance the transfer of innovation achievements.

Each specialty committee absorbed related experts to join personally and provide guidance and consultation on policies, R&D, technological innovation and clinical trials to provide practical services to PhIRDA's members.

第二届药物研发专业委员会

The 2nd Drug R&D Specialty Committee

名誉主任委员 蒋建东

中国医药创新促进会2017-2018年度会长

中国医学科学院药物研究所所长

Honorary Chairman, Jiang Jiandong

Annual Chairman 2017-2018 of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

Director of Institute of Materia Medica, Chinese Academy of Medical Science

主任委员 王印祥

北京加科思新药研发有限公司

董事长

Chairman, Wang Yinxiang

Chairman of Beijing Jacobio Pharma Co., Ltd.

副主任委员 张 丹

方恩（天津）医药发展有限公司董事长兼CEO

Vice-Chairman, Zhang Dan

Chairman & CEO of Fountain Medical (Tianjin) Co., Ltd.

副主任委员 陈建峰

中国工程院院士

中国工程院秘书长、北京化工大学副校长

Vice-Chairman, Chen Jianfeng

Academician of the Chinese Academy of Engineering, General Secretary of the Chinese Academy of Engineering, Vice President of Beijing University of Chemical Technology

副主任委员 房健民

荣昌生物制药（烟台）有限公司

总经理兼首席科学官

Vice-Chairman, Fang Jianmin

General Manager & Chief Scientist Officer of RemeGen, Ltd.

副主任委员 何 伟

浙江导明医药科技有限公司

总经理

Vice-Chairman, He Wei

General Manager of DTRM Biopharma

副主任委员 鲁先平

深圳微芯生物科技股份有限公司

董事长、总裁

Vice-Chairman, Lu Xianping

Chairman of the Board & President of Shenzhen Chipscreen Biosciences Co., Ltd.

副主任委员 徐希平

深圳奥萨医药有限公司董事长

Vice-Chairman, Xu Xiping

Chairman of the Board, Shenzhen AUSA Pharmaceuticals Ltd.

副主任委员 杨大俊

亚盛医药董事长

Vice-Chairman, Yang Dajun

Chairman of Ascentage Pharma Group Corp., Ltd.

副主任委员 俞德超

信达生物制药（苏州）有限公司

董事长兼总裁

Vice-Chairman, Yu Dechao

Chairman & President of Innovent Biologics, Inc.

副主任委员 陈 力

华领医药技术（上海）有限公司

创始人、首席执行官

Vice-Chairman, Chen Li

Founder & CEO of Hua Medicine (Shanghai) Ltd.

副主任委员 江宁军

基石药业（苏州）有限公司

首席执行官

Vice-Chairman, Jiang Ningjun

CEO of CStone Pharmaceuticals Co., Ltd.

第二届药物临床研究专业委员会

The 2nd Clinical Research Specialty Committee

名誉主任委员 孙 燕

中国工程院院士

中国医学科学院肿瘤医院国家新药临床研究中心主任

Honorary Chairman, Sun Yan
Academician of the Chinese Academy of Engineering,
Director of National New Drugs Clinical Research Center,
Cancer Hospital, Chinese Academy of Medical Sciences

名誉主任委员 葛均波

中国科学院院士

复旦大学附属中山医院心内科主任

Honorary Chairman, Ge Junbo
Academician of the Chinese Academy of Sciences
Director of Cardiology Department, Zhongshan Hospital Fudan University

主任委员 霍 勇

北京大学第一医院心内科及心脏中心主任

Chairman, Huo Yong
Director of Cardiology and Heart Center, Peking University First Hospital

副主任委员 王拥军

首都医科大学附属北京天坛医院常务副院长

Vice-Chairman, Wang Yongjun
Executive Deputy Dean of Beijing Tian Tan Hospital, Capital Medical University

副主任委员 季加孚

北京大学肿瘤医院院长

Vice-Chairman, Ji Jiafu
President of Beijing Cancer Hospital

副主任委员 石远凯

国家癌症中心副主任、
中国医学科学院肿瘤医院副院长

Vice-Chairman, Shi Yuankai
Deputy Director of National Cancer Centre,
Vice President of Cancer Hospital,
Chinese Academy of Medical Sciences

副主任委员 侯 健

第二军医大学长征医院血液科主任、
全军骨髓瘤与淋巴瘤中心主任

Vice-Chairman, Hou Jian
Director of Department of Hematology, Shanghai Changzheng Hospital,
Director of Myeloma and Lymphoma Disease Center of PLA

副主任委员 王广发

北京大学第一医院呼吸科主任

Vice-Chairman, Wang Guangfa
Director of Department of Respiration, Peking University First Hospital

副主任委员 崔一民

北京大学第一医院临床试验中心主任

Vice-Chairman, Cui Yimin
Director of Clinical Trial Center,
Peking University First Hospital

副主任委员 李文斌

首都医科大学附属北京天坛医院神经肿瘤综合治疗病区主任

Vice-Chairman, Li Wenbin
Director of Comprehensive Treatment Ward of Neuro-Oncology, Beijing Tian Tan Hospital, Capital Medical University

副主任委员 张抒扬

中国医学科学院北京协和医院副院长

Vice-Chairman, Zhang Shuyang
Vice President of Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

副主任委员 秦叔逵

解放军第八一医院副院长、
全军肿瘤中心主任

Vice-Chairman, Qin Shukui
Vice President of Chinese PLA Nanjing Bayi Hospital,
Director of PLA Cancer Center

副主任委员 吴一龙

广东省人民医院副院长

Vice-Chairman, Wu Yilong
Vice President of Guangdong General Hospital

第二届医药政策专业委员会

The 2nd Medicinal Policy Specialty Committee

主任委员 邵 蓉
中国药科大学研究生院常务副院长
Chairman, Shao Rong
Executive Deputy Dean of China Pharmaceutical University Graduate School

副主任委员 史录文
北京大学药学院药事管理与临床药学系主任
Vice-Chairman, Shi Luwen
Director of Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University

副主任委员 朱恒鹏
中国社会科学院经济研究所副所长
Vice-Chairman, Zhu Hengpeng
Deputy Director of Institute of Economics, Chinese Academy of Social Sciences

副主任委员 胡 欣
北京医院药学部主任
Vice-Chairman, Hu Xin
Director of Department of Pharmacy, Beijing Hospital

副主任委员 刘军帅
山东省青岛市社会保险研究会副会长
Vice-Chairman, Liu Junshuai
Vice President of Qingdao Social Insurance and Research Association

副主任委员 陈 川
北京华康管理咨询有限公司董事长
Vice-Chairman, Chen Chuan
Chairman of Beijing HuaKang Healthcare Consulting Co., Ltd.

副主任委员 武志昂
沈阳药科大学工商管理学院教授
Vice-Chairman, Wu Zhi'ang
Professor of School of Business Management, Shenyang Pharmaceutical University

副主任委员 陈 文
复旦大学公共卫生学院院长
Vice-Chairman, Chen Wen
Dean of School of Public Health, Fudan University

副主任委员 王 波
北京秦脉医药咨询有限责任公司董事长
Vice-Chairman, Wang Bo
Chairman of Beijing ChnMed Pharmaceutical Technology Development Co., Ltd.

副主任委员 邵 颖
沈阳药科大学亦弘商学院研究员
Vice-Chairman, Shao Ying
Researcher of Yeehong Business School, Shenyang Pharmaceutical University

副主任委员 冯 毅
方恩医药发展有限公司中国区总裁
Vice-Chairman, Feng Yi
President of China Region, Fountain Medical Development Ltd.

副主任委员 宣建伟
中山大学医药经济研究所所长
Vice-Chairman, Xuan Jianwei
Director of Institute of Medicine and Economics, Sun Yat-Sen University

第二届医药创新投资专业委员会

The 2nd Pharmaceutical Innovation Investment Specialty Committee

主任委员 田 源

深圳前海元明资产管理有限公司创始合伙人

Chairman, Tian Yuan
Founding Partner of Shenzhen Qianhai YuanMing Asset Management Co., Ltd.

副主任委员 杜 莹

再鼎医药（上海）有限公司董事长兼首席执行官

Vice-Chairman, Du Ying
Chairman of the Board & CEO, ZAI Lab (Shanghai) Co., Ltd.

副主任委员 李凯军

上海醴泽投资管理有限公司管理合伙人

Vice-Chairman, Li Kaijun
Managing Partner of LYZZ Capital Advisors Management, Ltd.

副主任委员 朱晋桥

深圳市倚锋投资管理企业（有限合伙）董事长

Vice-Chairman, Zhu Jinqiao
Chairman of Shenzhen EFung Capital Co., Ltd.

副主任委员 陈鹏辉

博远资本创始合伙人

Vice-Chairman, Chen Penghui
Founding Partner of Biotrack Capital

副主任委员 梁颖宇

启明维创创业投资管（上海）有限公司主管合伙人

Vice-Chairman, Liang Yingyu
Managing Partner of Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd.

副主任委员 易诺青

高瓴资本集团合伙人

Vice-Chairman, Yi Nuoqing
Partner of Hillhouse Capital Management, Ltd.

副主任委员 储慧斌

海捷投资控股集团首席合伙人

Vice-Chairman, Chu Huibin
Chief Partner of Hiyield Capital Holding Group

副主任委员 蔡达建

高特佳投资集团创始人、董事长

Vice-Chairman, Cai Dajian
Founder & Chairman of GTJA Investment Group

副主任委员 陆潇波

红杉资本中国基金医疗合伙人

Vice-Chairman, Lu Xiaobo
Partner of Sequoia Capital China

副主任委员 余世新

招商局集团健康产业事业部部长

Vice-Chairman, Yu Shixin
General Manager of Healthcare & Pharmaceutical Industry Development, China Merchants Group Limited

第一届创新研发服务专业委员会

The 1st Innovation R&D Services Specialty Committee

主任委员 谭凌实
缔脉生物医药科技（上海）有限公司董事长兼首席执行官
Chairman, Tan Lingshi
Chairman of the Board & CEO, dMed Biopharmaceutical Co., Ltd.

副主任委员 张 丹
方恩（天津）医药发展有限公司董事长
Vice-Chairman, Zhang Dan
Chairman of the Board, Fountain Medical (Tianjin) Co., Ltd.

副主任委员 洪 浩
凯莱英医药集团 (天津) 股份有限公司董事长兼CEO
Vice-Chairman, Hong Hao
Chairman of the Board & CEO, Asymchem Laboratories (Tianjin) Co., Ltd.

副主任委员 闻丹忆
上海立迪生物技术股份有限公司董事长
Vice-Chairman, Wen Danyi
Chairman of the Board, Shanghai LIDE Biotech Co., Ltd.

中国药促会2018年会长会议扩大会议（2018年1月5日·北京）

2018 PhIRDA President Board Meeting (January 5, 2018, Beijing)

参会代表合影
Photograph of Representatives

创新研发服务专业委员会成立大会（2018年3月17日·北京）

PhIRDA Innovation R&D Services Specialty Committee Inaugural Meeting (March 17, 2018, Beijing)

参会代表合影

Photograph of Representatives

医药创新投资专业委员会换届大会暨第二届第一次工作会议
(2018年5月18日·北京)

The General Election and the First Meeting of the 2nd PhIRDA Pharmaceutical Innovation Investment Specialty Committee
(May 18, 2018, Beijing)

参会代表合影
Photograph of Representatives

药物临床研究专业委员会第二届第二次工作会议
(2018年5月23日 · 杭州)

The 2nd working meeting of the 2nd PhIRDA Clinical Research Specialty Committee (May 23, 2018, Hangzhou)

参会代表合影
Photograph of Representatives

第十届会员大会第五次会议（2018年9月17日·苏州）

The Fifth Meeting of 10th PhIRDA General Assembly (September 17, 2018, Suzhou)

参会代表合影

Photograph of Representatives

会场全景
Plenary Meeting

2017-2018 年度会长蒋建东主持会议

Jiang Jiandong (PhIRDA Annual Chairman 2017-2018) chaired the meeting

执行会长宋瑞霖作工作报告

PhIRDA Annual Work Report delivered by Executive President Song Ruilin

新任会长刘殿波讲话

Addressed by Liu Dianbo (PhIRDA Annual Chairman 2018-2019)

2017-2018 年度会长蒋建东为
2018-2019 年度会长刘殿波颁发证书

Jiang Jiandong, PhIRDA Annual Chairman 2017-2018, presented certificate to Liu Dianbo, PhIRDA Annual Chairman 2018-2019

ICH药物警戒相关二级指导原则研讨会 (2018年3月17日 · 北京)

Seminar on ICH Related Pharmacovigilance Secondary Guidelines (March 17, 2018, Beijing)

中国药促会在北京召开了“ICH药物警戒相关二级指导原则研讨会”。本次会议围绕ICH E2A、M1、E2B的概念与应用角度，展示了我国实施ICH相关二级指导原则的监管要求、应用策略与企业操作实践。国家药品监督管理局ICH工作办公室主任周思源及药品审评中心、药品评价中心、信息中心、中国药学会、中国药促会等有关部门领导、工作人员以及全国各地从事药物警戒和创新药物研发相关工作的100多家企业的300余名代表参加了会议。

PhIRDA held the Seminar on ICH Related Pharmacovigilance Secondary Guidelines in Beijing. The seminar discussed the definitions and application of ICH E2A, M1 and E2B, presenting the regulatory requirements, strategies and operations on implementation ICH related secondary guidelines in China. Zhou Siyuan, Director of ICH Working Office in National Medical Products Administration, PhIRDA Executive President Song Ruilin and 300 representatives from CDE, CDR, CFDAIC, Chinese Pharmaceutical Association, relevant departments and over 100 pharmaceutical industries specializing on pharmacovigilance and innovation R&D attended the event.

会议全景
Plenary Meeting

首届中国生物医药创新投资人论坛（2018年5月18日·北京）

The First China BioMed Innovation Investors Forum (May 18, 2018, Beijing)

会议现场
Plenary Meeting

第三届中国临床研究质量管理 (GCP) 暨ICH大会 (2018年5月24日 · 杭州)

The 3rd China Cardiovascular Disease Clinical Research Quality Management Standard (GCP) Conference and ICH Conference (May 24, 2018, Hangzhou)

由中国药促会、中国心血管健康联盟、中国抗血栓药物治疗联盟、杭州市投资促进局和杭州经济技术开发区管委会共同主办的第三届“中国临床研究质量管理 (GCP) 暨ICH大会”在浙江省杭州市召开。大会紧密围绕我国药品监管改革和实施ICH相关指南对临床试验管理的新要求，以及新药研发企业与临床研究机构面临的热点与难点问题展开深入讨论。来自医学、临床研究机构及药物研究领域的众多专家，以及国内医药企业及临床研究机构相关工作人员共计300余人参加会议。

The 3rd China Cardiovascular Disease Clinical Research Quality Management Standard (GCP) Conference and ICH Conference was co-hosted by PhIRDA, China Cardiovascular Association, China Anti-thrombotic Drug Treatment Alliance, Hangzhou Investment Promotion Bureau and Hangzhou Economic-Technological Development Area in Hangzhou, Zhejiang Province. The conference held discussion on the reform of domestic pharmaceutical review and approval system, new demands for conducting ICH guidelines and hot issues for the enterprises and clinical trial institutions specialized in pharmaceutical innovation R&D. More than 300 people attended this conference, including experts from medical and clinical institutions, representatives from pharmaceutical companies and R&D institutions.

会议现场
Plenary Meeting

中美肿瘤专家圆桌会议（2018年7月6日·苏州）

SINO-U.S. Oncology Experts Roundtable (July 6, 2018, Suzhou)

会议现场
Plenary Meeting

第九届中国医院药学政策论坛 (2018年7月20日 · 北京)

The 9th China Hospital Pharmacy Policy Forum (July 20, 2018, Beijing)

由中国药促会、中国药师协会、中国医院协会和北京大学人民医院共同主办的第九届“中国医院药学政策论坛”在北京顺利召开。本届论坛以“中国医院改革和医院药学政策”为主题，主要围绕临床试验机构管理制度改革、全面发展药学服务、发挥药师在医保支付方式改革、医保控费及医院合理用药中的作用，转变药师职能等议题进行专家解读与讨论。国家卫健委医政医管局、部分省市医保基金管理处/医保结算中心、部分省市卫计委药政处/医政处等单位、四家主办方的相关领导及药学相关领域的代表共计400余人参加了会议。

The 9th China Hospital Pharmacy Policy Forum, co-hosted by PhIRDA, Chinese Pharmacists Association, Chinese Hospital Association, and Peking University People' s Hospital, was successfully held in Beijing on July 20th, 2018. More than 400 representatives attended the meeting, including leaders from the National Health Commission of the People's Republic of China, provincial and municipal Medical Insurance Management Centers, and representatives from pharmaceutical related fields.

会议现场
Plenary Meeting

2018 “独墅湖杯” 医药创新品牌评选系列活动

2018 “Dushu Lake Prize” Selection Activities of China Pharmaceutical Innovation Brand

推荐与评审专家委员会成立大会 (2018年4月3日 · 北京)
Inaugural Meeting of Expert Recommendation and Review Committee (April 3, 2018, Beijing)

复审会议 (2018年8月10日 · 北京)
Review Meeting (August 10, 2018, Beijing)



终审会议 (2018年9月17日 · 苏州)
Final Review Meeting (September 17, 2018, Suzhou)

颁奖典礼会场掠影 (2018年9月17日 · 苏州)

Photograph of Awards Ceremony
(September 17, 2018, Suzhou)

领导、颁奖嘉宾与获奖者合影 (2018年9月17日 · 苏州)

Presenters, Winners and VIP Guests at Award Ceremony
(September 17, 2018, Suzhou)

“最具影响力药物研发领军人物海外华人奖”获奖者陈列平（正中），
“最具影响力药物研发领军人物奖”
获得者吴蓓丽（右三）、杨大俊（左三）
和揭奖/颁奖嘉宾周健民（右二）、
李亚平（左二）、王晓东（右一）、
石远凯（左一）合影

Winner of Most Innovative Figure of Drug R&D in International Area: Chen Lieping (Middle), Winner of Most Innovative Figure of Drug R&D: Wu Beili (Third from right), Yang Dajun (Third from left), Awards Presenter: Zhou Jianmin (Second from right), Li Yaping (Second from left), Wang Xiaodong (First from right), Shi Yuankai (First from Left)

“医药创新特殊贡献奖”获奖者陈凯先院士（右二）与何维副主席
（左二）、蒋华良院士（左一）等合影

Winner of Special Contribution to Pharmaceutical Innovation, Academician Chen Kaixian (Second from right), Award Presenter: Prof. He Wei (Second from left), Academician Jiang Hualiang (First from left)

“最具影响力药物临床研究领军人物”
获奖者蒋立新（右二）、
霍勇（左二）和揭奖/颁奖嘉宾葛均波
（右一）、吴一龙
（左一）合影

Winner of Most Innovative Figure of Clinical R&D: Huo Yong (Second from left), Jiang Lixin (Second from right), Award Presenter: Ge Junbo (First from left), Wu Yilong (First from right)

“最具临床价值创新药”获奖代表谢炘（正中）、
“最具临床价值创新医疗器械”获奖代表
吉朋松（左二）和揭奖 / 颁奖嘉宾 陈建峰（左一）、
蒋建东（右二）、吴晓明（右一）合影

Winner of Innovative Drug with Most Clinical Value: Xie Xin (Middle), Winner of Innovative Medical Device with Most Clinical Value: Ji Pengsong (Second from left), Awards Presenter: Chen Jianfeng (First from left), Jiang Jiandong (Second from right), Wu Xiaoming (First from right)

“最具临床价值创新儿童药”获奖代表游丹（正中）
和揭奖 / 颁奖嘉宾 赵锴（右一）、
王军志（左一）合影

Winner of Innovative Pediatric Drug with Most Clinical Value: You Dan (Middle), Awards Presenter: Wang Junzhi (Left), Zhao Kai (Right)

“最具活力药物创新投资机构”获奖代表陈飞
（右二）、田源（右三）、胡雪峰（正中）、朱青生
（左三）、朱晋桥（左二）和揭奖 / 颁奖嘉宾
李林（右一）、方来英（左一）合影

Winner of the Most Successful Investment Institutions for Pharmaceutical Innovation:
Chen Fei (Second from right), Tian Yuan (Third from right), Hu Xuefeng (Middle), Zhu Jinqiao (Second from left), Zhu Qingsheng (Third from left), Awards Presenter: Li Lin (Right), Fang Laiying (Left)

第三届中国医药创新与投资大会 (2018年9月18日-20日 · 苏州)

2018 China BioMed Innovation and Investment Conference (September 18-20, 2018, Suzhou)

由中国药促会联合中国医疗器械行业协会、中国医院协会、香港交易所共同主办的第三届 "中国医药创新与投资大会" 在苏州工业园区召开。大会设置了包括临床数据首发、上市 / 非上市公司路演、医疗器械项目路演、国际路演、人工智能 (AI) 路演、罕见病路演、投资人经验分享论坛和跨境并购论坛及两场闭门会 (香港交易所与创新企业闭门座谈会和国际顶级科学家座谈会) 在内逾 21 场特色活动。

Co-hosted by PhIRDA, CAMDI, CHA and HKEX, 2018 China BioMed Innovation and Investment Conference was held in Suzhou Industrial Park. Over 21 special events, including Clinical-Trial Data Release of Innovative Drugs, Listed/Non-Listed Company Roadshow, Medical Devices Roadshow, International Roadshow, Artificial Intelligence Roadshow, Rare Diseases and Orphan Drugs Roadshow, Investors' Experience Sharing Forum, Cross-Border M&A Forum and other two closed meetings (HKEX & Innovative Pharmaceutical Companies Forum and Top Leading Scientists Meeting), were arranged in this event.

开幕式会场全景
Plenary Meeting of the Opening Ceremony

中国药促会会长、绿叶制药集团董事长刘殿波致辞

Addressed by Liu Dianbo, Chairman of PhIRDA and Chairman of the Board, Luye Pharma Group Co., Ltd.

苏州市副市长杨知评致辞

Addressed by Yang Zhiping, Vice Mayor of Suzhou

中国药促会执行会长宋瑞霖主持开幕式第一阶段

Song Ruilin, Executive President of PhIRDA chaired the 1st session

中国医院协会副会长方来英主持开幕式第二阶段

Fang Laiying, Vice President of Chinese Hospital Association (CHA) chaired the 2nd session

美国耶鲁大学教授陈列平围绕"癌症的免疫治疗：序幕才刚刚落下"作主题报告

Dr. Chen Lieping, Professor of Immunobiology, Dermatology and Medical Oncology at the Yale School of Medicine delivered keynote speech on Cancer Immunotherapy: The End of Beginning

全国政协副主席何维围绕"细胞治疗：药物干预进入第三纪元"作主旨报告

He Wei, Vice Chairperson of CPPCC National Committee, delivered keynote speech on Cell Therapy -- Pharmacological Intervention Enters a Third Era

香港交易所集团行政总裁李小加围绕"香港生物科技板块的启航"作主题报告

Charles Li, Chief Executive of Hong Kong Exchanges and Clearing Limited delivered keynote speech on Launch of New HKEX Biotech Chapter

泰康保险集团董事长兼 CEO 陈东升围绕"商业保险与大健康产业发展"作主题报告

Chen Dongsheng, Chairman & CEO of Taikang Insurance Group delivered keynote speech on Commercial Insurance and the Development of Big Health Industry

麦肯锡伦敦办公室高级合伙人、麦肯锡全球医药医疗业务负责人 Martin Dewhurst 围绕"全球医药创新及亚洲医药创新的活力"作主题报告

Martin Dewhurst, Senior Partner of McKinsey's London Office and Leader of McKinsey's Global Pharmaceutical and Medical Products Practice delivered keynote speech on The Vitality of Global and China Pharmaceutical Innovation

“全球医药创新发展趋势分析”主题讨论

Panel on Global Trends on Pharmaceutical Innovation R&D

“医药创新与投资界对话”主题讨论

Panel on the Dialogue between Pharmaceutical Innovation and Investment

香港交易所与创新企业闭门座谈会

Close Meeting between HKEX and Pharmaceutical Innovation Enterprises

《自然综述：药物发现》主编 Peter Kirkpatrick 与国内顶尖药物研发、临床专家互动交流

Dialogue between *Nature Reviews Drug Discovery* Chief Editor Peter Kirkpatrick and Experts in Domestic Pharmaceutical R&D and Clinical Trial

临床数据全球首发专场

Clinical-Trial Data Release of Innovative Drugs

上市公司路演专场

Listed Company Roadshow

国际专场

International Roadshow

非上市公司路演专场

Non-Listed Company Roadshow

医疗器械专场

Medical Devices Roadshow

投资人经验分享论坛

Investors' Experience Sharing Forum

开展政策研讨 积极建言献策

Making Discussions on Medical Policies & Providing Suggestions

2017-2018 年度，中国药促会先后承接了人社部、国家药监局等部委及企业委托的政策研究课题十多项，并通过召开研讨会、组建研发联盟等方式不断寻求完善医药创新政策环境的方案，促进医药产业健康发展。

In 2017-2018, PhRIDA was commissioned by MOHRSS, NMPA and other departments and enterprises to conduct more than 10 research projects through holding seminars and establishing alliance to explore plans to optimize the pharmaceutical innovation policy environment and facilitate the development of pharmaceutical industry in China.

建立我国基本医保药品目录动态调整机制研讨会
（2017年11月22日 · 北京）

Seminar on Establishing the Dynamic Adjustment Mechanism for NRDL (November 22, 2017, Beijing)

“关于药品管理法知识产权保护相关条款的研究”课题结题会
（2018年4月4日 · 北京）

Seminar on “Research on Drug Administration Law Concerning Intellectual Property Protection Related Items” (April 4, 2018, Beijing)

外宾的会见与交流

Meetings and Exchanges with Foreign VIP Guests

执行会长宋瑞霖会见安全网上药店联盟全球董事会成员代表团（2017 年 12 月 4 日 · 北京）

PhIRDA Executive President Song Ruilin met with the ASOP Global Delegation (December 4, 2018, Beijing)

执行会长宋瑞霖出席第 36 届 J.P. 摩根健康产业大会并在亚洲论坛上发表演讲（2018 年 1 月 10 日 · 美国旧金山）

PhIRDA Executive President Song Ruilin attended the 36th Annual J.P. Morgan Healthcare Conference and delivered speech in Asia Forum (January 10, 2018, San Francisco, U.S.)

合影 - 日本厚生劳动省副大臣高木美智代（右二）,JPMA 会长畑中好彦（左二）, 中国药促会执行会长宋瑞霖（右一）及卫材株式会社社长内藤晴夫（左一）（2018 年 4 月 10 日 · 日本东京）

Executive President Song Ruilin (first from right) met with Ms. Michiyo Takagi , State Minister of Health, Labor and Welfare, MHLW (second from right), Yoshihiko Hatanaka, President of JPMA (second from left), Haruo Natio, President of Eisai (first from left) (April 10, 2018, Toyko, Japan)



执行会长宋瑞霖会见荷兰王国驻华大使馆卫生、福利和体育参赞 Peter A. Bootsma（2018 年 9 月 19 日 · 苏州）

PhIRDA Excutive President Song Ruilin met with Peter A. Bootsma, Counselor of Health, Welfare and Sports, Embassy of the Kingdom of the Netherlands (September 19, 2018, Suzhou)

中国药促会代表团赴港参加“2018香港生物科技峰会”(2018年3月22日·中国香港)

PhIRDA Delegation Attended 2018 HKEX Biotech Summit (March 22, 2018, Hong Kong)

中国药促会组团赴港参加了由香港交易所主办的“2018香港生物科技峰会”。峰会为生物科技公司提供与投资者、市场参与者以及资本市场专家互相交流的渠道，共同建构香港生物科技的投融生态系统。中国药促会执行会长宋瑞霖结合中办、国办印发的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》作了精彩的主旨报告；应香港交易所邀请，中国药促会专门组织小组围绕“内地生物医药创新进展及发展趋势”进行了深入的讨论。

PhIRDA delegation attended the 2018 HKEX Biotech Summit. The Summit is dedicated to industry professionals to network, exchange insights and experience, and work together to promote the biotech investment eco-system in Hong Kong. PhIRDA Executive President Song Ruilin made a keynote speech on the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation and organized panel discussion on the development and trends of biopharmaceutical innovation in China.

执行会长宋瑞霖围绕“内地生物医药创新进展及发展趋势”作主旨报告

PhIRDA Executive President Song Ruilin delivered keynote speech on "the Development and Trends of Biopharmaceutical Innovation in China"

中国药促会组织的小组讨论现场

Panel Discussion organized by PhIRDA

中国药促会代表团赴日本考察访问（2018年4月10日-12日·日本东京）

PhIRDA Delegation Visited Japan (April 10-12, 2018, Tokyo, Japan)

应JPMA邀请，中国药促会执行会长宋瑞霖率团出席在日本东京召开的第七届亚洲制药组织合作会议（APAC）。中国药促会2017年9月正式成为APAC中代表中国医药行业的唯一成员，此次会议是中国药促会作为正式成员第一次参加会议。代表团还访问日本制药工业协会（JPMA），与JPMA知识产权委员会就日本药品知识产权保护制度和医药监管政策等开展调研。

Invited by JPMA (Japan Pharmaceutical Manufacturers Association), PhIRDA delegation, led by Executive President Song Ruilin attended the 7th Asia Partnership Conference of Pharmaceutical Associations (APAC) in Tokyo, Japan. In September, 2017, the APAC Steering Committee approved the application from PhIRDA, and henceforward PhIRDA became the only member that represents China's pharmaceutical industry in APAC. PhIRDA delegation visited JPMA and conducted investigation and research on Drugs Intellectual Property Protection Regulations and related policies in Japan with Intellectual Property Committee.

APAC参会各国机构、组织代表合影

Photograph of the Representatives from APAC Members and Associations

中国药促会执行会长宋瑞霖与JPMA会长畑中好彦合影

PhIRDA Executive President Song Ruilin and JPMA President Yoshihiko Hatanaka

中国药促会代表团与JPMA知识产权委员会等成员座谈会现场

Meeting between PhRIDA delegation and JPMA Intellectual Property Committee

中国药促会、消除癌症计划与美国癌症研究基金会共同主办中国脑癌攻关圆桌会工作组会议 (2018年4月13日 · 北京)

PhIRDA, Eliminate Cancer Initiative (ECI), National Foundation for Cancer Research (NFCR) co-hosted China Brain Cancer Mission-Working Group Meeting (April 13, 2018, Beijing)

参会代表合影
Photograph of the Representatives

会员单位及其代表

PhIRDA Members & Representatives

刘殿波
Liu Dianbo
绿叶制药集团有限公司董事长
Chairman of the Board, Luye Pharma Group Co., Ltd.

陈启宇
Chen Qiyu
上海复星医药（集团）股份有限公司执行董事、董事长
Executive Director, Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

闫希军
Yan Xijun
天士力控股集团董事局主席
Chairman of the Board, Tasly Holding Group

孙飘扬
Sun Piaoyang
江苏恒瑞医药股份有限公司董事长
Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.

蒋华良
Jiang Hualiang
中国科学院上海药物研究所所长，中国科学院院士
Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Academician, Chinese Academy of Sciences

丁列明
Ding Lieming
贝达药业股份有限公司董事长兼CEO
Chairman of the Board & CEO, Betta Pharmaceutical Co., Ltd.

蒋建东
Jiang Jiandong
中国医学科学院药物研究所所长
Director, Institute of Materia Medica, Chinese Academy of Medical Sciences

张伯礼
Zhang Boli
天津中医药大学校长，中国工程院院士
President, Tianjin University of Traditional Chinese Medicine, Academician, Chinese Academy of Engineering

蔡东晨
Cai Dongchen
石药控股集团有限公司董事长
Chairman of the Board, CSPC Holdings Co., Ltd.

任晋生
Ren Jinsheng
先声药业有限公司董事长
Chairman of the Board, Simcere Pharmaceutical Group

舒　畅
Shu Chang
上海医药集团股份有限公司副总裁
Vice President, Shanghai Pharmaceuticals Holding Co., Ltd.

柯尊洪
Ke Zunhong
成都康弘药业集团股份有限公司董事长
Chairman of the Board, Chengdu Kanghong Pharmaceutical Group Co., Ltd.

徐镜人
Xu Jingren
扬子江药业集团董事长
Chairman of the Board, Yangtze River Pharmaceutical Group

白礼西
Bai Lixi
太极集团有限公司董事长
Chairman of the Board, Taiji Group Co., Ltd.

胡季强
Hu Jiqiang
浙江康恩贝制药股份有限公司董事长
Chairman of the Board, Zhejiang Conba Pharmaceutical Co., Ltd.

李振江
Li Zhenjiang
神威药业集团有限公司董事长
Chairman of the Board, Shineway Pharmaceutical Group Co., Ltd.

李春波
Li Chunbo
浙江医药股份有限公司董事长
Chairman of the Board, Zhejiang Medicine Co., Ltd.

高任龙
Gao Renlong
华北制药集团有限责任公司首席科学家
Chief Scientist, North China Pharmaceutical Group Corporation

汲　涌
Ji Yong
东北制药集团股份有限公司总裁
CEO, Northeast Pharmaceutical Group Co., Ltd.

刘革新
Liu Gexin
四川科伦药业股份有限公司董事长
Chairman of the Board, Sichuan Kelun Pharmaceutical Co., Ltd.

李　聪
Li Cong
通化东宝药业股份有限公司总经理
General Manager, Tonghua Dongbao Pharmaceutical Co., Ltd.

李安平
Li Anping
山西振东制药股份有限公司董事长
Chairman of the Board, Shanxi Zhendong Pharmaceutical Co., Ltd.

张成海
Zhang Chenghai
美罗药业股份有限公司董事长
Chairman of the Board, Merro Pharmaceutical Co., Ltd.

顾浩亮
Gu Haoliang
上海上药信谊药厂有限公司董事长
Chairman of the Board, SPH SINE Pharmaceutical Co., Ltd.

李　昕
Li Xin
华润双鹤药业股份有限公司总裁
President, China Resources Double-Crane Pharmaceutical Co., Ltd.

陶德胜 Tao Desheng	丽珠医药集团股份有限公司总裁 President, Livzon Pharmaceutical Group Inc.
郭殿武 Guo Dianwu	杭州民生药业有限公司首席科学家 Chief Scientist, Hangzhou Minsheng Pharmaceutical Co., Ltd.
汪　涛 Wang Tao	浙江佐力药业股份有限公司总经理 General Manager, Zhejiang Jolly Pharmaceutical Co., Ltd.
欧阳静波 Ouyang Jingbo	广西梧州中恒集团股份有限公司总裁、副董事长、党委书记 President, Vice Chairman & Party Secretary, Guangxi Wuzhou Zhongheng Group Co., Ltd.
王　勇 Wang Yong	南京圣和药业股份有限公司董事长 Chairman of the Board, Nanjing Sanhome Pharmaceutical Co., Ltd.
赵　涛 Zhao Tao	山东步长制药股份有限公司董事长 Chairman of the Board, Shandong Buchang Pharmaceutical Co., Ltd.
于伟仕 Yu Weishi	悦康药业集团有限公司董事长 Chairman of the Board, Youcare Pharmaceutical Group Co., Ltd.
陈庆才 Chen Qingcai	江苏奥赛康药业股份有限公司董事长 Chairman of the Board, Jiangsu Aosaikang Pharmaceutical Co., Ltd.
王晓琳 Wang Xiaolin	重庆植恩药业有限公司副董事长 Vice Chairman, Zein Pharmaceutical Co., Ltd.
冯　鹤 Feng He	正大青春宝药业有限公司总裁 President, Chiatai Qingchunbao Pharmaceutical Co., Ltd.
徐希平 Xu Xiping	深圳奥萨医药有限公司董事长 Chairman of the Board, Shenzhen AUSA Pharmaceuticals Ltd.
娄　竞 Lou Jing	三生制药集团董事长兼首席执行官 Chairman of the Board & CEO, 3S Pharmaceutical Group
任武贤 Ren Wuxian	亚宝药业集团股份有限公司董事长 Chairman of the Board, Yabao Pharmaceutical Group Co., Ltd.
葛啸虎 Ge Xiaohu	常州方圆制药有限公司董事长 Chairman of the Board, Changzhou Fangyuan Pharmaceutical Co., Ltd.
李伯涛 Li Botao	齐鲁制药有限公司董事长 Chairman of the Board, Qilu Pharmaceutical Co., Ltd.
鲁先平 Lu Xianping	深圳微芯生物科技股份有限公司董事长、总裁 Chairman of the Board & President, Shenzhen Chipscreen Biosciences Co., Ltd.
张海英 Zhang Haiying	青岛黄海制药有限责任公司董事长 Chairman of the Board, Qingdao Huanghai Pharmaceutical Co., Ltd.
钟慧娟 Zhong Huijuan	江苏豪森药业集团有限公司董事长 Chairman of the Board, Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
叶宇翔 Ye Yuxiang	深圳信立泰药业股份有限公司总经理 General Manager, Shenzhen Salubris Pharmaceuticals Co., Ltd.
王善春 Wang Shanchun	正大天晴药业集团股份有限公司总裁 President, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
孔　泰 Kong Tai	北京泰德制药股份有限公司总裁 President, Beijing Tide Pharmaceutical Co., Ltd.
张贵民 Zhang Guimin	鲁南制药集团股份有限公司董事长、总经理 Chairman of the Board & CEO, Lunan Pharmaceutical Group Co., Ltd.
萧　伟 Xiao Wei	江苏康缘药业股份有限公司董事长 Chairman of the Board, Jiangsu Kanion Pharmaceutical Co., Ltd.
孙　毅 Sun Yi	成都百裕制药股份有限公司董事长 Chairman of the Board, Chengdu Baiyu Pharmaceutical Co., Ltd.
陈保华 Chen Baohua	浙江华海药业股份有限公司总裁 President, Zhejiang Huahai Pharmaceutical Co., Ltd.
杨代常 Yang Daichang	武汉禾元生物科技股份有限公司董事长 Chairman of the Board, Wuhan Healthgen Biotechnology Corp.

高　帆
Gao Fan
西藏易明西雅医药科技股份有限公司董事长
Chairman of the Board, Tibet Aim Pharm. Inc.

刘振腾
Liu Zhenteng
山东罗欣药业集团股份有限公司董事会执行董事长
Executive Chairman of the Board, Luoxin Pharmaceutical Group Co., Ltd.

吉朋松
Ji Pengsong
上海安翰医疗技术有限公司董事长
Chairman of the Board, Ankon Medical Technologies Co., Ltd.

冯凤仪
Feng Fengyi
中天（上海）生物科技有限公司董事长
Chairman of the Board, Microbio (Shanghai) Biotechnology Co., Ltd.

张　洁
Zhang Jie
四川九章生物科技有限公司董事长
Chairman of the Board, Sichuan Jiuzhang Biological Science and Technology Co., Ltd.

廖昕晰
Liao Xinxi
博雅生物制药集团股份有限公司董事长
Chairman of the Board, Boya Bio-pharmaceutical Group Co., Ltd.

吴劲梓
Wu Jinzi
歌礼生物科技（杭州）有限公司董事长
Chairman of the Board, Ascletis Bioscience Co., Ltd.

薛　群
Xue Qun
北海康成（北京）医药科技有限公司创建人、董事长及首席执行官
Founder, Chairman of the Board & CEO, CANbridge Life Sciences Ltd.

谢　东
Xie Dong
前沿生物药业（南京）股份有限公司董事长兼首席科学家
Chairman of the Board & CSO, Frontier Biotechnologies Inc.

桑会庆
Sang Huiqing
上海仁会生物制药股份有限公司董事长
Chairman of the Board, Shanghai Benemae Pharmaceutical Co., Ltd.

李翰明
Li Hanming
广东天普生化医药股份有限公司首席执行官
CEO, Techpool Bio-Pharma Co., Ltd.

郑立谋
Zheng Limou
厦门艾德生物医药科技股份有限公司董事长兼总经理
Chairman of the Board & CEO, Amoy Diagnostics Co., Ltd.

俞德超
Yu Dechao
信达生物制药（苏州）有限公司董事长兼总裁
Chairman of the Board & President, Innovent Biologics (Suzhou) Co., Ltd.

陈　力
Chen Li
华领医药技术（上海）有限公司创始人、首席执行官
Founder & CEO, Hua Medicine (Shanghai) Ltd.

杨大俊
Yang Dajun
亚盛医药董事长兼CEO
Chairman of the Board & CEO, Ascentage Pharma Group Corp., Limited

杜　莹
Du Ying
再鼎医药董事长兼首席执行官
Chairman of the Board & CEO, ZAI Lab (Shanghai) Co., Ltd.

王清梅
Wang Qingmei
和记黄埔医药（上海）有限公司资深副总裁
Senior Vice President, Hutchison MediPharma Limited

徐　霆
Xu Ting
苏州康宁杰瑞生物科技有限公司董事长兼CEO
Chairman of the Board & CEO, Suzhou Alphamab Co., Ltd.

江宁军
Jiang Ningjun
基石药业（苏州）有限公司首席执行官
CEO, CStone Pharmaceuticals Co., Ltd.

李怡平
Li Yiping
上海药明巨诺生物科技有限公司首席执行官
CEO, JW Therapeutics (Shanghai) Co., Ltd.

王印祥
Wang Yinxiang
北京加科思新药研发有限公司董事长
Chairman of the Board, Beijing Jacobio Pharma Co., Ltd.

崔霁松
Cui Jisong
北京诺诚健华医药科技有限公司总经理
General Manager, Beijing InnoCare Pharma Tech Co., Ltd.

吴晓滨
Wu Xiaobin
百济神州中国区总经理兼总裁
General Manager of China & President, BeiGene Ltd.

钟黎蕴华
Zhongli Yunhua
珐博进（中国）医药技术开发有限公司执行总裁
Managing Director, FibroGen (China) Medical Technology Development Co., Ltd.

房健民
Fang Jianmin
荣昌生物制药（烟台）有限公司总经理兼首席科学官
General Manager & Chief Scientific Officer, RemeGen, Ltd.

王思振
Wang Sizhen
北京泛生子基因科技有限公司首席执行官
CEO, Genetron Health (Beijing) Co., Ltd.

赵　宏
Zhao Hong
赛生医药江苏有限公司首席执行官兼总裁
CEO & President, SciClone Pharmaceuticals (Jiangsu) Co., Ltd.

刘世高
Liu Shigao
上海复宏汉霖生物技术股份有限公司总裁兼首席执行官
President & CEO, Shanghai Henlius Biotech, Inc.

李　宁 Li Ning	上海君实生物医药科技股份有限公司总经理 General Manager, Shanghai Junshi Biosciences Co., Ltd.
周明东 Zhou Mingdong	上海泽生科技开发股份有限公司董事长、总经理 Chairman of the Board & CEO, Zensun (Shanghai) Sci & Tech Co., Ltd.
黄纯莹 Huang Chunying	东曜药业有限公司总经理 General Manager, TOT Biopharma Co., Ltd.
路　杨 Lu Yang	杭州阿诺生物医药科技有限公司首席执行官 CEO, Adlai Nortye Biopharma Co., Ltd.
梁文青 Liang Wenqing	长风药业股份有限公司首席执行官 CEO, CF Pharmtech, Inc.
高小明 Gao Xiaoming	合肥天麦生物科技发展有限公司董事长 Chairman of the Board, Hefei Tianmai Biotechnology Development Co., Ltd.
臧敬五 Zang Jingwu	天境生物科技（上海）有限公司首席执行官 CEO, I-Mab Biopharma Co., Ltd.
储慧斌 Chu Huibin	海捷投资控股集团首席合伙人 Chief Partner, Hiyield Investment Holding Group
易诺青 Yi Nuoqing	高瓴资本管理有限公司合伙人 Partner, Hillhouse Capital Management, Ltd.
李凯军 Li Kaijun	上海醴泽投资管理有限公司管理合伙人 Managing Partner, LYZZ Capital Advisors
朱晋桥 Zhu Jinqiao	深圳市倚锋投资管理企业（有限合伙）董事长 Chairman of the Board, Shenzhen Efung Venture Capital Co., Ltd.
陆潇波 Lu Xiaobo	红杉资本股权投资管理（天津）有限公司合伙人 Partner, Sequoia Capital Equity Investment Management (Tianjin) Co., Ltd.
梁颖宇 Liang Yingyu	启明维创创业投资管理（上海）有限公司主管合伙人 Managing Partner, Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd.
田　源 Tian Yuan	深圳前海元明资产管理有限公司创始合伙人 Founding Partner, Shenzhen Qianhai YuanMing Asset Management Co., Ltd.
易八贤 Yi Baxian	上海浦东科技投资有限公司管理合伙人兼副总裁 Managing Partner & Vice President, Shanghai Pudong Science and Technology Investment Co., Ltd.
胡雪峰 Hu Xuefeng	深圳市高特佳投资集团有限公司主管合伙人 Managing Partner, Shenzhen GTJA Investment Group Co., Ltd.
苑全红 Yuan Quanhong	上海建信股权投资管理有限公司总裁 CEO, Shanghai Jianxin Capital Management Co., Ltd.
李振福 Li Zhenfu	北京德福悦安投资顾问有限公司董事长 Chairman of the Board, GL Capital Group
居伟民 Ju Weimin	中投海外直接投资有限责任公司总经理 President, CIC Capital Co., Ltd.
尹　飞 Yin Fei	平安银行医疗健康文化旅游金融事业部总裁 President, Finance SBU of Healthcare Industries of Ping An Bank
陈　可 Chen Ke	广州博信股权投资基金管理股份有限公司总经理 General Manager, Boxin Fund Management Co., Ltd.
陈鹏辉 Chen Penghui	博远资本创始合伙人 Founding Partner, Biotrack Capital
钱龙海 Qian Longhai	第一创业证券股份有限公司董事、总裁 Director & President, First Capital Securities Co., Ltd.
姚江涛 Yao Jiangtao	中航信托股份有限公司董事长 Chairman of the Board, AVIC Trust Co., Ltd.
王晓滨 Wang Xiaobin	宝石花医疗健康投资控股集团有限公司副董事长 Vice Chairman, Gem Flower Healthcare Investment Holding Group Co., Ltd.
周　浩 Zhou Hao	方圆基金管理（香港）有限公司合伙人 Partner, Prudence Investment Management (Hong Kong) Limited
赵　群 Zhao Qun	苏州工业园区元禾原点创业投资管理有限公司合伙人 Partner, SIP Oriza Seed Fund Management Co., Ltd.
施　毅 Shi Yi	礼来投资咨询（上海）有限公司创始人及管理合伙人 Founder & Managing Partner, Lilly Asia Ventures

方　瑛
Fang Ying
北京枫海资本管理中心（有限合伙）创始合伙人兼CEO
Founding Partner & CEO, Beijing Maplesea Capital Management Center

张　莉
Zhang Li
鼎晖投资合伙人
Partner, CDH Investments

王　晖
Wang Hui
宁波弘晖股权投资合伙企业（有限合伙）管理及创始合伙人
Managing & Founding Partner, HighLight Capital

李宏丽
Li Hongli
交银国际控股有限公司企业融资及环球资本市场部联席主管
Co-head, BOCOM International Holdings Co., Ltd.

余世新
Yu Shixin
招商局海通贸易有限公司总经理
General Manager, China Merchants Hoi Tung Trading Co., Ltd.

周海冰
Zhou Haibing
北京大数长胜资产管理有限公司首席战略官
CSO, Beijing Great Numbers Asset Management Co., Ltd.

刘　浩
Liu Hao
浩悦资本有限公司创始人兼首席执行官
Founder & CEO, HaoYue Capital Ltd.

蔡大庆
Cai Daqing
珠海夏尔巴股权投资管理有限公司创始人/管理合伙人
Founder & Managing Partner, Sherpa Venture Capital

曹彦凌
Cao Yanling
博裕投资顾问有限公司董事总经理
Managing Director, BOYU Capital Advisory Co., Ltd.

李　明
Li Ming
泰福资本管理合伙人
Managing Partner, TF Capital

刘兵军
Liu Bingjun
国泰君安证券股份有限公司产业研究院院长
Dean, Industry Research Institute, Guotai Junan Securities Co., Ltd.

张蕾娣
Zhang Leidi
国寿股权投资有限公司董事总经理
Managing Director, China Life Private Equity Investment Co., Ltd.

郑效东
Zheng Xiaodong
上海东富龙科技股份有限公司董事长
Chairman of the Board, Shanghai Tofflon Science and Technology Co., Ltd.

王锦刚
Wang Jin'gang
北京科信必成医药科技发展有限公司总经理
General Manager, CoSci Med-Tech Co., Ltd.

张　丹
Zhang Dan
方恩（天津）医药发展有限公司董事长
Chairman of the Board, Fountain Medical (Tianjin) Co., Ltd.

李　革
Li Ge
无锡药明康德新药开发股份有限公司董事长兼首席执行官
Chairman of the Board & CEO, WuXi AppTec Co., Ltd.

李　靖
Li Jing
药渡经纬信息科技（北京）有限公司董事长
Chairman of the Board, Pharmacodia (Beijing) Co., Ltd.

谭凌实
Tan Lingshi
缔脉生物医药科技（上海）有限公司董事长兼首席执行官
Chairman of the Board & CEO, dMed Biopharmaceutical Company Limited

张天泽
Zhang Tianze
零氪科技（北京）有限公司首席执行官
CEO, LinkDoc Co., Ltd.

洪　浩
Hong Hao
凯莱英医药集团（天津）股份有限公司董事长兼首席执行官
Chairman of the Board & CEO, Asymchem Laboratories (Tianjin) Co., Ltd.

闻丹忆
Wen Danyi
上海立迪生物技术股份有限公司董事长兼执行总裁
Chairman of the Board & CEO, Shanghai LIDE Biotech Co., Ltd.

陈志红
Chen Zhihong
浙江九洲药业股份有限公司总经理
General Manager, Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

宋青春
Song Qingchun
北京春天医药科技发展有限公司总经理
General Manager, Proswell Medical Co., Ltd.

吴晓明
Wu Xiaoming
中国药科大学原校长
Former President, China Pharmaceutical University

高思华
Gao Sihua
北京中医药大学原校长
Former President, Beijing University of Chinese Medicine

吴春福
Wu Chunfu
沈阳药科大学党委书记
Secretary of the Party Committee, Shenyang Pharmaceutical University

刘俊义
Liu Junyi
北京大学药学院原院长
Former Dean, Peking University School of Pharmaceutical Sciences

陆伟跃
Lu Weiyue
复旦大学药学院党委书记
Secretary of the Party Committee, School of Pharmacy Fudan University

刘克良
Liu Keliang
中国人民解放军军事医学科学院毒物药物研究所原所长
Former Director, Institute of Pharmacology and Toxicology Academy of Military Medical Sciences

李卓荣
Li Zhuorong
中国医学科学院北京协和医学院医药生物技术研究所副所长
Deputy Director, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College

王拥军
Wang Yongjun
首都医科大学附属北京天坛医院常务副院长、党委副书记
Executive Deputy Dean & Deputy Secretary of the Party Committee, Beijing Tiantan Hospital, Capital Medical University

陈建峰
Chen Jianfeng
北京市纳微化结构药物工程技术研究中心，中国工程院秘书长，北京化工大学副校长，中国工程院院士
Beijing Nanostructured Drug Engineering & Technology Center, General Secretary of the Chinese Academy of Engineering, Vice President, Beijing University of Chemical Technology, Academician, Chinese Academy of Engineering

赵玉沛
Zhao Yupei
中国医学科学院北京协和医院院长
President, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

会员单位简介（排名不分先后）

Brief Introduction of PhIRDA Members

绿叶制药集团有限公司

Luye Pharma Group Co., Ltd.

绿叶制药集团（02186.HK）是绿叶生命科学集团旗下专业制药公司，以研发为基础，以创新和国际化为方向，致力于创新药物的研发和生产，是最早在国际主流市场进行临床试验并取得突破性进展的中国制药企业之一。公司在烟台、北京、南京、泸州和德国米斯巴赫设有生产基地，在中国、美国和欧洲设有研发中心，在香港、新加坡和马来西亚设有分支机构，全球员工近4000 名。

绿叶制药30 余个上市产品覆盖中枢神经、抗肿瘤、心血管、消化及代谢等治疗领域；业务遍及中国、美国、欧洲、澳洲、日韩等全球主要医药市场。绿叶制药建立了与国际接轨的研发体系，在微球、脂质体、透皮释药和皮下植入剂等新型给药系统领域处于国际先进水平。公司拥有丰富的在研产品线，多个创新制剂及创新药在海外开展不同阶段的注册临床研究，并已取得突破性进展。

Luye Pharma Group (02186.HK), an affiliate of Luye Life Sciences Group, is a R&D driven pharmaceutical company with innovation and globalization as its two strategic focuses.

Dedicated to R&D and manufacturing of innovative medications, the company is one of the first Chinese pharmaceutical companies to conduct clinical trials in major international markets.

The company has state-of-the-art production facilities in Yantai, Beijing, Nanjing, Luzhou and Miesbach, R&D centers located in China, the U.S. and Europe, as well as overseas branch offices in Hong Kong, Singapore and Malaysia with approximately 4,000 employees.

Luye Pharma focuses on four therapeutic areas—central nervous system、oncology cardiovascular and metabolism. The company has a portfolio of over 30 products. The business of Luye Pharma covers global main pharmaceutical markets including China, the U.S, Europe, Australia, Japan and South Korean. Luye Pharma has established a professional R&D system of international standard, and reached international level in the area of new drug delivery system technologies such as microspheres, liposome and TDS. Currently, Luye Pharma has multiple innovative preparations and drugs that are undergoing different stages of registry clinical studies in the U.S and EU.

上海复星医药（集团）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

上海复星医药（集团）股份有限公司（简称“复星医药”，股票代码：600196.SH，02196.HK）成立于1994年，是中国领先的医疗健康产业集团。复星医药以促进人类健康为使命，业务覆盖医疗健康全产业链，主要包括药品制造与研发、医疗服务、医疗器械与医学诊断、医药分销与零售。复星医药始终将自主创新作为企业发展的源动力，持续完善“仿创结合”的药品研发体系，在中国、美国、印度等建立了高效的国际化研发团队，形成全球联动的研发体系。复星医药拥有国家级企业技术中心，打造了高效的化学创新药平台、生物药平台、高价值仿制药平台及细胞免疫平台。目前，复星医药在血液系统、中枢神经系统、代谢及消化系统、抗感染、心血管、抗肿瘤等治疗领域均有产品在各自细分市场占据领先优势。

面向未来，复星医药将秉承“持续创新 乐享健康”的品牌理念，围绕未被满足的医疗需求，在“4 IN”（创新Innovation、国际化Internationalization、整合Integration、智能化Intelligentization）战略的指导下，秉承“内生式增长、外延式扩张、整合式发展”的发展模式，致力于成为全球主流医疗健康市场的一流企业。

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices and medical diagnosis, as well as pharmaceutical distribution and retail. Fosun Pharma always regards innovation as the driving force for its business growth. The company continuously optimized its pharmaceutical R&D system that integrates biosimilars and innovative drugs and has established international R&D teams in China, the United States, India, etc., forming a globally interactive R&D system. Fosun Pharma maintains a national recognized enterprise technology center and establishes innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform. At present, Fosun Pharma maintains the leading position with its core products in various therapeutic areas, including oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system and anti-infection. All products occupy the leading position in each market segment.

Looking forward, Fosun Pharma will adhere to the brand philosophy of “Innovation for Good Health”. Focusing on the unmet needs in the medical field, it will adhere to the development model of “organic growth, external expansion and integrated development” under the guidance of “4IN” strategy (Innovation, Internationalization, Integration, Intelligentization), striving to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market.

天士力控股集团

Tasly Holding Group

天士力控股集团，是以大健康产业为主线，以大生物医药产业为核心，以健康保健产业和健康服务业为两翼协同发展的高科技国际化大型企业集团。

天士力创建于1994年，从一个现代中药高科技成果的产业化开始，走上创新与发展之路。集团核心企业——天士力医药集团股份有限公司于2002年8月上市。天士力始终秉承“追求天人合一，提高生命质量”的企业理念，以及“创造健康，人人共享”的企业愿景，指导大健康产业的发展，努力使天士力成为大健康理念的倡导者、大健康产品的创造者、大健康管理方案的设计者、大健康文化的践行者。持续打造现代中药第一品牌、大健康产业领先品牌。现在已经构筑了天士力国际、天士力医药、天士力资本、天士力保健与健康管理、天士力教育五大产业体系。

天士力积极倡导大健康新理念，推动大健康社会体系的建设，即：树立大健康理念体系、普及大健康教育体系、创新大健康技术体系、发展大健康产业体系、完善大健康服务体系；围绕让人们“生得优、育得好、活得长、病得少、走得安”的目标，坚定发展大健康产业，为早日实现“健康中国”加油助力。

Tasly Holding Group is a technological and international enterprise that develops great health industry as it main business; great biological pharmaceutical industry as its core business; health care industry and health service industry as its supporting businesses.

Tasly was founded in 1994, starting from the industrialization of the TCM high-tech achievement, and it is on its way to innovate and develop great biological pharmaceutical industry. Tasly Pharmaceutical Co., Ltd. is the core enterprise of Tasly Holding Group, listed in August 2002. Tasly follows the philosophy of ‘To pursue harmonization between human and nature, to improve life quality’ and the mission of ‘To share the joy of health with all’. It strives to become the pioneer of great health concept, the creator of great health product, the designer of great health management program, and the practitioner of great health culture. Tasly is committed to build the best modern TCM brand, and to become a leading brand in great health industry. Five industrial systems have been constructed, including Tasly international business, Tasly pharmaceutical industry, Tasly capital, Tasly healthcare& health management, and Tasly education.

Tasly strives to promote the new concept of great health, and push forward the construction of great health social systems: to build up great health ideological system; to promote great health education system; to innovate great health technological system; to develop great health industrial system; to complete great health service system.

Aiming to achieve the goal of ‘optimized birth, quality life, prolonged life, delayed diseases, and pacified leave’, Tasly will firmly develop the great health industry and make unremitting efforts for the early realization of Healthy China.

江苏恒瑞医药股份有限公司

Jiangsu Hengrui Medicine Co., Ltd.

江苏恒瑞医药股份有限公司始建于 1970 年，2000 年在上海证券交易所上市。公司以“科研为本，创造健康生活”为理念，坚持“质量第一，诚信经营”为原则，目前已发展成为国内最大的抗肿瘤药、手术药物的研究和生产基地，国家“重大新药创制”专项孵化器基地、国家抗肿瘤药技术创新产学研联盟牵头单位、国内最具创新能力的制药企业之一，同时也是国家重点高新技术企业、国家高技术研究发展计划（863计划）成果产业化基地，建有国家靶向药物工程技术研究中心、国家博士后科研工作站。公司在美国、欧洲、日本和中国多地建有研发中心或分支机构，全球员工15000人，目前各类研发人员2500多人，其中有1500多名博士、硕士及100多名海归人士，有2人被列入国家“千人计划”，每年科研经费占销售额的 10%左右。近年来，公司先后承担了 4 项国家 863 计划重大科技专项项目、30项国家“重大新药创制”专项，共申请了400多项发明专利，其中 140多项全球专利（PCT 专利），有 3个创新药艾瑞昔布、阿帕替尼和硫培非格司亭已获批上市，另有一批创新药处于不同的临床阶段。公司注射剂、口服制剂和吸入性麻醉剂先后通过美国FDA和欧盟认证，在海外主流市场销售，成为唯一一家将注射剂规模化销往欧美日市场的中国制药企业。公司将继续致力于让中国老百姓以合理的价格用上国际先进品质的药品。

Jiangsu Hengrui Medicine Co., Ltd., established in 1970 and listed in Shanghai Stock Exchange in 2000, holding the idea of “create a healthy life based on science and research” and philosophy of “quality first, integrity management”, is the largest research and manufacturing base of antineoplastics and surgical medicine in China as well as the special incubator base for “New Drug Development”. Known as the lead of National Anti-tumor Medicine Production Technology Innovation Alliance, one of the most innovative pharmaceutical enterprises, Jiangsu Hengrui Medicine is also the National Key High-tech Enterprise and industrialization base of National Science and Technology Major Project (863 Project), which has a national engineering technology research center of targeted drugs and National Post-doctoral Scientific Research Workstation.

Hengrui Medicine has constituted a thorough innovation system with R&D centers and clinic departments in American, Europe, Japan and China, wit h 15,000 employees worldwide. Now Hengrui Medicine is equipped with a R&D team of more than 2500, among which more than 1500 professional s with phD and master degree, and 100 overseas talent, two of them belongs to Recruitment Program of Global Experts. Scientific research funds occupy more than 10% of sales every year. In recent years, Hengrui undertakes four projects of National Science and Technology Major Project (863 Project) and 30 projects has been placed to “Major New Drug Development”. About 400 patents for invention have been applied, among which 140 are global patent (PCT). The innovative drug Imrecoxib, Apatinib and Mecapegfilgrastim have been approved for marketing; another batch innovative drugs are in different stages of clinical research. Over the last three years, injection drug, oral preparation and anesthesia inhalation have been certified by U.S. FDA and EU, and sold in overseas market. Therefore, Hengrui becomes the first national pharmaceutical enterprise which penetrates into U.S. and European markets with domestic injection products. Jiangsu Hengrui Co., Ltd. will continue to devote itself to making Chinese people be available of advanced international standard drugs with reasonable price.

中国科学院上海药物研究所

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

中国科学院上海药物研究所是我国历史最悠久的综合性药物研究机构。其前身是国立北平研究院药物研究所，创建于1932年，首任所长为赵承嘏。1933年南迁上海， 2003年落户浦东张江高科技园区。

建所以来，上海药物所秉承着“寻找治疗疾病的新药，为人民解除病痛”的办所宗旨，共研制开发新药100余种并投入生产，创制了蒿甲醚、二巯基丁二酸、石杉碱甲等一批在国内外具有影响的创新药物。近年来又研制了现代中药丹参多酚酸盐、抗菌新药盐酸安妥沙星等新药，另有一批新药正处于临床研究阶段。

自中国科学院开展“知识创新工程”以来，上海药物所确立了“出新药”战略，瞄准国际生命科学发展的前沿领域以及药物研究的重要科学问题，开展创新药物基础和应用基础研究，发展药物研究新理论、新方法和新技术。

重点围绕治疗恶性肿瘤、心脑血管系统疾病、神经精神系统疾病、代谢性疾病、自身免疫性疾病及感染性疾病等开展新药研发，并加强现代中药的研发。

经过几代人的努力，上海药物所已发展成为学科齐全、成就卓著、人才荟萃、在国内外享有较高声誉的综合性创新药物研究机构。

Shanghai Institute of Materia Medica (hereafter referred as SIMM), Chinese Academy of Sciences (hereafter referred as CAS), has the longest history as a comprehensive research institution for drug discovery in China. SIMM was evolved from Peking Institute of Materia Medica, Academia Sinica, founded in 1932 by Professor Chenggu Zhao (T. Q. Chou). It was relocated to Wukang Road, Shanghai in 1933, then to Yueyang Road in 1953, and settled down in Zhang Jiang Hi-Tech Park, Pudong New District in 2003.

In line with the mission of “Discovering new drugs to relieve patients suffering from various diseases”, SIMM has developed and commercialized over 100 new drugs. Among them, a number of innovative drugs such as Artemether, Dimercaptosuccinic acid, and Huperzine A gained recognition both home and abroad. Recent years have witnessed the development of some novel drugs from SIMM, including Depsides salts, a modern Traditional Chinese Medicine (TCM), and Antofloxacin Hydrochloride, a novel fluoroquinolone antibacterial agent. SIMM has currently a number of candidates in clinical stages.

Since the implementation of the Knowledge Innovation Program of CAS, developing novel drugs has become a paramount research focus of SIMM in recent years. In line with frontiers in life sciences and aiming at solving key scientific problems in drug discovery, SIMM carries out both basic and applied studies and develops new theories, methods and technologies. Research priorities are given to treat major diseases, such as cancer, cardio-cerebrovascular disease, neuropsychiatric disease, metabolic disease, autoimmune disease, and infectious disease. SIMM pays also attention to the development of modern Traditional Chinese Medicine (TCM).

Through several generations’ efforts, SIMM has become one of the leading interdisciplinary centers of excellence in China. It is recognized worldwide by its outstanding achievements and distinguished research team.

贝达药业股份有限公司

Betta Pharmaceutical Co., Ltd.

贝达药业股份有限公司是一家由海归博士团队创办的、以自主知识产权创新药物研究和开发为核心，集研发、生产、营销于一体的国家级高新技术企业。公司现有员工1000余人，归国博士20多位，其中5位入选国家“千人计划”。2016年11月7日，公司在深交所创业板成功挂牌上市。

贝达历时近十年研发我国首个小分子靶向抗癌药“埃克替尼”（商品名：凯美纳），于2011年获批上市，填补了国内空白，打破进口药的垄断，被誉为民生领域的“两弹一星”。2014年，埃克替尼获批用于晚期非小细胞肺癌的一线治疗。上市6年来，埃克替尼已惠及16万余名肺癌患者，累计销售近50亿元，免费赠药累计314万盒，市场价值70多亿元，取得了非常好的经济和社会效益。先后获国家科技进步一等奖、中国工业大奖等荣誉。

贝达建立了完整的新药研发体系，在杭州、北京和美国分别设有新药研发中心，现有在研创新药30余项，其8项进入临床试验。并先后与美国安进、Xcovery、Tynogenex、Capio等国内外领先制药企业达成战略合作，致力于创新药物的研发，努力为百姓研制更多用得起的好药。

Betta Pharmaceuticals Co., Ltd. was founded by a group of overseas returnees and is mainly developing innovative therapeutics, including R&D, manufacturing and marketing. Currently, Betta has more than 1000 employees, including over 20 Ph.D.s returning from overseas and 5 “Thousand Talent” members. On Nov. 7, 2016, Betta was listed on Shenzhen Stock Exchange.

After nearly 10-year R&D, Betta has successfully marketed a oncology innovative drug – icotinib hydrochloride (Conmana®), which was approved by China Food and Drug Administration (CFDA) in 2011. In Nov, 2014, icotinib was approved by the CFDA as the first-line treatment for the non-small cell lung cancer patients. Since icotinib’s launch, it has benefited more than 160,000 lung cancer patients; the accumulated sales has been reached nearly 5,000,000,000; the number of free drug donation boxes has surpassed 3,140,000; the market value has reached more than 7,000,000,000, which generates great economic value and wins good social reputation. In addition, icotinib also wins many honors, such as the 1st prize of National Science and Technology Progress Award and China Industry Award.

Betta has successfully established completed new drug R&D system, and has new drug research centers in Hangzhou, Beijing and the United States respectively. Moreover, Betta cooperates with Amgen, Xcovery, Tyrogenex, Capio and other leading pharmaceutical companies home and abroad, and try to reasearch and develop more new drug which can benefit more patients.

中国医学科学院药物研究所

Institute of Materia Medica, Chinese Academy of Medical Sciences

中国医学科学院药物研究所（以下简称“药物所”）成立于1958年，隶属于中国医学科学院北京协和医学院。

药物所始终以寻找和研究防治严重危害人民健康的常见病、多发病及疑难疾病的药物为主要方向，坚持以创制具有自主知识产权的新药为重点，是国家重点药物研究机构之一，采用现代医药学理论和高新技术开展多学科综合性研究，旨在走出有中国特色的新药创制之路。药物所主要研究方向包括抗肿瘤药物、防治心脑血管疾病药物、治疗神经精神类疾病药物、抗代谢紊乱药物、抗感染药物、抗炎免疫类药物、治疗老年退行性疾病药物等。

药物所现建有1个国家重点实验室，即天然药物活性物质与功能国家重点实验室；7个省部级重点实验室和国家药物及代谢产物分析研究中心、国家新药开发工程技术研究中心、国家药物筛选中心、中国医学科学院北京协和医学院新药安全评价中心、药物所药物晶型研究中心。“十一五”以来，国家“新药创制”重大专项在药物研究所建立了包括综合大平台在内的多个技术平台,有效地增进了研究所的研究能力。自建所以来，药物所作为第一完成单位共获得国家级奖31项；持有的有效专利700余项，获得授权的国内外专利344项；共编写著作354本。近年来，药物所发表论文质量取得明显提升，2016年以第一完成单位发表SCI论文 188篇。

药物所与国内及美国、法国、日本、德国、西班牙、加拿大等国家和地区的制药公司、大学、科研机构、全球非营利性组织建立了密切的协作关系，进行了广泛的科技合作和学术交流。自1989年开始，药物所还与新疆维吾尔自治区药物研究所（简称新疆药物所）建立了横向合作关系，新疆药物所挂牌为“中国医学科学院药物研究所新疆分所”，共同为推动新疆民族医药事业的发展而努力。

药物所还负责编辑出版《药学学报》、Chinese Chemical Letters（CCL，中国化学快报）、Journal of Asian Natural Products Research（JANPR，亚洲天然产物研究）及Acta Pharmaceutica Sinica B （APSB，《药学学报》英文刊）四种学术期刊；其中CCL和JANPR为SCI收录杂志，APSB被Medline及ESCI等收录，《药学学报》成为青蒿素诺贝尔奖获奖奠基论文的发表杂志。

药物所人始终以“献身、创新、求实、协作”的精神为指引，勤奋钻研、刻苦攻关、与时俱进、继往开来，努力为我国医药卫生事业的可持续发展，为创造社会效益和增强人类健康贡献力量。

The Institute of Materia Medica (IMM) at CAMS and PUMC was founded in 1958. Its mandate is to discover and research innovative drugs for treating or preventing human diseases. IMM's scientists use the latest biomedical theories, cutting-edge technologies, and state-of-the-art clinical resources to develop drugs from botanic compounds, synthetic chemicals, and bioproducts.

Principle drug research efforts at IMM focus on cancer, cardiovascular diseases, neurodegenerative and psychiatric diseases, metabolic disorders, infectious diseases, and inflammation. IMM researchers have made significant contributions in phytochemistry, analytic chemistry, computer-aided drug design, molecular pharmacology, high-throughput screening, synthetic biology, and drug-delivery systems, and have had notable successes developing new drugs that serve patients in China and abroad.

The institute hosts a State Key Laboratory of Bioactive Substance and Function of Natural Medicines and seven Ministry-level Key Laboratories. The departments in IMM include: Synthetic Medicinal Chemistry, Natural Medicinal Chemistry, Pharmacology, Pharmaceutical Analysis, Biosynthesis, Drug Screening, Polymorphic Drugs, Drug Delivery Systems, Drug Metabolism, and New Drug Research and Development. The Comprehensive Drug Platform funded by the National Science and Technology Project for Major New Drug Innovation and Development is one of the very few state drug programs established by the central government in China. Establishment of such programs has significantly enhanced IMM's research capabilities.

The institute has 495 staff and faculty members, of whom 123 are full or associate professors and 62 are principle investigators. Five scientists are academicians of the Chinese Academy of Sciences or the Chinese Academy of Engineering. IMM is housed on the main campus of the PUMC School of Pharmacy and provides training for senior pharmaceutical professionals and postdoctoral scientists. The Ministry of Education has classified Pharmaceutical Sciences at IMM as a National Key Discipline in Medicine. IMM currently has more than 380 graduate students and has graduated 1,488 students to date, granting 782 doctoral and 706 Master's degrees.

Since the institute's establishment, its scientists have discovered or developed hundreds of new drugs and acquired 130 new drug certificates from the China FDA, including numerous innovative drugs such as butylphthalide, bicyclol and imrecoxib. IMM's contributors have won 286 awards from the government and professional societies for drug research and development, including 13 at the national level. Notably, IMM won the first prize in the 2015 National Scientific and Technological Progress Awards for its research on creating an artificial musk. IMM has published 7,777 academic papers and 349 monographs, and holds 277 approved patents.

IMM stresses translational research and development, and has two wholly owned enterprises: Beijing Union Pharmaceutical Factory and Beijing Union Second Pharmaceutical Factory. It is also the major shareholder of Beijing LianXin Pharmaceutical Co., Ltd.; Beijing Union-Genius Pharmaceutical Technology Co., Ltd.; and Beijing Collab Pharma Co., Ltd.

IMM has established extensive partnerships and collaborations with pharmaceutical companies, universities, and research institutes worldwide, including in the United States, France, Japan, Germany, Spain, and Canada.

IMM hosts the editorial offices of four scientific journals: Acta Pharmaceutica Sinica, Chinese Chemical Letters, the Journal of Asian Natural Products Research, and Acta Pharmaceutica Sinica B. In the spirit of its motto, “Devotion, Innovation, truth-seeking, and Cooperation,” staff and faculty at IMM look forward to continuing their tradition of excellence in research, creating a sustainable future for Chinese medicine and the Chinese health care industry.

天津中医药大学

Tianjin University of Traditional Chinese Medcine

天津中医药大学始建于1958年。学校建有中医学、中药学、中西医结合3个博士后科研流动站，中医学、中药学、中西医结合3个一级博士点，25个二级博士点和46个二级硕士点，25个本科专业。学校在校生达12000人，其中留学生达到2000人。学校拥有6所附属医院，共有4000张床位，年门诊量400余万人。

学校现拥有中医内科学和针灸推拿学国家级重点学科2个、28个省部级重点学科，2个国家级实验室，中意中医药联合实验室，23个省部级重点实验室，3个省部级工程中心。

学校以“进德修业，继承创新”为校训，以重点学科建设和中医药对外教育为特色，以科学研究为优势，以中医药学为主，医、理、文、管、工、教育等多学科协调发展。坚持“传承与创新协同，科研与服务并举，以质量求内涵，全面协调发展”方针，建设高层次、外向型、国内一流、国际知名的教学研究型中医药大学。

Tianjin University of Traditional Chinese Medicine was founded in 1958. The school has three post doctoral research stations, three primary doctoral disciplines (Chinese medicine, Chinese materia medica and integrative of Chinese and western medicine), 25 secondary doctoral disciplines, 46 secondary master disciplines and 25 undergraduate professionals. There are more than 12000 students, including about 2000 overseas students. The school also has 6 affiliated hospitals, which have 4000 beds and more than 4 million outpatient services.

The school has two national key discipline and specialties (internal medicine of TCM and acupuncture) and 28 provincial or ministerial level key discipline and specialties. There are also two national level laboratories, two Sino-Italian joint laboratories of TCM, 23 provincial or ministerial key laboratories and 3 provincial engineering centers.

The school motto is "improve the virtue and refine the achievements, inheritance and innovation". This school takes key disciplinary building-up and education for foreign students as its characteristic and has the advantage of scientific research on TCM, Besides TCM, other disciplines including medicine, science and engineering, literature, management and education develop in phase.

石药控股集团有限公司
CSPC Holdings Company Limited

石药控股集团有限公司建于1938年5月，现有资产总额320亿元，员工2200人。在港上市公司（01093.HK）市值1500亿港币，是香港知名医药上市企业之一，也是香港恒生红筹股指数成份股。

石药集团主要从事医药产品的开发、生产和销售。产品包括心脑血管、抗生素、维生素、解热镇痛、消化系统用药、抗肿瘤用药等七大系列近千个品种，有30多个产品单品种销售过亿元，产品销售遍及全国和世界100多个国家和地区。

石药集团是“国家级创新型企业”，新药研发实力位居全国制药企业最前列。目前集团在研新药项目200个，涉及心脑血管、精神神经、内分泌、抗肿瘤等领域。集团成功上市的具有自主知识产权的一类新药“恩必普”是脑卒中治疗领域的全球领先药物，在全球86个国家受到专利保护。创新药的研发和快速成长推动企业实现了转型升级，原料药、成药的销售比重由原来的7:3转变为3:7，石药集团成为国内传统药企成功实现“主动转型”的典范。

为追求卓越，迈向高端，石药集团对标国际高端制药标准，持续提升产品质量的内涵。截至目前，集团旗下所有药品都通过了新版GMP认证，此外，共取得了16张CEP证书和33个DMF登记号，有30个产品顺利通过美国FDA现场检查。另一方面，企业加大了在美国、欧盟地区注册非专利药的力度，已经有盐酸曲马多片、二甲双胍片等14个产品在美国批准并上市。与此同时，石药集团在美国建立了研发实验室，多个药物正在美国开展临床试验，未来，将陆续有更多的新药产品在欧美等国际高端市场上市销售。

CSPC holding company limited has been founded from May,1938 with total assets of 32 billion RMB, approximately 22,000 staff members. CSPC is one of HK's well known listed Pharmaceutical companies and also one of Hang Seng red-Chips Index Component stocks, whose market value over 150 billion HK dollars.

CSPC is mainly engaged in the development, production and sales of pharmaceutical products. Its key products content nearly 1,000 varieties of 7 series in cardiovascular and cerebrovascular, antibiotic, vitamin, xanthine, digest system and anti-tumor. 30 more varieties have been achieved sales volumes over 100 million RMB, meanwhile, the products are sold throughout China and over 100 countries and regions in the world.

CSPC is a “National Innovative Enterprise”. The R&D ability of new drugs is far ahead among the pharmaceutical companies in China. CSPC currently holds 200 new drug researching projects, involving cardiovascular and cerebrovascular, nervous system, anti-tumor, endocrine and other fields. NBP, a successfully promoted National Class I drug, is the third with independent intellectual property rights and it is also protected in 86 countries around the world. The development and rapid growth of innovative drugs accelerate the upgrading pace of CSPC. The proportion of API and Finished product changes from original 7:3 to 3:7 and CSPC become a model of domestic pharmaceutical enterprises which is successfully realized “initiative transformation”.

In search of excellence and high-end, CSPC has been continuously improving the products quality to meet the international high standard of manufacture. Up to now, all products of CSPC group have successfully passed the new GMP certification. Besides, CSPC has obtained 16 CEP certificates and 33 DMF registration numbers, and 30 products pass the on-site inspection of FDA. On the other hand, CSPC put strength in the registrations of non-patent drugs in the US, Europe and other countries. Now, 14 products such as tramadol hydrochloride tablets and diformin tablets have been on the market in the US. Meanwhile, a new R&D lab has been set up in America and varieties of drugs have been on clinical trials. This symbolizes that products from CSPC is able to compete in the international high-end market and can be sold directly in the US pharmacies, and also symbolizes the quality of CSPC products has reached at the international advanced level.

先声药业有限公司

Simcere Pharmaceutical Group

先声药业成立于1995年，当时是仅有几十名员工、注册资金200多万元的小型药品经销公司。经过二十年的发展，先声药业已发展成为集生产、研发、销售为一体，拥有5家通过GMP认证的现代化药品生产企业，2家全国性的药品营销企业、1家药物研究院，拥有员工4200余人的新型药业集团。

目前，先声药业拥有45种以上药品的强大产品组合，重点覆盖抗肿瘤、心脑血管、感染等疾病治疗领域。并拥有“先声®”“必存®”“再林®”“英太青®”四个“中国驰名商标”。

先声药业一直致力于新药创新开发，每年将销售额的8%～12%用于新药研发，2007年以来，先声药业共计申请发明专利359项；获中国授权发明专利200多项，国外授权专利近20项，近年来承担10多项国家“重大新药创制”项目。先声药业先后获得“国家科学技术发明二等奖”和“国家科学技术进步二等奖”各1次。从2014年开始，启动“精准医疗百家汇”创新项目，旨在通过开放的商业创新模式，建立协同创新和完全市场化的开放运行机制，加快公司的创新开发。

先声药业于2003 年获准设立国家企业博士后工作站，2005 年批准成立“国家认定企业技术中心”；2008 年批准设立“江苏省抗肿瘤分子靶向药物重点实验室”；2009年各生产企业重新被认定为“国家高新技术企业”；2009 年获准设立“江苏省企业院士工作站”；2015年批准成立“转化医学与创新药物国家重点实验室”。

2010 年11 月，跨国公司百时美施贵宝与先声药业同时宣布开展抗肿瘤药领域的国际合作研发，此后先声走上了国际合作开发新药的道路。2011年先声的必奇原料和制剂产品通过欧盟GMP 认证，标志着先声质量管理水平提升到了一个新的高度。

2010年以来，先声药业有近10个一类创新药进入和即将进入临床研究阶段。先声药业近几年均被中国医药信息中心和南方所评为“中国最具创新力的企业”。

Founded in 1995, Simcere was a small medicine distribution company with just handful persons and registered capital of 2 million Yuan. 20 years later, Simcere has become a new pharmaceutical group which can manufacture, R&D and promote medicines. Simcere owns 5 GMP modern manufacturing plants, 2 national medicine promoting companies, 1 R&D institution, and over 4200 employees.

Currently Over 50 branded drugs of Simcere are in production and available on market, of which therapeutic areas focus on oncology, neuroscience, infectious diseases and rheumatoid arthritis.We have four China Well-known Trademarks: "Simcere""Bicun""Zailin" and "Yingtaiqing".

Simcere has been committed to researching developing new drugs and have invested 8% to 12% of sales revenue each year for new drug research and development.Since 2007, Simcere had totally applied for 359 invention patents, have gained more than 200 Chinese invention patents and nearly 20 foreign licensing patents.In recent years, we undertook more than 10 National Major New Drug Discovery projects and obtained the Second place of both "National Science and Technology Invention Award" and" National Science and Technology Progress Award".Since 2014, To speed up the innovation, Simcere started an innovation project called BioSciKin, in order to build an open mechanism to comply with innovation and the market though an open business innovation model.

Simcere was authorized to build National Enterprise Postdoctoral Workstation in 2003 and National Enterprise Technology Center in 2005. In 2008, we were approved to build Jiangsu Provincial Key Laboratory of Anti-tumor Molecular Targeted Drugs. In 2009, all 5 production enterprises of Simcere were assessed as National High and New Technology Enterprises and allowed to build the Jiangsu Provincial Enterprise Academician Workstation.In 2015,Our laboratory of Translational Medicine and Innovative Drug was admitted as State Key Laboratory.

In November 2010,Simcere and multinational company BMS announced to develop a R&D partnership in oncology at the same time. In 2011,Simcere's branded antidiarrheal drug Biqi API and formulation product passed the Eu-GMP inspection, which means QA of Simcere has reached a new level.

Since 2010, Simcere has nearly 10 State Class I New Medicine enter or be about to enter the clinical research stage. And Simcere has been named as The Most Innovative Companies by China Medical Information Center and Southern Medicine Economic Research Institute.

上海医药集团股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.

上海医药集团股份有限公司（以下简称“上海医药”或“公司”）是沪港两地上市的大型医药产业集团。公司主营业务覆盖医药研发与制造、分销与零售，2017年营业收入1308亿元，综合排名位居全国前列，入选上证180指数、沪深300指数样本股、恒生指数成分股、摩根斯坦利中国指数（MSCI）。

上海医药重视研发创新，坚持仿创并举，致力于为重大疾病和慢性病提供安全有效的治疗药物，通过中央研究院与分院、国家级企业技术中心以及10个省市级企业技术中心、海外研发中心建立起互动一体化的研发体系。公司合作完成的两个项目分获2014、2015 年国家科技进步一等奖。公司采用开放式研究模式，与各大科研院所等合作开展创新药物研发。

上海医药制造覆盖化学和生物药品、现代中药和保健品、医疗器械等领域，产品聚焦五大治疗领域，过亿产品28个。公司旗下拥有多个中国驰名商标。公司所有药品生产企业全部通过新版GMP 认证，并全面实施精益六西格玛管理，积极推进两化融合。公司有多个原料药或制剂通过了WHO、FDA、欧盟以及其他发达国家的质量认证。

上海医药分销业务规模位列全国前三。公司在院内供应链延伸服务、第三方物流服务、药品直送服务、进口药品一站式服务、药库信息化管理和临床支持服务等创新业务模式方面处于国内领先水平。

上海医药药品零售销售规模居全国药品零售行业前列，上海华氏大药房拥有药房的数量在华东地区名列前茅，门店覆盖全国16个省、直辖市及自治区，门店总数近1900 家，有国内最大新特药DTP服务网络。旗下上海医药云健康致力于打造以电子处方流转为基础的创新医药电商模式。

公司倡导“创新、诚信、合作、包容、责任”的企业核心价值观，致力于持之以恒，提升民众的健康生活品质，努力打造受人尊敬、拥有行业美誉度的领先品牌药制造商和健康领域服务商。

Shanghai Pharmaceuticals Holding Co., Ltd.(referred to as “Shanghai Pharma” or “SPH”), is a large pharmaceutical group with dual listings in Shanghai and Hong Kong’s stock exchanges. The company’s core business covers pharmaceutical R&D, manufacturing, distribution and retailing. In 2017, the company reported a total revenue of RMB 130.8 billion, making it one of the major forces in the industry in China. It is included in the sample stocks of both the SSE 180 and CSI 300 indexes, and also selected into the Hang Seng Index Compositional Stocks and MSCI.

Shanghai Pharma’s Research & Development team is dedicated to providing innovative, safe and effective drugs against serious and chronic diseases. The company has set up an R&D system with a Central Research Institute as a technical core. SPH owns one state-level, ten provincial/city-level Corporate Technology Centers and overseas R&D center. In 2014 and 2015, two cooperative projects won the First Class National Scientific and Technological Progress Award. SPH has adopted an open R&D philosophy. As a result, we have built strategic alliances in R&D with both research institutions and corporations, in order to develop innovative drugs.

Shanghai Pharma’s manufacturing business provides products ranging from chemicals and bio-pharms to modern Chinese medicine, healthcare products and medical devices. We are focused on five major therapeutic areas.28 products have annual sales revenues of over RMB 100 million. SPH manages a number of renowned trademarked Chinese brands. All our production lines have passed the new GMP certification. The company has implemented a Lean Management system, optimized production and conducted pilot programs to integrate information technology and industrialization. A number of our APIs and preparations have passed quality authentications from the WHO, FDA, EU and other developed countries.

Shanghai Pharma’s distribution network covers the whole Chinese territory. Our distribution system is the third largest in size nationwide. In China, The Company is in a leading position in terms of innovative business model, such as, supply chain extension service within hospitals, the third-party logistics service, direct-delivery drug service, one-stop service for imported drugs, information management of drug stocks, and clinical support service.

Shanghai Pharma is one of the top pharmaceutical retailers in China in terms of sales revenue. Our Huashi Pharmacy is one of the largest drugstore chains in Eastern China with about 1900 locations covering 16 provinces, autonomous regions and municipalities. The company has the largest new drug and miracle drug DTP service network. SPH Health Cloud is building an e-commerce platform of prescription drug.

With a solid foundation anchored in our core values – innovation, integrity, cooperation, inclusiveness and responsibility – Shanghai Pharma is continuously dedicated to the providing a healthier life to the general public, while striving to be recognized as a respected manufacturer of leading pharmaceutical brands, as well as a healthcare services provider with a stellar reputation.

成都康弘药业集团股份有限公司

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

成都康弘药业集团股份有限公司（以下简称康弘药业）是一家致力于中成药、化学药及生物制品的研发、生产、销售及传播服务的医药集团，总部位于四川省成都市，销售网络遍布全国。

康弘药业坚持以专业、创新、国际化为核心发展战略，开创了“聚焦领域 - 需求导向 - 深入研究 - 专利新药 - 规范生产 - 专业营销”六位一体的独特经营模式，完成了在中枢神经系统、消化系统、眼科及其他等重点临床领域具有“康弘特色”的产品布局。

康弘药业的核心竞争力来源于长远战略布局和持续专业创新能力，研发投入远高于行业平均水平，且正向国际平均水平靠拢。依托国家认定企业技术中心、国家级博士后科研工作站以及四川省重点实验室，康弘药业建立了多个创新平台，承担了11项国家级课题；现已获授权专利100余项，其中30余项为国际专利。

2009年，商标被国家工商总局认定为“中国驰名商标”。2010年，康弘药业被国家知识产权局列入“全国企事业知识产权试点单位”；2011年，被中国化学工业协会评为“中国化学制药行业创新型企业品牌十强”；2012年，被国家科技部、国务院国资委、中华全国总工会列入国家第五批“创新型试点企业”。

康弘药业将不断努力研制专业创新的医药产品，促进人类健康事业的进步，努力成为中国最杰出的药业集团之一。

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a modern medicinal enterprise located in Chengdu, China. Kanghong’s core business is to develop, manufacture, market and promote innovative medicine including Traditional Chinese Medicine, small molecule and biologic drugs.

Kanghong, always maintaining development strategy as profession, innovation and internationalization, created a distinctive business model as core therapy areas focused, demand oriented, research in-depth, patent drug, manufacture standardized and professional marketing. Kanghong has set up a product layout of Kanghong’s own characteristics in C.N.S, digestive system, ophthalmology and others.

The core competitiveness of Kanghong is the ability of long term strategic layout and sustained professional innovation. Kanghong has established several innovative platform including the National-level Enterprise Technology Center, the National Post-doctoral Scientific Research Workstation, Key Laboratory of Sichuan Province and so on. Until now, Kanghong has authorized more than 100 patents, among which there are more than 30 foreign patents.

Since the establishment of the Kanghong, it has received wide-spread identity from various levels of government, clients and consumers from all walks of life. We are the only corporation in Sichuan province that has been awarded“National Pilot Innovative Corporation”in 2012. We are National Experimental Enterprise for Intellectual Property. The Kanghong trade mark is awarded“Famous Trade Mark of China”.

Kanghong will always focused on developing and researching innovative medicine to promote human health and to becoming one of the most outstanding Chinese pharmaceutical enterprise.

扬子江药业集团

Yangtze River Pharmaceutical Group

扬子江药业集团创建于1971年，是一家跨地区、产学研相结合、科工贸一体化的国家大型医药企业集团，也是科技部命名的全国首批创新型企业。集团总部位于江苏省泰州市，旗下20多家成员公司分布北京、上海、南京、广州、成都、苏州、常州等地；营销网络覆盖全国各省、市、自治区。

多年来，集团始终秉承“求索进取，护佑众生”的理念，践行“高质 惠民创新 至善”核心价值观。企业综合经济效益自1996年起，连续十多年排名江苏省和全国医药行业前列，并跻身“中国企业500强”、“中国民营企业500强”、“全国纳税500强”。据国家工信部公布的数据，扬子江药业集团有限公司主营业务收入名列2014年度中国医药工业百强榜首位。

集团坚持以创新引领发展，加快实施“三药并举”研发创新战略。依托产学研联合建成设施一流的江苏省（扬子江）新药研究院，拥有国家级企业技术中心、药物制剂新技术国家重点实验室、中药国家工程研究中心等创新研发平台。经过多年的持续积累和创新，产品体系中西药并举，覆盖10多个领域、20多种剂型、200多个品规。

集团视质量为企业的生命。现有20多个产品被评为“江苏省名牌产品”，11个产品获“中国名优产品”称号，9个产品被列入“国家中药保护品种”，2个产品获“国家科技进步二等奖”；另有4个车间（6个产品）已通过欧盟GMP认证。集团自2005年以来蝉联全国医药行业QC成果评比一等奖总数“十一连冠”，并被中国食品药品检定研究院、江苏省食品药品监督管理局指定为“实训基地”。

面向未来，奋进中的扬子江药业集团以振兴民族医药为己任，怀着科学、严谨、负责的态度，竭诚为全人类的健康服务，努力向世界一流制药企业的目标迈进。

Established in 1971, YRPG is a large cross-regional pharmaceutical group that features industry-university-institute cooperation and integrates scientific research, industrial production and sale. It is among the first group of Innovative Enterprises named by the Ministry of Science and Technology. Headquartered in Taizhou (Jiangsu Province), The sales network spans all of China. YRPG has over 20 subsidiary companies.

Since its inception, YRPG follows its philosophy of "seeking progress at all times and safeguarding all human beings" and principle of "benefiting the general public through quality products and innovation". Since 1996, the group's overall economic strength has topped the list of pharmaceutical industry in Jiangsu as well as in China. According to figures from the Ministry of Industry and Information, YRPG's prime operating income was among the top three of the Chinese pharmaceutical companies since 2009.

YRGP upholds the principle of developing through innovation,. It is now stepping up the R&D strategy of "three medicines in one go". it has built the Jiangsu (YRPG) New Medicine Institute through industry-university-institution cooperation.Its R&D platforms include a nation-level class enterprise technological center, a key state-level laboratory of pharmaceutical preparation,and an engineering R&D center for traditional Chinese medicine.With these platforms .Through years of work, its products include both Chinese and Western medicines, encompassing over 10 fields, 20 preparations and 200 sizes for medicine.

YRPG sees quality as the life of our company. It now has over 20 products awarded "Jiangsu Well-known Brands", 11 "Chinese Excellent Products" and 9 "National Protected TCM Medicine". Two of YRPG's products won Second Prize for National Science and Technology Progress.More than 20 products meet the pharmacopeia standards in the U.S.A and EU.,and three facilities have gained EU GMP qualification. Since 2005, it has consecutively won first-place prizes year after year from the National Pharmaceutical Industry QC. It was also designated a training center by the Chinese Food and Drug Administration and Jiangsu Food and Drug Agency.

Looking forward, YRPG will continue working to help build up the Chinese pharmaceutical industry, and serve all human beings scientifically, rigorously and responsibly.

太极集团有限公司

Taiji Group Co., Ltd.

太极集团有限公司（简称太极集团）是中国企业500强之一，中国医药工业10强。2016年3月1日前，完成 “太极实业”、“西南药业”、“桐君阁”三家上市公司整合为一。“太极”（TAIJI）为中国首批驰名商标，OTC品牌药企第一名，2016年集团销售总额达330亿元，2021年将跨越千亿大关。

太极集团拥有10000家药房、13000名员工、20多家医药商业公司、13家制药厂及太极医药研究院、重庆中药研究院两大研发机构。1998年，太极集团与国内外15所院校合作建立博士后工作站；1999年，太极集团技术中心被认定为国家级企业技术中心；2014年，获国家批准建立太极院士专家工作站，中国工程院近20位院士成为太极研发顾问。

太极集团现有中西药品种1200多个、全国独家生产品种50多个、获得国家中药保护品种50多个、国家基药品种165个，获国家专利137项、年销售额逾亿元的品种15个。

太极集团的快速发展主要得益于日益增强的科研开发能力，日益完善的国内市场网络，日益成熟的信息化管理，先进的生产装备，畅销的外贸营销渠道，一流的员工队伍和管理团队，颇具中国特色的管理经验。更为重要的是，太极员工多年受“忠诚、责任、团结、努力”的太极精神熏陶，充满了 “光大太极、振兴中华”的必胜信念。

习近平、张德江、江泽民、李鹏、温家宝、吴邦国、李源潮等党和国家领导人多次亲临太极集团视察工作，充分肯定太极集团的发展壮大之路，江泽民同志亲笔书写“太极集团”四个金光闪闪的大字予以鼓励。

阴阳互根方能相长，阴阳平衡万事万物方能和谐发展。太极集团渴望交流，期待合作，愿和您为中国医药事业走向世界而共同努力！

Taiji Group Co., Ltd. (short for TaiJi Group) is one of the top 500 Chinese enterprises , having 20 billion yuan assets.

We have been integrated “Taiji industry”、“Tong Jun Ge”and“Southwest Pharma Ceutical”with single company."Tai Ji" (TAIJI) have been a well-known brand in China, In 2016,the gross sales was33.0 billion yuan, In 2021,Taiji Group plans to reach one billion yuan in the next decade.

Taiji Group owns more than 1,200 drugs varieties, of which 50 exclusive products, 165 national base products.The enterprise has achieved 137 patens and 15 of single product sales reach one billion per year.

The great achievements we made is mainly due to the growing research and development capabilities, increasing domestic market, advanced equipment, outstanding workforce and specialized management.

More importantly, Taiji staff observe the spirit of "loyalty, responsibility, unity, and hardwork " for many years, having the notion of contributing to long-term development of the company.

Xi Jinping,Zhang Dejiang,Jiang Zeming, Li Peng,Wen Jiabao and other state leaders have been visited Taiji and totally gave affirmation to our company. Moreover, Jiang Zeming handwritten “tai ji ji tuan” four glittering characters to encourage Taiji Group.

Taiji Group longs for communication and desperately waiting for cooperation with all the excellent companies. Let’s make efforts to push traditional Chinese medicine into the international market. We are always dedicated to the health of people around the world!

浙江康恩贝制药股份有限公司

Zhejiang Conba Pharmaceutical Co., Ltd.

浙江康恩贝制药股份有限公司是一家集药品研发、生产、销售及药材种植为一体的医药上市企业。

公司前身为创建于1969年的“兰溪云山制药厂”，目前管理总部设在浙江省杭州市，公司在杭州、兰溪、金华，以及江西、云南、内蒙古、四川等地拥有先进规范的药品生产基地，并在兰溪建有国内最大的现代植物药制造基地——康恩贝植物药产业园。公司旗下拥有浙江康恩贝中药有限公司、浙江金华康恩贝生物制药有限公司、云南希陶绿色药业股份有限公司、杭州康恩贝制药有限公司、江西天施康中药股份有限公司、上海康恩贝医药有限公司、云南康恩贝植物药有限公司、内蒙古康恩贝药业有限公司等多个颇具规模和实力的全资及控股子公司。

公司为国家高新技术企业、国家创新型企业、国家知识产权试点企业，建有国家认定企业技术中心、国家博士后科研工作站、院士工作站，并拥有一支由博士、硕士和高中级技术人员组成的实力雄厚、专注于现代植物药和特色化学药研发的团队，已建立新药研发的多个技术平台，在心脑血管系统用药、泌尿系统用药、抗糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发，以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面，研发具有自主知识产权的新药，在药材种植、植物提取、制剂生产、市场营销等各环节，已建立起规范高效的产业体系。

公司历来十分重视产品品牌和企业品牌的培育和保护，在药品多个领域建立了消费者熟知与认可的品牌，“康恩贝”、“前列康”是中国驰名商标，“天保宁”、“阿乐欣”、“金康”、“金奥康”、“希陶”、“天保康”、“天狮”等均在各自领域拥有较高的品牌知名度，在同类竞争产品中已树立起了较突出的品牌优势。

Zhejiang Conba Pharmaceutical Co., Ltd. (founded in 1969, listed in 2004, stock code 600572) is a holding subsidiary and main member enterprise of Conba Group Co. Ltd. It is a listed pharmaceutical enterprise integrating herbs planting and pharmaceutical R&D, production and sales. The company was previously known as “Lanxi Yunshan Pharmaceutical Factory” founded in 1969 and was renamed “Zhejiang Conba Pharmaceutical Co., Ltd.” in October 1999. The company was registered in Lanxi , Zhejiang Province, with head office set in Hangzhou, Zhejiang. It owns advanced and standard pharmaceutical production bases in Hangzhou, Lanxi, Jinhua as well as Jiangxi, Yunnan, Inner Mongolia and Sichuan, etc., and has built domestic largest modern herbal medicine manufacturing base, Conba Herbal Medicine Industrial Park in Lanxi. The company owns a dozen of wholly owned and holding subsidiaries of considerable size and strength including Zhejiang Conba Chinese Medicine Co., Ltd.,Zhejiang Jinhua Conba Bio-Pharm. Co., Ltd., Yunnan Xitao Green Pharmaceutical Co., Ltd., Hangzhou Conba Pharmaceutical Co., Ltd., Jiangxi Herbisky Co., Ltd., Zhejiang Conba Pharmaceutical R&D Co., Ltd., Zhejiang Conba Pharmaceutical Sales Co., Ltd., Shanghai Conba Pharmaceutical Sales Co., Ltd., Yunnan Conba Herbal Medicine Co., Ltd. and Inner Mongolia Conba Pharmaceutical Sales Co., Ltd., etc.

Zhejiang Conba Pharmaceutical Co., Ltd. always adheres to building its own core competitiveness. R&D and brand have always been two advantages of company.

First of all, Company has multiple new drug R&D technology platforms and an elite technical team. It has established long-term strategic partnership and strategic alliance relationship with domestic and foreign well-known research institutions, colleges and universities. In the fields of drug R&D as well as plant extraction and separation, structure modification and new drug release system application, etc., it develops new drugs with independent intellectual property right, and in the links of herbs planting, active pharmaceutical ingredients and plant extraction, new drug R&D, preparation production and marketing, etc., it has built a standard and efficient industrial system and become the only enterprise integrating national technology center, national post-doctoral research workstation, academicians workstation, national innovative enterprise and Zhejiang key enterprise research institute in traditional Chinese medicine industry in Zhejiang.

Secondly, company attaches particular importance to product brand and enterprise brand cultivation and protection, so it has built brands familiar to and recognized by consumers in several fields including urinary system and cardiovascular system, etc. Now, the company has become one of the enterprises owning the most famous trademarks and brand products, among which “Conba”, “Prostate Plus”, "Zhenshiming" are identified as famous trademark of China, while “Prostate Plus”, as the company’s leading herbal medicinal product, has become the first brand in domestic Chinese herbal medicines treating BPH; “Tianbaoning” is China's first modern herbal medicine preparation meeting international quality standards. In addition, “Alocin”, “Xitao”, “Yuanbang”, “Baby” and “Omeprazole”, etc., have considerable brand awareness in their respective fields and set up considerable brand advantages in similar competitive products.

神威药业集团有限公司

Shineway Pharmaceutical Group Co., Ltd.

神威药业集团是集研发、生产、销售于一体的大型现代医药企业集团，中国中药行业前五强，香港联合交易所主板市值最大的现代中药企业，拥有“神威”、“五福”、“神苗”三个中国驰名商标，是全国规模最大、技术水平最高、质量控制能力最强的现代中药注射剂、软胶囊、颗粒剂专业制造商，成为全国唯一的中药制剂高技术产业化示范基地，被国家科技部等五部委联合授予国家认定企业技术中心、国家技术创新示范企业、国家级知识产权优势企业。

神威拥有全国唯一的“中药注射剂新药开发技术国家地方联合工程实验室”，每年有数个国家级新药投入市场，多项科研成果获得国家、省级科学技术进步奖和国家发明专利。神威清开灵注射液、参麦注射液、舒血宁注射液为“全国百姓放心药”，占据了国内同品种70%以上市场份额，降脂通络软胶囊、舒筋通络颗粒等多个品种被列为国家中药保护品种，五福心脑清软胶囊、小儿清肺化痰颗粒、滑膜炎颗粒等知名产品畅销全国。神威主导完成的“中药注射剂全面质量控制及在清开灵、舒血宁、参麦注射液中的应用”技术获国家科技进步奖二等奖。神威与中国中医科学院、澳大利亚知名科研单位联合开发组分中药塞络通胶囊，治疗老年性痴呆，首开中药国际产学研合作模式先河。

Shineway Pharmaceutical Group is a large modern pharmaceutical enterprise in herb planting, research and development, manufacture and distribution in China, recognized as one of the top 5 enterprises in the Chinese medicine industry, the Group is the largest modern Chinese medicine enterprise listed on the Main Board of Hong Kong Stock Exchange by market value, holding 3 “China Famous Brand” —“Shineway”,”Wufu”,”Shenmiao”, it is the professional manufacturer of modern Chinese medicine injections, soft capsules, granules with the largest scale, the highest technology and the strongest quality control, and became the only modern Chinese medicine formulation high-tech industrialization demonstration base, authorized by five national ministries including the Ministry of Science and Technology as National Enterprise Technology Center, National Technology Innovation Demonstration Enterprise, and National IPR Advantageous Enterprise.

Only Shineway has the "Chinese medicine injection new drug development technology national local joint engineering laboratory", in each year several national new drugs will be released into the market, a lot of scientific research achievements are honored with the National or Provincial Science and Technology Progress Award and the National Invention Patents. Shineway’s Qingkailing injection, Shenmai injection, Shuxuening injection are regarded as " Assured Drug", which occupy more than 70% domestic market share in similar varieties, Jiangzhi Tongluo soft capsules, Shujin Tongluo granules and other species are listed as a national Chinese medicine protection species, Wufu Xinnaoqing soft capsules, Xiaoer Qingfei Huatan granules, Huamoyan granules are well known and sold nationwide. Shineway leads to complete the "traditional Chinese medicine injections comprehensive quality control and the application in Qingkailing Shuxuening Shenmai Injection" obtain the National Science and Technology Progress Award. Shineway combine with China Academy of Chinese Medical Sciences, Australia renowned research institutions to jointly develop components of traditional Chinese medicine SLT capsules, aiming at the treatment of senile dementia, it is a precedent to open traditional Chinese medicine international cooperative mode on industry-study-research.

浙江医药股份有限公司

Zhejiang Medicine Co., Ltd.

浙江医药股份有限公司是于1997年5月组建的大型股份制综合制药企业。1999年8月经中国证监会核准，公司向社会公开发行了人民币A股5800万股，同年10月公司股票在上海证券交易所挂牌上市。截止2015年末，注册资本9.3亿元，总资产82亿元。

浙江医药现拥有新昌制药厂、维生素厂、昌海生物分公司、浙江来益生物技术有限公司、浙江来益医药有限公司等五家主要分公司（子公司）和医药工业研究院、上海来益生物药物研究开发中心两家研发单位，为国家高新技术企业，国家创新型企业，拥有国家级企业技术中心，设有国家级博士后科研工作站。现有员工6000余名，其中各类专业技术人员2000余名，占员工总数的40%以上。

目前，浙江医药已经形成了脂溶性维生素，类维生素，喹诺酮类抗生素，抗耐药抗生素等系列产品的专业化、规模化生产。公司原料产品：维生素E产量国内最大，为全球第二大生产商；天然维生素E产量为国内最大，全球第三大生产商；β-胡萝卜素和斑蝥黄素是全国最大、全球第三大供应商；盐酸万古霉素及替考拉宁已占全球产量的40%以上；公司制剂产品：乳酸左氧氟沙星注射液（商品名“来立信”）占全国销售的20%以上，注射用盐酸万古霉素（来可信）占全国销售的30%以上，注射用替考拉宁（加立信）为国内最大供应商。

浙江医药通过认真实施“创新创业、竞争发展、科技兴企、人才强企”的发展战略，紧紧抓住产品开发这条主线，突出结构调整，整合各种资源，加强原始技术创新和优势产品技术创新，做好优势品种的DMF文件注册和FDA认证工作，大力推行清洁生产、循环经济，以全球化为立足点，构建完善的市场网络，树立良好的品牌形象，创建先进的企业文化，大力提升了企业的核心竞争力，目前，浙江医药已发展成为一家技术先进、规模庞大、实力雄厚、对全球市场具有影响力的医药企业。

Zhejiang Medicine Co., Ltd. (hereinafter referred to as “ZMC”) is a large pharmaceutical stock-shared corporation established in May 1997. After being approved by the CSRC, ZMC issued 58 million public A shares in August 1999 and was listed via Shanghai Stock Exchange in October of the same year. With a registered capital of RMB 936 million, the current corporate annual sales income is close to 5 billion yuan and its total assets, up to 8 billion yuan.

ZMC currently owns six subsidiaries (Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang Health Creation Pharmaceutical Co., Ltd. and Shanghai Vital Health Management Co., Ltd.) and two R&D units (Research Institute of Pharmaceutical Industry and Shanghai Health Creation Biological Drug Research and Development Center). It is rated as the “National High-Tech Enterprise” and “National Innovative Enterprise” having National Enterprise Technology Center and National Post-doctor Scientific Research Station at its core.

ZMC specializes in large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. The corporation has formulated a range of dominant products through in depth and extensive studies. In addition to fat soluble vitamins which include VE, natural VE, VA, Biotin, Coenzyme Q10, carotenoids likeβ-carotene, Canthaxanthin, Astaxanthin, Lycopene, Zeaxanthin and Lutein, ZMC also produces Vancomycin HCl, Teicoplanin, Levofloxacin, Miglitol, in the form of APIs and FDF. Manufacturing in ZMC’s domestically model FDF Industrial Park is the 8 other dosage forms: large-volume injections, small-volume injections, freeze dried powder injections, tablets, hard capsules, soft capsules, pills and oral solutions.

Taking globalization as its standpoint, the development strategy of ZMC encompasses innovative entrepreneurship, competitive development, scientific technology advancement and talent implementation. By focusing on developing products, highlighting structure readjustment, re-organizing and integrating various resources, and strengthening its technological innovation in methods and products, ZMC is to build a consummate market network and to build a pristine image for its branded products on top of promoting its corporate culture and competitiveness in its core business. At presence, ZMC is recognized as a large global influential pharmaceutical corporation with advanced technology, strong capital and technical strengths.

华北制药集团有限责任公司

North China Pharmaceutical Group Corporation

华北制药集团公司是中国最大的化学制药企业之一。1953年建厂，开创了中国大规模生产抗生素的历史。经过60余年的发展，现已拥有三十余家子公司，公司产品涵盖了抗生素与半合成抗生素，生物技术药物，抗肿瘤药物，维生素，农兽药等600多个品种的原料和制剂。2017年华北制药实现销售收入93.56亿元。

华北制药华民药业有限责任公司成立于2010年，是华药头孢抗生素生产基地，也是目前中国最大的头孢产品生产基地。占地面积300亩，总投资12亿元。厂房及布局设计完全按照cGMP规范要求进行设计、施工，生产过程闭环管理、生产环节自动监控、产品质量全程跟踪，立体仓库实现了自动化物流信息管理。目前有9个模块18条生产线，产品涵盖四代头孢所有主导产品，年生产能力粉针9亿支，片剂7亿片，胶囊25亿粒，颗粒剂1亿袋。形成了从药用中间体原料至制剂的完整的头孢产业链及丰富的头孢产品群。

华北制药新制剂分厂是华药制剂生产基地，占地面积388亩，总投资26亿元。厂房及布局设计完全按照cGMP 规范要求进行设计、施工。现有生产线25条，年生产能力粉针制剂5亿支、口服制剂159.3亿片（粒、袋）、小容量注射剂3亿支、滴眼剂4300万支。有无菌粉针制剂、小容量注射剂、滴眼剂、胶囊剂、片剂、颗粒剂等主流剂型。产品涵盖心脑血管类、免疫抑制剂类、新抗生素类、保健品类等。

华北制药生物技术分公司是华药生物技术药物生产基地，是国内规模最大、技术水平最高、工艺设备先进的中国第一家重组人血白蛋白产业化基地。厂房及布局设计完全按照国际GMP标准建造，年产吨级以上产品，质量达到国际先进水平。基因重组人血白蛋白项目是国家重大新药创制重点课题，拥有自主知识产权，截止到2017年底，重组人血白蛋白技术已获得专利20余项，比传统血源人血白蛋白具有纯度更高、无动物组分、不含病毒残留的优势，产品更安全、更可靠。加上金坦公司已建成的，华北制药已具备三个成熟的细胞表达系统，拥有丰富的生物技术产业化经验。

华北制药实施“10+6+N”的发展战略，准备培育10家重点骨干型企业，构建完善6个平台型企业，成立N个合资合作企业。现诚邀国内外研发机构、制药企业和医药商业公司进行技术、生产及市场方面的合作。

NCPC is one of the largest pharmaceutical enterprises in China. Established in 1953, NCPC created a history of large-scale production of antibiotics. During more than 60 years' development, NCPC owns over 30 subsidiaries, covering more than 600 kinds of APIs and preparations, such as antibiotics, semisynthetic antibiotics, biologicals, antineoplastic, vitamins, pesticides and veterinary etc. NCPC brand obtains the comprehensive awareness in domestic and abroad market, renowned both inside and outside the country. NCPC achieved the sales revenue of NCPC achieved the sales revenue of RMB 9.356 billion in 2017.

NCPC HebeiHuamin Pharmaceutical Co., Ltd. was established in 2010, is the production base for cephalosporins in NCPC and the largest production base for cephalosporins in China. Covering an area of 388 acres,and the total investment is RMB 1.2 billion. The plant and layout design are designed and constructed according to the requirements of cGMP, the closed-loop management in the production process, the automatic monitoring at the production steps and the whole-process tracking on the product quality, and the automatic logistics information management in the stereoscopic warehouse. At present, there are 9 modules and 18 production lines, covering all of the leading products in the 4th generation cephalosporins, the annual production capacity of 900 million vials powder for injection, 700 million tablets, 2.5 billion capsules and 100 million sachets granules. The complete cephalosporin industry chain and the abundant cephalosporin products group covering from the intermediate material to formulation products have been established.

NCPC New Formulation Branch Factory is the production base for formulation, covers an area of 388 acres, total investment is RMB 2.6 billion. The plant and layout design are designed and constructed according to the requirements of cGMP. There are 25 production lines, the annual production capacity of 500 million vials powder for injections, 15.93 billion tablets (capsules, sachets) oral preparation, 300 million ampoules small volume injections and 43 million eye drops. Covering the main dosages of sterile powder for injection, small-volume injection, eye drops, capsules, tablets and granules etc. The products cover the therapeutic drugs of cardiovascular and cerebrovascular, immunosuppressant, new antibiotics and healthcare products etc.

NCPC Biotechnology Branch Company is a production base for biotechnology drug in NCPC, is the first industrialization base for rHSA in China, has the Largest scale, highest technology and advanced process equipments. The plant and layout design are built according to cGMP standard, the annual capacity is more than tons of products, and the quality reaches advanced international level. rHSA project is a National innovative key project for important new drug, holds proprietary intellectual property rights, up to the end of 2017, the project has obtained over 20 related patents, compared with the traditional natural human serum albumin, rHSA has the advantages of higher purity, no animal components or virus residues, the product is much more safe and reliable. Including the cell expression system that Jin Tan company has been built, NCPC has three mature cell expression system, has rich experience in the biotechnology industry.

NCPC implements the development strategy of "10+6+N", preparing to establish 10 key backbone enterprises, build and improve 6 platform enterprises and found a number of joint ventures. Now NCPC heartly invites R&D institutes, pharmaceutical enterprises and medical commercial corporations domestic and abroad to cooperate in technology, manufacturing and marketing.

东北制药集团股份有限公司

Northeast Pharmaceutical Group Co., Ltd.

东北制药集团股份有限公司（简称“东北制药”）前身为东北制药总厂1946 年始建于佳木斯，1949 年迁至沈阳，1993 年6 月成立东北制药集团股份有限公司，并于1996 年在深交所上市。截至2017年底，东北制药总资产97.6亿元，从业人员9500人，年营业收入56亿元，年出口创汇1.15亿美元，是大型综合性制药企业集团。

拥有化学原料药、化学制剂、生物医药、医药商业、医药工程五大业务板块，主要生产抗生素类、维生素类、消化系统类、麻醉药品类、生物诊断试剂类等10大系列产品，400多种医药中间体、化学原料药和制剂产品。主导原料药产品VC系列、磷霉素系列、左卡尼汀系列等占国际供应市场强势地位，远销100多个国家和地区。拥有制剂产品国家批准文号366个，现有244个品规药品进入《国家基本医疗保险、工伤保险和生育保险药品目录》甲乙类目录。东北制药是国内定点麻精药品生产企业，占据国内抗艾药物统一采购近70%的市场份额,特色产品卡孕栓为全球独家。

东北制药具备完善的质量管理体系，产品质量符合新版GMP、EP8.0、USP37、JP16、BP2014、CP2010等最新质量标准。公司多个产品先后通过了EDQM、FDA、日本厚生省、BRC、HALAL、KOSHER等国际高端认证。主导产品通过了美国、欧洲、日本、巴西、俄罗斯、波兰等多个国家和地区的注册和质量审计。

东北制药设有研究院、设计公司、国际贸易公司和医药商业公司，旗下东北大药房遍布东北、辐射全国。公司拥有股份公司及子公司沈阳第一制药、东瑞精细化工、辽宁生物、沈阳施德5家高新技术企业。拥有“东北”、“复美欣”两个中国驰名商标及一大批省市驰名商标。先后多年跻身中国制造业企业500强，并被确认为国家认定企业技术中心。

面向未来发展，东北制药以“一切为了健康，向未知与不可能挑战”为核心价值观实现“公司有朝气、产品有名气、员工有福气”的企业愿景，着力打造国内一流、国际知名的大型医药企业集团。

Northeast Pharmaceutical Group Co.,Ltd(Northeast Pharm) formerly known as Northeast General Pharmaceutical Factory founded in Jiamusi in 1946, then moved to Shenyang in 1949. In June 1993, Northeast Pharmaceutical Group Co.,Ltd was established and became public company listed on the Shenzhen Exchange Stock in 1996. By the end of 2017, Northeast Pharm has total assets of RMB9.76 billion, 9500 employees, annual revenues of RMB 5.6 billion and annual exports amount of $115 million, is the large-scale comprehensive pharmaceutical enterprise group.

Northeast Pharm have five business sectors including APIs, chemicals, bio-pharmaceuticals, pharmacy chains &medical distribution, pharmaceutical engineering, mainly focus on the production of 10 series products including antibiotics, vitamins, digestive system drugs, such as narcotic drugs, biological diagnostic reagents etc. and more than 400 kinds of pharmaceutical intermediates, chemical raw materials and finished products. Leading products including VC series, fosfomycin series, levo-carnitine series, possess strong position in the international market and are exported to more than 100 countries and regions. We have 366 preparation products national approval numbers, and 244 existing drugs are in the the national basic medical insurance, work injury insurance and maternity insurance drug list A and B class list.

Northeast Pharm has a perfect quality management system, the quality of products meet most of the latest quality standard including the new version GMP, EP8.0, USP37, JP16, BP2014, CP2010. Many products have passed the EDQM, FDA, Japan MHLW, BRC, HALAL, KOSHER and other international authorization. Leading products are either registered in or passed the quality audit of the United States, Europe, Japan, Brazil, Russia, Poland and other countries or regions

Northeast Pharm have research institutes, design company, manufacturing and installation company, international trading companies and commercial pharmaceutical companies, pharmacies of the Northeast Pharm spread all over northeast and radiate national wide. The company has 5 subsidiaries including the ShenYang No.1 Pharmaceutical Corporation, Dong Rui Fine Chemicals Company, Liaoning Bio-Pharm Company, Shenyang ShiDe Pharmaceutical Company. We have two well-known trademark of "DONGBEI" and "FuMeiXin" and a large number of provincial famous brand in China. We have ranked among China's top 500 manufacturing enterprises for many years and were recognized as a national enterprise technology center.

Future-oriented developing, Northeast Pharm will take " All for health, we will challenge the unknown and the impossible!" as the core values, pursue the corporate vision of "Energetic Company Leading Products Happy Employees ", and take efforts to create domestic first-class, international well-known large pharmaceutical groups.

四川科伦药业股份有限公司

Sichuan Kelun Pharmaceutical Co., Ltd.

创立于1996年，历经20年发展，现已成为拥有海内外90余家企业的现代化药业集团。集团的产业板块，科伦药业(SZ002422)于2010年6月3日在深圳证券交易所成功上市，全球最大的大输液专业制造商和运营商在资本市场扬帆启航。

2016年科伦集团营业收入超过400亿元、利税超过20亿元人民币。根据商务部发布的2012年中国药品流通行业销售排序和工信部医药统计年报，科伦集团旗下的商业和产业双双进入全国前十强。

作为科伦集团旗下的产业板块，科伦药业生产和销售包括大容量注射剂(输液)、小容量注射剂(水针)、注射用无菌粉针(含分装粉针及冻干粉针)、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液以及原料药、医药包材、医疗器械，以及抗生素中间体等共计588个品种978种规格的产品。其中，拥有114个品种共274种规格的输液产品、383个品种共608种规格的其它剂型医药产品、还拥有45个品种共47种规格的原料药、10个品种的抗生素中间体、32个品种的医药包材、4个品种共7种品规的医疗器械产品，是中国输液行业中品种最为齐全、包装形式最为完备的医药制造企业之一。以具体产品计，公司有117个品种纳入《国家基本药物目录》，是目前国内产业链最为完善的大型医药集团。

截至目前，科伦药业及子（分）公司共申请专利2771 项，其中已获授权专利2254 项。目前，科伦已启动针对肿瘤、细菌感染、肠外营养等多个疾病领域共330余个项目的药物研究，着力于解决重大疾病未满足的临床需求和临床用药的可及性。科伦共申报92个项目，29项为国内首家申报，截至目前获批临床49项，待批生产36项。科伦快速高效的自主研发能力，跻身中国首批研发第一方阵，业界瞩目，叹为奇迹。2015年1月，公司自主研发的可立袋®因其技术创新性突破、推动行业科技进步作用明显、经济效益和社会效益显著，获得“国家科技进步二等奖“。

多年来，公司先后被国家发展与改革委员会、科学技术部、财政部、海关总署、国家税务总局、国务院国资委、工业和信息化部、国家工商总局、中华全国总工会授予“国家认定企业技术中心”、“国家第三批创新型企业”、“国家技术创新示范企业”、“国家地方联合工程实验室”、“工业品牌培育示范企业”、“国家级信息化和工业化深度融合示范企业”、“守合同重信用企业”、“两化融合管理体系贯标试点企业”、“2015年全国工业企业质量标杆”等多种荣誉称号。

Founded in 1996, Kelun Group has developed into a modern pharmaceutical group, with more than 90 subsidiaries (branches) both at home and abroad; all this rapid development took place within just 20 years. On June 3, 2010, the bell at Shenzhen Stock Exchange rang to declare the listing of Kelun Pharmaceutical (SZ002422), the industrial segment of the Kelun Group. That memorable day marked the entrance of the biggest manufacturer and distributor of IV Solutions into the capital market.

Kelun Group´s sales revenues in 2016 exceeded RMB 40 billion, and profit tax was over RMB 2 billion. According to the 2012 Sales Ranking of Chinese Drug Circulation Industry released by the Ministry of Commerce and the Pharmaceutical Statistic Annals of the Ministry of Industry and Information Technology (MIIT), the business and industrial segments of the Kelun Group ranked within the Top 10.

As the industrial segment of the Kelun Group, Kelun Pharmaceutical is specialized in manufacture and sale of 588 different products in 978 specifications, including LVP (IV Solutions), SVP (small volume parenterals), sterile powder for injections (including dispensed & lyophilized), tablets, capsules, granules, oral solutions, dialysis solutions, APIs, pharmaceutical packaging materials, medical devices, and antibiotic intermediates, among which 274 specifications in 114 varieties belong to IV solutions; 608 specifications in 383 varieties belong to pharmaceutical products in other dosage forms; 47 specifications in 45 varieties belong to APIs; 10 varieties belong to antibiotic intermediates; 32 varieties belong to pharmaceutical packaging materials; 7 specifications in 4 varieties belong to medical devices. Kelun is the pharmaceutical manufacturing enterprise with the largest number of different products and packaging forms in the IV solution industry of China. In terms of specific products, 117 varieties of Kelun products have been included in the National Essential Drugs List. At present, the company is the largest pharmaceutical group with the most complete industrial chain in China.

So far, Kelun Pharmaceutical, including its subsidies, has applied for 2,771 patents in total, of which, 2,254 have been approved. Besides, more than 330 medicine research programs on tumor, bacterial infection, parenteral nutrition and other fields are in process, targeting at unsatisfied clinical demands and accessibility of clinic medicine for critical diseases. In the 92 projects declared by Kelun, 29 are the first of its kind in China. Data as to the present shows that 49 clinical programs are approved and 36 to be put in batch production. The speedy, high-efficient and independent R&D capacity of Kelun contributes a lot to its promotion to the 1st R&D array of the first batch in China, winning attention and admiration in the industry. In January 2015, Collapsible PP Bottle (Uniflex®), a result of its independent R&D, was awarded the “National 2nd Prize of Technological Progress” for its breakthrough in technical innovation, significance to technological progress, economic and social benefits of the industry.

For years, the Company has received numerous titles from the National Development and Reform Commission, Ministry of Science and Technology, Ministry of Finance, General Administration of Customs, State Taxation Administration, State-owned Assets Supervision and Administration Commission of the State Council, Ministry of Industry and Information Technology, State Administration of Industry and Commerce and All-China Federation of Trade Union, including “National Recognized Enterprise Technology Center”, “National 3rd Batch of Innovative Enterprise”, “National Model of Technology Innovation”, “National-Local Jointed Engineering Laboratory”, “Industrial Brand Cultivation Model”, “National Model of Deeply Integrated Information and Industrialization”, “Contract-Honoring and Credit-Valuing Enterprise”, “Pilot of Management System Standard Implementation of Information and Industrialization Integration”, and“Quality Benchmark for National Industrial Enterprises of the Year 2015”.

通化东宝药业股份有限公司

Tonghua Dongbao Pharmaceutical Co., Ltd.

通化东宝药业股份有限公司始建于1985年12月1日，1992年11月改制为股份制有限公司，1994年在上海证券交易所挂牌上市。公司最早以发展中药产业为主，研制推出的“镇脑宁胶囊”，成为中药治疗头痛的经典产品。公司从1998年开始发展生物制药，于1998年成功研制出具有中国独立知识产权的重组人胰岛素“甘舒霖”，填补了国内空白，使中国继美国、丹麦之后成为世界上第三个能生产重组人胰岛素的国家，项目获国家科技进步二等奖。人胰岛素的生产打破跨国企业对中国人胰岛素市场的垄断，经过十余年专业化的市场营销，目前东宝人胰岛素市场占有率已经超越部分跨国企业排第二位。公司秉承"坚持自主创新、创造世界品牌"的发展理念，加快胰岛素类似物产品开发，目前市场上在售的所有类似物通化东宝均已申报注册，未来通化东宝将成为胰岛素制剂最全的公司。为东宝立足于糖尿病领域的发展打下坚实基础。

通化东宝在加大产品研发同时，不断加大产能建设，到今年9月通化东宝的胰岛素生产能力从原料到制剂都能独自承担上亿中国糖尿病人的胰岛素治疗需求，成为中国糖尿病人的坚强依靠。2013年4月通化东宝年产3吨的人胰岛素原料生产线通过欧盟GMP认证，标志通化东宝成为世界一流重组人胰岛素生产企业，也是世界三大重组人胰岛素生产基地之一。通化东宝正一步一个脚印朝着一流的生物制药企业前进。

Tonghua Dongbao Pharmaceutical Co., Ltd. was founded on December 1, 1985, restructured into joint-stock Co., in November, 1992, and listed on the stock exchange of Shanghai in 1994. Initially, Tonghua Dongbao mainly focused on traditional Chinese medicine industry and produced “Zhennaoning Capsule”, which is the classic treatment to headache. The company began to develop biopharmaceuticals in 1998, and successfully produced the recombinant human insulin “Ganshulin” with Chinese independent intellectual property rights in that year, filling the blank of human insulin field in China. This breakthrough made China become the first three countries in the world that are able to produce the recombinant human insulin, ranking after the United States and Denmark. The project won the second class prize of the National Scientific and Technological Progress. Production of human insulin broke the monopoly of the multinational enterprises in Chinese market. After more than ten years of professional marketing, the market share of Dongbao human insulin has bypassed some multinational enterprises, ranking the second. The company adheres to the concept of development, “to independent innovation, create a world brand”, to accelerate the development of insulin analogue products. Currently, Tonghua Dongbao has declared to be registered on the market for sales of all analogues. In the future, Tonghua Dongbao will become the most comprehensive insulin preparations company, which will lay a solid foundation in the field of diabetes for the future development of Dongbao.

When Tonghua Dongbao increases the product research and development, we also increase the capacity of production. By September of this year, Tonghua Dongbao’s production capacity of insulin from the raw material to the preparation alone will meet the demand of hundreds of millions of diabetes insulin treatment, becoming a strong support for Chinese diabetes patients. In April 2013, Tonghua Dongbao’s production line that produces 3 tons of insulin raw materials has attained the EudraGMP approval, which made it become the world first class human recombinant insulin production enterprise. It is also one of the world’s three largest production base for recombinant human insulin. Tonghua Dongbao is walking towards the first class biological pharmaceutical enterprise by one step at a time.

山西振东制药股份有限公司

Shanxi Zhendong Pharmaceutical Co., Ltd.

振东制药股份有限公司是山西省首家登陆创业板的上市企业，为高新技术企业，拥有中药材开发公司、北京研究院、生物健康科技公司、医药物流公司和振东、泰盛、安特、开元、康远五个药品和两个饮片七大生产基地。主要生产抗肿瘤、心脑血管等八大系列 615 个品种，现已形成中药材种植、研发、生产、销售为一体的完整产业链。

振东制药长期与国内外多家科研院所进行合作。国内与中国医学科学院、中国军事医学科学院、中国中医科学院、中国药科大学等合作，进行新产品的研制开发，并承担了国家重大专项科技项目；国外与澳大利亚阿德莱德大学、美国国立卫生研究院及沃特世公司、荷兰 SU 生物医药公司等进行国际合作，旨在推动中医药走出国门，造福全球人类。

振东制药营销网络覆盖全国 400 余个城市，与全国数千家医疗单位建立了业务关系，形成了“多渠道，多模式”的销售体系，有完善的学术支持、售后服务与信息反馈渠道。

面向未来，振东制药将以“百年企业，百亿振东”为目标，以“好人好药，好药好人”为理念，全力打造“振东制药”全国知名品牌，为人类的健康事业贡献力量。

The Zhendong Pharmaceutical Co., Ltd., located in Shanxi Province, is the first listed high-tech company on the Growth Enterprise Market, which comprises Chinese Herbal Medicine Development Company, Beijing Pharmaceutical Research Institute, the Bio-health Technology Company, the Pharmaceutical Logistics Company, and also has five drugs and two Chinese herbal pieces of production basis (the Zhendong Pharmaceutical, the Taisheng Pharmaceutical, the Ante Pharmaceutical, the Kaiyuan Pharmaceutical, the Kangyuan Pharmaceutical). It has 615 kinds of products in eight medicine series for antitumor, cardiovascular and etc. A health industrial chain with the integration of Chinese herbal materials planting, researching, manufacturing and marketing has been formed completely.

The Zhendong Pharmaceutical Co., Ltd. has established a long termcooperation relations with home and abroad institutes and universities. Seeking national cooperation with institutions and university like the Chinese Academy of Medical Sciences, the Academy of Military Medical Sciences, the China Academy of Chinese Medical Sciences and the China Pharmaceutical University is dedicated to the research and development of new medical products as well as some of the national key Science and Technology Special Projects. Purpose of international cooperation with the United States National Cancer Research Center, Australia Adelaide University, the Waters Company and SU BioMedicineB.V. of the Netherlands is to promote Chinese herbal medicine abroad and benefit the global human beings.

Zhendong Pharmaceutical Co., Ltd, whose marketing network has covered more than 400 Chinese cities, has established business relations with thousands of medical institutions nationwide, and formeda marketing system of “multiple channels, and multiple modes” with its well-developed academic mechanism, after-sale service and information feedback channels.

Looking forward to the future, Zhendong Pharmaceutical Co., Ltd will take “century-old enterprise and 10 billion yuan Zhendong” as target, establish the philosophy of “being good person for high quality drug, high quality drug from good person”, make great efforts to create the national well-known brand “Zhendong Pharmaceutical” and contribute to human’s health industry.+

美罗药业股份有限公司

Merro Pharmaceutical Co., Ltd.

美罗药业股份有限公司是药品研发、制造和销售的大型专业化公司，注册资本3.5亿元，是国家级高新技术企业，国际化先导企业和省级企业技术中心，拥有“国家级博士后工作站”。现已通过美国FDA认证、澳大利亚TGA认证等。2017年自主研发的缓释剂首批出口澳大利亚；同年与阿斯利康合作首个重磅药品上市许可持有人项目。

美罗药业拥有占地面积23万平方米，建筑面积13万平方米的现代化医药产业基地。有生产中心和美罗中药厂两个生产基地，包括五大主体车间、两个研发大楼等18个单体，其中国际化制剂车间单体面积2.58万平方米，是国内最大的符合美国cGMP 标准的出口药品单体车间。

美罗药业一直致力于化学药制剂、生物医药、中药、植物药的研究、生产和销售，在行业内具有突出地位。

美罗药业未来发展三个方向：国家基本药物、国际仿制药和生物医药的研发、制造，并在现有的200多个产品基础上重点发展缓控释制剂和生物制剂，全力推进国际医药市场产品、技术的广泛合作，以构建符合欧美等先进国家GMP标准工厂为中心，大力开拓国际、国内两个市场，把美罗建设成为一个运用科技、服务卓越、精于变化的国际制药公司。

Merro Pharmaceutical Co., Ltd. is a large professional pharmaceutical company specializing in R&D,manufacturing and marketing of pharmaceutical products, with registered capital of 350 million yuan.

Merro is a National High-tech Enterprise, International Leading Enterprise, and Provincial-level Technology Center, has a state-level post-doctoral working station. Now it had been approved by US FDA and Australian TGA Regulatory.

Merro is a modern medicine industry base which covers a land of 230,000 square meters and the build-up area is 130,000 square meters, contains Chemical Medicine Production Center, Dalian Merro Traditional Chinese Medicine Factory and Merro Drug Research and Development Center etc.,which including five workshops and two R&D buildings. The built-up area of International OSD workshop is 25,800 square meters which is the largest unit as a medicine export workshop to compliance with the US cGMP standard in China.

Merro has been devoting to the development, manufacture and sales of chemical medicine, biological medicine, Chinese traditional medicine and herbal medicine, Merro is a leading company in the pharmaceutical field.

Merro’s core strategies are: developing and manufacturing of National Essential Drugs, Generic drugs and Biomedicines; focusing on ER preparation and biologicals based on more than 200 products;

Merro collaborates widely with international pharmaceutical companies, improving the company’s innovation capability and becoming an international pharmaceutical company, to meet the US and EU cGMP standard ,with high technology, superior service and adaptability to changes.

上海上药信谊药厂有限公司

SPH SINE Pharmaceutical Co., Ltd.

上海上药信谊药厂有限公司是上海医药直属企业。信谊品牌始创于1916，是近代中国最早的民族化学制药企业之一。历经百年传承，不断发展壮大，成为集制造、销售、研发为一体的大型民族制药企业。旗下拥有九大工业生产基地，四大商业公司、一家市级研发中心。信谊具有强大的渠道和终端覆盖能力，营销网络辐射全国30多个省、市、自治区，覆盖了全国近10000 家医院终端、800余家主要经销商、150多个地级市，拥有一支1200多人的高素质、专业化的终端销售队伍。

信谊是中国化学制药企业产品最多、剂型最全的产业实体之一，拥有产品批文1114个，涉及14个治疗领域，覆盖16种剂型，有3个国家一类新药品种，其中“培菲康”是国家一类生物制品，已获得中国、美国、英国、加拿大、澳大利亚等多国专利。2012 年，“培菲康”被选为益生菌制剂“国家标准菌种”，目前正作为自主知识产权产品在申报美国FDA注册。公司在保持处方药领先的基础上，以“培菲康”为主要产品进入OTC业态，将通过未来几年的不懈努力，使之成为中国制药行业最具规模的企业之一，并始终成为引领微生态领域发展的先行者。

信谊品牌已获得“中国驰名商标”、“中国最具历史文化价值品牌”、“上海市著名商标”等多项殊荣，作为上海医药产业的重要组成部分，信谊人将秉承 “以信治厂，以谊为人”的经营理念，立足于品类发展、产业整合、品质提升、职能管控四大创新，提高企业的核心竞争力。

SINE is an affiliate of Shanghai Pharmaceuticals Holding Co., Ltd. Established in 1916, this brand is one of the first national chemical and pharmaceutical companies in modern China. With over one century of experience, we have become a large national pharmaceutical company with manufacturing, sales, and R&D capabilities.We have nine industrial production bases, four business companies, and one R&D center at municipal-level. SINE has our powerful channels and a marketing network of more than 30 provinces, cities, autonomous regions in the nation, covering nearly 10,000 hospitals, more than 800 major dealers, and more than 150 prefecture-level cities. We have a high-quality and professional sales team consisting of 1,200 employees.

SINE is one of the Chinese pharmaceutical enterprises with the largest and most comprehensive product portfolioand formulations. We have gained official approval for 1,114 products involving 14 treatment fields and covering 16 formulations, and 3 State Type I new drugs where “Bifico” is a State Type I biologicalproduct and patented in China, U.S., UK, Canada, and Australia.

SINE has been granted a “Chinese national well-known trademark,” a “Chinese brand with the greatest historical and cultural value,” and “well-known trademark of Shanghai.”Jinqiao Development ZoneCMC’s good Service philosophies and practical service initiatives provide much assistance and support for us. As an important component of the Shanghai pharmaceutical industry, SINE employees adhere to the business philosophy “Govern Factory By Trust, Be Friendly”,and practice four innovations “Category Development, Industry Consolidation, Quality Improvement, and Competency Control &Management” to improve our core competitiveness.

SINE R&D center focuses on independent research and development while fully utilizing the social resources and insisting on the collaborative R&D thinking. To master core technologies, we work with the domestic and overseasscientific research institutions in various professional fields to build a R&D platform for probiotics products. SINE Institute has established a good relation with Shanghai Institute of MateriaMedica, China Academy of Science, Institute of MateriaMedica, Chinese Academy of Medical Science & Peking Union Medical College, and Institute of Pharmacology and Toxicology,Academy of Military Medical Sciences. It has also worked with East China University of Science and Technology, National Institutes for Food and Drug Control, Tongji University, Shanghai Sixth People’s Hospital Affiliated Shanghai Jiao Tong University School of Medicine, and Nanjing Drum Tomer Hospital, the Affiliated Hospital of Nanjing University Medical School to build a probiotics R&D platform. It has built a branded generics R&D platform in cooperation with Chinese Academy of Medical Science & Peking Union Medical College, National Pharmaceutical Engineering Research Center, Shanghai Institute of Pharmaceutical Industry, Second Military Medical University, and Fudan University.

华润双鹤药业股份有限公司

China Resources Double-Crane Pharmaceutical Co., Ltd.

华润双鹤药业股份有限公司拥有 70 余年制药历史，1997 年挂牌上市【股票代码 600062】，2010 年进入位列世界 500 强企业的华润（集团）有限 公司旗下，成为其医药板块化学药平台的支柱企业。目前拥有16家子公司， 近1.4万名员工，年工业收入 53.67 亿元，净利润 8.4亿元，是“中国驰名商标” 企业和“国家高新技术企业”。经济实力、竞争活力和可持续发展能力位居 国内制药公司前列。

公司主要产品聚焦大输液、心脑血管、内分泌和儿科等领域；拥有〇号、冠爽、糖适平、儿泻康、珂立苏、压氏达等多个知名产品；销售网络深 入医院、社区医疗卫生服务站、地县卫生院及药店等终端。

公司坚守“关心大众，健康民生”的企业宗旨，秉承华润集团“诚实守信、 业绩导向、客户至上、感恩回报”的价值观，正向着“百亿工业”发展战略 目标稳步迈进。

China Resources Double-Crane Pharmaceutical Co., Ltd. has over 70 years of history in pharmaceutical industry. The company was listed in 1997 (Share Code: 60006), acquired by China Resources (Holding)Co.,Ltd. (Global 500) in 2010 and becoming one of its pillar enterprises in Chemical Pharmaceuticals. Currently, the company has 16 subsidiaries, over 14 thousand employees, Industrial annual revenue of 5.37 billion RMB, and net profit of 840 million RMB. The company is recognized as “China Top Brand” and “National High-tech Enterprise” and its economic strength, competition vitality, and development sustainability are ranked among the highest in the nation. The company’s main product focuses on four therapeutic areas: IV solution, cardiovascular and cerebrovascular diseases, endocrine diseases, and pediatric pharmaceuticals. The company has developed a wide range of well-known products including Hypertensive No.0, GuanShuang, Tangshiping, Erxiekang, Kelisu and Yashida. Sales network covers hospitals, community health service stations, county hospitals,and pharmacies. China Resources Double-Crane Pharmaceutical Co., Ltd. has been advocating tenet of the company: “Care for People and Promote Health”and adhering to the enterprise value of China Resources: “Integrity,Pursuing Excellence, Customer Come First, and Return to Community.”China Resources DoubleCrane Pharmaceutical Co., Ltd. has beenmoving forward steadily to achieving 10 billion-industry strategic objective.

丽珠医药集团股份有限公司

Livzon Pharmaceutical Group Inc.

丽珠医药集团股份有限公司是集医药研发、生产、销售为一体的综合性企业集团，创建于1985年1月，注册资本为4.25亿元，截止2016年，公司总资产逾100亿元人民币，年度营业收入76亿元，公司员工超过8000人。

丽珠集团拥有化学药、中成药、诊断试剂等400多个品种，有18个专利产品，21个独家产品，其中参芪扶正注射液、艾普拉唑和中药产业化项目先后荣获广东省科技进步一等奖。2016年1月，集团原研新药艾普拉唑荣获国家科技进步二等奖。1993年，丽珠A、B股相继上市；2014年，公司完成了B转H股，成为行业第一家完成A+H股的上市公司。

近几年来，公司先后获得国内多个行业荣誉：2011年被评为中国最具竞争力医药上市公司20强，2012年被评为最佳上市企业治理10强；2013年被评为上市企业投资价值TOP10强，2014至2016年连续被评为中国最具品牌价值500强企业。

2016年，集团已整体搬迁至金湾区丽珠工业园，工业园占地42.7万平方米，总投资约20亿元人民币，是按美国FDA和欧盟标准建造的国际一流的现代化制药生产基地，其过硬的硬件设备和全自动智能化运行均处于世界领先水平。

公司秉承以人为本、以精立业、以质取胜、以诚服务的经营理念，以永远致力于人类的健康事业为使命！以提供国内领先、国际一流的特色专科药为目标！以开拓和布局“精准医疗”相关领域的业务为愿景！

近几年，公司以科研创新驱动发展，成立单抗生物技术有限公司，拥有国家千人计划专家评审以及广东省领军人才为骨干成员的海外生物医药研发团队，建立了“国内领先、国际接轨”的单抗生物制药研发平台。2016年公司又紧跟国家发展步伐，布局“精准医疗”，相继成立了丽珠圣美和丽珠基因检测公司。根据公司发展战略，到2017年将实现销售100亿的战略目标。

Livzon Pharmaceutical Group Inc., founded in 1985, is a comprehensive pharmaceutical enterprise integrating development & research, production and sales of pharmaceutical products. Livzon has 9 GMP production plants located in Guangdong, Shanghai, Sichuan, Fujian, 3 plantation bases for Chinese drug preparation production located in Shanxi, Gansu, Yunan of China, with more than 5,700 employees.

Livzon has modern industrial chain and product group, operates to manufacture drug preparation, bulk medicines and intermediates, as well as diagnostic reagents and equipment, with approximate 280 products therapeutically grouped as gastrointestinal, cardio-cerebral-vascular, anti-biotic, gonadotropic hormone etc. Meanwhile, Livzon possesses production bases as leading manufacturer of Chinese drug preparation injection, and specialist bulk medicines and intermediates such as fermented antibiotics, sterile cephalosporins, and hypolipidemic “statins”.

All production lines are compliant with GMP requirements, including some DMFs, USA FDA inspection and COS approvals etc. Benefited from the regulatory compliance, an extensive overseas market is under robust development, including India, Japan, Eastern Europe for bulk medicines and intermediates, and the Philippines, Kyrgyzstan, Uzbekistan, Tajikistan, Hong Kong and Pakistan for drug preparation.

In recent years, Livzon implement the strategic transformation of R&D, focusing to antibody medicines and vaccines, and it has already established laboratories of antibody medicines and vaccine development. At the meanwhile, Livzon adjusts R&D direction of chemical pharmaceutical for carrying out transformation and upgrade. Livzon forms a complete research system. In addition, Livzon has established long-term cooperative relationship with more than 30 domestic and overseas scientific research institutes.

杭州民生药业有限公司

Hangzhou Minsheng Pharmaceutical Co., Ltd.

杭州民生药业有限公司（杭州民生药厂）创建于1926年，是中国最早的四家西药厂之一，同时也是中国最早的针剂生产厂家。90余年来，民生药业一直专注于西药制药产业，见证了中国整个西药制药的历史。2006年被商务部评为第一批"中华老字号"企业。经过多年的积累和发展，民生药业成为了一家专业化、负责任的现代化制药公司。

2013年，民生药业整体搬迁至余杭经济技术开发区，新民生工厂公司总体投资7亿多元，占地11.4万平方米，建筑面积12万平方米。新厂区包含各类针剂、输液、片剂、胶囊、眼药、外用药等生产厂房及其他各辅助设施。新工厂全部生产线均通过新版GMP认证。

90余年来，数代“民生人”艰苦奋斗，自强不息，同心同德，开拓创新，走出了具有民生特色的发展之路，打造了全国知名品牌21金维他。现阶段民生药业致力于四大生产线：以血液肿瘤为主的肿瘤药产品线、以滴眼液为主的外用药产品线、麻醉营养领域产品线、肝病领域产品线，为人们提供了健康保障，践行了“发展企业，合作共赢，贡献社会，造福员工”的企业宗旨。

民生药业以传播科学健康观为己任，不断追求卓越，致力于打造充满活力的百年企业。

Established in 1926, Hangzhou Minsheng Pharmaceutical Co.,Ltd (former is Hangzhou Minsheng Pharmaceutical Factory) is one of the earliest four chemical pharmaceutical factories and has the longest history of injection manufacture in China. Since 1926, the company has been specializing in the chemical medicine industry, witnessing the entire history of western medicine in China. In 2006, Minsheng Pharma was awarded “China time-honored brand” in the first group by the Ministry of Commerce of the People's Republic of China. After years of development, the company has grown as an extremely professional and responsible modernized pharmaceutical company.

Minsheng Pharmaceutical Company has removed to Yuhang Economic and Technological Development Zone since 2013. 700 million yuan was allocated to the construction of the new factory, whose floor area is 114,000 m2 and covered area is 120,000 m2. Minsheng Pharma has abundant product lines such as injections, transfusions, tablets, capsules, ophthalmic preparations, externally applied agents. The whole production lines of the new factory have been granted GMP certificate.

For over 90 years, generations of "Min Shengers" have made their own way to unique development. They work hard and never stop fighting. They make unremitting efforts to improve themselves as well as the company. In the path to a brighter future, all "Min Shengers" have devoted themselves to creation and innovation with one heart and one mind, and have built the nationally known brand "21 Super-Vita". At the present stage, we are devoted to four product lines: anti-cancer products mainly for hematologic tumor; externally applied medicines mainly for eye drops; production line for anaesthetics and nutraceuticals, and production line for hepatopathy. Providing safeguards for people’s well-being, Minsheng Pharma has long been practiced the enterprise purpose ---- ‘‘to develop the company, to cooperate and achieve the mutual benefits, to contribute to the society, and to benefit the employees”.

Min Shengers have regarded the philosophy of science and health as our duty. We constantly strive for excellence and commit to developing into a dynamic centennial enterprise.

浙江佐力药业股份有限公司

Zhejiang Jolly Pharmaceutical Co., Ltd.

浙江佐力药业股份有限公司发起设立于2000年1月，是一家集科研、生产、销售于一体的国家高新技术制药企业。2011年2月22日，公司成功登陆创业板（股票代码300181），成为浙江省湖州市第一家创业板上市公司。目前，公司拥有浙江佐力健康产业投资管理有限公司一家全资子公司，青海珠峰冬虫夏草药业有限公司、浙江凯欣医药有限公司、浙江百草中药饮片有限公司、浙江百草医药有限公司四家控股子公司，投资并参与了德清县第三人民医院合作办医。

公司位于风景秀丽的莫干山脚下，占地200余亩，建筑面积10万多平方米，拥有现代化的原料药、片剂、胶囊、颗粒和冻干粉针等生产流水线。公司研发中心是省级高新技术研究开发中心、浙江省企业技术中心、药用真菌制药技术国家地方联建工程实验室。

公司立足于药用真菌生物发酵技术生产中药产品，通过多年的研发、改进，实现了珍稀中药材——乌灵参的产业化生产，实现了传统中药材和现代生物技术的结合。公司利用从天然乌灵参中分离获得的菌种，运用现代生物发酵技术，实现了乌灵参发酵菌粉（乌灵菌粉）的工厂化、规模化生产。公司以市场为导向，不断加强对乌灵菌粉的深度研究，成功开发了国家一类新药乌灵胶囊，以及用于治疗更年期综合症的灵莲花颗粒和用于治疗前列腺增生的灵泽片等乌灵系列产品。通过收购控股青海珠峰冬虫夏草药业有限公司，公司在药用真菌领域又收获重磅产品--冬虫夏草发酵制剂产品百令片。

多年来，公司坚持产品创新、市场创新和管理创新，积极开拓市场，连续实现销售、利税的大幅增长，取得了快速发展。与此同时，公司也获得了诸多荣誉：“国家级火炬高新技术企业”、“国家高新技术企业”、“全国模范劳动关系和谐企业”、“全国五一劳动奖章”、“浙江省绿色企业”、“浙江省诚信守法企业”、“浙江省文明单位”、“浙江省创新型试点企业”、“浙江省优秀民营企业”、“中国驰名商标”、“浙江省著名商标”、“浙江省知名商号”、“浙江名牌产品”等。

公司在加强内生式增长的同时，通过外延式并购以及现有的资源优势，在医药制造流通、医疗服务、精准医疗领域进行了一系列的产业布局，积极布局大健康产业，拓展发展新空间。公司将始终秉承“辅佐人类身体健康，致力祖国医药发展”的使命，倡导“创新、奉献、卓越、合作、共赢”的核心理念，坚持以乌灵系列产品为起点，以药用真菌的产业化为己任，同时，结合中药饮片、配方颗粒等资源，发展中医门诊以及特色医疗服务项目，专注大健康领域，构建‘慢病及健康管理’生态系统。

Zhejiang Jolly Pharmaceutical Co., Ltd is a national high-tech enterprise with an integration of scientific research, production and marketing which was founded in Jan, 2000. On Feb. 22nd, 2011, it successfully became a public company in the Growth Enterprises Market in Shenzhen Stock Exchange(Stoke Code：300181), which is also the first public enterprise in the Growth Enterprises Market of Huzhou. At present, the company has a wholly-owned subsidiary, Zhejiang Jolly Health Industry Investment Management Co., Ltd., two subsidiaries, Qinghai Everest Cordyceps Sinensis Pharmaceutical., Ltd and Zhejiang Kaixin Medicine., Ltd. Moreover, the company also invests and participates in Deqing No.3 People's Hospital's cooperating medical service.

Our company is located at the foot of the scenic Mount Mogan, covering an area of over 200 mu, and reaching an construction area of 100 thousands square meters. We have modern production lines, including raw materials, tablets, capsules, particles, frozen dry powder injection. Our R & D center is titled as “Provincial High-Tech Research and Development Center”, “Zhejiang Enterprise Technology Center” and “National & Local Co-operational Engineering Lab for Medicinal Fungi Pharmaceutical Technology”.

Based on bio-fermentation technology, our company uses medicinal fungi to produce traditional Chinese medicinal products, and with years of research and improvement, we have developed an industrialized production pattern for Wulingshen, a rare Chinese herbal medicine, which successfully combines the traditional Chinese herbal medicine and the modern biotechnology together. Applying modern bio-fermentation technology, we use Wuling strains, which come from natural Wulingshen, to develop an industrialized production pattern for Wulingshen fermentation power (Wuling Powder). By taking the market-oriented approach, our company keeps an intensive research in Wuling Powder, and has successfully developed Wuling series products, Wuling Capsule, a kind of national first class new medicine, Linglianhua Particle for menopausal syndrome treatment, Lingze Tablet for BPH treatment. With the acquisition of Qinghai Everest Cordyceps Sinensis Pharmaceutical., Ltd, we successfully own a blockbuster, the “Bailing Tablet”, a cordyceps sinensis fermented preparation which belongs to the medicinal fungi field

For years, our company keeps on product innovation, market innovation and management innovation. Thanks to the actively development of the market, we have achieved growth in sales, profits and tax payment in succession, and consequently our company is developing at an incredible speed. Meanwhile, we have also received many honors like “National Torch High-tech Enterprise”, “State High-tech Enterprise ”, “National Model Harmonious Enterprise”, “National Labor Medal ”, “Zhejiang Green Enterprise”, “Zhejiang Honest and Faithful Enterprise”, “Zhejiang Model Unit”, “Zhejiang Innovation-based Pilot Enterprise ”, “Zhejiang Excellent Private Enterprise”, “Chinese Famous Trademark”, “Zhejiang Famous Brand”, “Zhejiang Well-known Enterprise” and “Zhejiang Famous Brand product”.

We will stick to our enterprise spirit: “assist human health and attribute to the pharmaceutical development of China”, take “innovation, dedication, excellence, cooperation and win-win” as our core concepts, stick with the Wuling-series products and take the industrialization of medicinal fungi as our responsibility, and rely on "pharmaceutical manufacturing, pharmaceutical distribution, medical services" the three major platforms to construct chronic disease and health management ecosystems.

广西梧州中恒集团股份有限公司

Guangxi Wuzhou Zhongheng Group Co., Ltd.

广西梧州中恒集团股份有限公司简介（简称：中恒集团），是一家以制药为核心主导，拥有健康食品等延伸板块的多元化、现代化集团上市公司（股票代码：600252），国家级高新技术企业、中国医药制造业百强企业，华南地区最大的心脑血管中药注射剂生产企业。

中恒集团下属的梧州制药，是我国中药行业前端的一颗璀璨明珠，在近90年的创新发展中，拥有了广西医药产业工程院、广西药物提纯工程技术研究中心、广西千亿元研发中心、院士工作站等技术平台，自主创新能力处于领先地位，已成功研发了注射用血栓通、中华跌打丸、妇炎净胶囊等核心科技产品，拥有了13大类217个品种，收载于《中国药典》品种102个。尤其注射用血栓通（冻干），属国家基本药物、医保甲类品种，在上市20多年中，质量保证、疗效显著、使用安全，成为中药注射剂治疗心脑血管疾病的首选用药。

集团下属的双钱实业，是我国最大的龟苓膏健康食品生产企业，主导产品“双钱”牌是中华老字号，深得消费者喜爱。

中恒集团牢牢把握国家新一轮深化改革开放，全面建成小康社会，大力推进“一带一路”战略，以及中国—东盟自贸区开放带来的历史性机遇，以医药医疗健康领域的传承与创新，提升人类生命质量体验为使命，以中药产业链为主体，以消费者健康为延伸，以特色化学药为补充，以研发、营销、资本为核心抓手，致力于培育“品质、创新、包容、卓越”的核心价值观，塑造“执行、分享、创造、成长”的企业团队精神，打造全球医药健康价值链的服务运营商，成为医药健康产业综合性企业集团，为助力健康中国再立新功。

Guangxi Wuzhou Zhongheng Group Co., Ltd. (short for Zhongheng Group), is a diversified and modernized listed group enterprise (stock code: 600252) with pharmaceuticals as the business core and healthy food as one of the business extensions, which receives reputations as National High-tech Enterprise, Top 100 of Chinese Pharmaceutical Enterprises and the Largest TCM injection manufacturer for cardio-cerebrovascular diseases in Southern China.

Wuzhou Pharmaceutical, a subsidiary of Zhongheng Group, is a splendid pearl at the leading edge of TCM industry. In nearly 9 decades' innovative development, Wuzhou Pharmaceutical has possessed technology platforms such as Guangxi Pharmaceutical Industrial Academy of Engineering, Guangxi Technological Research Center of Purification Engineering, Guangxi Hundred-billion Yuan R&D Center and Academician Workstation, successfully developed core technology products includes Xueshuantong for Injection, Zhonghua Dieda Pill and Fuyanjing Capsule, and developed 217 varieties of medicine in 13 categories, among which 102 varieties are collected into Chinese Pharmacopoeia. Specially the Xueshuantong for Injection (lyophilized), the national essential drugs and the catalog A medicine in medical insurance, during the 20 years marketing history, with assuring quality, significant efficacy and safe usability, has become the preferred drug to cure cardio-cerebrovascular diseases among TCM injections.

Wuzhou Double Coins, another subsidiary of Zhongheng Group, has been Chinese biggest manufacturing enterprise of Guiling Gao healthy food. The 'Double Coins' Guiling Gao is the leading product, which is the Chinese time-honored brand and deeply praised by the customers.

Zhongheng Group firmly grasps the historical opportunities brought by the policy of China's deepening reform and opening-up, comprehensive construction of moderately prosperous society, vigorous promotion of 'One Belt, One Road' strategy and the opening-up of ASEAN-China Free Trade Area, closely embraces the mission of inheritance and innovation in Medical & Health Care area and improving human life quality. Taking TCM industrial chain as the main, customers' health as the intension, characteristic chemical medicine as the supplement and R&D, marketing and capital as the key points, Zhongheng Group strives to cultivate the core values of 'Innovation, Quality, Inclusiveness and Excellence', shape the team spirit of 'Execution, Sharing, Creation and Development', create a service provider of worldwide Health and Medicine value chain, so as to become a comprehensive enterprise group in Health and Medicine industry and give more contribution for building healthy China.

南京圣和药业股份有限公司

Nanjing Sanhome Pharmaceutical Co., Ltd.

南京圣和药业股份有限公司始建于1996年，是一家集新药研发、药品生产和市场营销为一体的国家重点高新技术企业。

圣和人以“让更多的人享受健康的快乐”为使命，努力提高新产品的科技含量，致力于新产品的科技开发，迄今已获新药证书近百本，拥有国家发明专利及国际专利数十项。通过自有技术、独立开发的中西药品种中有国家一类新药，有国家重点新产品，有国家中药保护品种，有全国独家产品。公司承担了包括国家863计划、重大新药创制专项、国家创新基金、国家高技术产业化专项、国家火炬计划在内的国家和省级重点科研项目。新产品的开发不仅为企业的建设增添了经济实力，还为企业可持续发展蕴藏了生机。2008年，国家人力资源和社会保障部批准设立“博士后科研工作站”；圣和还设有省级工程技术研究中心、省级企业技术中心、省级企业院士工作站以及国家级创新药物孵化平台等。

圣和药业目前拥有片剂、颗粒剂、胶囊剂、冻干粉针剂、粉针剂、软膏剂、大容量注射剂、小容量注射剂等十多种剂型生产线，多达30余种的药品行销国内市场，其中“圣诺安”、“圣诺灵”、“消癌平”、“优诺安”等多个主导产品分别被国家、省、市认定为“高新技术产品”。现有 20个创新药处在不同的研发阶段， 2个1.1类创新药已获得临床批件， 2个1.1类创新药正在申报临床阶段。未来公司将不断推出疗效好、市场前景广阔的新品上市，形成了本企业科技创新的特色。

公司建立二十年来，一步一个脚印走出自己发展的路子。2004年，中华全国总工会授予本公司“五一劳动奖状”荣誉称号，公司还先后被国家、省市有关部门评定为“国家重点高新技术企业”、“中国优秀民营科技企业”、“中国化学制药工业企业百强”、“中华全国工商业联合会科技进步奖”、“江苏省科学技术进步一等奖”、“江苏省优秀民营科技企业”、“江苏省质量信用等级A级企业”、“中国专利优秀奖”和“中国医药制造业守法诚信企业”等荣誉称号。

Nanjing Sanhome Pharmaceutical Co., Ltd.was founded in 1996, and it is aState Key High-tech Enterprise integrating new drug development, production and marketing.

Sanhome’s corporate values are to help more people enjoy the healthy life, so we are motivated to improve the novelty and technology of the drug product. So far, we have been granted almost one hundred new drug certificates by the CFDA, and dozens of China invention patents as well as international patents. There are National New Products, National Protected Traditional Medicines and exclusive drug products in our pipeline. Sanhome also undertakes many national and provincial key programs, including National High-tech R&D Program of China (863 Program), National Science and Technology Major Projects for "Major New Drugs Innovation and Development", National Fund for Innovation, National Industrialized High-technology Program, and National Torch Project. In 2008, the Ministry of Human Resources and Social Security of the People's Republic of China granted Sanhome to set up a “Post-doctoral Research Center”. In addition, Sanhome is also granted to set up several R&D centers by the government, including Provincial Engineering Technology Research Center, Provincial Enterprise Technology Center, Provincial Enterprise Academician Workstation and National Incubator for Innovative Drugs.

Sanhome is capable to manufacture multiple drug formulations such as tablets, granules, capsules, freeze-dried powder injection, powder injection, ointment, large and small volume injections. More than 30 types drugs are distributed in China, and “Sheng Nuo An”, “Sheng Nuo Ling”, “Xiao Ai Ping” as well as “You Nuo An” are designated as the High-tech Products by the government. At present, we have 20 new molecular entities (NME) in the pipeline. Two of them are Type 1.1 New Drug and their IND applications have been approved by the CFDA. Another two NME is in progress for IND. Sanhome will keep bringing out new drug products with good efficacy and safety to the drug market.

During the past 20 years, Sanhome has proven itself as an innovative pharmaceutical company. Sanhome has been awarded “the National May 1 Labour Medal”, “State Key High-tech Enterprise”, “Top 100 Enterprises of Chemical and Pharmaceutical Industry in China”, “All China Federation of Industry and Commerce (ACFIC) Award for Progress in Science and Technology”, “the First Prize Winner of Jiangsu Science and Technology Progress Award”, “Jiangsu Excellent Private Science and Technology Enterprises”, “Grade A Enterprise of Quality Credit Rating in Jiangsu”, “China Excellent Patent Award” and “China Pharmaceutical Manufacturing Industry Law-abiding Integrity Enterprise”.

山东步长制药股份有限公司

Shandong Buchang Pharmaceutical Co., Ltd.

步长的事业起步于1993年，经过二十余年艰苦奋斗，已发展成一个以医药产业为主，同时涉足高科技产业、健康产业等众多领域，多元化经营的产业集群。其医药板块“步长制药”是一家专注于中药专利药研发、生产、销售的国内知名企业。在山东、陕西、河北、吉林设有生产基地，同时在北京、上海、广东设有分公司，分支机构遍布中国主要省份。经过多年发展，公司已建成一支高素质、专业化团队，拥有十个事业部、十家药厂，销售网络交叉覆盖全国3万个医院和20万零售药店。

赵涛董事长1996年被评为全国优秀青年企业家，中国侨商投资协会副会长，并被推选为中国企业家协会常务理事。2001年中国“创业之星”，陕西“三五”人才，2003年与杨利伟等人荣膺十大中华英才称号，2004年荣获“中国十大风云人物”。2008年11月荣获“最具社会责任企业家”，2008年12月荣获“2008品牌中国年度人物”，2010年，赵步长、赵涛父子被誉为“中国特色慈善家”。2012年在第九届中国最佳企业公民评选颁奖盛典中赵涛被评为“中国最具社会责任企业家”。2012年荣获中国创业发明金奖。2013年荣获“年度慈善家”。

自2008年起，公司创始人赵步长教授、赵超博士双双当选第十一届、第十二届全国人大代表，这是党和国家给予步长的最高荣耀和最大鼓励。2010年11月，丹红注射液荣获“中国首个中药专利金奖”；“步长脑心通”荣获“中药产品品牌十强”等荣誉称号。2012年，步长制药凭借在企业社会责任方面的突出表现再次荣膺“最佳企业公民”大奖。2013年，步长蝉联中国制药工业百强中药企业第一，并荣膺“2013中国五星级企业公民”荣誉称号。

公司勇于承担社会责任，在社会公众心目中树立了良好的企业形象。公司自1997年起，连续多年位居当地民企纳税前茅；社会公益事业方面的捐款4亿多元。共铸中国心活动自2008年发起至今，共组织近5000名医生志愿者，先后走过四川、宁夏、山东、内蒙古、西藏、青海等地区的300多个乡镇，为二十多万人次进行过诊疗救治，并免费救助先心病儿童，使300多名先心病儿童手术后重获健康。 公司已连续多年荣获“中国医药卫生行业社会责任孺子牛奖”。

Buchang Pharma, established in 1993, has developed into a diversified industrial cluster after twenty-year arduous struggle, based on main pharmaceutical industry and meanwhile involved in high-tech, health, education and many industries. The pharmaceutical part, Buchang Pharma CO. LTD., is a famous enterprise in China, engaged in the research & development, production and sales of TCD (traditional Chinese Drugs) patent medicines. Buchang Pharma has production bases in Shandong, Shaanxi and Heibei province, at the same time, set up filiales in Beijing, Shanghai and Guangdong. Branched organizations are all over China. According to years of development, the company has have owns a highly qualified and professional team, 10 business departments, 10 pharmaceutical manufacturers, and the sales network has covered 30,000 hospitals and 200,000 drug stores.

In 1996, Mr. Zhao Tao, the Chairman of Buchang, was awarded as the National Outstanding Young Entrepreneurs, vice president of China Overseas Chinese Investment Association, and was elected as the standing director of China Entrepreneurs Association. China Enterprising Star in 2001, "the third five years plan" shaanxi talent; In 2003, honored Ten Prominent Chinese award, including Yang Liwei as the same title; In 2004, won the China Top Ten Person; In November 2008, won the "most social responsibility of entrepreneurs". In December 2008 was awarded "2008 China Brand Person of the year". In 2010, Zhao Buchang and Zhao Tao (both father and son) were known as "China Characteristics Philanthropist". In 2012 in the ninth China awards best corporate citizen evaluation, was named "China's most socially responsible entrepreneurs"; In 2012, won the Golden Award of Chinese Entrepreneurial Invention; In 2013, rewarded the “Annual Philanthropist".

Since 2008, the founder of Buchang Pharma, Prof.Zhao Buchang and the President Dr. Zhao Chao, were both elected the representatives of the 11th and the 12th National People's Congress, which was the greatest honor and the biggest encouragement of the government and the country. In November 2010, Buchang Danhong Injection obtained "The First Gold Prize of Traditional Chinese Medicine"; Buchang Naoxintong Capsule got the "Top 10 Product Brand of Traditional Chinese Medicine"etc. In 2012, with outstanding performance in social responsibility,Buchang Pharma got the "Best Corporate Citizens" award again. In 2013, Buchang Pharma had continuously won the first one of National Top 100 Pharmaceutical Industry Enterprises and got the 2013 China Five-star Enterprise Citizen honorary titles.

Buchang Pharma undertakes the social responsibility valorously and sets a good corporate image in the public minds. Since 1997, Buchang company has ranked first of tax pay private enterprise continuously for many years in the local place. Donate up to 400 million Yuan in social public welfare. since launched in 2008 to now, Build China Hearts activity has organized nearly 5000 doctors volunteers, successively passed Sichuan, Ningxia, Shandong, Inner Mongolia, Tibet, Qinghai and more than 300 villages and towns regions, which has been diagnosis and treatment for more than 200,000 patients. Meanwhile, it also gives free relief to the congenital heart disease children, which makes more than 300 congenital heart disease children regain his health after the operation. Buchang Pharma has won the China Medicine and Health Industry Social Responsibility - A Willing Ox Award consecutively for many years.

悦康药业集团有限公司

Youcare Pharmaceutical Group Co., Ltd.

悦康药业集团创建于1988年，2001年在北京经济技术开发区建厂并成立集团总部，是一家集新药研发、药品生产和流通销售于一体的医药集团企业。自成立以来，集团围绕做好产品、做大产能、完善产业链的三个中心任务，在国内建立了以安徽原料药基地为基础，以北京、上海、广州、重庆四个特色制剂基地为核心的医药全产业链发展格局。2008年起集团连续多年入选中国医药工业企业百强，医药工业研发十强；2010年被科技部认定为国家火炬计划重点高新技术企业，是中国医药工业制剂国际化先导企业和北京生物医药产业跨越发展工程G20领军企业；2016年被工信部、财政部认定为国家技术创新示范企业。

创新产品是悦康的发展战略和肩负的责任。集团从仿制到创新，从普药到新药，不断研制生产出保障百姓健康需求的好药。目前，集团主要产品覆盖抗生素类、消化类、心脑血管类、抗肿瘤类、免疫调节类、抗病毒类、降糖类等十多个治疗领域，剂型囊括小水针、冻干粉针、片剂、胶囊剂、颗粒剂、栓剂、膏剂、凝胶剂等。其中，悦康头孢类粉针制剂和消化类微丸缓控释制剂等系列产品产销量连续多年稳居全国市场前列。2015、2016年连续两年获得国家科技进步二等奖，并被批为头孢药物晶型研究国家地方联合工程实验室。

悦康不仅立足国内，更瞄准国际市场。目前，集团已有70多个品规产品在德国、英国、俄罗斯、巴基斯坦、非洲、拉美等40多个国家和地区注册并销售。2011年，悦康固体片剂和胶囊剂生产线通过欧盟GMP认证后，以奥美拉唑肠溶胶囊为代表的认证产品相继打入德国、英国市场。2015年通过了再认证，为开拓欧美市场奠定了基础，同年集团广州药厂通过日本JGMP认证。

“营造全球喜悦，关爱人类健康”是悦康的企业宗旨，悦康人在“合和”文化的感召下，加强国内国际的融合，诚信勤奋，为实现“创行业名牌，建药业航母”的目标努力奋斗。

Youcare Pharmaceutical Group, was founded in 1988. In 2001, the manufacturing site and headquarter of Youcare were established in Beijing Economic-Technological Development Area. Till now , Youcare is a multi-aspect pharmaceutical enterprise integrated with new drug research, drug manufacturing, sales and distribution. Since its foundation, Youcare has always focused on the continuous improvement of product quality, capacity ramp-up to completion of industrial chains. The Group has set up an API production base in Anhui and 4 major specific core formulation manufacturing sites in Beijing, Shanghai, Guangzhou and Chongqing. Since the year of 2008, the Group has been listed in the TOP 100 China Pharmaceutical & Industrial Enterprises and the TOP 10 Pharmaceutical Enterprise in R&D for many consecutive years. In 2010, Youcare Group was also recognized by the Leap-forward Development Program for Beijing Bio-Pharmaceutical Industry(G20) as the leading enterprises. In the same year, Youcare was recognized by the Ministry of Science and Technology as the key high-tech enterprise of National Torch Plan. In 2016, Youcare was identified by the Ministry of Industry and Information and the Ministry of Finance as the National Model Enterprise for Technological Innovation.

Innovation is Youcare's development strategy and responsibility. From the production of generic drugs to the development of new drugs, the group is incessantly developing high-quality drugs for people's health. To date, Youcare’s products have covered a wide range of therapeutic fields such as antibiotics, digestive system, cardio-cerebrovascular disease, anti-tumor, regulation of the immune system, antivirus, and glucokinin. The products also exhibits a variety of dosage forms, including vial injection, freeze-dried powder for injection, tablet, capsule, granule, suppository, paste and gel. Among the abovementioned products, the cephalosporin powder for injection and the sustained release digestive pellets haven been dominant in the domestic market for years, contributing leading sales volumes in the industry. In Jan, 2016, the Omeprazole development project in which Youcare has participated was awarded the second price of the State Scientific and Technology Progress Award. Meanwhile, Youcare was also certified as the National Joint Engineering Laboratory of Crystalline Cefalosporins.

YOUCARE focuses on domestic market as well as aims at international market. By far, there are over 70 drugs of certain specification registered and sold in more than 40 countries and regions including Germany, UK, Russia, Pakistan, Africa and Latin America. Since Youcare’s production lines of tablets and capsule passed EU GMP certification in 2011, its certified products, taking Omeprazole enteric capsule as a representative, have entered German and British market in succession, which laid a foundation for the market development in Europe and America. In the year of 2015, Guangzhou Youcare manufacturing site was certified by the Japanese GMP.

"Creation of global joy, Care of human health" is the long-term concept Youcare observed. Taking "Hehe Culture (cooperation and harmony)" as root, Youcare actively integrates the home and the abroad together, and strives to create a leading famous brand within industry with its integrity and diligence.

江苏奥赛康药业股份有限公司

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

江苏奥赛康药业股份有限公司起源于董事长陈庆财博士1992年创办的江苏省第一家非公有制药物研究机构----南京海光应用化学研究所。公司专注于抗消化道溃疡药物质子泵抑制剂（简称PPI）和抗肿瘤药物等领域药品的研发、生产和销售，是中国PPI注射剂细分领域的国内领军企业，2016年位列中国医药工业百强企业第73位。

奥赛康药物研究院，下设6个研究所，并在美国建立了独资的奥赛康美国生物医药研究所（AskGene），专门从事生物医药前瞻性研究和创新药研发，研发团队先后入选“南京市高端人才团队引进计划”、”江苏省双创团队”、其中2人入选“国家千人计划”，5人入选“江苏省双创个人计划”。

奥赛康建有江苏省手性药物重点实验室、国家级博士后工作站，是江苏省抗消化道溃疡药物工程技术研究中心、江苏省企业技术中心、江苏省靶向抗肿瘤药物工程中心。荣获“江苏省科技奖----江苏省企业技术创新奖”、首批“江苏省创新示范企业”、 “中国医药创新力企业”20强。

奥赛康的产品均为自主研发，获得授权专利164件，2016年荣获“中国专利金奖”1项（发明专利），2017年荣获国家知识产权示范企业。

公司近几年还先后荣获“全国五一劳动奖状”、“南京市市长质量奖”、“江苏省质量奖”、“中国医药质量管理奖”等荣誉。

ASK originates from Nanjing Haiguang Applied Chemistry Research Institute founded by chairman Dr. Chen Qingcai in 1992, the first provincial, non state-owned drug research institute. ASK specializes in the R&D, production, and sales of proton pump inhibitor (PPI) for anti-peptic ulcer and anticancer products, hence the national leading enterprise in the Chinese PPI injection niche market, ranked at 73rd in the “Top 100 National Pharmaceutical Companies ” list 2016.

ASK Drug Research Institute has subsidiaries of six research institutes, and established ASKGene Pharma US in USA as the sole investor, engaging in the prospective research of biopharmaceuticals and research of innovative drugs. Its R&D team has been accredited for “Nanjing City Program for High-Level Talent Team Introduction” and “Jiangsu Province Innovative and Entrepreneurial Team”, in which two people have been chosen for the “National 1000 Talents Plan”, and five people have been accredited for “Jiangsu Province Innovative and Entrepreneurial Individual Program”.

ASK has established the Jiangsu provincial key laboratory for chiral drug research and national postdoctoral workstation, functioning as Jiangsu province anti-peptic ulcer drug engineering technology research center, Jiangsu province enterprise technical center, and Jiangsu province targeted anticancer drug engineering center. ASK’s honors include Enterprise Technology Innovation Prize of Science and Technology Prize in Jiangsu Province, the first batch of Model Innovative Enterprise in Jiangsu Province, Top 20 Chinese Pharmaceutical Corporates in innovation, etc.

ASK’s products are all developed on its own, which has acquired 164 authorized patents altogether, including a “Chinese Patent Golden Award (patent for invention)” in 2016 and “National Intellectual Property Model Enterprise” in 2017.

In these years, ASK also received numerous honors such as “National May First Labor Award”, “Nanjing Mayor Quality Award”, “Jiangsu Province Quality Award”, “Chinese Pharmaceutical Quality Management Award”, etc.

重庆植恩药业有限公司

Zein Pharmaceutical Co., Ltd.

重庆植恩药业有限公司创办于2001年，是立足于重庆的一家集研发、生产和销售一体化的新兴医药企业，是一家集两江工程中心、手性工程中心和新药设计工程中心等三大研发中心、原料药生产基地、制剂生产基地和销售总部的集团公司。

植恩药业在研发方面具有丰富的经验。目前已经获得新药证书33项、临床批件32项、生产批件51项；申请国家发明专利数十项，其中已获国外专利授权3件，国内专利授权12件。公司已开展研发项目32项，承担包括国家重大新药创制项目（“11.5”和“12.5”）等70余项各类课题，并获得全国及省级奖项数十项。目前在研项目涉及神经系统药物、代谢系统药物、消化系统药物及其他类药物，其中神经系统药物已成为公司发展的主要方向，其中包括化药1类新药2项、中药5类新药1项。

植恩药业产业化能力较强，产能正逐步扩大。现有原料药生产基地年生产能力超过40吨，新建82000平方原料药生产基地将使产能提高到每年60吨-80吨，核心API品种奥利司他质量及产能达到国际先进水平，产品已热销巴西、澳大利亚、德国、波兰、新加坡和韩国，且已经在美国和印度递交上市申请，未来国际市场将进一步拓宽。现有制剂生产线可生产胶囊剂、颗粒剂、片剂、栓剂等剂型，在建制剂生产线将新增冻干剂型、小/大容量注射液等剂型，在建制剂产业化基地建筑面积33330㎡。

公司产品丰富，后续产品充足。目前主打产品有奥利司他、盐酸多奈哌齐、盐酸罗匹尼罗、甲磺司特等，即将上市的重点产品包括盐酸他利克索和盐酸兰地洛尔等。

植恩药业具有强大的一级市场到达终端市场的分销商网络。目前拥有零售终端及医院终端销售人员500余人。产品覆盖30个城市 2000 多家医院，40000家药店。外贸方面，原料药出口到全球20多个国家。

公司以“木直因心，植药为仁”为座右铭，以“创建中国医药与健康服务的领先企业”为发展目标。在强大的医药研发团队、高效的医学注册能力、广泛坚固的医药渠道网络、专业化的市场销售能力、权威的政府事务及专业机构合作能力支持下，将公司打造成行业内知名的高新技术医药企业。

Founded in 2001, Zein is a pharmaceutical enterprise in Chongqing, which focused on research, production, sales and market. As a group company, Zein owns three R&D centers which are Liangjiang Medicine Co., Ltd., Chiral Engineering Center and New Drug Design Engineering Center, an API manufacturing base, a preparation manufacturing base and a sales company.

Zein is experienced in R&D. At present, it has obtained 33 new drug certificates, 32 clinical approvals and 51 production licenses and has already applied dozens of National Invention Patents, in which 3 foreign patents and 11 domestic patents have been authorized. Zein has initiated 32 R&D projects, assumed more than 70 projects, including “Major National New Drug Development Project” (“11.5” and “12.5”) and acquired dozens of national/province awards. Zein’s understudied projects involve drugs of neural system, metabolic system and digestive system etc, in which neural drugs are the main products, including 2 State Category I New Drugs and 1 Chinese Herb Category V New Drug.

Zein is equipped with a strong capability of industrialization which is growing continually. The production capability of the API manufacturing base is more than 40 tons, and the new 82,000 m2 API manufacturing base that is under construction will increase the capability to 60-80 tons. The quality and capability of core API, Orlistat, reaches the international advanced level and Orlistat is popular in Brazil, Australia, Germany, Poland, Singapore and Korea. The listing applications have been submitted to United States and India to explore the potential international market. The existing preparation production line meets the manufacturing requirements of capsule, granule, tablet and suppository etc. The new line under construction that covers a building area of 33330 m2, will add the production of lyophilized powder and large/small volume injection.

Zein owns a rich product catalog and plenty of follow-up products. Currently, the fist products are Orlistat, Donepezil Hydrochloride, Ropinirole hydrochloride and suplatast tosilate. The key products, including Talipexole Hydrochloride and Landiolol Hydrochloride will be marketed soon.

Zein also owns a strong distributor network from primary market to terminal one. There are more than 5000 salesmen distributed from the retail terminal to the hospital terminal. Zein’s products cover 30 cities, including 2,000 hospitals and 40,000 drugstores. Zein’s APIs are exported to more than 20 countries worldwide.

Zein develops medicines with a beneficent heart and pursues to be one of the leading companies in Chinese medicine and health service. With the supporting of strong pharmaceutical research and development team, efficient medical registration ability, wide selling network, professional market-selling ability, and cooperation with government and professional institutes, Zein is growing to be a well-known and high-tech pharmaceutical enterprise.

正大青春宝药业有限公司

Chiatai Qingchunbao Pharmaceutical Co., Ltd.

在杭州西郊桃源岭下，有一座高度现代化的中药城——正大青春宝药业有限公司，其前身杭州第二中药厂原为百年老店胡庆余堂的制胶车间。早在上世纪80年代，就被树为我国中药行业的“样板企业”和对外开放的窗口。而今正大青春宝，在充满生机的古树林下，鸟语花香的丛林当中续写新的故事，创造新的辉煌。

正大青春宝由一间只有37万元资产的落后中药作坊起步，逐步发展成为国内规模最大、设备最先进、以生产天然药物为主的集科研、生产、经营一体化的综合性制药企业之一，现为上海医药集团股份有限公司直属企业，是国家火炬计划重点高新技术企业、国家中药现代化科技产业（浙江）基地示范企业。合作完成的“中成药二次开发核心技术体系创研及其产业化”项目，荣获了2014年度国家科技进步一等奖，成为国内首个获此殊荣的单体制药企业。

正大青春宝以“振兴国药”为己任，致力于继承和弘扬传统中药，并努力进行现代化改造。2016年公司在浙江德清投资的正大青春宝（德清）药业有限公司奠基，将建成集信息化、自动化、智能化为一体的现代化中药制造基地，为正大青春宝的发展插上了腾飞的翅膀。

青春宝品牌的知名度和美誉度已深入人心。建厂至今，前来视察、指导、参观、学习、交流的国家领导人、外国元首、社会名流以及五大洲四大洋的各界朋友已逾十万。

让人类拥有健康，拥有青春，是“青春宝”人永远的追求。

In the western suburbs of Taoyuan Ridge, Hangzhou, there is a highly modern Chinese medicine city - Chiatai Qingchunbao Pharmaceutical Co., Ltd., whose predecessor, Hangzhou Second Traditional Chinese Medicine Factory, was originally Hu Qing Yu Tang's glue-making workshop with hundred years of history. As early as the 1980s, it was examplified as a “model enterprise” and opening window to the Chinese medicine industry in China. Nowadays, Chiatai Qingchunbao continues to write new stories and create new brilliance under the ancient woods full of vitality and the jungle with birds and flowers. Chiatai Qingchunbao was started by a backward Chinese medicine workshop with only RMB 370,000 in assets. It gradually developed into one of the largest and most advanced equipment manufacturers in China that integrates research, production and management with the production of natural medicines. It is now directly subordinated to Shanghai Pharmaceutical Group Co., Ltd. It is a key high-tech enterprise of the National Torch Plan and a demonstration enterprise of the National TCM Modernization Science and Technology Industry (Zhejiang) Base. The project “Creation Research and Industrialization of the core technology system for the secondary development of proprietary Chinese medicines ”developed by collaboration has won the first prize of the National Science and Technology Progress Award and it has become the first monomer pharmaceutical company in China to win the first prize for national science and technology progress.

Chiatai Qingchunbao is committed to “revitalizing the traditional Chinese medicine” and inheriting and promoting traditional Chinese medicine and is striving to modernize it. In 2016, the company laid the foundation for Chiatai Qingchunbao (Deqing) Pharmaceutical Co., Ltd. invested in Zhejiang Deqing and will build a modernized Chinese medicine manufacturing base that integrates information, automation and intelligence into one. It will add soaring wings to the development of Chiatai Qingbao.

The popularity and reputation of the Qingchunbao brand have been deeply rooted. Since the establishment of the plant, the number of people including country leaders, foreign heads of state, social celebrities and all walks of life from four oceans of the five continents that have come to inspect, guide, visit, study and communicate has been more than one hundred thousand. Rendering humans healthy and youthful is the eternal pursuit of Qingchunbao people.

深圳奥萨医药有限公司

Shenzhen AUSA Pharmaceuticals Ltd.

深圳奥萨医药有限公司为国家级高新技术企业，深圳市南山区民营领军企业、南山国税纳税百强企业，奥萨主要针对严重影响大众健康的心脑血管疾病，研究、开发安全有效的诊断和治疗产品，提供从预防、预测到治疗的系统解决方案。

奥萨已申请专利200多项，82项已经获得授权，成功研发出国家一类新药“依叶”和配套的基因诊断试剂盒，组成全球首个高血压领域“基因诊断-药品”精准医疗产品对，相关研发成果被纳入国内外多个有关脑卒中或高血压的防治指南。H型高血压治疗药物“依叶”荣获2013年中国药学发展奖创新药物奖、2015年首届最具临床价值创新药物奖、2015年中国教育部科技进步奖一等奖、2015年中华医学会中华医学科技奖一等奖、2016年国家科技进步二等奖。近三年，“依叶”疗效评价的中国脑卒中一级预防研究（CSPPT）发表SCI学术论文68篇，影响因子超过460分，其中5分以上文章20多篇。

奥萨的主营销售收入近几年来持续快速增长，复合平均增长率为68%。 “依叶”销售位居同类降压药全国第三名、复方高血压药物销售全国第七名（前十位的其它均是外企产品）。

Shenzhen AUSA Pharmaceutical is a national high-tech enterprise, one of the Shenzhen Nanshan region’s “Top 100 Tax Payer” and “Leading Eneterprise”, primarily focuses on combatting cerebral and cardiovascular diseases, major public health challenges in both China and the world, through the research and development of safe and effective diagnostic and treatment products, and through the provision of systematic solutions ranging from primary prevention, prediction, to the treatment of these diseases.

AUSA has applied for over 200 patents, and has already been awarded with 82. A landmark breakthrough is the successful development of the national type-1 drug “Yiye” and its accompanying gene diagnostic kit. This is the world’s first “gene diagnostics-drug”, a precision medicine product for H-type hypertension and stroke prevention. To date, these research results have been included in numerous hypertension and stroke prevention and treatment guidelines both nationally and globally, and Yiye has helped to save numerous lives. In 2013, “Yiye” received the China Pharmaceutical Development Award and Innovative Medicine award; In 2015, “Yiye” received the first Clinical Value Innovative Medicine Award and the China Education Department Scientific Development Award; In 2016, “Yiye” received the China National Scientific Development Award, second place.

In the past 3 years, the China stroke primary prevention trial (CSPPT) evaluating the efficacy of “Yiye” treatment has made significant contribution to the field, including 68 SCI publications, including more than 20 of which have an impact factor of over 5, reaching an overall impact factor of over 460.

AUSA’s primary sales revenues have increased rapidly in recent years, with a composite growth rate of 68%. In 2016, “Yiye” sales ranked third nationally among same-type antihypertensive medication, and placed seventh among compound antihypertensive medications (All other medicines ranked within the top 10 were products by foreign manufacturers).

三生制药集团

3S Pharmaceutical Group

三生制药集团是一家集研发、生产和销售为一体的生物制药领军企业，致力于以高品质的药品提高患者生存质量，为人类健康造福。目前，集团拥有73项国家发明专利授权，30余种上市产品，覆盖肿瘤、自身免疫、肾病、代谢及皮肤科等治疗领域。集团拥有抗体药物国家工程研究中心以及生物药和化药双平台的4大研发中心，共有31种在研产品，其中16种作为国家一类新药正在研发，并拥有符合GMP标准的5大生产基地。未来，三生制药集团将继续秉持“珍爱生命、关注生存、创造生活”的理念，全力打造全球领先的中国生物制药企业。

3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 73 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 31 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 5 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world's leading bio-pharmaceutical company in China.

亚宝药业集团股份有限公司

Yabao Pharmaceutical Group Co., Ltd.

亚宝药业是一家有着37年历史的集团公司。集药品和大健康产品的研发、生产、物流、销售和中药材种植于一体，下设23个分子公司，有员工近6000人，是山西省医药行业首家上市公司和首批认定的高新技术企业。

公司建有8大生产基地、5大研究基地、2大中药材种植基地。8大生产基地全部通过国家新版GMP认证，其中，北京生物制药通过了美国FDA cGMP认证，三分公司通过了欧盟GMP认证。

主要产品有中西药制剂、原料药和药用包装材料等共计300多个品种，主要为老年慢性病用药和妇女儿童用药，拳头产品丁桂儿脐贴是国家标志性名牌产品。

现有各类营销人员3000多人，建立了专业的商务、代理、临床、电子商务、国际贸易营销队伍，销售网点覆盖全国32个省市的终端市场。同时，公司还建立了药品配送中心，开展药品配送业务。

公司拥有一支国际化的专业研发队伍，各类研发人员总计410余人，其中博士22人，硕士150人。

在全国5030家医药企业中，亚宝药业综合实力排名第87名，是工信部认定的“中国医药工业百强企业”。其中，创新力居第15名，是“中国医药企业创新力20强”。“亚宝”商标为中国驰名商标。

Yabao Pharmaceutical Group Co., Ltd. has a history of 37 years, integrating R&D, production, marketing, logistics and plantation of Chinese herbal medicine with 23 subsidiary companies and about 6000 employees. Yabao is the first listed company among Shanxi Pharmaceutical enterprises and the first batch of new high-tech enterprise.

Yabao owns 8 production bases, 5 R&D bases and 2 Chinese herbal plantation bases. All the 8 production bases has passed the new GMP certification, thereinto, the production line of Beijing Yabao Bio-pharmaceutical Company has passed the FDA certification and No.3 Branch has passed EU GMP certification.

Yabao has more than 300 products in term of Chinese and western medicine, API, and pharmaceutical packaging materials, which are dominated by the medicines for the old age chronic illness and for women and children. Thereinto, “Diarrago”, is a kind of landmark product in China.

Yabao has more than 3000 marketing personnel and has established the marketing teams for professional commerce business, agents, clinic, e-commerce and international trade, with 32 provinces and cities covered by sales network. At the same time, Yabao has established drug distribution center for drug delivery.

Yabao has a internationalized research team with more than 410 research employees; thereinto, there are 22 doctors and 150masters.

Among the 5030 pharmaceutical enterprises, Yabao took the 87th place in term of comprehensive strength, being an accredited “China Hunderd Pharmaceutical Enterprises”. Its innovation strength takes the 15th place and is one of the 20 innovative pharmaceutical enterprises in China. The trade mark of “Yabao” is a famous trademark in China.

常州方圆制药有限公司

Changzhou Fangyuan Pharmaceutical Co., Ltd.

常州方圆制药有限公司其前身是江阴方园制药有限公司，始创建于1994年4月，仅为研发代号“8907”（后定名硫酸依替米星）的科技型孵化企业。为形成产业化生产，江阴方圆制药有限公司于2000年4月迁址常州国家高新技术产业开发区“三药”科技产业基地，更名常州方圆制药有限公司。目前，常州方圆制药有限公司已成为国家重点高新技术企业，市场营销网络已覆盖全国。

公司主导产品硫酸依替米星（商标名“创成”）是拥有自主知识产权的抗生素类一类新药，为新一代半合成氨基糖苷类抗生素，具有高效、低毒、抗耐药菌等优点。该产品同时获得中国、英国、美国、俄罗斯、哈萨克斯坦、日本等国家专利， 2002年分别被评为国家科技进步二等奖，江苏省科技进步一等奖。

为进一步提升产品质量及满足新产品的投产需要，2011年公司在常州生命健康产业园征地96亩建设一期制剂厂区。制剂厂区采用了自动化程度高的设施设备，提高了工作效率，保障了产品质量。水针剂和冻干粉针剂车间2015年被评为江苏省示范智能车间。2015年在内蒙古赤峰市征地302亩，建设原料药生产基地（即内蒙古普因药业有限公司），建成5条原料药生产线，达产后年产22吨各类原料药。

常州方圆制药有限公司坚持“以人为本” 理念， 制定政策，鼓励、选拔和引进各类人才；建立“我以服务方圆为责任，我以方圆发展为荣誉” 的企业文化，以市场为导向，以创新为动力，以质量为中心，致力做精做强做优企业，使之具有较强创新发展能力和抗衡风险能力的优质企业。

Changzhou Fangyuan Pharmaceutical Co., Ltd. whose predecessor is Jiangyin Fangyuan Pharmaceutical Co., Ltd. was founded in April 1994. It was a technical incubated enterprise for the development of code-named "8907" (later named Etimicin Sulfate). For the industrial production, Jiangyin Fangyuan Pharmaceutical Co., Ltd. moved to Changzhou National High-tech Industrial Development Zone, "three drugs" technology industry base, renamed Changzhou Fangyuan Pharmaceutical Co., Ltd. in April 2000. At present, Changzhou Fangyuan Pharmaceutical Co., Ltd. has become a national key high-tech enterprise, marketing network has covered all the country.

The company's leading product of Etimicin Sulfate (trademark "chuangcheng") is a class I new antibiotics with independent intellectual property rights, as a new generation of semi-synthetic aminoglycoside antibiotics, has the advantages of high efficiency, low toxicity, anti-resistant bacteria. The product owns the patents of China, Britain, the United States, Russia, Kazakhstan and Japan. In 2002, it was awarded the second prize of National Advancement in Science and Technology and the first prize of Jiangsu provincial Advancement in Science and Technology.

In 2011, to further enhance the quality of Etimicin and meet the needs of new products put into operation, the company bought 96 acres of land to build phase I preparation plant in Changzhou Life and Health Industrial Park, using high degree of automation facilities and equipment to improve the produce efficiency and assurance of product quality. The small volume injection workshop and the lyophilized powder for injection workshop were named the Jiangsu Provincal demonstration of intelligent workshop in 2015. The company bought 302 acres of land in Inner Mongolia Chefeng City in 2015, to construct the raw materials production base (Inner Mongolia Puyin Pharmaceutical Co., Ltd.), built five raw material production line, up to an annual output of 22 tons of various raw materials.

Changzhou Fangyuan Pharmaceutical Co., Ltd. adhere to the "people-oriented" concept, formulate policies to encourage, select and recruit all kinds of talents. Establish "To serve Fangyuan as our responsibility, take Fangyuan’s development as our proud" corporate culture. Insist of market-focuing, innovation as the driving force, quality as the axis, devote to make fine , stronger, excellent enterprise, make Fangyuan become a excellent enterprise who has a strong ability to innovational development and anti-risk capability.

齐鲁制药有限公司

Qilu Pharmaceutical Co., Ltd.

公司总部位于山东省济南市，是中国大型综合性现代化制药企业，专业从事治疗肿瘤、心脑血管、抗感染、精神系统、神经系统、眼科疾病的制剂及其原料药的研制、生产与销售。现有员工8000余人，其中大专学历以上人员占72.8%。

公司始终坚持创新发展战略，以市场需求为核心，以产品创新为先导，广泛拓展国内外科研开发合作，注重人才的引进与培养，建有一支高素质的科研队伍，具备专业而高效的研发能力，已先后研制成功了近百个国家级新药，为公司未来的发展建立了合理的在研产品线，多项研究被评为国家、省级科技进步奖，并创造了良好的社会效益。

公司建有占地190万平方米的制剂、化学合成、生物技术、抗生素发酵等七大生产基地以及现代化的生产车间，全自动生产线和其他主要生产设备及检测仪器均购自于世界主要专业制药设备制造商，抗生素类原料药、头孢类原料药、抗肿瘤类原料药等数个产品已具有国内乃至世界领先的生产能力和生产水平。

做最优质、最安全的产品是齐鲁人坚定的承诺和行动。公司建设了严格规范的质量控制机构和完善的质量保证体系，是首批国家食品药品监督管理局GMP认证企业。其中非无菌原料药（发酵、化学合成）、无菌原料药及多种制剂通过了美国、欧盟、澳大利亚、英国、南非以及其它国家和地区药品监管机构的认证。

公司的产品结构科学完整，已上市产品达160余种，具有治疗领域广、产品系列化特点。凭借过硬的产品质量、全心全意为客户的服务宗旨，在医药领域树立了齐鲁品牌，拥有遍布全国各大省市，远销欧洲、北美、俄罗斯、南美、东南亚、中东等地的世界级销售网络，以卓越的服务向中国和世界呈现着完全可以信赖的真诚。

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological and Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has 8000 employees.72.8% of them have junior college or above educational backgrounp.

Oriented by market demands, Qilu Pharmaceutical adopts a strategy of innovation & development. The company widely cooperates with domestic and international partners on R&D projects. Qilu enrolled many qualified personnel and have a highly qualified research team. Many projects are awarded State or Provincial Scientific and Technological Progress Award and benefit greatly to the society.

Qilu Pharmaceutical has seven manufacturing sites covering an area over 1,900,000 ㎡including finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The automatic production lines, key equipment and analytical instruments are imported from major professional vendors. Now Qilu Pharmaceutical is one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Thanks to the integrated and stringent system of quality control and quality assurance, the company is a leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.

深圳微芯生物科技股份有限公司

Shenzhen Chipscreen Biosciences Co., Ltd.

微芯生物(CHIPSCREEN BIOSCIENCES)始终秉承：“原创、安全、优效、中国”——致力于为患者提供可承受的创新机制治疗药物。

2001年，微芯生物在深圳创立，专长于原创小分子药物研发，以自主创建的“基于化学基因组学的集成式药物发现及早期评价平台”为其核心竞争力，是一家“以研发为驱动力，市场为中心”的原创新药物研发领域的领军企业。目前公司已形成针对恶性肿瘤、糖尿病、内分泌及自身免疫性疾病的多条原创新药产品线，抗肿瘤原创新药西达本胺（爱谱沙®）已获国家食品药品监督管理总局（CFDA）批准上市。

微芯生物也是国家“创新药物孵化基地”、“国家高新技术企业”，独立承担多项国家“863”计划、“十五”、“十一五”、“十二五”及“十三五”国家重大科技专项及“重大新药创制”项目。

与此同时，公司通过对国外制药公司实施专利授权，建立国际临床联合开发以及与跨国药企高水准合作研究的商业模式，实现了中国原创新药全球同步开发的步伐。

Chipscreen is a leading integrated biotech company specialized in discovery and development of novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of commercial, clinical and preclinical stage programs in a number of therapeutic areas including oncology, metabolic disease and autoimmune/inflammatory diseases. Our core competence is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise.

Chipscreen's business strategy is to generate differentiated drug candidates across multiple therapeutic areas. Drug candidates are either developed by Chipscreen or co-developed and commercialized in a partnership at the research, preclinical and clinical stages.

Chipscreen was established as Sino-foreign joint venture in 2001 by several highly regarded Chinese returnees from the United States with academic, scientific, and industrial experience. Our founders established our company out of a common vision to create the leading drug discovery and development firms, and to provide affordable innovative pharmaceuticals in China.

青岛黄海制药有限责任公司

Qingdao Huanghai Pharmaceutical Co., Ltd.

青岛黄海制药有限责任公司是中国研发、生产、销售缓控释制剂的高新技术企业。历经医药改革大潮的洗礼，现拥有全资子公司三家，控股公司两家，形成了以医药制剂生产为主业，向上覆盖药用原辅料生产，向下涵盖药品物流配送的综合性医药产业格局。

公司以打造中国缓控释制剂领军企业为战略目标，以心脑血管用药、内分泌用药、神经类疾病用药、抗肿瘤药物为产业重心，产品涵盖片剂、胶囊剂、口服液体制剂、颗粒剂、小容量注射剂等100 多个品种规格。主要产品有伲福达、伲利安、畅欣达、麦特美、元顺、复方甘草口服溶液等。其中，伲福达连续多年在全国同类品种中的产销量排名中名列第一，被多次认定为“山东名牌产品”，具有极高的社会美誉度。

公司建立了完善的生产质量管理体系，2012 年一次性通过口服制剂新版GMP 认证，产品质量名列前茅。公司以缓控释技术为核心，是国内缓控释制剂的生产基地。公司积极与国内外一流的医学院校、研发机构合作，装备有国际先进水平的研发设备和检验仪器，研发实力雄厚。公司营销以学术服务为主要特色，营销网络遍布全国各地。公司先后荣获“国家AAA 级信誉企业”、“中国医药制造业纳税百强企业”、“中国化学制药行业工业企业综合实力百强企业”、“山东省医药行业最具实力企业”等荣誉称号。公司秉承“真诚、务实、专业责任”的企业文化，不断完善，不断进取，在“呵护生命每一天”的品牌理念指引下，为人民大众的生命健康而不懈努力。

Qingdao Huanghai Pharmaceutical Co., Ltd. is a R&D based high-techenterprise; focus on the discovery, development, manufacture and marketing of sustained and controlled release drugs. After the reform, it has three wholly-owned subsidiaries, two shareholding companies, covering not only pharmaceutical preparations, but also the upstream and downstream, including API and excipient supply, drug logistic and distribution. The company has set upa comprehensive whole industry chain management pattern.

Leading in China sustained and controlled-release preparation technology is the company strategic goal. The enterprise architecture rests on four pillars, which are four therapeutic areas, cardio-cerebral vascular, endocrine, neurology and oncology. The products cover a wide range, more than 100 varieties including granules, small volume injections, tablets, capsules, oral solutions etc., and main branded products include Nifedipine (Nifedipine Sustained-release Tablets II), Nilian (Candesartan Cilexetil Capsules),Changxinda (Isosorbide Dinitrat Sustained-release Tablets), Metformi(Metformin Hydrochloride Sustained-release Tablet) , Yuanshun (Paracetamol,Caffeine, Pseudoephedrine Hydrochloride and Chlorphenamine Maleate Capsules), and Compound Glycyrrhiza Oral Solution, etc.. Among these products, Nifuda production and sales are ranked No. 1 in the country for many years. It has been repeatedly identified as “Shandong Famous Brand”, with high social reputation.

The company established an advanced production quality management system,which passed oral preparation new GMP certification in 2012. The products are of high quality and reliable. The sustained and controled-release preparation technology is company’s core competitiveness, QingDaoHuangHai is the production base of sustained and controled-release preparation technology. The company has been collaborating with domestic first-class medical institutions, research institutions. The advanced R&D equipment and testing equipment help to strengthen the R&D capability. The sales and marketing of company products is based on academic services, building a sales network throughout the country.

The company has been honored as “national AAA credit enterprise”, “Chinese medicine manufacturing tax hundred enterprises”, “Chinese industrial enterprises in the chemical and pharmaceutical industry, the overall strength of hundred enterprises”, “Shandong Province pharmaceutical industry’s most powerful enterprise”. Sincere, Pragmatic, Professional and Responsible are the key of company culture. Qingdao Huanghai will continuously improve its products and services through continuous innovation to contribute to life and healthcare. “Caring For Life every day “ is not only brand philosophy, but also the actions.

江苏豪森药业集团有限公司

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

江苏豪森药业集团有限公司，成立于1995年，经过21年的持续稳健的发展，已成为集化学、生物药物研究，医药中间体、原料药合成，制剂生产和产品销售于一体的现代化创新型医药集团。豪森连续多年位居“全国医药工业百强”前30强，“中国创新力十强医药企业”前3强。豪森被国家工信部、财政部认定为“国家技术创新示范企业”。

从美国新泽西、上海到连云港，豪森建立了完整的药物研发体系。3万平米的研发中心、近千人的专业技术人员、上千台国际先进的研发设备和检测仪器、每年数亿元的研发投入，豪森已成为行业内技术集聚、人才集聚、资金集聚的研发高地！

在抗肿瘤、精神、糖尿病、心血管等6大疾病领域，豪森已有近50个品种正在服务于患者。盐酸吉西他滨荣获国家科技进步二等奖；近20个研发项目列入国家“重大新药创制”科技重大专项。历经十多年的研发，两个自主创新药物吗啉硝唑和甲磺酸氟马替尼将率先投放市场，还有10多个1.1类创新药物正在进行临床研究。

药品质量事关患者的生命安全。豪森坚持“全员、全过程、持续改进”的质量方针，以“质量源于设计”等先进理念为引导，建立了从研发、生产至销售全过程的质量管控体系。

豪森的所有产品已全部通过新版GMP认证，抗肿瘤注射剂率先通过美国FDA认证，这是世界对豪森品质的肯定。

面向未来，豪森将以创新为发展的主旋律，在产业高端构建研发优势、品质优势、人才和管理优势，做响豪森品牌，做优民族医药，做强中国创造！

Jiangsu Hansoh Pharmaceutical Group, established in 1995, through 21 years of sustained and steady development, has grown into a modern innovative pharmaceutical group covering chemical & biological drug research, pharmaceutical intermediates & active pharmaceutical ingredients synthesis, finished dosage formulation manufacturing and sales. Hansoh ranked among Top 30 in 100 of National Pharmaceutical Industry and Top 3 in 10 Innovative Pharmaceutical Enterprises in China for many years. Additionally, Hansoh is awarded National Technology Innovation Model Company by National Ministry of Industry and Information Technology and National Ministry of Finance.

Hansoh has a complete R&D system for drugs, with the R&D centers located in New Jersey of U.S.A., Shanghai and Lianyungang. With 30,000 square meters of R&D center, nearly 1000 professional technical personnel, thousands of international advanced R&D equipments and testing instruments, and hundreds of millions of R&D investment every year, Hansoh has become an R&D highland attracting technology, talents and capital in the pharmaceutical industry.

Nearly 50 kinds of products, covering six major disease fields, such as Oncology, Psychotropic, Diabetic and Cardiovascular, Hansoh’s products are serving patients in need. Among them, one product named Gemcitabine HCl, was granted the second prize of National Scientific and Technological Progress, and nearly twenty R&D projects are listed in Major New Drug Discovery and Manufacture of National Major Scientific Special Project. Through more than ten years research and development, two innovative drugs, which are developed and researched by Hansoh independently, named Morinidazole and Flumatinib Mesylate will take the first lead and be launched on the market. Besides, over 10 Class 1.1 drugs are under clinical research.

Quality of a drug is connected to the safety of patients’ lives. Sticking to the quality policy of “All staff, The whole process, Continuous Improvement”, and lead by the advanced concept of “Quality by Design”, Hansoh has established the quality control system covering the whole area from R&D, manufacture to sale.

All the products of Hansoh have been granted with new GMP certificates, and the anticancer injectables have been approved by US FDA ahead of the peers, which to some certain extent, is the global affirmation to Hansoh’s product quality.

Confronted with the future, Hansoh will still prioritize innovation, trying to build superiority in R&D, quality, talents and management. Standing at the high-point of the pharmaceutical industry, we firmly believe Hansoh people will further promote their brand and strengthening China creation.

深圳信立泰药业股份有限公司

Shenzhen Salubris Pharmaceuticals Co., Ltd.

深圳信立泰药业股份有限公司成立于1998年，是集高端处方药、介入医疗器械等产品研发、生产、销售于一体的综合性医药上市公司（股票代码：002294），主营业务集中于心血管、生物医疗工程、创新生物药等高端医药医疗领域，市值位列国内医药工业企业前茅。公司荣获“国家火炬计划重点高新技术企业”、“国家级创新型试点企业”，技术中心被评为“国家级企业技术中心”，已稳步发展成为以心血管产品为主，拥有核心知识产权的国内自主创新龙头企业。

公司主营产品均为国内创新或首家上市的高端处方药，已在心脑血管领域形成产品体系和领先优势。同时，公司在抗肿瘤、抗感染、降血糖、骨科、自身免疫性疾病等多领域、多层次布局，实现全方位发展。

ShenZhen Salubris Pharmaceuticals ,established in 1998, is a comprehensive medicine listed company(Stock code: 002294) integrated with R&D, manufacturing and distribution for the product of High-end prescription drugs, interventional medical device etc. & mainly marketing in the high-end medical field of Cardiovascular, Bio-medical engineering, Innovative biological medicine etc. Market value among the forefront of the domestic pharmaceutical industry enterprises. Company won the honor of "Key high-tech enterprises of China Torch Program", "National innovative pilot enterprises". Technology center was regarded as "National Enterprise Technology Center ". Company has steadily developed cardiovascular products, and become domestic independent innovation leading enterprises with the core intellectual property rights.

The company has formed a product system in the field of cardiovascular and cerebrovascular and now in a leading position. Almost all company’s main products are domestic innovative or first to markets. At the same time, in anti-cancer, anti-infection, hypoglycemic, orthopedics, autoimmune diseases and other fields company has multi-level layout and achieve all-round development.

正大天晴药业集团股份有限公司

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

正大天晴药业集团是集科研、生产和销售为一体的创新型医药集团企业，是国内最大的肝健康药物研发和生产基地，为国家重点高新技术企业、国家火炬计划连云港新医药产业基地重点骨干企业，2015年位列中国医药工业百强企业榜第17位，在江苏省医药行业中位列第二。2016年，肝病用药在国内医院市场占有率达22.5%，肝病用药市场占有率连续多年稳居行业第一。2016年初，正大天晴与美国强生公司签署独家许可协议，将一款肝炎治疗创新药的国际开发权许可给强生公司，协议总额达2.53亿美元，标志着公司进军国际化的步伐加快。

正大天晴始终将科技创新作为企业发展的重要战略，是国内创新药物研究投入最多的药企之一，研发投入占比逐步从销售收入的8%提高到15%，向跨国公司看齐。正大天晴以研究院为创新载体，“江苏省新型肝病药物工程技术研究中心”、国家博士后科研工作站、国家级企业技术中心、“江苏省抗病毒靶向药物研究重点实验室”等高层次研发平台相继建立，自主创新能力不断增强。目前，研究院在研项目200多个，其中一类新药20多个，生物药近30个。截止2016年底，公司有效专利及专利申请582项，其中发明专利547项；授权公告的专利259项，其中发明专利228项；国际授权专利32项。

“十三五”期间，公司将持续强化核心竞争力的打造，在保持肝健康国内龙头地位的基础上，重点打造肿瘤及肿瘤辅助用药等治疗领域，推动企业从“聚焦肝病”向“两核多强”转变，从化学药向“化学药与生物药并举”转变、从“仿创结合”向“创仿结合”转变、从“专注国内”向“国内外协调发展”转变，同时创新技术路径和商业模式，带动产品研发、生产技术和营销模式的转型升级，以及产业体系的提质换档，向创新型、国际化的医药集团稳步迈进。

CTTQ is an innovative pharmaceutical group that engages in drug R&D, manufacturing, and marketing. It has the largest R&D and manufacturing base for liver disease drugs in China, is honored as one of the National Key High and New Tech Enterprises, and ranked 17th in National Top 100 Medical and Pharmaceutical Powers in 2015.

CTTQ currently has 10 subsidiaries, 3 manufacturing plants, 2 R&D centers (in Nanjing and Lianyungang), 4 joint labs (in Shanghai and Chengdu), and 1 business development office in California, USA. CTTQ has passed multiple EU and US GMP inspections, and it is the first company that obtained the national new version of GMP certification in 2011. Its customer base spans over 30 countries. With more than 8000 employees, CTTQ has 2014 sales totaled RMB 10 billion.

Innovation and cooperation are CTTQ’s core values. Its R&D investment on innovative drugs takes the leadership among domestic counterparts. In recent years, it has developed several high level R&D platforms, including Jiangsu Province Liver Disease Innovative Drugs Technology Research Center, Jiangsu Province Antiviral Targeting Drug Research Key Laboratory, National Postdoctoral Research Fellow Station, and State-level Enterprise Technology Center. More than 10 projects were designated as National Key New Drug Innovation Science and Technology Project. Its R&D Institute has a highly capable research team of over 700 employees, with about 60% holding post-graduate degrees or senior technical certificates.

CTTQ invests over 10% of its annual sales revenue as R&D budget every year. At present, it manufactures 70 prescription medicines in China in 5 main therapeutic categories, including liver diseases, oncology, respiratory diseases, diabetes, and antibiotic. It has more than 200 projects in its product pipeline, in which State Categorylinnovative drug projects make up more than 10%.

CTTQ attaches great importance to intellectual property and patent protection. It has filed 582 patents, including 547 inventions by the end of 2016. Among them, 259 patents we have been granted, including 228 inventions and 32 patents granted in foreign countries. Tian Qing Gan Mei, one of our top-selling products, won China Golden Patent Award.

As a responsible corporate citizen, CTTQ is driven by a strong desire to improve Chinese medical treatment and promote public health, through both Tianqing Liver Disease Research Fund and CR-HepB Program. It donated RMB 10 million to establish the former in 2011, which was designed for healthcare professionals in under-developed areas to study liver diseases, and overall national improvement of liver disease prevention and medication. CR-HepB Program is a unified registry system in China, forming an important data resource for government and medical institutions to achieve standardized management of HBV patients. CR-HepB data have been published in EASL, AASLD, and APASL.

In the future, CTTQ aims to increase R&D investment from 8% to 15% of sales revenue to match international standards. This will significantly strengthen CTTQ’s core competitiveness and optimize its R&D system. In addition to maintaining the leading position in the domestic liver health market, CTTQ will expand its focus on oncology, and other therapeutic areas. CTTQ will also improve its strength of R&D and manufacturing capabilities in protein drug and therapeutic antibodies. In addition, CTTQ will enter into markets outside China to develop and commercialize high valuable generics and innovative medicines for unmet therapy.

北京泰德制药股份有限公司

Beijing Tide Pharmaceutical Co., Ltd

北京泰德制药股份有限公司成立于1995年，是中国第一家能够研发、生产和销售系列靶向药物的高科技制药企业，现有员工约2700人，注册资本5亿元人民币。

泰德制药先后被国家科技部和北京市认定为国家重点高新技术企业、北京市G20工程企业、北京市脂质靶向制剂工程技术研究中心、新型制剂北京市国际科技合作基地，入选中关村国家自主创新示范区创新型试点企业、“十百千工程”、工信部两化融合管理体系贯标试点企业和全国质量标杆企业等。

泰德制药现已成为北京生物医药制造业权重企业,并保持了科学高效的发展。已连续六年位列国家工信部中国医药行业工业企业主营业务收入全国百强，2017年位列50强。在奔驰、拜耳、京东等国际国内大型企业云集的开发区纳税连续多年位列前五名，累计纳税逾52亿元人民币。2017年净利润超10亿元，同比增长17%，远高于国内医药行业发展的平均水平。

泰德是中国第一家能够研发、生产和销售脂微球药物的高科技制药企业，经过二十多年的积淀，泰德研发的产品因其独特的临床优势和高质量标准，成为行业领域的品牌标杆。

公司正在北京经济技术开发区建设打造全新的生产基地，总建设规划40余万平方米，打造一个集高端药品、高端医疗器械、特医食品、大数据医疗等大健康产业的孵化平台。未来，泰德制药将秉承“关怀生命、精益创新”的宗旨，依托健康产业园和现代化原料药基地，积极布局大健康领域，推动泰德“布局中国泰德 跨越世界泰德”的梦想快速迈进，继续为社会提供更优质的新药产品，为改善大众的健康水平而不懈努力！

Founded in 1995, Beijing Tide Pharmaceutical Co., Ltd. (hereinafter referred to as Tide Pharmaceutical) is the first high-tech pharmaceutical enterprise, which is specializing in developing, producing and selling targeted drugs in China. It has about 2,700 employees, and the registered capital is RMB 500 million Yuan.

Tide pharmaceutical has been a authoritative enterprise in Beijing biomedicine manufacturing industry and has maintained a scientific and efficient development through unremitting efforts and strong support from the development zone government. Tide pharmaceutical has been ranked by the national Ministry of Industry and Information (Ministry of Industry and Information) for the top 100 in China's pharmaceutical industry for six consecutive years, and what’s more, it has been listed in top 50 in 2017. In the development zones of large international and domestic enterprises, such as Mercedes Benz, Bayer, Jingdong and other large enterprises, the tax Tide pharmaceutical paid has been top five in consecutive years with total tax of more than 5.2 billion Yuan. The net profit in 2017 was over 1 billion Yuan with a year-on-year growth 17%, which is far more than the average level of the domestic pharmaceutical industry.

Tide is the first high-tech pharmaceutical enterprise in China to develop, produce and sell lipid microspheres. After more than 20 years of accumulation, Tide's product has become a brand marker in the field of industry because of its unique clinical advantages and high quality standards.

The company is building a new production base in the Beijing economic and Technological Development Zone. The total construction area is more than 40 square meters, so as to create an incubator for high-end health products, high-end medical devices, special medical foods, big data healthcare and other comprehensive health industries. In the future, Tide pharmaceutical will adhere to the purpose of "care for life and lean innovation" and actively lay out a field of great health with rely on the health industrial park and modern pharmaceutical raw materials base. At the same time, we will promote rapid development towards the dream of "laying out China’s Tide across the world" and continue to provide better new products for the society and make unremitting efforts to improve the public's health level.

鲁南制药集团股份有限公司

Lunan Pharmaceutical Group Co., Ltd.

鲁南制药集团是集中药、西药、生物制药的生产、科研、销售于一体的国家大型综合制药集团、国家重点高新技术企业，成员企业包括鲁南厚普制药有限公司、鲁南贝特制药有限公司、山东新时代药业有限公司、鲁南新时代医药有限公司等八家子公司，位列中国大企业集团竞争力500强，连续七年荣登山东省纳税100强榜。

鲁南制药集团高度重视科技创新，设有国家手性制药工程技术研究中心、哺乳动物细胞高效表达国家工程实验室、中药制药共性技术国家重点实验室、国家级企业技术中心、博士后科研工作站、“泰山学者”岗位等科研平台。在加强自主创新体系建设的同时，企业与100余所国内外知名院所建立了长期合作关系， 成功地完成了400多项研究课题，多次承担国家科技支撑计划、国家863计划、国家重大新药创制专项、国家火炬计划、国家重点新产品计划，100多个项目获得科技奖项。其中获得山东省科技进步一等奖4项，国家科技进步二等奖6项。多个产品顺利通过美国FDA认证、欧盟CEP认证。公司积极开拓国际市场业务，目前公司产品已出口美国、德国、韩国、日本等60多个国家和地区。公司高度重视环保工作，坚持科学发展，着力建设“资源节约型”、“环境友好型”企业。公司高度重视知识产权保护工作，截止目前已申报国际、国内发明专利900多项，已获授权专利500多项。国家知识产权局举办的第十七届中国专利奖颁奖大会上，鲁南制药舒尔佳（奥利司他）获得2015年度中国专利金奖。

鲁南制药集团始终坚持“造福社会、创造美好生活”的经营宗旨，以“创新引领、服务推动”为指导方针，秉承“不怕困难、挑战困难、战胜困难”的企业精神，坚持“以改革为动力、以市场为中心、以科技为先导”的指导思想。风华正茂、立志全球的鲁南制药集团正以“保持化学制药的优势，大力发展中药，做强生物制药”为目标，大力加强以企业自主创新为主体、市场为导向、产学研协同创新的科技创新体系建设，在为成为国内领先、世界一流的国际化综合制药集团而不懈奋斗！

Lunan Pharmaceutical Group Corporation is a comprehensive, major national hi-tech enterprise that produces, researches and sells traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products. The group is comprised of eight subsidiary companies including Lunan Hope Pharmaceutical Co., Ltd., Lunan Better Pharmaceutical Co., Ltd., Shandong New Time Pharmaceutical Co., Ltd., Lunan New Time Bio-Tech Co., Ltd. etc.. It was selected into the top 500 enterprises of China and Shandong top 100 taxpayer in seven consecutive years.

Lunan Pharmaceutical Group Corp. pays high attention to technology innovation and it is equipped with National China Pharmaceutical Engineering Technology Research center, National Mammalian Cells Efficiently Express Engineering Laboratory, New Technology of TCM State Key Lab, National Enterprise Technology center, Postdoctoral Scientific Research workstation, Mount Taishan Scholars Post etc. The group builds its own technology innovation system and is collaborated with more than 100 foreign and domestic famous institutes. The company has finished more than 400 research subjects, including National Science and Technology Support Plan, National 863 Plan, National Key New Drugs Special Formulate, National Torch Project, National Key Product Plan, more than 100 projects received Science and Technology Progress Award, Provincial Science and Technology Progress First Prize 4 and National Scientific and Technological Progress Second Prize 6. Several products have already finished the registration and authentication of FDA and EU. The company explore the international market continuously and its products export to more than 60 countries, including America, Germany, Korea and Japan. Lunan Pharmaceutical Group pays high attention to environment protection, insists on develop scientifically and build Resource-efficient and Environment-friendly type enterprise. Also the company pays high attention to the protection of intellectual property, until now the company already apply more than 900 items of international and domestic invention patent. In the 17th Chinese Patent Award Presentation Ceremony holding by State Intellectual Property Office of the P.R.C, Shu Erjia (orlistat) by Lunan was awarded the Gold Prize of Chinese Patent in 2015.

Lunan Pharmaceutical Group Corp. insist on the principle of “benefit society and create a better life”, “innovation leads, service promotes”, “no fear of difficulties, challenge difficulties and overcome difficulties” and following the strategic guiding ideology: taking reform as the power, market as the center, science and technology as the guide. With the goal of “Keep the advantage of chemical pharmaceutical industry, strive to develop traditional Chinese medicine, make biological pharmacy stronger”, the flourishing & globalizing Lunan Pharmaceutical Group Corp. is developing the enterprise innovation ability and a scientific innovation system of production and research collaboration, it will turn into a leading domestic level, world class and comprehensive pharmaceutical group.

江苏康缘药业股份有限公司

Jiangsu KANION Pharmaceutical Co., Ltd.

江苏康缘药业股份有限公司成立于1996年，2002年在上海证券交易所上市，是集中药材种植、中药研发、生产、贸易为一体的大型中药企业，已成为中国中药行业领军企业之一，先后被评为国家重点高新技术企业、国家创新型试点企业、国家技术创新示范企业、中国制药工业百强企业（34位），是中国中药行业获新药证书最多、拥有发明专利最多的企业以及推进中药国际化最为深入的企业之一。

公司秉承“精品国药、康缘创造”的宗旨，立足创新发展，以中药现代化、国际化为己任，着力打造科技制高点，形成了“以国家级科研平台建设为依托，体制创新和机制创新为手段，高层次人才引进与培养为核心，产学研协同创新为重要补充”的创新模式，建有中药制药过程新技术国家重点实验室和中成药智能制造国家地方联合工程研究中心等国家级科研机构，拥有一支博硕士比例在60%以上的300多人的科研队伍，建成我国第一个中药数字化智能制造工厂，列入国家工信部智能制造试点示范项目（中药行业唯一），推进中药制造技术和装备水平逐步达到国际药品制造先进水平。

Jiangsu KANION Pharmaceutical Co., Ltd. was established in 1996 and listed on the Shanghai stock exchange in 2002. It is a large enterprise of traditional Chinese medicine which includes planting of Chinese herbal medicines, researching and developing, producing, and trading of traditional Chinese medicine. It has become one of leader enterprises among traditional Chinese medicine industry. It has been honored as National Key High-tech Pharmaceutical Enterprise, National Pilot Enterprise of Innovation, National Model Enterprises of Technological Innovation, top 100 Pharmaceutical Enterprise In China (34th). In addition, it is one of the enterprises which acquire the most new drug certificates, owning most invention patents and pushing forward the internationalization of traditional Chinese medicine at the deepest level.

Jiangsu KANION Pharmaceutical Co., Ltd. adheres to the purpose of ‘high-quality Chinese medicine, made in KANION’. It is based on innovation and development and regard modernization and internationalization of traditional Chinese medicine as its own responsibility. It focuses on promoting science and technology. Thus it has formed an innovation model that rely on the construction of scientific research platform at the national level, using institutional innovation and mechanism innovation as the means, focusing on introducing and training of high-level talents, supplying with collaborative innovation of production, education and research. It has built many scientific research institutions, such as a national key laboratory for new technique in the manufacturing process of traditional Chinese medicine and a national local joint engineering research center on the intelligent manufacturing of Chinese patent medicine. What’s more, it has a scientific researching team of 300 people in which there are over 60 percent of them own doctor and master degree. We build the first intelligent manufacturing factory for digitalization of traditional Chinese medicine which is listed in the intelligent manufacturing pilot project by Chinese Ministry of Industry and Information Technology (the only one in the Chinese medicine industry). Thus, we improve manufacturing technology and equipment of traditional Chinese medicine to gradually reach the most advanced level of international drug manufacturing.

成都百裕制药股份有限公司

Chengdu Baiyu Pharmaceutical Co., Ltd.

成都百裕制药股份有限公司（简称百裕制药）注册成立于2005年，是一家专业从事药品研发、生产和销售为一体的科技型高新技术企业。下设5家子公司，成都百裕制药股份有限公司、成都百裕金阁莱药业有限公司、成都金百裕医药有限责任公司、四川上善银杏农业开发有限公司、白果裕康信息服务有限公司等。目前公司多条生产线已通过国家GMP认证。主营产品为银杏内酯注射液、依诺肝素钠注射液、兰索拉唑等多个新特药品。

百裕制药是具有国际技术领先性的生物医药制造企业，也是推动中药现代化和国际化进程中的先锋者。公司先后获得相关荣誉或奖励有：“国家高新技术企业”、四川省“成长性”中小企业、“四川省知识产权试点企业”、“四川省创新型企业”、“四川省企业技术中心”等。

公司秉承“百年济世，裕享安康”为企业使命；坚持以“创新、执着、求实、利他”作为企业的核心价值观，把人才视为公司的可持续发展的宝贵财富，把专注于独立知识产权的高科技产品的开发作为企业发展的核心竞争力。公司先后开发上市新特药品近10个，在研产品约50余个，申请国内外发明专利约80项目，其中获得国内发明专利授权29项，美国发明专利1项。相关项目先后获得“国家重大科技专项重大新药创制专项”、“国家科技型中小企业技术创新基金”、“四川省重大成果转化项目”、“四川省科技创业领军人才专项”、“四川省战略性新兴产品计划专项”、“四川省专利实施与促进专项资金专项”、“四川省战略性新兴产业发展专项”等立项。

Incorporated in 2005, Chengdu Baiyu Pharmaceutical Co., Ltd. (referred to as Bai Yu Pharmaceutical) is a new high-tech enterprise engaged in research and development, production and sales of drugs. It has five subsidiaries including Chengdu Baiyu Pharmaceutical Co., Ltd., Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd., Chengdu Jinbaiyu Pharmaceutical Co., Ltd., Sichuan Shangshan Ginkgo Agricultural Development Co., Ltd. and Baiguo Yukang Information Service Co., Ltd. At present, a number of production lines of the company have passed the national GMP certification. The main products include Ginkgo Biloba Injection, Enoxaparin Sodium Injection, lansoprazole and other new drugs.

Baiyu Pharmaceutical, as a pharmaceutical manufacturing enterprise with leading international technology as well as a pioneer in advancing modernization and internationalization of traditional Chinese medicine, has successively won many honors like ‘National High-tech Enterprise’, ‘The Growing Small And Medium-Sized Enterprise In Sichuan Province’, ‘Pilot Enterprise of Intellectual Property Rights in Sichuan Province’, ‘The Innovative Enterprise in Sichuan Province’, ‘The Enterprise Technology Center in Sichuan Province’ .

The company adheres to the enterprise mission of "Benefit the Society, Enjoy Good Health", follows the core value of "Innovation, Dedication, Truth-Seeking and Altruism", regards the personnel as wealth for the sustainable development of the company, and takes the development of high-tech products with independent intellectual property rights as the core competitiveness for company development. The company has developed and marketed nearly 10 new and specific drugs, more than 50 products under research, applied for invention patents of about 80 items at home and abroad, of which 29 have won domestic invention patent authorization, one has won the patent of the United States. The relevant projects have won the "Special Major New Drug Discovery of National Major Science and Technology", "Technology Innovation Fund for National Science and Technology Small and Medium-Sized Enterprise", "Major Achievements Transformation Project in Sichuan Province", "Science and Technology Leader in The Entrepreneurial Talent in Sichuan Province", "Strategic New Product Plan in Sichuan Province", "Patent Implementation and Promotion of Special Funds in Sichuan Province", "Special Development of Strategic Emerging Industries in Sichuan Province” and other awards.

浙江华海药业股份有限公司

Zhejiang Huahai Pharmaceutical Co., Ltd.

浙江华海药业股份有限公司创立于1989年，是一家集化学药、生物药、医药包装及贸易流通为一体的制药企业，并于2003年在上交所上市。目前，公司拥有注册资本10.4亿元，总资产88亿元，占地面积150多万平方米，并在美国、日本、香港、上海、江苏、浙江等地设有30多家分子公司，共有员工6000多人。

公司是国家重点高新技术企业、国家创新型企业、中国医药工业百强企业，设有“国家级企业技术中心”、“博士后科研工作站”、“院士工作站”、“企业研究院”，拥有一支1600多人的高学历、高技术、具有丰富研发经验的科研队伍，其中10人入选国家“千人计划”，14人入选省“千人计划”，博士40多人，教授级高工、高级工程师20多人，在绿色合成、工业结晶、药物新剂型、新工艺研发等方面已形成强大的创新实力，并积极布局高端新剂型、生物制药和新药领域，为华海实现一次次跨越发展提供了不竭动力。

通过多年的转型升级和产业结构调整，公司建立了完善的原料药和制剂产业链，形成了以心血管类、精神类、抗病毒、抗肿瘤等药物为主导的产品系列，不仅是世界前10大制药企业的主要原料药供应商，更是在美国规模化销售制剂产品的首家中国药企。公司产品远销全球200多个国家和地区，制剂产品已基本覆盖美国所有大中型药品采购商，同时以欧美高端市场为起点，逐步向南美、俄罗斯、中东等市场拓展，深度融入国际制药产业链。

Zhejiang Huahai Pharmaceutical Co., Ltd. was initially founded in 1989, engaging in developing, manufacturing, packaging and marketing of Chemical drugs and biopharmaceuticals. The company’s stock was successfully listed in Shanghai Stock Exchange in 2003. With a registered capital of RMB 1.04 billion and total asset of 8.8 billion, the company has more than 30 branches (subsidiaries) in the United States, Japan,Hong Kong, Shanghai, Jiangsu and Zhejiang of China. It occupies an area of 800,000 square meters, and has over 6,000 employees.

As High-Tech Enterprise, National innovation-driven Enterprise and Top 100 pharmacy industry of China, The company has a highly-educated, skilled and experienced R&D team, which have more than 1,600 technicists. Well established technology of green chemistry, industrial crystallization, designing new dosage forms and new processes, Huahai is now trail-blazing into for the realm of modified-release technology, biopharmaceuticals and new drug discovery, which underpin the Second Transformation and Upgrading.

After years of upgrading and restructuring, Huahai has become a leading vertically integrated pharmaceutical manufacturer for both APIs and formulations. Cardiovascular, neurological, antiviral and anti-tumor drugs has become main series of products. These products are sold to over 200 countries and regions, finished drug products sells to almost all major distributors of U.S. And we take European and American markets as a start point, gradually expanding to South America, Russia, and Middle East etc. Huahai is becoming part of the global pharmaceutical supply chain.

武汉禾元生物科技股份有限公司

Wuhan Healthgen Biotechnology Corp.

武汉禾元生物科技股份有限公司（禾元生物）创立于2006年，是一家专门从事分子医药技术研究与产品开发的国家高新技术企业。公司始终坚持原始创新和市场导向，在董事长、国家“千人计划”、武汉大学教授杨代常先生的带领下，建立了国际领先的水稻胚乳细胞生物反应器技术平台和国际先进的重组蛋白质纯化技术平台，建立了我国首个植物表达体系的新药研发平台，较好地解决了国际植物生物反应器的表达量低、纯化工艺复杂、规模化困难和痕迹量宿主蛋白检测技术难题，具有表达量高、安全性好、规模化容易、成本低和绿色环保等优势。开创性地利用植物表达体系，自主研发的生物制品I类重磅新药“植物源重组人血清白蛋白注射液”，是我国首个获得的重组白蛋白注射液临床批件，现已进入临床研究，标志着我国在植物生物反应器领域达到了世界领先水平。

公司具有雄厚的技术研发团队，在“十一五”、“十二五”和“十三五”期间，承担并完成多项国家重大科技专项，获得了国家授权发明专利9项和国际授权发明专利18项；公司的植物表达技术平台被列入“十二五”期间的重大突破性科技前沿技术，获得国家科学技术发明二等奖、湖北省科学技术发明一等奖两项和国家优秀专利奖等。公司致力于为全世界人民提供绿色、安全、廉价、充足的生物医药产品，为中国医药的“智能制造”进向国际做出努力和贡献。

Healthgen Biotechnology Corp. (Healthgen Biotech), a private company dedicating to plant-based molecular pharming was founded in 2006. Under the leadership of President and Chief scientist DaichangYang, who also gained the “Thousand Talents program” of the National Central Organization Department, Healthgen Biotech has being developed series of peptides and proteins with in-house R&D pathways using OryzHiExp. Our first major potential candidate in clinical development is recombinant human serum albumin derived from Oryza sativa(OsrHSA), which has been approved by CFDA for clinical trial. It marks a milestone of plant-based molecular pharming around the world. Healthgen Biotech owned the largest facilities for processing of plant-based biopharmaceuticals in the world and has established GMP-compliance facilities and quality control system. Healthgen Biotech’s state-of-arts technology, OryzHiExp, is protected by 9 granted patents in China and 18 granted patents in international-wide. OryzHiExp has the advantages of high expression level, easy scale-up of processing,more safetyand environment-friendly with low cost. Healthgen Biotech has R&D team who has capacity to undertaken the major national Scientific Research Projects.The state-of-arts technology honored Invention Award of National Science and Technology, Invention Award of Hubei Province government. Its mission is providing the biopharmaceuticals with environment-friendly, safety, inexpensive and adequate supply for people all over the world.

西藏易明西雅医药科技股份有限公司

Tibet AIM Pharm. INC.

西藏易明西雅医药科技股份有限公司（以下简称“公司”或“易明医药”），创始于2003年，是一家集新药研发、中藏药材种植、药品生产、经营销售、产业投资为一体的全产业链新型医药企业。经过10余年的发展，公司于2016年成功登陆A股市场，股票代码SZ002826。

公司拥有拉萨和成都两个实验中心，实验室面积近2000平米，已引进waters-EMPOWER 和岛津-Lab Solutions CSLite数据管理系统等先进实验设备，使得公司在实验数据管理方面达到行业领先水平。公司固定职工约400人，95%以上研发人员拥有药学相关专业本科及以上学历，核心技术人员均拥有15年以上药物研发经验，与国内多家科研院所建立密切合作关系，并聘请了10余名国际、国内著名专家为技术顾问。

公司先后承担并完成了国家科技部火炬计划项目、科技型中小企业创新基金项目、西藏（成都）科技孵化器项目、西藏自治区重点科技项目等一系列科技项目；获得“中国心脑血管病诊疗产业技术创新战略联盟理事单位”、“中国专利优秀奖”、“国家火炬计划·产业化示范项目证书”、“自治区工程技术研究中心”等一系列荣誉；多个产品获得四川省名牌称号。

公司采用Q-marker研究理念建立的一整套药品全程质量控制及质量溯源体系已经推广使用，口服制剂一致性评价、中药注射剂再评价等工作进展顺利，一些战略领域和品种的新药开发已经启动，原料及制剂的国际注册申请陆续获批。随着这一系列项目的实施和落地，易明医药将在中国医药创新及国际化之路迈向新的里程碑。

Tibet AIM Pharm. INC.(hereinafter referred to as the Company or AIM Pharm.) was founded in 2003. It is a new industry chain pharmaceutical corporation which integrates R&D, TCM and Tibetan medicine plantation, drug manufacture, sale and industrial investment. After a decade development, the Company is listed on the main board of the A share market in 2016 (SZ002826).

The Company owns two laboratory center in Lhasa and Chengdu which covers an area of 2000 square meters and introduced advanced experiment installations like waters-EMPOWER and Shimadzu-Lab Solutions CSLite. This makes the Company achieved an industry-leading position in laboratory data management. The Company has fixed staff of 400 people, among which more than 95% had a pharmaceutical related bachelor degree or above. The core technical staff owns more than 15 years of pharmaceutical R&D experiences, and have built a close cooperation with many domestic scientific institutions. The Company has employed more than 10 domestic and international experts as technical consultant.

The Company has finished a series programs including Torch Program of National Ministry of Science and Technology, Science and Technology SME Innovation Fund Project, Tibet (Chengdu) Technology Incubator Project, Tibetan Autonomous Region Key Science and Technology Projects; The Company has also been honored as “Member of China Cardiovascular and Cerebrovascular Disease Diagnosis and Treatment Industry Technology Innovation Strategic Alliance Governing”, “China Patent Excellence Award”, “National Torch Plan-Certificate of Industrial Demonstration Project”, “Autonomous Regional Engineering Technology Research Center”, etc.. Many products of the Company received Famous Brand in Sichuan Province.

The Company adopted Q-marker research concept to build a complete all-phase drug quality control and tracing system to be promoted and implemented. Projects including Consistency evaluation of oral preparations and Reevaluation of TCM injections progressed smoothly. Some of the strategic products and new drug R&N has been initiated, whilst the registration for raw material and preparation have been successively approved. With the implementation of this series of projects, AIM Pharm. will target toward a new milestone in the journey of innovation and internationalization of Chinese pharmaceutics.

山东罗欣药业集团股份有限公司

Luoxin Pharmaceutical Group Co., Ltd.

山东罗欣药业集团股份有限公司于1988年在山东临沂成立，并于2001年改制为股份制企业，是一家集药品研发、生产、贸易和健康服务为一体的大型医药企业集团。公司现有员工4000余人，其中科研人员占总人数的12%。罗欣集团自2011年起连续被评为中国医药研发产品线最佳工业企业，是国家重点高新技术企业、国家技术创新示范企业。此外，公司拥有国家企业技术中心、国家地方联合工程实验室、国家博士后科研工作站等研发机构，形成了强势的国家级科研技术中心；并承担了国家“重大新药创制”科技重大专项、国家火炬计划项目、国家重点新产品计划等多项科技项目；荣获国家科技进步奖二等奖 1 项。

罗欣药业集团坚持实施“展望长远、兼顾当前、创仿同步”的产品研发战略，并于2014年在上海张江高科园区设立了罗欣上海科研中心——罗欣生物科技（上海）有限公司，与集团和各科研院校形成了三位一体的科研体系。目前，公司主要致力于消化系统、呼吸系统、心血管系统、抗感染、抗肿瘤等领域药品的开发，已开展的创新药研发项目达到 7 项；其中，创新药LXI-15028作为一种新型的钾离子竞争性酸抑制剂（P-CAB），已于2017年6月通过CFDA评审进入临床试验研究；创新药LXI-15029作为mTORC1和mTORC2的双重抑制剂，也已进入临床试验阶段，并将有望成为同机制治疗肿瘤疾病的第一个有效化合物。

2016年罗欣药业集团股份有限公司在工信部发布的中国医药工业百强榜单中位列第37位，实现营业收入65亿元。未来，罗欣药业集团将持续对研发的投入,不断推出高科技含量、高质量、高附加值的“三高”产品，为企业持续发展奠定坚实的产品基础。

Luoxin Pharmaceutical Group Co., Ltd. is a large-scale pharmaceutical enterprise group dedicated to integrating medicine R&D, production, trade and health services. Originally established in Shandong Linyi in 1988, Luoxin successfully restructured into a joint-stock enterprise in 2001. The company currently boasts more than 4000 employees, of which 12% are R&D personnel. Since 2011, Luoxin Pharmaceutical Group has been rated “the best industrial enterprise in Chinese Pharmaceutical Industry with R&D pipeline,” among numerous other awards like the “National Key High-tech Enterprise” and “Technological Innovation Model Enterprise”. The Group has also established research institutes such as National Enterprise Technology Center, National and Local Engineering Laboratory, and National Postdoctoral Programme, through which the company has undertaken a number of award-winning projects under nationally-recognized scientific and technological programs including the Major New Medicine Development, National Torch Plans and the National New Products Program.

Luoxin Pharmaceutical Group adheres to its R&D vision of “Looking into the Future, Focusing on the Present and Parallel Advancement on Generic and Innovative Products”. Most recently, in June 2014, Luoxin Pharmaceutical Group established its Shanghai R&D Center in Shanghai Zhangjiang Hi-Tech Park, to drive innovative medical research with the group and the other Research Institutes. The company focuses on the R&D of pharmaceutical products of several therapeutic areas including gastrointestinal disease, respiratory disease, cardiovascular disease, infectious disease and cancer. So far, we have launched seven R&D projects on innovation drugs; among them, the innovation drug LXI-15028, a new potassium ion competition inhibitor (P-CAB), received permission from CFDA to initiate clinical trials in June 2017. The innovation drug LXI-15029, a double-inhibitor of mTORC1 and mTORC2, also received permission to initiate clinical trials, and is expected to become a First-in-Class drug of this mechanism for the treatment of tumors.

In 2016, Luoxin Pharmaceutical Group ranked thirty-seventh in the Top 100 List of Chinese Pharmaceutical Industries, and achieved 6.5 billion RMB operating income. In order to lay a solid product foundation for the enterprise’s sustainable development, the company will continue to pursue its 3 guiding fundamentals for all products: high-tech, high-quality, high value.

上海安翰医疗技术有限公司

Ankon Medical Technologies Co., Ltd.

上海安翰医疗技术有限公司专业从事医疗器械研发、生产、销售及服务，是成功研制 “磁控胶囊胃镜系统”并实现商业化的公司。

安翰由高科技孵化专家牵头，集聚了首批中组部“千人计划”特聘专家和多位国内外杰出博士，拥有磁场控制、光学成像、芯片集成、智能传感、无线通信等国内外专利百余项，作为牵头单位制定了《医用内窥镜胶囊内窥镜》国家行业标准。

安翰完全自主研发的 “磁控胶囊胃镜系统”， 是能够对人体胃部进行精准检查的胶囊胃镜，只需患者吞服一粒胶囊，15分钟左右即可完成胃部检查，无痛无创无麻醉，无交叉感染风险，与传统胃镜准确性一致，得到国内国际学术界高度认可，获得国家药监总局三类医疗器械注册证。目前世界上尚无其它同类产品。

安翰在数字化医学图像采集的基础上，与影像认知分析技术相结合，通过互联网传输+人工智能云平台，实现安翰胶囊胃镜检查的远程诊断和智能化辅助阅片，“患者在哪里，专家就在哪里”。磁控胶囊胃镜系统与互联网和人工智能的结合，为实现分级诊疗及广泛区域和广大人群的消化道疾病诊断和筛查提供了最优解决方案。

安翰磁控胶囊胃镜系统自2013年获得国家食药总局三类注册证以来，已在国内近千家医疗机构为数十万百姓做了舒适的健康服务，并获欧盟CE认证，在欧洲市场广受青睐，被誉为“21世纪消化道疾病检查和内镜发展的革命性创新”，荣膺“2016中国十大医学进展”。在“砥砺奋进的五年”大型成就展中，与“蛟龙号”载人深潜器、“复兴号”中国标准动车组等共同成为向世界展示中国自主创新成果的“名片”。

2017年7月，中华医学会、中国医师协会、中国抗癌协会等五大医学专委会专门联合制定发布了《中国磁控胶囊胃镜临床应用专家共识》，文件指出：“随着临床应用实践经验和研究证据的逐步积累，磁控胶囊胃镜技术将对我国胃部疾病的早发现和早诊断发挥越来越重要的作用。”

目前，安翰磁控胶囊胃镜系统已经在全国近千家医疗机构投入大规模临床应用，胃镜检查再也不是令人望而生畏的医学检查手段，而将成为每个人的日常体检项目和健康生活方式。

Led by experienced entrepreneurs and outstanding technical team, Ankon Medical Technologies Co. Ltd, has developed and commercialized Magnetically Controlled Capsule Endoscope system.

Ankon capsule robot achieves gastroscopy without intubation, and enlisted among 2016 China’s top ten medical progress, known as the “21st century revolutionary innovation with respect to gastric disease examination and endoscopic development”. Ankon won the 2013 Ernest & Young Most Promising Early Enterprise in China. The same paper published and recommended by the international famous academic periodical and official journal of American International Journal of Gastroenterology (AGA), CGH and the Japanese journal of gastroenterological endoscopy shows that the accuracy rate of Ankon capsule endoscopy on gastric examination is completely consistent with the “Gold Standard” of conventional video gastroscope.

NaviCam magnetically controlled capsule endoscope system opens a new era of gastric diagnosis. Patented magnetic control and positioning technologies enable capsule endoscope for complete gastric diagnosis. The product provides consumer a painless, non-invasive, and cross infection free experience and the complete gastric examination can be done in as quickly as 15 minutes. It is becoming an important tool to compliment standard video endoscopy for early gastric disease screening.

NaviCam magnetically controlled capsule endoscope system has gained approval from China FDA and EU CE mark since January 2013. Since Ankon obtained CFDA certificates in 2013, Ankon capsule robot has been applied in nearly a thousand medical institutions in China and countries including the United Kingdom, Germany, Italy, and Hungary. In addition, Ankon Internet plus artificial intelligence cloud platform has achieved networked reading and intelligent auxiliary reading, which can be described as “where the patient is, where the experts are”. Meanwhile, Ankon intelligent capsule endoscopic technology is combined with image cognitive analysis technology, to assist the digestive tract imaging diagnosis through artificial intelligence, thus to improve the diagnostic efficiency and accuracy of experts.

At present, NaviCam magnetically controlled capsule endoscope system has been widely used in clinical, gastroscopy is no longer frightening, will become everybody's daily physical examination items and healthy lifestyle.

中天（上海）生物科技有限公司

Microbio (Shanghai) Biotechnology Co., Ltd.

中天（上海）生物科技有限公司为台湾中天钻石生技集团的成员之一，中天钻石生技集团为台湾规模最大的生技集团，旗下包括新药、保健、创投与有机事业，集团投资总额超过45亿人民币，拥有从植物新药、化学新药、抗体新药、醣分子新药、适体新药到细胞治疗新药，一系列First in class或Best in class的新药族群，并且建立自主的发酵、抗体与适体研发技术平台，具有与国际大药厂分庭竞争的新药研发实力。

中天上海于2012年在上海松江新城建立企业总部及GMP药厂，并取得中天钻石生技集团九项新药于中国大陆的专属授权或合作研发权利，已建立自主研发团队与技术平台，包括全球唯一在三期临床达到60%以上完全愈合率的糖尿病足部溃疡(DFU)新药、全球唯一长效型异位性皮肤炎(AD)单抗新药、独家的肠道菌厌氧共生发酵新药，以及系列的Unmet Medical Need肝病新药及单抗新药，目前DFU新药正执行三期临床中，其他新药也即将陆续开展大陆临床试验或新药药证之申请。

两岸中国人同文同种、血脉相连，新药产业之开发对两岸同胞之生命健康与福祉息息相关，自2015年8月以来CFDA大刀阔斧改革药品管理，成为第十位加入ICH的会员国，并实行国际标准审核管理新药，未来大陆新药研发必将成为全球新药产业的标竿，在这个关键时刻，中天上海秉持诚信与创新的经营理念，将以拥有全球独家智财权的新药研发技术与实力，一起为两岸中国人的健康贡献心力，以共创两岸中国人的繁荣盛世。

Microbio (Shanghai) Biotechnology Co., Ltd. is a member of Microbio and Diamond BioFund Group, one of the largest biotech groups in Taiwan, covering business of new drugs, health care, venture capital and organic produce. With a total investment of more than 4.5 billion RMB in the pipeline including a series of first-in-class or best-in-class new drugs in botanical extracts, NCE, antibody, glycan molecule, aptamers and cell therapy, the Group has established platforms for in-house fermentation, anti-body and aptamer development technology, equipping the Group with the capability in research and development to compete with international leading pharmaceutical companies.

Microbio Shanghai has headquartered in Songjiang New Town Center in Shanghai since 2012 and built a pharmaceutical production plant in compliance with GMP standards. Microbio Shanghai has established its own research team and technical platform after obtaining the exclusive license by Microbio and Diamond BioFund Group for sales and development of nine new drugs in mainland China, including a new drug targeting DFU with world-leading clinical results achieving an over-60% complete healing rate in phase III trial, the world's only long-acting monoclonal antibody new drug for atopic dermatitis (AD), the exclusive new drug by intestinal anaerobic symbiotic fermentation, as well as a series of new drugs for liver diseases and monoclonal antibodies to fulfill unmet medical needs. Currently, the DFU new drug is undergoing phase III clinical trial in mainland China while other new drugs will proceed to application for clinical trials in mainland China or new drug approval.

The cross-strait Chinese speak the same language and come from the same ancestral origin, and the development of new drug industry is closely linked with the well-being and benefits on both sides of the Strait. CFDA ‘s drastic reforms in drug administration since August 2015 has made its way into the 10th member country of ICH and adopted international standards to review and manage new drugs. Foreseeably, mainland China will surely become the benchmark in research and development of new drugs among global pharmaceutical industry. At this crucial moment, on the basis of honesty and innovation as company core value, Microbio Shanghai will make joint contribution to the health of cross-strait Chinese with its technology and capability in new drug development under internationally-exclusive intellectual property rights in a humble attempt to create future prosperity for both sides of the Strait.

四川九章生物科技有限公司

Sichuan Jiuzhang Biotech Co., Ltd.

四川九章生物科技有限公司，成立于1999年，致力于从事天然活性产物的筛选、分子结构改造和相关应用的全面研究，是集科研、生产和销售为一体的高新技术企业。

公司经过长期、深入的药学和临床研究，在全球范围内第一次将绿原酸单体作为药物研发并应用于重大疾病（癌症）的治疗，于2013年获得CFDA颁布的绿原酸原料药及制剂的临床批件（批件号2013L01856和2013L1855），注册分类为1.2类化药。

围绕绿原酸的系统研究与产品开发，公司与中国医学科学院药物研究所（以下简称药物所）建立了长期、紧密的战略合作关系，共同搭建绿原酸及相关产品的高端研发平台。中国著名药理学专家药物所陈晓光教授和著名医药学专家药物所蒋建东教授，作为绿原酸药理作用机制研究的两位学术带头人，分别从免疫和细胞两个层面对绿原酸及其制剂的药效、作用机制和其它应用等进行了深入研究。目前的研究显示，绿原酸及其制剂可从免疫和细胞两个层面发挥抗肿瘤作用，具有多靶点、多通道的作用特点，是新型的天然小分子免疫哨卡抑制剂，可以诱导肿瘤细胞的分化，从而从免疫和细胞层面控制恶性肿瘤的生长和转移，延长患者的生存期。此外，作为治疗恶性肿瘤的新型药物，绿原酸制剂的临床试验研究显示，其具有高效、抗瘤谱广且低毒、不致敏的作用特点，可以应用于肿瘤治疗的早、中、晚期，具有极强的临床应用价值和很高的安全性。目前，四川九章注射用绿原酸品种正处于临床Ib期研究阶段。

Established in 1999, Sichuan Jiuzhang Biotech Co., Ltd. is dedicated to screening of natural active products, modifications of their molecular structures and comprehensive research on their related applications. It is a high-tech enterprise that integrates R&D, production and sales.

After long-term and in-depth pharmaceutical and clinical research, the company has employed the chlorogenic acid monomer for pharmaceutical development and for the treatment of major diseases (cancer) for the first time in the world. The company has secured the clinical approval documents for chlorogenic acid API from CFDA in 2013 (approval numbers: 2013L01856 and 2013L1855) and its preparation, with the registration category of 1.2.

The company has established a long-term and close strategic cooperative relationship with the Institute of Materia Medica, Chinese Academy of Medical Sciences (hereinafter referred to as IMM) in terms of system research and product development of chlorogenic acid, and has built a high-end R&D platform for chlorogenic acid and related products jointly. As two academic leaders of research on the pharmacological mechanism of chlorogenic acid, Professor Chen Xiaoguang, a famous pharmacological expert in China from IMM, and Professor Jiang Jiandong, a famous pharmaceutical expert, have carried out in-depth studies on chlorogenic acid's and its preparation's efficacy, its mechanism of action and other applications from both the immune and cellular levels respectively. Current studies have shown that chlorogenic acid and its preparation can play anti-tumor effects from both the immune and cellular levels, and display such characteristics as multiple targets and channels. They are novel natural small-molecule immune checkpoint inhibitors that can induce the differentiation of tumor cells, thereby controlling the growth and metastasis of malignant tumors from both the immune and cellular levels, and prolonging the survival of patients. Moreover, the clinical trial of the chlorogenic acid preparation as a novel drug for the treatment of malignant tumors shows that it demonstrates such characteristics as high efficacy, a broad spectrum of anti-tumor activities, low toxicity and no sensitization. It can be used for the treatment of tumors in early, middle and late stages, and shows a strong value of clinical application and a high safety profile. At present, chlorogenic acid for injection by Sichuan Jiuzhang Biotech Co., Ltd. is under the phase Ib clinical study.

博雅生物制药集团股份有限公司

Boya Bio-pharmaceutical Group Co., Ltd.

博雅生物制药集团股份有限公司，其前身为江西博雅生物制药股份有限公司，创建于1993年，是以血液制品业务为主，集生化药、高端小分子化学药、原料药等为一体的综合性医疗产业集团，总部位于人杰地灵的江西省抚州市。

公司于2012年3月成功登陆中国深交所创业板（证券代码：300294），先后荣获福布斯中文版2013年、2014年及2016年中国潜力上市公司100强，2014年中国上市公司创业板50强，2015年中国最受投资者尊重的百强上市公司，2016年中国上市公司金牛价值投资150强，2017年最具投资价值医药公司10强等荣誉奖项。目前，公司旗下拥有6家成员企业，整体营业收入超20亿元；产品包括血液制品、糖尿病及抗感染类化学药、骨科及产科用药等，拥有90余个品种、近200个规格，其中纤维蛋白原产品收得率和市场份额在国内独占鳌头；产业遍布江西、贵州、江苏、广东、北京、四川等地。

公司是国家高新技术企业，建有江西省血液制品工程研究中心、复旦大学-博雅生物联合实验室，设有院士工作站及博士后科研工作站，并以此为依托，实现多平台联动、资源互补，配套人才激励机制，培养和吸引高精尖人才，打造高端研发人才的集聚地。公司具备国内一流的综合研发能力，与国际先进的血液制品企业和药品研发机构在技术交流、产品研发等方面开展了广泛合作。

公司践行“传递爱与生命”的伟大使命，坚持以市场为导向的发展思路，构建了以“血液制品为核心、专注医药产业”的“1+N”大发展战略，站在集团化发展的高度，以产业和资本双轮驱动，致力于成为世界级血液制品企业、国内制药标杆企业。

Boya Bio-pharmaceutical Group Co., Ltd. with its name changed from Jiangxi Boya Bio-pharmaceutical Co., Ltd. was founded in 1993. Headquartered in Fuzhou City, Jiangxi Province, it is a comprehensive pharmaceutical group specializing in blood products and integrating various products such as biochemical drugs , hydrone chemical drugs and raw API medicine.

In March, 2012, Boya had its stocks gone public on the Shenzhen Stock Exchange, successfully listed on Growth Enterprise Board (stock code: 300294). Till now, Boya has won lots of titles including “Forbes top 100 most potential listed companies” of year 2013,year 2014 and year 2016, “top 50 Growth Enterprise Board listed companies” of year 2014, “top 100 China investors most respected listed companies” of 2015., and so on. At present, the company owns six subsidiary companies, with total revenue over 2 billion. Boya has various products such as blood products, anti-diabetic drugs, anti-infective chemical drugs, Orthopedics drugs and gynecological medicines, altogether 90 assortments with more than 200 strengths, among which its human fibrinogen products reaches the highest yield and the biggest market share in the domestic market. As for the company property, it covers through Jiangxi Province, Guizhou Province, Jiangsu Province, Guangdong Province, Sichuan Province, Beijing, etc.

As a high-tech enterprise, Boya has established the Jiangxi Province Blood Products Engineering Research Center, Fudan University-Boya Associated Laboratory, Post-doctoral Station and Academician Station, on the basis of which Boya can realize the cooperation of muti-platforms and resource complementation with an incentive mechanism to attract, gather and train high-level talents .

With the state-of-the-art R&D capability, Boya often conduct broad exchanges and cooperation related to technology and product development with internationally advanced blood products enterprises and drug Research organizations.

To fulfill the great mission of “Share Love and Save Life” and adhere to the market-oriented developing path, Boya has set the “1+N” strategy with its positioning- “Specialize in blood products and focus on medical industry ”. From the perspective of the group development, and with the double-wheeled drive of property and capital, Boya is committed to become a world-class blood product manufacturer and a domestic model enterprise in pharmaceutical industry.

歌礼生物科技（杭州）有限公司

Ascletis Bioscience Co., Ltd.

歌礼的使命是成为一家世界级生物技术公司，致力于解决抗病毒、癌症及脂肪肝疾病三大治疗领域中尚未被满足的医疗需求。在具备深厚专业知识及优秀过往成就的管理团队的带领下，歌礼已发展成为一体化的抗病毒平台，覆盖丙肝、艾滋病、乙肝、肝癌、脂肪肝等五大疾病领域从新药探索和开发直到生产和商业化的完整价值链。

慢性病毒性丙型肝炎是歌礼当前的重点研究领域。已获批上市的戈诺卫（达诺瑞韦）是首个由中国本土企业开发的丙肝创新药物；已递交新药上市申请并获受理的拉维达韦与戈诺卫联用组成首个中国本土原研全口服无干扰素丙肝治疗方案。

歌礼目前共承担包括丙肝药物、艾滋病药物等在内的四项国家“重大新药创制”科技专项研究任务，并被国家卫计委择优遴选为“重大新药创制”科技专项丙肝课题全国牵头单位。

2016年，歌礼入选浙江省领军型创新创业团队；2017年，歌礼获得第六届中国创新创业大赛生物医药行业总决赛冠军；2018年8月，作为香港交易所主板新规则后全球首家未有盈利的生物科技公司，歌礼成功在港交所主板挂牌上市（1672.HK）。

Ascletis' mission is to become a world-class biotechnology company addressing unmet medical needs in three therapeutic areas: anti-viral, cancer and fatty liver disease. Led by a management team with deep expertise and a proven track record, Ascletis have developed an integrated anti-viral platform covering the entire value chain from discovery and development to manufacturing and commercialization.

Hepatitis C is the primary focus of Ascletis. Ganovo (Danoprevir) is the first HCV cure at commercial-stage developed by a domestic company in China. On June 8, 2018, Ascletis got the NDA approval for Danoprevir. Ravidasvir, combined with Ganovo, forms the first all-oral, interferon-free, HCV regimen developed by a domestic company in China. Ascletis has received the acceptance letter from CFDA for Ravidasvir new drug application.

Ascletis has undertaken four research tasks of National Science and Technology Major Project for “Innovative Drug Development” and was selected by the State Health Planning Commission as the leading unit of the Project on hepatitis C. In 2016, Ascletis was selected as the Leading Innovative and Entrepreneur Team of Zhejiang province. In 2017, Ascletis won the champion of the sixth national innovation and entrepreneurship competition in bio pharmaceutical sector. On Aug. 1, 2018, Ascletis was listed on the mainboard of the Hong Kong Stock Exchange as the world's first pre-revenue biotech since the implementation of the new rules (1672.HK).

北海康成（北京）医药科技有限公司

CANbridge Life Sciences Ltd.

北海康成是一家总部设在中国北京的创新型医药科技企业，通过对接世界最大的生命高科技医药产品线与全球增长最快、潜力最大的应用市场，以加速高端、特效的医药产品在中国和亚洲的市场化。

公司的创建人和首席执行官薛群博士(James Xue, PhD, MBA)，曾任美国健赞公司(Genzyme)高管及健赞中国区第一任总经理，是集美、中研发、营销、创业和企业管理经验于一身的优秀高端海归人员。

北海康成的核心竞争力不仅表现在世界级一流的顾问和管理团队上，与同行业其他企业相较，北海康成筛选、评估、获取优质项目的能力，项目执行及管理能力，临床开发的科研实力均表现出其超群的优越性。

CANbridge Life Sciences Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

Its founder and CEO, James Xue PhD, MBA was a former Genzyme executive and founding general manager of Genzyme China.With its world-class management and advisory team, CANbridge has the capability to select, acquire, develop and deliver future therapeutics and diagnostics with high potential to meet seriously unmet medical needs among Chinese and Asians.

前沿生物药业（南京）股份有限公司

Frontier Biotechnologies Inc.

前沿生物药业（南京）股份有限公司（前沿生物）由海归“千人计划”专家创立于2002年，是一家立足中国、面向全球，在抗病毒及长效制剂领域，具有核心国际竞争力的生物医药企业。致力于研究、生产、商业化针对未满足的重大临床需求的创新药物。历经十几年的磨砺与积累，建立了一支具有国内外药品开发经验的优秀团队，拥有全球自主知识产权的长效多肽药物开发平台和多个原创在研产品。

主研产品艾博卫泰是全球艾滋病治疗领域首个长效新药，拥有全球自主知识产权。该药由前沿生物潜心耕耘15年，填补了中国在抗艾药研发领域的空白。目前Ⅲ期临床试验已提前达到主要终点指标，已于5月提交新药申请，并获药审中心提供绿色通道，给予快速审评。

重磅级产品3BNC117，为全人源广谱高效中和性HIV抗体，由美国洛克菲勒大学顶级科研成果，前沿生物授权引进。公司计划将艾博卫泰与3BNC117联合使用，组成拥有全新作用机制的两种长效药物全注射配方，为全球首个长效抗艾配方，将颠覆性的改变艾滋病治疗模式。

另一主打产品AB001为第三代新型透皮贴片制剂，用于治疗急性和慢性骨骼、肌肉、关节疼痛，为中国首创，将打破中国非甾体抗炎药贴片剂的治疗格局、安全有效，使用方便，市场潜力巨大。

在自主研发项目的同时，前沿生物不断寻求机会，与业界领先的科研机构合作，加速创新药物的研发，通过授权和收购等形式增强产品线，为医生和患者提供多元化的治疗选择。在未来，前沿生物药业将尽心竭力，为中国及世界医药事业的发展做出贡献。

Frontier Biotech is a research-based, clinical stage pharmaceutical company founded in 2002 by a group of Returnees. We are dedicated in the discovery, development and commercialization of innovative therapeutic products for unmet medical needs and under-served patients.The management team have extensive business and development experiences in the US and China pharma/biotech industry. Frontier Biotech leverages China's large patient population, and rapid growing economy and pharmaceutical market, develops innovative pharmaceutical products with worldwide IP protection and to be marketed in the near future.

Our lead product candidate, Albuvirtide, is a treatment-paradigm shifting long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. An NDA was accepted by Chinese FDA in July 2016 and selected for priority review. Albuvirtide could become the first long-acting anti-HIV new drug worldwide.

Another blockbuster candidate, 3BNC117, is a novel broad-spectrum high-potent HIV neutralizing antibody. It was discovered and developed by The Rockefeller University and licensed by Frontier. Combining 3BNC117 with albuvirtide, we will form an all-injectable, long-acting, two-drug regimen that has novel mechanism of action for the treatment and prophylaxis of HIV infection and AIDS.

A third candidate, AB001, is designed as a best-in-class topical patch product for the treatment of acute and chronic muscle and joint pain and inflammation. It's a third-generation patch product with patent-protected and non-hydrogel based matrix formulation for superior skin penetration and tissue permeability, anti-inflammation and pain relief potency.

Frontier Biotech has built up its product pipeline through internal discovery and in-licensed drug candidates. Collaborating with top research institutes, Frontier Biotech will expedite innovative drug discovery and development to provide differentiated therapies for patients in need.

上海仁会生物制药股份有限公司

Shanghai Benemae Pharmaceutical Co., Ltd.

上海仁会生物制药股份有限公司始建于1999年1月，专注于重大疾病领域创新药的研究和开发。公司自成立以来承担了多项上海市及国家相关部委的科研开发课题，包括国家科技部重大新药创制项目和上海市战略新兴产业重大项目等。

贝那鲁肽注射液是全球首个氨基酸序列与人源完全一致的GLP-1类药物，也是仁会生物首个开发上市的国家一类新药，实现了中国在2型糖尿病治疗领域拥有自主知识产权创新药（除中药外）零的突破。GLP-1类药物具有有效降糖却不产生低血糖，减轻体重和降低血脂，从而改善心血管影响因素等显著优势。目前，贝那鲁肽注射液已在中国上市销售，并正在美国开展减肥适应症的临床研究。

公司多年来持续研发投入，研究涉及内分泌代谢、自身免疫、心血管及肿瘤等治疗领域。经过数十年的技术积累，公司建立了基因工程串联技术、多肽蛋白药物制备技术、生物药物长效制剂技术、抗体药物筛选技术等具有较强专业优势的技术平台；并已形成众多专利技术。截至2017年12月31日，已申请中国发明专利16项，获得授权14项；国际发明专利60项，获得授权38项。

公司于2014年1月完成股份制改造，并于同年8月实现了全国中小企业股份转让系统挂牌，证券代码为830931。挂牌后公司融资近四亿元，同时，公司还成为中国第一家带有期权激励制度挂牌的企业。

公司将始终秉承“更好满足临床需求”的宗旨，坚持科学严谨的态度，持续致力于创新生物药的开发、生产和销售，希望成为更多患者的健康选择！

Shanghai Benemae Pharmaceutical Corporation was founded in January 1999, focusing on the research and development of innovative drugs for the treatment of critical diseases. Since then the company has been undertaking a number of research and development projects from Shanghai Municipality and relevant National Ministries and Commissions, including the Significant New Drug Creation Project of the Ministry of Science and Technology and the Great Strategic Emerging Industries Project of Shanghai Municipality.

Benaglutide injection, independently developed by Benemae, is the first completely humanized GLP-1 drug in the world, and was launched as the category I of new drug in China. It was a breakthrough to be the first independently developed innovative drug with intellectual property (except for Chinese Medicine) for the treatment of Type 2 Diabetes in China. GLP-1 drugs have significant advantages including exerting a glucose concentration-dependent hypoglycemic effect, losing weight, improving cardiovascular health by lowering blood lipid levels and so on. Presently, Benaglutide injection has been marketed in China and clinical research on obesity treatment is being carried out in the United States.

The company has been investing in R & D for many years and the research fields involve endocrine, metabolism, autoimmune, cardiovascular diseases, tumors etc.. Based on decades of technology accumulation, the company has established the highly professional technical platforms of tandem gene engineering, polypeptide and protein drug preparation, long-acting bio-drug preparation, antibody drug screening etc.. Moreover, many patents have been granted to Benemae. By December 31, 2017, the company had been granted 14 patents out of 16 Chinese patent applications, and 38 out of 60 international patent applications.

The company completed the process of Shareholding System Reform in January 2014, and was being listed in the Share Transfer System of Small and Medium Sized Enterprises in China with the stock code 830931 in August 2014. After that, the company financed nearly 0.4 billion RMB. At the same time, the company became the first enterprise being listed with stock option incentive mechanism in China.

The company will always adhere to the tenet of "better meet the clinical needs", maintain a scientific and rigorous attitude, and continue to be engaged in the development, production and sales of innovative bio-drugs. Benemae looks forward to being the healthy choice of more and more patients!

广东天普生化医药股份有限公司

Techpool Bio-Pharma Co., Ltd.

广东天普生化医药股份有限公司作为上海医药集团控股的成员公司之一，地处广州市天河智慧城，是集生物医药研发、生产、营销于一体的全球生物蛋白质制药标杆企业，公司参照欧洲EMEA或美国FDA标准建立具有国际先进水平的原料药和冻干粉针、水针、预灌针等制剂生产线，是广州市第一家通过新版GMP认证的制药企业。且公司具备覆盖全国范围内垂直密集型的营销网络、高效的市场准入及营销团队、国际化的管理团队，2017年被评为“中国医药工业最具投资价值10强企业”。天普主要业务聚焦在危重症领域，核心产品是：独家二类新药天普洛安，具有抑酶抗炎的良好作用，适用于急慢性胰腺炎及急性循环衰竭（休克）的治疗，主要应用于急诊、重症及外科等治疗领域；全球首创一类新药凯力康，适用于轻-中度急性血栓性脑梗死。

As a member of Shanghai Pharma, Seated in Tianhe Intelligent Business District (IBD) of Guangzhou, Techpool Biopharmaceutical Co. Ltd. is a leading manufacturer of bio-protein pharmaceuticals of global significance, integrating arms of R&D, production and sales. Following EMEA (Europe) and FDA (U.S.) standards, Techpool has set up state-of-the-art production lines for APIs and finished dosage forms including lyophilized powder injection, liquid injection and pre-filled injection, and is the first Guangzhou-based enterprise to receive the new GMP certification. Leveraging a vertically-structured, dense sales network with national coverage, high-performing teams in market access and product sales, and a management team with international expertise, Techpool was honored as a “Top 10 Chinese Pharmaceutical Enterprise with Highest Investment Value” in 2017. Focusing on critical care, Techpool offers two flagship products: Techpool Roan®, a proprietary national Class-II New Drug with proven enzyme inhibiting and anti-inflammatory effect, used for the treatment of acute and chronic pancreatitis and acute circulatory failure (shock) in therapeutic areas of emergency, critical disease and surgery; Kailikang®, a world-pioneering national Class-I New Drug treating mild to moderate acute thrombotic cerebral infarction.

厦门艾德生物医药科技股份有限公司

Amoy Diagnostics Co., Ltd.

厦门艾德生物医药科技股份有限公司（股票代码：300685），由“千人计划”国家特聘专家郑立谋教授于2008年回国创办，集肿瘤精准医疗诊断产品的研发、生产、销售、服务为一体，同时具备三类体外诊断试剂生产经营资质及独立临床医学检验资质。

公司自有厂区50亩，具备一流的研究中心和国际标准的GMP厂房，获得国家药监局（CFDA）和欧盟ISO13485资质认证，下设厦门艾德医学检验所，专业从事第三方分子检测服务。公司获得国内外发明专利授权20余项（核心专利获得中国、美国、欧洲、日本授权），拥有行业内国际领先、完全自主知识产权的ADx-ARMS®、Super-ARMS®两大技术平台，打破了跨国企业的技术垄断，在短短几年内成长为细分领域领先企业。基于专利技术，针对目前肿瘤精准医疗最重要的EGFR、KRAS、BRAF、EML4-ALK、PIK3CA、ROS1、NRAS、Her-2等基因，公司陆续研发的14种基因检测产品均为我国首批获得CFDA医疗器械注册证书和通过欧盟CE认证的产品，其中ROS1试剂盒获得日本PMDA批准并进入日本医保，是中国企业首个在海外获批的肿瘤伴随诊断试剂，EGFR试剂盒是中国CFDA首次按照伴随诊断试剂标准审评并批准上市的产品。这些产品与靶向药物同等重要，是实现肿瘤精准医疗必不可少的配套检测试剂，有效避免靶向药物的误用、滥用，大大节约了社会医疗成本。

目前全球50多个国家和地区的数百家大中型医院选择了艾德产品，每年有数十万肿瘤患者从中受益，艾德生物的技术和产品质量为国内外客户广泛认可。基于技术与产品优势，公司是AstraZeneca、Boehringer-Ingelheim、Pfizer、Merck、Illumina等跨国企业在肿瘤分子诊断技术领域的合作伙伴，赢得了良好的市场声誉和广泛的客户认可，是国际知名的民族品牌。

Amoy Diagnostics Co., Ltd. (AmoyDx) (Stock Code: 300685), was founded in 2008 by Professor Zheng Limou, a special national appointment expert of “The Recruitment Program of Global Experts" scheme. AmoyDx is integrated with the research and development, production, sales and service of cancer precision medical diagnosis products, with qualifications of production and management of Class III in Vitro Diagnostic Reagents and certification of clinical medical examination.

The company has its own factory area of 33,333 m2, with the first-class research center and international standard GMP manufacturing plant, qualified with CFDA and the EU ISO13485. AmoyDx clinical medical laboratory, is specialized in the third party molecular testing services. AmoyDx has gained more than 20 patents both domestically and internationally (the core patents are authorized by China, the United States, Europe and Japan). With world leading and fully owned intellectual property rights of the two technology platforms, ADx-ARMS and Super-ARMS, AmoyDx has broken the technical monopoly of multinational companies and become a leading company in the field within a few years. Based on patented technologies, AmoyDx has developed 14 kinds of gene detection products for most important genes such as EGFR, KRAS, BRAF, EML4-ALK, PIK3CA, ROS1, NRAS, Her-2, and other genes in cancer precision medicine. Among them, the ROS1 kit has obtained Japan PMDA approval and entered Japan's medical insurance, the very first Chinese company owning a cancer companion diagnostic kit approved oversea. The EGFR kit is the first product approved CFDA following the companion diagnostic standards. Of equally importance as targeted drugs, these products are essential for precision medicine of cancer, effectively avoiding misuse and abuse of targeted drugs, and saving the cost of social medical treatment significantly.

At present, hundreds of large and medium-sized hospitals in more than 50 countries and regions of the world have chosen AmoyDx products, and one hundred thousand cancer patients benefit from them each year. The technology and product quality of AmoyDx are widely recognized and well received by customers all around the world. Based on the advantages of technology and products, AmoyDx has been the diagnostic partner of AstraZeneca, Boehringer-Ingelheim, Pfizer, Merck, Illumina and other multinational companies in the field of tumor molecular diagnostics. AmoyDx has won a good market reputation and a wide range of customer recognition, as an internationally famous Chinese brand.

信达生物制药（苏州）有限公司

Innovent Biologics (Suzhou) Co., Ltd.

信达生物成立于2011年，致力于开发、生产和销售用于治疗肿瘤等重大疾病的单克隆抗体新药。

自成立以来，公司凭借创新成果和国际化的运营模式在众多生物制药公司中脱颖而出，获得了富达、礼来亚洲基金、美国资本集团、君联资本、淡马锡、国投创新等全球多家知名创投基金资本支持。已建立起了一条包括17个单克隆抗体新药品种的产品链，覆盖肿瘤、眼底病、自身免疫疾病、心血管病等四大疾病领域，其中2个品种入选国家“重大新药创制”专项，7个品种进入临床研究，4个品种进入临床III期研究。

目前，公司按照CFDA、美国FDA和欧盟EMA的GMP标准建成高端生物药产业化基地。产业化生产线已通过合作方国际制药集团产业化生产要求的GMP审计。已组建了一支具有国际先进水平的高端生物药开发、产业化人才团队，包括60多位海归专家。公司立足自主创新的产品与美国礼来制药集团达成了两次总金额超过15亿美元的全面战略合作，创造了多个“中国第一”。

“始于信，达于行”，开发出老百姓用得起的高质量生物药，是信达生物的理想和目标。

Our mission is to create a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs that are affordable to ordinary people.

Since the founding of Innovent in 2011, we have developed our fully-integrated platform which includes R&D, CMC (Chemistry, Manufacturing, and Control), clinical trial and commercialization capabilities. These capabilities have enabled us to build a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases. The full integration of our platform enables efficient collaboration between different functional groups at key points in the lifecycle of a drug candidate with the aim of increasing both the speed of development and the likelihood of success while at the same time reducing the cost of development. This platform is the engine that drives our business and allows us to manage the risks of drug development.

Leveraging our platform, we have built up a pipeline of 17 antibody drug candidates in the last seven years, led by our four core products that are in late-stage clinical development in China. In addition, out of our pipeline of 17 antibody drug candidates, seven have entered in clinical development, four have entered Phase III clinical trials and a BLA for one product has been accepted by CFDA with priority review status.

Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of our clinical and commercial facilities are in compliance with the cGMP standards of CFDA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. In addition, Innovent also has a highly talented international team, including over 60 expert returnees, focusing on high-end biopharmaceutical drug discovery, development and production. We have also entered into two strategic alliances with Eli Lilly and Company that could generate more than 1.5 billion USD in upfront and milestone payments.

Innovent has raised 580 million USD in private financing from numerous world-renowned VC firms, including Fidelity, Lilly Asia Ventures, Capital Group, Legend Capital, Temasek, Rock Springs Capital, Cormorant Private Healthcare, Hillhouse Capital, China Life, Ally Bridge Group, Taikang Insurance Group, and SDIC Fund.

Inspired by our corporate spirit of "Start with Integrity, Succeed through Action," Innovent 's mission is to commercialize high quality biopharmaceutical products that are affordable to ordinary people.

华领医药技术（上海）有限公司

Hua Medicine (Shanghai) Ltd.

华领医药是一家立足中国，针对全球糖尿病患者尚未满足的临床需求，研发全球原创新药的生物技术公司。华领医药汇聚全球高端人才和科技资源，以国际顶级生物医药投资团队为依托，成功实现了全球首创糖尿病新药Dorzagliatin（HMS5552）在中国完成药品可开发性临床验证，率先进入注册性临床试验阶段。公司已在中国开展2个III期临床试验，分别针对新发未经治疗的和二甲双胍治疗失效的2型糖尿病患者人群。公司将启动药品生命周期管理相关临床试验，并拓展糖尿病个性化治疗和管理的先进理念，联合中国和美国糖尿病领域专家，实现对糖尿病和代谢性疾病及其并发症的有效控制。

Hua is a leading, clinical stage innovative drug development company in China focused on novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA enabling stage and started 2 Phase 3 trials in China for drug naive and met form in treated T2D patients. The company also has initiated product life-cycle management studies of this novel diabetes drug, and advanced knowledge in personalized diabetes care. Hua's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working very closely with disease experts in China and rest of world to advance diabetes care solutions for global patients.

亚盛医药

Ascentage Pharma

亚盛医药是一家立足中国、面向全球的原创新药研发企业，在肿瘤、乙肝及与衰老相关的疾病治疗领域已成功布局，尤其在细胞凋亡和自噬双通道调控抗肿瘤药物领域的研发领先全球，所有在研项目均为新化合物结构的原创1类新药，并旨在进军国际高端医药市场。

公司在基于靶向蛋白结构的药物设计与优化领域形成了多项核心技术，拥有一百多项国际发明专利，已成功开发近10项原创小分子靶向抗肿瘤药物进入临床前或不同阶段国际临床研究，其中6项已分别进入到中国、美国及澳大利亚的I-II期临床开发阶段。

亚盛医药专注于已为临床验证的癌症靶点，其研发产品管线主要为细胞凋亡路径关键蛋白的抑制剂，通过抑制BCL-2/ Bcl-xL、IAP和MDM2-p53等，重启肿瘤细胞的凋亡程序；第二代和第三代的针对癌症治疗中出现的激酶突变体的抑制剂；与肿瘤治疗的有密切相关性的表观遗传学靶点的抑制剂等。

此外，亚盛医药已与美国领先的生物技术公司UNITY Biotechnology建立合作，旨在全球范围内共同合作开发基于清除衰老细胞的新型抗衰老治疗药物；公司的主要合作伙伴还包括密西根大学及美国默克等。

公司现有研究人员100多人，其中中组部“千人计划”国家特聘专家入选者3人，具有多年海外原创药物研发经验高层次人才10余人，硕士及博士人数占公司总人数一半以上。

Ascentage Pharma is a global, clinical-stage biopharmaceutical company, dedicated to discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs in cancers, hepatitis B and age-related diseases.

Ascentage has world-leading proprietary Protein-Protein Interactions (PPIs)-targeting drug discovery technologies and holds over 100 international patents. Ascentage currently has six small molecule drugs in phase I-II trials in US, Australia and China and additional programs in preclinical stages.

The established R&D pipeline of Ascentage includes the inhibitors to a number of key proteins, including IAP, Bcl-2/Bcl-XL and MDM2-p53, that regulate programmed cell death process; 2nd and/or 3rd generation of kinase inhibitors that overcome mutant resistance in cancer therapy; and inhibitors of epigenetics.

Ascentage is partnering with UNITY Biotechnology to co-develop senolytic therapies addressing the age-related diseases. The other major partners of Ascentage include University of Michigan and Merck .

再鼎医药

ZAI Lab (Shanghai) Co., Ltd.

再鼎医药是一家总部位于上海的高科技生物制药公司。公司拥有一支具有全球创新药物研发背景及丰富经验的新药研发团队，公司立足中国，致力于研制世界一流的创新药物。

公司采用自主创新与合作开发并举的研发策略，一方面自主研发“全球新”的创新药，为全球患者解除病痛提供治疗手段；另一方面，基于对中国患者现有的及不断增长的治疗需求的深刻洞察，积极与领先的跨国制药公司或高度创新的生物技术公司进行战略合作，将国内急需的全球领先的创新药物早日引入中国，惠及于中国患者。通过这种双轮驱动的创新策略，再鼎医药已经打造了一个遍布研发各阶段、极具竞争力的新药产品线。未来，公司将继续通过积极的外部合作和内部研发策略不断扩大产品线。

Zai Lab is a Shanghai-based biopharmaceutical company. Our globally-experienced drug development team is passionate about bringing transformative medicines to China and discovering and developing our own therapeutics for patients worldwide.

Our vision at Zai Lab is to create a premier drug discovery, development, manufacturing and commercialization organization built on a foundation of world-class expertise and insights into the existing and expanding needs of Chinese patients. We have assembled a team of leaders who have a collective track record in all aspects of our business, including pioneering success in the regulatory process in China. We have established a pipeline of best-in-class biopharmaceuticals at different stages of development by securing partnerships with leading multinational pharmaceutical and highly innovative biotechnology companies. Our pipeline will grow through additional collaborations and from our internal discovery and development efforts.

和记黄埔医药（上海）有限公司

Hutchison MediPharma Limited

和记黄埔医药（上海）有限公司于2002 年9 月成立，总部位于中国上海张江高科技园区。公司立足于中国本土创新，专注研发具有自主知识产权保护的治疗癌症和自身免疫性疾病的创新靶向药物，以满足全球医药市场的需求，是国际先进、国内最为领先的新药研发企业之一。

和记黄埔医药拥有一套完整的药物研发体系和一流的研发平台，拥有最先进的仪器配置、国际AAALAC 认证的试验动物中心、激酶筛选平台、转化医学中心、 计算机辅助化学结构设计平台、药代动力学评估中心、初步毒性评估平台等。并设置有肿瘤研究部、免疫研究部、化学部、药代部、药物安全评价部、分析及质量部、药学部、临床与法规事务部、商务开发部等完备研究开发部门，协同研发、无缝衔接。

和记黄埔医药的十几位高级管理层均留学美国等著名高等院校和研究机构，在世界知名医药及生物科技公司工作数十年，并先后参与多个国际重磅炸弹药物的研究开发工作，拥有丰富的专业知识和成功研发新药的从业经验。以资深管理层为核心，公司组建了一支由330 余名拥有丰富中西药研发经验的科学家所构成的队伍，90%的科研人员拥有硕士或博士学位，其中约10%的员工曾留学欧美，在国外著名院校或研究机构接受过系统的专业学习和前沿科学研究工作。同时，公司还拥有一批富有经验且熟知中国临床开发及药事法规的本土研究人员。另外，公司拥有近8000 平米的研发中心和一个近4500 平米的GMP 制剂生产基地，建立了集研发、中试和产业化生产于一体的完整产业链条。

深耕创新16年，现如今，和记黄埔医药取得了极为瞩目的成绩。公司目前共有8个1类小分子新药，在欧美、澳洲、中国同步进行共计33项临床研究。其中有4个已经处于临床关键三期的晚期开发阶段。值得一提的是，和记黄埔医药携手合作伙伴阿斯利康近期启动了沃利替尼治疗乳头状肾癌(PRCC)的临床三期、国际多中心研究，这不仅是全球史上首个具有伴同诊断，遴选携带MET基因驱动的PRCC患者的三期注册研究，也是中国民族药企研发的靶向创新药物第一次在全球范围内开展以上市为目的的注册性临床研究。沃利替尼有望成为首个由中国民族药企为全球市场研发的重磅炸弹式药物，彻底改变中国生物医药研发在国际上的形象，掀开中国新药研发史的全新篇章。更值得一提的是，和记黄埔医药与合作伙伴礼来共同开发的小分子靶向药物呋喹替尼在治疗晚期结直肠癌的临床三期中达到所有的研究终点，体现了同类最优的疗效和安全性，并完成新药申报，即将获批上市造福广大晚期结直肠癌患者。这也标志着和记黄埔医药从生物创新公司到生物制药公司的成功转型。

Hutchison MediPharma Ltd. (“HMP”) was established in September, 2002, located in Zhangjiang Hi-Tech Park, Shanghai, China. HMP is an innovative biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases.

HMP has built a large-scale and first-class fully integrated drug R&D platform with the state-of-the-art equipment configuration, the experimental animal center with AAALAC international certification, the kinase screening platform, the translational science center, the computer aided chemical structure design platform, the pharmacokinetic evaluation center, the preliminary toxicity evaluation platform, etc., covering chemistry, biology, pharmacology, toxicology, chemistry and manufacturing controls for clinical and commercial supply, clinical and regulatory and other functions, which work seamlessly together.

The leadership team members in HMP comprise mainly of returnees trained in USA and other western countries, with an average 20-year experience in multinational pharma & biotech companies, and participated in the discovery & development of numerous blockbusters. There are more than 330 scientists and staffs in HMP, 90% of the scientific research personnel have a master or doctoral degree, and about 10% of them were educated in well-known colleges, universities or research institutions in Europe or USA, and joined HMP with rich experience in innovative drug R&D. Meanwhile, HMP also has a group of locally trained researchers that are familiar with China's clinical development and regulations. In addition, HMP has nearly 8000 square meters of R&D center and approximately 4500 square meters of GMP formulation production base for industrialization and production of the new drugs.

HMP has made remarkable achievements since it was established in 2002. HMP has built a rich pipeline with 8 clinical candidates in 33active trials (including 4 candidates in Phase III pivotal registration trials) in United States, Europe, Australia and China. It's worth to mention that HMP and its partner AstraZeneca initiated a global, Phase III registration trial of savolitinib in Papillary Renal Cell Carcinoma (“PRCC”) recently. This is the first pivotal study ever conducted in MET-driven PRCC and the first molecularly selected trial in renal cell carcinoma worldwide, and also the first innovative anti-cancer drug candidate, discovered in China, entering a global pivotal registration trial to date. Savolitinib has the potential to become a blockbuster drug for global market, which could set a landmark in the history of Chinese innovation for drug R&D. Moreover, the novel drug fruquintinib, discovered independently by HMP and being co-developed with Eli Lilly, convincingly met all primary and secondary endpoints in its Phase III pivotal study for advanced colorectal cancer, and showed best-in-class potential. The NDA submission to CFDA has been completed and is pending for approval. We believe that the launch of fruquintinib will not only transform HMP into a biopharmaceutical company with commercial products, but also offer the Chinese cancer patients a choice for better treatments.

苏州康宁杰瑞生物科技有限公司

Suzhou Alphamab Co., Ltd.

苏州康宁杰瑞生物科技有限公司是从事生物大分子药物研发的生物技术制药公司，由国家千人计划特聘专家徐霆博士于2009 年归国创建。

至目前为止公司已累计投入研发经费4 亿多人民币，拥有6000 余平方米的专业实验室与符cGMP标准的中试车间。建立了从大分子药物的早期筛选、工程化、细胞株构建、工艺开发、质量研究到临床试验及申报注册的完整研发功能链，产品涵盖肿瘤、抗凝、不孕不育及重大传染性疾病诸领域。

公司建立了拥有自主知识产权的多个技术平台， 其中包括蛋白质工程及单域抗体、双特异性抗体、混合抗体生产平台。提出技术及产品专利50余项 ，获授权6项， 进入PCT 阶段的9 项，其中三个专利已经获得国际专利授权。目前共有8 个新药申报临床，其中一类新药长效卵泡刺激素、国内首个PDL1 单域抗体和Nulojix生物类似药已获批进入临床研究。

康宁杰瑞在立足自主研发的同时还积极开展与外界的科研协作，建立起开放共赢的研发模式。通过与包括芝加哥大学，哈佛大学、中科院以及东南大学、上海交大、浙江大学等著名学府及机科研机构的合作来培养人才及提升自身的研发能力。公司成立有江苏省研究生及博士后工作站；与东南大学成立校企共建技术中心；与美国Thermo Fisher公司合作建立技术平台。

同时我们也正着力推动研发品种的产业化进程。总投资二十亿元、位于苏州工业园区核心地带的康宁杰瑞江苏产业化基地的建设已经启动，一期工程预计将建成具有12000升能力的多个大分子药物生产线，以期在不久的将来实现在研产品的工业化生产。

我们期待通过研发及产业化体系的不断建设和持续创新，将康宁杰瑞打造成国内领先、国际一流的创新型、综合性、国际化大型生物制药企业。为国内患者同步提供可获得的、国际领先的先进治疗药物，从而满足临床需求、造福社会。

Suzhou Alphamab Co., Ltd. is a clinical-stage innovative biotech based in BioBAY China.

Founded in 2009, Alphamabis a leading biotechnology company focusing on the discovery, development and manufacture of innovative biologics therapeutics. With multiple in-house proprietary platforms, includingantibody screening, bi-specifics, mix-mAb production,protein engineering, and CMC development, Alphamab and its subsidiaries have developed a robust pipeline of over 20 innovative biologics programs in immune-oncology, infertility, infectious diseases and several other areas, such as KN035 PD-L1 domain antibody (the first subcu PD-L1/PD-1 mAb) under clinical development in the US and China, and the best-in-class long-acting FSH in phase I.

Alphamab is striving to develop 1st-in-class or best-in-class biologics medicine to address unmet medical needs globally.

基石药业（苏州）有限公司

CStone Pharmaceuticals Co., Ltd.

基石药业是一家总部设于中国苏州，以创新药研发为驱动的生物制药公司，致力于肿瘤免疫药物的开发，拥有丰富的产品线。公司于2016年7月完成A轮融资，共募集到1.5亿美元（约9.75亿人民币）资金，由三家颇具声望的投资公司参与，分别是元禾原点、博裕资本及毓承资本。

公司的领导团队均来自国际知名药企管理层，已成功构建起以临床研发和转化医学为核心竞争力的团队，并且将以国际标准开展高质量的临床研究。特别是在广受瞩目的肿瘤治疗领域，基石药业以其出色的肿瘤免疫药物为核心，凭借其世界级的研发团队，最前沿的药物研发项目， 以及开放式创新的策略有望引领国内新药研发行业走向全球， 并成为跨国药企与国际生物制药公司在中国以及亚太地区进行产品共同开发的最佳合作伙伴。

公司重组抗PD-L1全人源单克隆抗体注射液CS1001于2017年6月27日获得国家食品药品监督管理总局（CFDA）颁发的临床试验批件，标志着我国首个自然全长、全人源抗PD-L1单克隆抗体成功进入临床研究开发阶段。这是公司发展的重要里程碑，并为基石药业后续进行具有开创性的，以PD-L1为骨架的多种联合治疗开发奠定了坚实的基础. 目前，全球已有五个PD-1/PD-L1新药获得批准上市，涉及10余种适应症，中国尚无同类产品成功开发上市。基石药业独立开发的CS1001未来有望满足中国患者对此类药物的迫切需求。

CStone Pharmaceuticals, headquartered in Suzhou, is a biopharmaceutical company devoted to the development of a new generation of innovative drugs. CStone has a rich oncology pipeline with a strategic focus on immuno-oncology. In July of 2016, CStone Pharmaceuticals announced the completion of its $150 million Series A financing, led by three prestigious VC/PE funds: Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures.

All members of the management team are seasoned executives from top multinational pharmaceutical companies. CStone has successfully built up an industry leading team with clinical development and translational medicine as its core competence. This enables CStone to accelerate the drug approval timeline while applying global standard practices to ensure clinical trial quality. The unique advantages in pipeline, clinical development, and funding also positions CStone as the partner of choice for multinational pharmaceutical / biotech companies to develop drugs in China and the Asia Pacific region.

CStone received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) on June 27th, 2017 for its investigational agent CS1001. This is China's first fully human, full-length anti-PD-L1 monoclonal antibody to successfully enter the clinical development stage. This event is a significant milestone for the company, which lays a solid foundation for subsequent development of multiple combination therapies using anti-PD-L1 as the backbone treatment. Currently, five anti-PD-1 / PD-L1 drugs are approved by the U.S. FDA in more than 10 indications, but none has been approved in China. As such, CStone’s CS1001 has the potential to address the urgent needs of Chinese patients for this class of drugs.

上海药明巨诺生物科技有限公司

JW Therapeutics (Shanghai) Co., Ltd.

上海药明巨诺生物科技有限公司成立于2016年2月，是以科技创新为先导的细胞免疫治疗公司，拥有一支在全球制药企业和研发机构富有经验的顶尖创业团队。公司致力于研发，转化及应用领先的精准细胞免疫疗法，并引进了全球公认的肿瘤细胞免疫治疗领军企业 Juno Therapeutics 的核心技术（Juno是纳斯达克上市公司，也是当前全球研发储备最深厚，研发进度最为领先的行业内翘楚），并在中国最大的药物研发服务企业药明康德全力支持下，建立起的一家独立的立足于中国，世界一流，中国领先的细胞治疗公司，服务于中国肿瘤患者，成为中国和世界细胞治疗领域的领导者。

药明巨诺依托国际化的技术资源和团队的多年积累，发挥中国优势，力争在中国做出具有全球影响力的世界级创新。我们也希望与中国和世界各地合作伙伴展开多种形式的合作，为肿瘤患者带来更多变革性的治疗解决方案。

李怡平(James Li)先生担任药明巨诺公司首席执行官，李先生是药明巨诺联合创始人，之前曾担任凯鹏华盈合伙人以及安进中国公司总经理。李革博士担任药明巨诺公司董事长，公司董事会成员包括李怡平先生，Hans Bishop先生 （Juno CEO），Steve Harr先生 (Juno CFO)，以及药明康德首席财务官兼首席投资官胡正国先生。

Established in Feb 2016, JW Therapeutics (Shanghai) Co, Ltd. is an innovation driven cellular immunotherapy company, led by a group of industry veteran with extensive global bio-pharmaceutical and R&D experiences. Supported by the R&D and technology from Juno Therapeutics (a NASDAQ listed global leader in the field) and the expertise of Wuxi Aptec (the largest bio-pharma CRO / CMO in China), the company aims to become a leader in the immune-cell therapy field in China and globally, focusing on research, translational, development, quality manufacturing, and commercializing of the best cell therapy solutions for the Chinese patients.

JW Therapeutics will capitalize on its global R&D assets and intellectual resources, leverage the unique opportunities in China, and become a global innovator and leader in the immune-cell therapeutics space. We are open to collaboration and partnership opportunities in China and globally to provide the transformative therapeutic solutions to patients.

Mr. James Li is the CEO and co-founder of JW Therapeutics; previously he was a partner of KPCB China and General Manager of Amgen China. The board of directors includes Dr. Li Ge (Chairman, Chairman & CEO of Wuxi), James Li, Hans Bishop (Juno CEO), Steve Harr (Juno CFO), and Ed Hu (Wuxi CFO).

北京加科思新药研发有限公司

Beijing Jacobio Pharma Co., Ltd.

北京加科思新药研发有限公司成立于2015年，是一家致力于创新药物研发的高新技术企业。注册资本金1.6亿元，由王印祥博士、胡邵京博士、王晓洁女士、周文来博士等组成的留美海归博士团队领军，他们具有数十年的新药创制和研发管理实践经验，在中国有数个有影响力的创新药上市。

公司位于开发区生物医药园5号楼，拥有4000平米实验室，下设合成、分析、制剂、药理、QA、注册、医学等专业功能平台，拥有顶尖的科研团队。

由加科思所管理的创新引导基金-屹唐加科思基金，首期规模2亿元，定位于天使投资，全部投资于加科思新药研发助推器遴选出的项目公司以及部分开发区内新药研发的初创企业。

加科思致力于为重大疾病治疗提供突破性创新产品，公司的内部研发专注于小分子肿瘤免疫和分子靶向药物研发。同时，加科思建立“平台+基金”的“捆绑式创新工场”模式拓展外部研发，吸引海外科学家带着有开发潜力的项目回国创业，致力于成为新药研发创业者的助推器，发掘并帮助创业者在北京亦庄创业并成长为细分领域内的行业标杆乃至全球具有影响力的生物医药企业。

Beijing Jacobio Pharma Co., Ltd , founded in 2015, is dedicated to innovative drug discovery and development.The registered capital of 160 million yuan, by the United States Dr. team leader, Such as Dr. Wang Yinxiang, Dr. Hu Shaojing, ,Ms.Wang Xiaojie and Dr Zhou Wenlai. they have decades of drug discovery research and management experience, in China several influential listed drug innovation.

Jacobio is located in Beijing Yizhuang Biomedical Park, with 4000 square meters of experimental buildings, under the synthesis, analysis, preparation, pharmacology, QA, registration, medical and other professional function platform, with the top team.

By the management of Jacobio about innovation guide capital–ET-Jacobio Capital, the first phase of the scale of 200 million yuan, aimed in angel investment.The total investment Jacobio drug development boosters selected item company as well as part of the development zone of new drug research and development of start-ups.

Jacobio is committed to providing groundbreaking innovative products for the treatment of major diseases, the company's internal research and development focus on small molecular tumor immunology and molecular targeted drug research and development. At the same time, the establishment of Jacobio’s"platform + fund" "bundled Innovation workshop" model to expand the external development, attract overseas scientists with potential for the development of the project Returning to business, is committed to become a booster for new drug research and development of entrepreneurs, to explore and to help entrepreneurs in BDA and grow to the benchmark and the world influential biological medicine business segments within the industry.

北京诺诚健华医药科技有限公司

Beijing InnoCare Pharma Tech Co., Ltd.

诺诚健华是一家植根于中国且具全球视野的新药创制公司。公司的核心团队都具有丰富的新药研发经验，曾成功开发出超过100个新药专利和候选新药。公司的科学顾问委员会由来自清华、北大的生命科学带头人、跨国公司新药研发专家以及国内顶尖医院的医疗专家组成。他们与公司的研发团队一起，构成公司的核心竞争力。

面对在中国发病率居高不下且缺乏有效治疗的肝癌、胃癌及类风湿关节炎、系统性红斑狼疮等自身免疫疾病，诺诚健华自创立之日起，就把“利用最新的科学技术与发现驱动新药研发，提供患者治疗所需的新药，为改善公众健康而努力”作为自己的使命。为达成这一使命，我们专注于国际一类新药与新技术产品开发，通过“自主研发、外部引进与国际合作”等途径，有效整合各方资源并加快新药研究在中国从实验室到医院的进程，在帮助中国患者尽早用到国际一类新药的同时，把公司打造成国内外生物医药行业的领军企业。

InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. InnoCare' s core scientific team members have strong educational backgrounds and rich drug innovation experiences in the U.S. and China. InnoCare also has an elite Scientific Advisory Board (SAB) comprising of professionals from leading universities, hospitals, academic institutions and pharmaceutical industry. InnoCare is forging forward on the critical path of defeating diseases and pushing the boundaries of innovation into unchartered territories.

The mission of InnoCare is to become a global leader in providing patients with safe, effective and affordable treatments to address the unmet medical needs in cancer and autoimmune diseases. We pay special attention in targeting Chinese populations because of their high incidence rates yet insufficient effective treatments or cures for diseases such as liver cancer, gastrointestinal cancer, and autoimmune diseases including lupus and rheumatoid arthritis. To achieve our goal, we have employed numerous synergistic approaches including internal research and development, licensing-in, and international collaborations to accelerate the development process of the First- and/or Best-in-Class drugs.

百济神州（北京）生物科技有限公司

BeiGene (Beijing) Co., Ltd.

百济神州是一家植根中国的全球性商业化生物医药公司，致力于成为分子靶向药物和免疫肿瘤药物研发，及商业创新领域的全球领导者。

目前，百济神州拥有三款处于临床后期的在研候选药物:

•Zanubrutinib （BGB-3111）——一款在研小分子BTK抑制剂，其作为单药和与其他治疗手段进行联合用药，以针对多种淋巴瘤的注册性临床试验正在全球和中国广泛开展。

•Tislelizumab （BGB-A317）——一款在研针对免疫检查点受体（PD-1）的人源化单克隆抗体，目前其注册性临床试验正在中国进行；与此同时，我们也计划在全球范围内开展其作为单药和与其他治疗手段联合针对多种实体瘤和血液癌症的注册性临床试验。

•Pamiparib （BGB-290）——一款针对PARP1和PARP2靶点的在研小分子抑制剂，其作为单药和联合用药作用于多种实体瘤的潜在疗效正在接受评估。目前，Pamiparib（BGB-290）在中国正处于关键性临床试验阶段，预计很快也会在全球范围进入后期临床开发。

2017年，百济神州与新基公司达成战略合作伙伴关系，向新基转让了tislelizumab（BGB – A317）在美国、欧洲、日本和亚洲以外的其他地区的实体瘤开发和商业化的独家权益，保留了在亚洲（除日本外）开发和商业化tislelizumab用于治疗实体瘤的权益，以及用于治疗恶性血液肿瘤和进行内部组合疗法的全球范围权益。

此外，百济神州获得了新基公司在华获批药物——注射用白蛋白紫杉醇（ABRAXANE®），瑞复美（REVLIMID®）和 维达莎（VIDAZA®）的独家授权，并接管其在华商业运营团队。这使得百济神州从2017年9月开始获得产品销售收入，并为未来百济神州自主研发的候选药物和未来计划引进药物的上市奠定基础。

目前，百济神州在全球各地拥有超过1100名员工，其中包括在中国、美国、澳大利亚和瑞士的超过650名科学家及临床医学专家。公司在中国的北京、上海；美国的马萨诸塞州Cambridge，新泽西州Fort Lee和加利福尼亚州旧金山Emeryville和San Mateo，瑞士的巴塞尔均设有办事机构。除此之外，百济神州在中国大陆还拥有位于北京的研发中心，苏州、广州两大生产基地，以及在上海的商业运营中心。

BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

We have three internally-developed late-stage clinical drug candidates:

•Zanubrutinib (BGB-3111) — an investigational small molecule inhibitor of Bruton's tyrosine kinase, or BTK, that is currently being evaluated in a broad registrational clinical program globally and in China as a monotherapy and in combination with other therapies to treat various lymphomas;

•Tislelizumab (BGB-A317) — an investigational humanized monoclonal antibody against the immune checkpoint receptor PD-1 that is currently being evaluated in a broad registrational clinical program globally and in China, as a monotherapy and in combination with other therapies to treat various solid and hematological cancers; and

•Pamiparib (BGB-290) — an investigational small molecule inhibitor of PARP1 and PARP2 that is being evaluated as a potential monotherapy and in combinations for various solid tumors. It is currently in a pivotal clinical trial in China and is expected to enter late-stage development globally in 2018.

In 2017, we entered into a strategic collaboration with Celgene Corporation, or Celgene, in which we granted Celgene exclusive rights to develop and commercialize tislelizumab for solid tumors in the United States, Europe, Japan, and the rest of the world outside of Asia. We retained rights to tislelizumab for solid tumors in Asia (ex-Japan) and for hematological malignancies and internal combinations globally.

In addition, Celgene granted us an exclusive license to market its approved cancer therapies ABRAXANE®, REVLIMID®, and VIDAZA® in China excluding Hong Kong, Macau and Taiwan, and also transferred its commercial operations and personnel in China to us, which has allowed us to generate product revenue in China since September 2017 and which we expect to expand in preparation for the potential launch of our own internally developed drug candidates and our other in-licensed drug candidates in China.

To date, we have a global team of over 1,100 employees, including more than 650 scientists and clinicians, in China, the United States, Australia and Switzerland. Our offices are located in Beijing; Shanghai; Cambridge, MA; Fort Lee, NJ; the San Francisco Bay Area, CA; Basel, Switzerland; including a research and development center in Beijing, manufacturing sites in Suzhou and Guangzhou, and commercial operations in Shanghai.

珐博进（中国）医药技术开发有限公司

FibroGen (China) Medical Technology Development Co., Ltd.

珐博进（中国）医药技术开发有限公司（“珐博进（中国）”）是一家于2011年在北京经济技术开发区成立的生物医药科技公司，致力于研发创新性生物技术、化学药品，以解决中国患者亟需满足的临床需求。目前，珐博进（中国）注册资本为2.1亿元，投资总额6.3亿元，现有员工120人。

目前，珐博进（中国）的在研产品包括的在研产品包括用于治疗慢性肾病相关贫血的罗沙司他和用于治疗因角膜功能障碍引起的视力缺陷的创新医疗器械生物合成角膜。

罗沙司他是具有全新作用机制的1类创新药。珐博进（中国）已于2017年下半年完成罗沙司他在中国开展的治疗慢性肾病患者相关贫血的两项III期临床试验并提交上市申请。罗沙司他有望成为首个口服治疗、无需注射、无需静脉铁剂补充的抗贫血新药，为中国数百万慢性肾病贫血患者提供革命性的创新疗法。

生物合成角膜是一种基于全新生物材料制作的创新型III类医疗器械，具有国际领先水平，是以高纯度生物合成人胶原蛋白制成的透明生物合成角膜，有望通过再生医学的原理置换眼角膜，治疗因角膜功能障碍引起的视力缺陷。

珐博进（中国）在北京经济技术开发区投资建设了高水准的中试研发基地，于2014年取得《药品生产许可证》，并以卓越的研发实力被先后评定为“中关村高新技术企业”、“北京市级企业科技研究开发机构”和“北京生物医药产业跨越发展工程（G20工程）- 后备企业”。

珐博进（中国）在上海和河北沧州设有分公司，上海分公司主要开展临床研究和医学事务活动，沧州分公司正在建设的原料药工厂，投产后将为北京的罗沙司他制剂工厂供应原料药。

FibroGen (China) Medical Technology Development Co., Ltd. (“FibroGen China”), a biopharmaceutical company established in Beijing Economic Technology Development Area (“BDA”), Beijing in 2011, is committed to researching and developing innovative drugs to address urgent unmet medical needs for patients in China. As ofJune 6 2018, FibroGen China had a registered capital of RMB 210 million, a total investment amount of RMB 630 million, and 120 employees.

Currently, FibroGen China has two product candidates under development, including Roxadustat for the treatment of anemia in chronic kidney disease (“CKD”) patients, and biosynthetic cornea for the treatment of visual impairment caused by corneal dysfunction.

Roxadustat is a Class 1 innovative drug with a novel mechanism of action. FibroGen China completed two phase III clinical trials of Roxadustat for the treatment of CKD anemia in China and file a new drug application in the second half of 2017. Roxadustat is expected to be the first oral anemia therapy that does not require injection or IV iron supplementation, offering millions of CKD anemia patients in China with a revolutionary novel therapy.

The biosynthetic cornea is an internationally advanced Class III innovative medical device based on a type of novel biomaterial. This transparent biosynthetic cornea is made of high-purity biosynthetic human collagen, and intended to treat visual impairment caused by corneal dysfunction by replacing human corneal tissues based on regenerative medicine.

FibroGen China invested in and built an advanced pilot plant in BDA that has been granted the Pharmaceutical Production Permit in 2014. Due to its significant R&D capabilities, FibroGen China has been recognized as a “ZhongGuanCun High-tech Enterprise”, a “Beijing Municipal Enterprise Technology Research and Development Institute” and a “Reserve Enterprise of the Beijing Leap-Forward Development Program (G20 Program) for Biopharmaceutical Industry”, successively.

FibroGen China has established branch offices in Shanghai and Cangzhou, Hebei Province. Shanghai branch mainly carries out activities in relation to the clinical development and medical affairs, whereas the Cangzhou branch is building out an active pharmaceutical ingredients (“API”) plant to supply API to FibroGen China’s Roxadustat drug production facility located in Beijing.

荣昌生物制药（烟台）有限公司

RemeGen., Ltd.

荣昌生物制药（烟台）有限公司由荣昌制药与房健民教授于2008年7月共同发起创办。公司专注于生物药物的研发及产业化，拥有国际水平的研发和运营管理团队，配备多规格的全球最先进的可弃式生物反应器及相关的纯化、制剂设备，具有符合欧美及中国GMP管理标准的生产、物控、质量、项目、验证等管理体系，确保实验室和生产车间严格按照美国FDA、欧盟EMA、中国CFDA的GMP要求建设和运营。

荣昌生物自成立以来，针对自身免疫及恶性肿瘤等人类重大疾病，先后自主研发了抗体融合蛋白药物“RC18”，双靶标抗体融合蛋白药物“RC28-E”、“RC28-T”，抗体-药物偶联（ADC）新药“RC48”等创新生物药物，这些新药上市后将给无数患者带来新的希望。

系统性红斑狼疮、类风湿性关节炎、干燥症、视神经脊髓炎、多发性硬化症等自身免疫疾病是威胁人类健康的严重疾病，传统治疗手段无法满足病人的需要。荣昌生物研发的“RC18”是攻克这一类顽疾的“新型武器”，已经进行到Ⅲ期临床研究阶段，预期在2019年取得新药证书。“RC18”具有自主知识产权，药物分子结构获得全球专利保护。

在癌症治疗领域，荣昌生物研发出了抗体-药物偶联（ADC）新药“RC48”，用于治疗Her2过度表达的胃癌、乳腺癌、肺癌、卵巢癌、膀胱癌等多种癌症。“RC48”通过“精确制导”直达癌细胞内部，达到治疗肿瘤的目的，是我国首个进入临床研究的ADC新药，现已展开Ⅲ期临床，预期2019年取得新药证书。

荣昌生物的研发管线中还有多个具备自主知识产权的生物一类新药，承担国家“863”和重大新药专项10余个。荣昌生物将“用科学提高生命质量”作为自己神圣的使命，放眼全球，在技术、人才、产品、服务、管理等方面不断提高竞争力，在自身免疫疾病、肿瘤等疾病领域持续保持领先优势，通过各种形式和途径为全球客户提供技术、产品和服务，为人类的健康事业做出贡献。

RemeGen., Ltd. (hereinafter referred to as “RemeGen”) was founded by Rongchang Pharmaceutical Manufacturing Co. and Dr. Fang Jianmin in July, 2008. Company focused on the R&D and industrialization of biological drugs, with the international level of research and development and operating management team, equipped with many specifications of the world's most advanced disposable bioreactor and related equipment of purification and filling, has production, material control, quality, project, validation, etc. management system in accordance with EU, US and Chinese GMP management standards, to ensure that the laboratory and production workshops strictly comply with GMP requirements of US FDA, EU EMA and Chinese CFDA to construct and operate.

Since the company’s establishment, has focused on autoimmunity and malignant tumor and so on the major human diseases, has independently researched and developed the “RC18” antibody fusion protein, dual-targeting antibody fusion protein “RC28 – E” and “RC28 – T”, antibody – conjugate (ADC) “RC48”, etc. innovative biological drugs, these new drugs will bring new hopes to millions of patients after marketing.

Systemic lupus erythematosus, rheumatoid arthritis, xerosis, optic myelitis, multiple sclerosis, etc. autoimmune diseases are serious threats to human health, and traditional treatments cannot satisfy the patients’ needs. “RC18” that researched and developed by RemeGen is a “new weapon” for conquering this kind of diseases, has been underway to III period clinical phase, expected to obtain new drug certificate in 2019. “RC18” has proprietary intellectual property rights and its drug molecular structure is protected by global patent.

In the field of cancer therapy, RemeGen developed antibody – conjugate (ADC) “RC48”, is used to treat Her2 excessive expression of gastric cancer, breast cancer, lung cancer, ovarian cancer, bladder cancer and other cancers. “RC48” through “Precision Guidance” straight to the inside of cancer cells, in order to treat tumor, it is China's first ADC new drug that went into the clinical research, has begun III period clinical, expected to obtain new drug certificate in 2019.

There are multiple first-class new drugs with proprietary intellectual property rights in the development pipeline of RemeGen, and more than 10 national "863" and major new drugs projects. “Science enhances the quality of life” is the mission of RemeGen, to think globally, to improve competitiveness in technology, personnel, products, services, management, etc. aspects, to continue to lead in the field of autoimmune diseases, cancer and other diseases, through various forms and channels to provide technology, products and services for global customers, and to contribute to human health.

北京泛生子基因科技有限公司

Genetron Health (Beijing) Co., Ltd.

泛生子基因科技有限公司是世界领先的精准医疗专家，致力于以覆盖癌症全周期诊疗各个环节（风险评估、早期筛查、分子病理诊断、用药指导和预后监测）的健康管理产品，将基因组学有效应用，协助医疗专家、科研机构等，为癌症患者、癌症高危人群及健康人群，提供可靠的分子诊疗方案、专业的癌症遗传风险评估。

自2013年成立以来，泛生子已成立了美国北卡、中国北京双研发中心，并先后在北京、上海、杭州、重庆建成了总面积超过10,000平米的临床医学检验中心，同时，泛生子建成国际上最先进、全面、多元的检测平台，具有自主知识产权信息分析软件的世界级生物信息分析平台，符合美国病理学家协会（CAP）等最高要求标准的临床样本处理平台。

泛生子聚焦癌症精准医疗，与美国最权威的两大癌症研究中心——杜克大学和约翰霍普金斯大学，建立长期合作伙伴关系，并拥有来自世界顶级大学和科研机构的专家团队，学术背景覆盖癌症遗传学、癌症基因组学、生物信息学、药理学、临床病理等多领域，凭借多年科研工作经验和转化医学开发经验保障企业核心科研实力。

根据中国市场特点，泛生子确立了服务与产品并驾齐驱的业务模式，业务范围现已覆盖全国数百家科研机构和临床医院，并与上下游产业积极联动。

未来，泛生子将继续以自身强大的癌症基因组学基础和高效的临床转化能力，专注科学研究、技术创新、产品服务，持续拓展产品销售网络，联通整合上下游产业资源，以最科学、最专业、最个性化的服务和产品，成为行业发展的驱动力。

As a world-leading expert in precision medicine, Genetron Health is committed to developing health management products that cover all elements of full-cycle cancer clinical treatment (including risk assessment, early screening, molecular pathology diagnosis, medication guidance and prognosis monitoring) and effectively applying genomics to assist medical experts and research scientists to provide cancer patients, high-risk and healthy individuals with reliable molecular clinical services and professional cancer genetic risk assessment.

Since its establishment in 2013, Genetron Health has set up joint research and development centers in Beijing, China and North Carolina, USA, building clinical medicine testing centers successively in Beijing, Shanghai, Hangzhou, and Chongqing, with overall 10,000 square meters areas. In the meanwhile, with world's most advanced, most comprehensive and most diverse testing platform, Genetron Health develops world-class bioinformatic analysis platform that has information analysis software with independent intellectual property rights, and clinical samples processing platform that meets the highest requirements and standards of College of American Pathologists(CAP).

Genetron Health focuses on cancer precision medicine, establishing a long-term partnership with two most authoritative cancer research centers in the United States, namely Duke University and Johns Hopkins University, having teams of experts from top universities and scientific research institutions all over the world, covering many academic fields including cancer genetics, cancer genomics, bioinformatics, pharmacology, and clinical pathology. The company secures its core scientific research strength by its years of scientific research experience and translational medicine developing experience.

Based on the features of Chinese market, Genetron Health has established a business model of developing services and products at the same time, with diverse business scope covering hundreds of scientific research institutions and clinical hospitals nationwide, and actively cooperating with upstream and downstream firms.

In the future, on the basis of its own strong background in cancer genomics and efficient clinical and translational abilities, Genetron Health will continue to focus on scientific research, technological innovation, and product service, expanding products sales network, cooperating with and integrating industrial resources of upstream and downstream firms, becoming the driving force of the industry's development with the most scientific, professional, and personalized services and products.

赛生医药江苏有限公司

SciClone Pharmaceuticals (Jiangsu) Co., Ltd.

赛生医药江苏有限公司（下称“我公司”）系由美国赛生药业公司（SciClone Pharmaceuticals, Inc.,下称“美国赛生”）全资所属管理型公司——赛生医药（中国）有限公司初期投资人民币4500万元（注册资本人民币3000万元）设立的内资企业。

公司是一家以中国为中心的专业制药公司。赛生的产品进入中国超过20年，具有相当的商业规模和国际业务。旗舰产品日达仙®（胸腺法新或胸腺肽阿尔法1）在中国免疫调节剂市场份额超40%，长期占领导地位，是中国进口量最大的药物之一，2003年被列为国家储备药。除自研药物外，赛生还通过海外合作将大量国际领先药物、医疗器械引入中国。2014年8月，治疗肝癌的新型产品 DC Bead®经国家食品药品监督管理总局注册并已上市。预计在2020至2023年，公司将有3个三类新药（Loramyc, Angiomax, Cleviprex）和1个一类新药（PT-112抗肿瘤药）在中国上市。

在研发方面，公司拥有一支专业的研发团队，致力于抗肿瘤领域1.1类国产新药的研发。目前已有数个在研项目，其中一个已经进入CFDA的IND程序。

2015年9月24日，公司注册成立。于2016年3月22日取得了《药品经营许可证》，并于2016年8月3日取得了《药品经营质量管理规范》认证证书。

公司的经营范围为药品研发、批发，医疗器械销售等。公司现有员工78人，设有质量部、采购部、销售部、人事行政部、财务部5个部门。注册地址为泰州市药城大道1号科技大厦502、503室，办公面积253.5平方米。

公司组织架构健全，人员配备齐全，制定了质量管理制度、操作规程，岗位职责等质量体系文件，能够满足药品研发，销售等质量管理的需求。

SciClone Pharmaceuticals (Jiangsu) Company Limited (hereinafter referred as “Our Company”) is a local company invested by SciClone Pharmaceuticals (China) Co. Limited. The registration capital is 30 million RMB.

Our company is a China focused specialty pharmaceutical company. SciClone’s products have been listed in China market for more than 20 years and are widely accepted by the local market. Our flagship product Zadaxin® (Thymofalsin or Thymosin α1) covers 40% market share in the China immunomodulatory market. It is also one of the largest imported products in China which was listed as “national reserve drug” in 2003. On top of the in-house development programs, SciClone also works with overseas companies to introduce the world-leading drugs and medical devices into China. Back in Aug 2014, our innovative medical device “DC Bead® was approved by CFDA for treating HCC. It is estimated that, between 2020 to 2023, we will commercially launch another 3 Class III new drugs (Loramyc, Angiomax, Cleviprex) and 1 Class I new drug (PT-112).

On the research and development side, we have a specialized professional R&D team that focus on Class I anti-tumor drugs. We have several new drug development projects and one of them is now in the CFDA IND process.

Our company was registered on September 24, 2015 and obtained our “Drug Trading License” on March 22, 2016. We also received our GSP license on Aug 3, 2016.

Our business scope includes but not limited to drug development, drug and medical device selling. We have now a total of 78 employees. Our registered address is Suite 502 &503, 1 CMC avenue, Taizhou, Jiangsu Province, China.

Our company is fully compliant with local quality laws and regulations and is fully capable of conducting drug development and selling.

上海复宏汉霖生物技术股份有限公司

Shanghai Henlius Biotech, Inc.

上海复宏汉霖生物技术股份有限公司（以下简称“复宏汉霖”）由复星医药与海外科学家团队于2009年12月合资组建，公司主要致力于应用前沿技术进行单克隆抗体生物类似药、生物改良药以及创新型单抗的研发及产业化。目前复宏汉霖正在开发的产品主要覆盖肿瘤、自身免疫性疾病等领域。以全球联动整合创新为产品开发理念，公司在中国上海、美国加州和台北均设有研发实验室。

复宏汉霖总部位于上海市漕河泾高新技术开发区，公司按照国际GMP标准，采用一次性生物反应器等设备，于2015年底完成了国际先进的抗体药物中试以及产业化生产基地的建设。2017年底，为满足产业化升级需求，复宏汉霖与上海市松江区人民政府正式达成项目投资协议，于上海市松江区投资设立现代化智能生物药产业化基地（二），以满足产品陆续上市后的产能需求。

截至目前，公司团队已完成11个产品、16项适应症IND申报的高效研发，位于国内同行业领先地位，四个产品已全部进入临床III期研究阶段。第一个产品利妥昔单抗HLX01已经于2017年10月向CFDA递交NDA申请并正式获得审评受理，随后被纳入优先审评程序药品注册申请名单，可望成为中国第一个获得上市批准的生物类似药产品。以生物类似药为先导，复宏汉霖创新型单抗产品也快速跟进，已有三个创新单抗HLX06、HLX07及HLX10已全部获得获得中国大陆、台湾和美国三地临床试验批准，现于台湾开展一期临床试验。

Shanghai Henlius Biotech, Inc., (hereinafter referred to as “Henlius”), a joint venture between Fosun Pharma and a team of overseas scientists founded in December 2009, is primarily committed to research, development and industrialization of biosimilars, biobetters, and novel monoclonal antibodies by cutting-edge technology. The products currently developed by Henlius mainly cover the treatments of tumors and autoimmune diseases. With the strategy of globally-integrated innovation, Henlius has established R&D laboratories in Shanghai, China; California, US; and Taipei.

Headquartered in Shanghai Caohejing Hi-Tech Park, Henlius completed the construction of an internationally-advanced biopharmaceuticals pilot and industrial production facility at the end of 2015. The manufacturing facility has been built in accordance with international GMP standards and uses advanced equipment such as single-use bioreactors. In order to meet the needs of industrialization upgrade, the company officially signed an investment agreement with Shanghai Songjiang District Government at the end of 2017 to build a modern intelligent biological manufacturing facility (II) in Songjiang District.

As of now, Henlius has completed IND filing of 11 products with 16 indications, and started phase III clinical trials for 4 products. In October 2017, Henlius received a notice from the CFDA that its first new drug application (NDA), which was soon accepted and assigned by CFDA into their priority evaluation list. For the biosimilar rituximab HLX01, is officially under review, closing in on the first biosimilar approved in China. With the biosimilar as leading products, Henlius has been devoting continuous efforts in developing novel mAbs in a timely fashion. Three innovative products - HLX06, HLX07 and HLX10, developed by Henlius, have already obtained clinical trial approvals in mainland China, Taiwan, and the United States sequentially, and are currently in Phase I clinical trials in Taiwan.

上海君实生物医药科技股份有限公司

Shanghai Junshi Biosciences Co., Ltd.

上海君实生物医药科技股份有限公司（简称“君实生物”）于2012年12月由多名毕业于中美两国知名学府、具有丰富跨国科技成果转化及产业经验的团队创办。创办之初，就确立了“大人不华，君子务实”的核心价值观，并且构建了“以自主创新为动力、以先进技术为依托、根植中国，为国内外病患提供帮助”的愿景。

君实以开发治疗性抗体为主，专注于创新单克隆抗体药物和其他治疗性蛋白药物的研发与产业化。在成立的五年时间里，通过广泛的国内外技术合作，已搭建先进的创新人源化抗体药物产品研究开发和生产技术平台，目前在全球拥有员工近三百人，分布在美国旧金山和马里兰，中国上海，苏州和北京。其中作为上海市战略性新兴产业项目之一的建设规模超过7万平方米的第二个抗体生产厂正在建设中。

君实目前具有丰富的在研产品管线，包括13个创新药，1个生物类似物，主要覆盖肿瘤免疫、自身免疫、心血管疾病和骨质疏松、神经和疼痛等领域。其中针对PD-1，PCSK9、BlyS等全球热门靶点的单抗研发进度均位居国内前列：国内第一个创新PD-1抗体（广谱抗癌）临床研究已进入后期。国内第一批修美乐生物类似物（类风湿性关节炎）临床Ⅲ期进展顺利；国内第一个创新Blys抗体（系统性红斑狼疮）临床I期以及国内第一个创新PCSK9抗体（心血管疾病）临床I期研究正在进行。这些项目获得了三个国家十二五，十三五重大创新药专项支持，且在全球同步开发并已于2018年初在美国开展临床试验。

公司于2015年8月在全国中小企业股份转让系统挂牌上市，融资超过18亿元，截止到2018年4月13日市值为132亿元。

Junshi biosciences, as a high-tech biopharma player, focuses on development, production and commercialization of monoclonal antibody drugs and therapeutic protein drugs for tumor, autoimmune diseases, osteoporosis, cardiovascular disease, migraine, and other diseases. With a mission of “intelligence orientation, global presence and overseas market service offering”, the Company has built its industrialized production and clinical trials center in Shanghai (the headquarters), an antibody screening location in San Francisco, and a new targets discovering facility in Maryland.

There are two commercialized manufacturing facilities located in Suzhou and Lin’gang respectively, which are designed in compliance with GMP/cGMP requirements. Junshi has established an integrated pharmaceutical capabilities from target discovery, process development to commercial manufacturing. As of now, the company has 14 products under research and four products have obtained clinical trials approval from CFDA. Among them, PD-1 monoclonal antibody has also been approved by FDA for clinical trials launched in the US at the same time.

Junshi undertakes 3 National Major Scientific and Technological Special Project for “Significant New Drugs Development “, 2 of which are of the “12th Five-Year Plan” and 1 is of the “13th Five-Year Plan”. The Company has been supported by Strategic Emerging Industry Project in Shanghai, undertaking the construction of biopharmaceutical industrialization base and the development of monoclonal antibody drugs.

Junshi is listed and traded at Beijing NEEQ #833330. Market Cap April 13 2018: 13.2B CNY (2.0 Billion US$).

上海泽生科技开发股份有限公司

Zensun (Shanghai) Sci & Tech Co., Ltd.

上海泽生科技开发股份有限公司于2000年由海外留学归国科研人员创办，是一家以国际医药市场需求为主导、以创新研究为基础、具有重大获利潜力的生物医药高科技企业。目前公司的研发管线专注于心肌细胞和能量代谢两大治疗领域，以一流科学研究、基于对疾病原理的深刻认识开发创新药物。主要在研产品包括：通过全新机制直接作用于心肌细胞治疗心力衰竭等多个适应症的重组蛋白药物重组人纽兰格林（rhNRG-1，Neucardin®）、治疗重度心力衰竭的基因治疗药物重组人肌球蛋白轻链激酶基因腺相关病毒（AAV9.cMLCK）、治疗性肿瘤疫苗——重组人纽表位肽等靶点、机制机理全球创新的First-in-Class国际首创新药。公司在原创新药相关领域的科学研究、药物开发和知识产权保护均走在国际前列，在研产品具备很强的国际市场竞争力。在申请专利总计186项，已授权专利73项。

泽生科技作为一家国际化的医药企业，与医药领域的最高标准看齐，向全球引进智力资源，让尽可能广大的全球患者受益于我们的最新发现，同时也吸引到众多所在领域的前沿专家，不断融入全球最新的科技发现，得到了拥有深远视野的长期投资。公司将始终致力于具有自主知识产权的原创新药开发研究，让全球患者受益于最新科学发现。

Zensun (Shanghai) Sci & Tech Co., Ltd. is a biopharmaceutical company focusing on the development of innovative 'First in Class' bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. We discover new medicines using novel disease specific targets and innovative technologies. The patented discoveries are then developed into therapies. Zensun's current pipeline covers cardiomyocyte and energy metabolic therapies. Novel durgs/biologics under development include "First-in-Class" Neucardin®(with multiple cardiovascular indications), gene therapy construct rAAV9.cMLCK, and other modified drugs treating a variety of medical indications. As a bio-technology company with global reach, Zensun has gathered experts and pioneers in medical research from throughout the world, and has attracted investors of forward vision and broad outlook. Zensun leverages the leading technology to best serve our patients and deliver maximum return for investors.

东曜药业有限公司

TOT Biopharma Co., Ltd.

东曜药业有限公司（以下简称“东曜药业”）成立于2010年7月，总部设在中国苏州工业园区，是一家专业从事抗肿瘤新药研发、生产和市场营销的生物医药高新技术企业。公司打造了一条涵盖生物药和化学药的高质量抗癌药物产品链，搭建了国际水平、经验丰富的人才团队。

大规模、符合国际标准的药品产业化基地：东曜药业规划投资建设50000平方米符合GMP规范、设施先进的抗肿瘤药品产业化基地。目前，一期工程约10000平方米的抗癌药厂已建成运营，包括2个化药口服车间、1个针剂车间以及1个500升规模生物药中试车间。2018年，东曜药业投资建设二期工程13000平方米的生物药产业化基地落成启用，抗体生产能力可达16000升，可满足上市产品商业化生产；生产基地内还将建设3条制剂生产线，也可依据产品进行不同规格的灌装。未来预充针制剂线,冻干制剂线，还有符合OEL-5级别抗体偶联药物（ADC）工业化生产车间将陆续到位。东曜单抗药物生产基地的设计预留了产能扩充与空间调整的灵活性。结合现有的500升级别生物药中试平台，可满足生物药从上游研发、中试生产、临床试验用药及商业化生产需求。

国内领先的抗癌药物研发、产业化综合技术平台：目前，东曜药业已经建成了一个国内领先的集溶瘤病毒、治疗性单克隆抗体及抗体交联药物、特殊剂型脂质体药物关键技术为一体的抗肿瘤药物的技术平台。公司研发中心被评为“江苏省外资研发中心”、“苏州市肿瘤基因治疗药物工程技术研究中心”，相关平台技术已获得授权发明专利4项，申请发明专利15项；申请PCT国际专利3项，其中：2项已经获得美国及日本授权、1项已经进入国家阶段。

利用公司建立的技术平台，东曜药业研究开发了多个系列、多个品种的抗肿瘤药物，形成了完整、高质量的药物产品链。目前，4个生物药和3个化学药品种递交了临床试验申请，其中：6项获批进入临床研究、1项在审。产品中1个生物药品种进入临床Ⅲ期研究。

国际水平、经验丰富的人才团队：东曜药业组建了以海内外制药行业精英领衔的科研、生产和管理团队。团队核心成员包括20多位国内外技术专家，拥有20年以上的制药行业经验，熟悉欧洲、美国、中国大陆和台湾的药政法规。

2017年，在各级政府及领导的支持和关注下，东曜药业取得了一系列成绩及荣誉。东曜药业陆续获评为“高新技术企业（复审）”、“技术先进型服务企业”、“江苏省外资研发中心”、“姑苏创新创业领军人才”、“苏州工业园区2017年度经济贡献突出企业”、“苏州工业园区最具社会责任感企业”、“2017生物产业最具投资价值企业”和“两岸四地康复论坛公益奖”等。同时，东曜药业和苏州开拓药业合作成为江苏省首个获得CFDA批准的MAH试点品种，标志着MAH制度在江苏省正式落地。

东曜药业始终坚持“人文与科技平衡”的经营理念，致力于开发高技术壁垒和经济价值的新药产品，专注研究患者能负担得起的抗肿瘤药品，提供适合且价格合理的产品组合。东曜药业是您最佳的抗癌合作伙伴。

Founded in 2010, TOT BIOPHARM COMPANY Ltd. is headquartered in Suzhou Industrial Park in China. It is a bio-pharmaceutical company specializing in developing, manufacturing and commercializing oncology drugs.

TOT BIOPHARM has 3 technology platforms: (1) monoclonal antibodies/ ADCs, (2) oncolytic virus products, and (3) specialty anti-cancer drugs (liposomal drugs). 4 mAbs and 3 small molecules INDs were submitted, and 6 INDs have been approved by CFDA. A Phase III study of a mAb is ongoing.

TOT BIOPHARM establishes a competitive oncology drugs manufacturing base in Suzhou Industrial Park. The stage 1 construction includes a 500L-biologic pilot plant, OEL-5 isolator for ADCs, BSL-2 certified viral facility, and small molecule plants (oral and injectable). The Stage 2 construction is a state- of-the-art antibody production site with 16,000L capacity to accommodate the high-quality commercial manufacturing.

TOT BIOPHARM has internationalized and experienced team of talents. More than 20 core members have more than 20-year experience in the domestic and international pharmaceutical industry, and are familiar with the drug administration regulations in Europe, the United States, China, and Taiwan.

TOT BIOPHARM has received recognition of excellence from many tiers of government agencies, in recognition of the company’s achievements. TOT BIOPHARM’s accolades include National High-Tech Enterprise, National Advanced Service Enterprise, Outstanding Economic Contribution, Foreign-Funded R&D Center in Jiangsu Province and Pioneer of Entrepreneurial Talent in the Gusu region, the most valuable biotech enterprise to invest in 2017, and the company has also received countless awards for its philanthropy and social responsibility initiatives.

TOT BIOPHARM has developed its own sales and marketing team and networking, and keeps close cooperation with oncology experts and key opinion leaders in oncology field. TOT BIOPHARM is your best partner in the fight against cancer.

杭州阿诺生物医药科技有限公司

Adlai Nortye Biopharma Co., Ltd.

杭州阿诺生物医药科技有限公司是一家以原创新药为核心竞争力、并致力于为患者提供可承受创新机制治疗药物的临床阶段的生物技术公司，聚焦肿瘤免疫治疗。公司为国家高新技术企业，拥有浙江省高新技术企业研发中心，曾连续承担国家“十一五”、“十二五”重大新药创制专项课题，目前已获得23项国内授权专利，已申请PCT专利7项。公司研发产品既有小分子也有抗体及生物制品，产品多为FIC或BIC药物。

公司目前已有两个临床阶段产品，其中，与加拿大Oncolytics合作的全球进展最快的可通过静脉注射给药的溶瘤病毒Reolysin项目，即将进入全球多中心临床3期；从日本卫材授权许可全球权益（日本及部分亚洲国家除外）的全球进展最快的肿瘤免疫EP4拮抗剂（AN0025）项目，目前处于欧美临床1b期阶段。

阿诺医药成立以来，与国内外知名药企及科研院所保持良好合作关系，曾参与多项药物开发及注册上市。通过多年的技术积累、联合创新、平台合作、人才引进等方式，现已成为具备核心技术竞争力的全球性创新型生物医药研发企业。公司与北京大学深圳研究生院、美国AvantGen公司、上海嘉和生物药业有限公司、华东医药股份有限公司、中国医学科学院/北京协和医学院药物研究所建立了长期合作关系。

公司核心团队来自国际顶尖药企，拥有一支由海外知名专家、留学归国博士和国内“985”、“211”重点大学毕业人才组成的国际化专业研发队伍，具备丰富的创新药物研发和临床试验经验。公司核心技术团队具备美、欧、日大型制药企业多年的药物研发工业化背景，具有丰富的产品开发经验和国际视野，其中由团队成员研发并临床成功上市的药物6个，由团队成员主要研发进入临床的新药近30个。公司愿景是成为国内一流、国际上有显著影响力的创新型生物制药企业。

Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs. We focus on discovering and developing important new treatments for cancer and metabolic diseases. Our mission is to improve patient lives by identifying and acquiring differentiated innovative medicines that help people live better and longer.

We have 23 patents granted and 7 PCT published. With extensive experience in peptide and protein drugs, we have expanded our expertise into small molecules and therapeutic antibodies. Through close collaborations with global partners, we have successfully positioned ourselves in the fields of immuno-oncology, and have several programs ongoing from early pre-clinical to phase 3 ready.

长风药业股份有限公司

CF Pharmtech, Inc.

长风药业股份有限公司由留美科学家和管理团队于2008年创立，是一家专注于呼吸系统吸入细分领域，以国内外市场为导向的集研发、生产、销售为一体的高科技制药企业。公司自创立起专注于研发目前国内市场长期依赖跨国公司的高端吸入制剂药物，研发产品涉及哮喘（Asthma）、慢性阻塞性肺病（COPD）、过敏性鼻炎（Allergic Rhinitis）等多个临床需求大的治疗领域。目前公司已成功建立先进的吸入制剂全剂型的研发平台和生产场地。公司的创业团队曾先后荣获“国家千人计划”、“江苏省创新创业高层次人才”、“科技领军型团队”、“姑苏领军人才”等多项荣誉。研发团队由具有丰富药物研发经验的资深科学家领导，在美国留学及工作、创业二十余年，拥有海外丰富的药物研发和创新企业管理经验，熟悉欧美药物申报法规。公司经过多年发展，已培养出一批在吸入制剂领域具备专业素质和技能的研发队伍。公司创业的使命是为患者全方位提供高品质的吸入制剂药物，同时积极参与欧美市场吸入制剂高水平的竞争。 立志于成为中国治疗哮喘、慢性肺阻病、鼻炎的吸入制剂领域领导企业；一个积极参与国际交流合作的全球化制药企业，做中国制剂出口的领先企业。

长风药业秉承“服务大众、营造健康呼吸生活”的发展理念，坚持在药品吸入给药领域做大、做强，不断超越自我，全力打造国内一流、世界知名的专业领域制药企业，为人类的呼吸健康贡献自己的力量。

CF PharmTech, Inc. was founded in 2008 by seasoned industry experts and entrepreneurs with a successful track record in the US pharmaceutical industry, it is a high-tech pharmaceutical company focusing on the development, manufacturing and commercialization of high-quality inhalation niche products for the domestic and global market. Since its inception, the company has been dedicated to developing high-end inhalation drugs for which China market has a heavy reliance on multinational companies. The products are in great demand for the treatments of asthma, COPD and allergic rhinitis.

CF PharmTech has established state-of-art R&D platform and manufacturing site for inhalation drugs. Its entrepreneurial team was honored by China National “1000 Elite” program, received Jiangsu Provincial Innovation Award, Leading Team of Technology Award, and Suzhou Leading Talents Award.

The R&D team is led by senior scientists with pharmaceutical research experience who have studied and worked in the US for more than 20 years, gained advanced management experience and mastered regulations of drug submission in Europe and the US. After several years’ growth, CF PharmTech boasts a senior R&D team with professional skills in inhalation field. Its mission is to provide patients with high-quality inhalation drugs and take an active part in international competition with European and American counterparts. It is committed to becoming a leading company in inhalation therapy for asthma, COPD and allergic rhinitis, an active participant in international cooperation as well as a top exporter of inhalation drugs in China.

CF PharmTech adheres to its philosophy of “dedicated to respiratory health” and insists on improving itself in respiratory area so as to build a first-class and renowned pharmaceutical company, thus contributing to the respiratory health of mankind.

合肥天麦生物科技发展有限公司

Hefei Tianmai Biotechnology Development Co., Ltd.

合肥天麦生物科技发展有限公司（“天麦生物”）成立于2007年，坐落在有“大湖名城，创新高地”之称的科教名城——中国合肥的国家级经济技术开发区，是一家致力于国际先进生物技术的引进与吸收、生物制药产品的开发、生产和销售的创新型高科技生物制药企业。

天麦生物目前已建成约9000平米的研发及中规模生产车间，近7000平米的胰岛素制剂车间，以及约17000平米面积的胰岛素原料车间。原料药工厂的年生产能力达到600千克，制剂工厂的年生产能力超过7000万支。公司的生产设施按照欧盟GMP和中国GMP标准设计、建造，主要设备均从欧美进口。

在市场营销与服务方面，天麦生物将打破传统的药品销售模式，致力于打造中国最具影响力的专业化的，包括研发、生产、销售和慢病管理的一站式管理平台，为广大糖尿病患者提供专业优质的服务。

天麦生物以“关爱生命、承诺未来”为己任，公司目标是成为以重组人胰岛素、胰岛素类似物等产品为代表的、面向全球的生物医药产品研发和生产基地，及糖尿病慢病管理服务，成为值得尊敬和信赖的全球糖尿病领域产品及服务提供商。同时，振兴发展民族药业，以优质的产品和服务回馈社会，为所有现身于本使命的从业人员提供成功的机遇。

Hefei Tianmai Biotechnology Development Co., Ltd. (“HTBT”) is founded in 2007 and located in the national economic and technological development zone in Hefei, a well-known scientific and educational city in China, reputed as “a celebrated city with a big lake and a high ground of innovation” HTBT is an innovative high-tech bio-pharmaceutical enterprise committed to the introduction and absorption of international advanced biotechnology, and the development, production and sales of bio-pharmaceutical products.

HTBT has built up the R&D center and the pilot plant of 9000m2, one insulin Formulation & Filling plant of 7000m2 and one API Insulin plant of 17000m2. Annual production capacity of API plant reaches to 600KG and that of F&F plant exceeds 70 million units. Our production facilities are designed and built in accordance with the EU GMP and CFDA GMP standards and main equipments are all imported from Europe and USA.

In aspect of marketing and service, HTBT will break the traditional drug sales model, establish a most influential and professional one-stop management platform in China, including R&D, production, sales and chronic disease management and provide professional and high quality service for diabetics.

HTBT takes “Caring for the life, caring for the future”as its own obligations and aims at growing into the global R&D and production base of biological products, including recombinant human insulin, insulin analogs and other products as well as the diabetic chronic diseases management base. In addition, HTBT makes abundant efforts to provide the global diabetes products and become the respectable and reliable supplier. To promote the national biopharmaceutical industry, and to provide the products and service with high qulity. To provide the opportunities to the people who is willing to devote to the career.

天境生物科技（上海）有限公司

I-Mab Biopharma Co., Ltd.

天境生物成立于2014年，是一家聚焦肿瘤免疫和自身免疫疾病治疗的生物新药研发公司。公司前身为三境生物，由臧敬五博士领衔的新药研发团队与泰格医药、百家汇精准医疗控股集团有限公司共同创建，2016年6月获得由健桥资本领投的A轮融资。

天视珍生物科技成立于2015年，由健桥资本、上海天士力药业有限公司及境外生物科技公司Genexine Inc.三方共同投资组建，业务领域主要覆盖糖尿病、肿瘤、自身免疫性疾病药物的开发。

2017年3月21日，三境生物与天视珍生物合并成为天境生物，并获得由康桥资本和上海天士力药业领投的B轮融资。天境生物立足于中国，面向全球开发创新性抗体药物，研发团队具有平均15年以上在跨国、本土医药企业研发管经验。

天境生物的科学家在早期研发、抗体分子工程、靶点发现和验证、抗体工艺开发和临床前评价、质量科学和管理、临床研究等领域均有强劲的实力。凭借我们在靶点生物学、抗体分子工程研发以及创新药物的转化医学研究上的优势，天境生物正在快速推进一条具有国际竞争力的项目管线。

天境生物的研发管线分为两个项目集，共有12个在研项目，分别面向全球研发及中国的临床研发。2017年，天境生物成功递交了3个IND申报（一个临床I期试验，2个国际多中心临床II期试验），近期还将启动2个国际多中心的临床试验（临床II期）。预计到2018年将有5个创新抗体项目处于临床I期和II期， 5个项目递交IND申报（包括中国与美国）。除自主研发外，天境生物也积极探索与国际生物医药公司在临床阶段的研发合作，利用公司在中国的临床研究优势和能力来推进产品在中国以及亚洲地区的开发。2016年，我们与瑞士FERRING公司合作独家引进开发重组IL-6可溶性受体拮抗剂Olamkicept，该产品即将启动国际多中心临床研究（临床II期）。

I-Mab Biopharma and Company Milestones: A China-based global player in innovative biologics

I-Mab Biopharma was established through a merger of Third Venture Biopharma, an innovative antibody start-up, and Tasgen, a joint venture biotech by Tasly Pharmaceuticals, Genexine and C-Bridge Capital. The merged Company now combines novel antibody discovery and regulatory/clinical development expertise from Third Venture Biopharma and Tasgen's unique strength in biologics CMC, QA/QC and pre-clinical development, thus covering the full spectrum of innovative biologics R&D.

The Company successfully completed Series B financing of $150 million led by C-Bridge Capital after the merger in 2017. I-Mab's R&D operations is mainly based in Shanghai with an office in Beijing, specializing in regulatory affairs and clinical operations. The Company has an in-house discovery laboratory and a specialized CMC laboratory. The current pipeline is composed of two portfolios, “In China for Global", focusing on innovative monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune disease, and "In China for China" designed to meet unmet medical need in China. In 2017, I-Mab has been geared towards 3 IND submissions (one Ph 1 and two Ph 2 clinical trials) and subsequent start of two multi-regional clinical trials (Ph 2). As planned, the pipeline will hit a series of critical milestones, including five Ph 1 and Ph 2 clinical trials and five IND submissions (US and/or China) of novel monoclonal or bi-specific antibodies by the end of 2018. In addition to in-house discovery and development efforts, I-Mab is actively seeking partnerships with global biotech or pharmaceutical companies to co-develop innovative clinical assets for China market through I-Mab's unique development expertise. One of the most recent examples is Olamkicept, a Ph 2 ready fusion protein from Ferring, which is now in a multi-regional clinical trial (Ph 2).

海捷投资控股集团

Hiyield Investment Holding Group

海捷投资控股集团是在长沙、上海设有公室的全国性投资机构，成立于2002年。公司业务涵盖风险和股权投资、上市及并购重组、定增与市值管理等多个领域。其中，管理人民币股权投资基金七支，分别为海捷先进装备产业基金（国家创业引导基金）、海捷津杉创投基金、海捷医药产业基金、海捷慕士创投基金、宁波智能产品创新发展基金、湘江新区产业基金和厦门时尚创意基金；公司还设立了新三板投资基金两支和海捷领投系列基金数支；股权投资基金管理规模168亿元人民币。

公司股权投资专注于新材料、高端装备、医疗健康、文娱体育、教育传媒及大数据等行业，创立以来共投资70多家企业，其中A股上市10家，香港上市5家，新三板挂牌10家（创新层3家），IPO在会审核1家。公司凭借精深的专业能力和在资本市场的良好关系，推动所投资企业达到业务发展，上市融合或并购重组之目的。

公司资产管理业务行业领先，先后参与了67家上市公司定向增发，累计管理定增基金145亿元人民币，管理资产规模创造了优异的业绩，树立了卓越的品牌。

公司九位资深合伙人在证券、投资及金融领域具有丰富的经验。自1996年始，作为中国证券业投资银行先行者之一，核心团队先后主持了三一重工、电广传媒、酒鬼酒、华数传媒、隆平高科、华天酒店、华帝股份、振华重工等超过30家上市公司的股改、发行、上市、再融资、重组等工作，深度参与了中国资本市场的变革与成长，见证了中国投资银行及上市公司的飞速发展。

公司在医疗/大健康产业先后发起设立有两只医疗产业基金，投资涉足 医药、医疗器械、移动医疗、精准医疗、医疗大数据等多个领域，在肿瘤、 精准医疗产业有深度布局，并与千山药机、尔康制药、云南白药等多家上市 公司等形成战略联盟，在产业培育、资产并购、市值管理等层面展开深度合作。

公司投资理念——时间见证诚信，专业创造价值。

Hiyield Investment Holding Group, found in 2002, is a national investment agency launched offices in Changsha and Shanghai.

The company's business covers a variety of capital models, including equity investments, mergers and acquisitions, IPO, capitalization. In charge of 7 RMB funds, respectively, the Hiyield Advanced Equipment Industrial Fund (National Fund for Entrepreneurship boot), Hiyield Jinshan Venture Capital Fund, Hiyield HealthCare Industrial Funds, Hiyield Mousse Venture Capital Funds, Hiyield New Materials Industrial Funds and series of Hiyield Leader Investing Founds. Until now, there is 16.8 billion RMB of assets under management.

Our funds primarily invested in those companies have excellent managementteams, in developing or have the potential to become the leaders of theindustries. Investment fields contain with TMT, consumption and culture, newmaterials, manufacturing and healthcare industry.So far our company has invested more than 70 enterprises, in which 10 have IPO in China A share market, 5 have IPO in Hong Kong stock market, 10 have listed in new third board market, 1 have IPO reviewed listing. Typically, those enterprises Hiyield invested in could get convenience in finance and management consulting from Hiyield Croup.

The company participated in 67 additional directions on public companies, the total asset in charge is 14.5 billion RMB, which created a good profit and brand reputation.

Our nine senior partners have extensive experience in securities, investment and finance. Since 1996, as one of China's securities industry pioneer Investment Bank, our core team has presided over 30 public companies, such as Sany Group. (600031), TV and Broadcast media Culture Development Co(000917), Jiu Gui Jiu (000799), Hua-Tian Hotel (000428), Vatti Corporation Ltd.(002035), Shanghai Zhenhua Heavy Industry Co. (600320) and so on.

In HealthCare Industry, we has initiated and established two HealthCare Industrial Investment Funds, investment involved in medicine, medicalequipment, mobile healthcare, precision medical fields, medical big data,etc., especially in tumor and precision medical industry we programed plentyof potential startups. Meanwhile we has formed strategic alliances of publiccompanies in healthcare industry, such as China Sun Pharmaceutical Machinery(300216), Er-Kang Pharmaceutial(200267), Yunnan Baiyao Group (000538),we has cooperated on industry incubation, asset acquisition and market valuemanagement.

Our investment idea – Time attest integrity, profession create value.

高瓴资本管理有限公司

Hillhouse Capital Management, Ltd.

高瓴资本集团是一家专注于长期结构性价值投资的公司，以其卓越的投资业绩在全球投资界享有盛誉。高瓴资本由张磊先生于2005年创立，经过十余年的发展，高瓴现已成为亚洲地区资产管理规模最大的基金之一，管理资金规模超过300亿美金。高瓴资本受托管理的资金主要来自于目光长远的全球性机构投资人，包括全球顶尖大学的捐赠基金、医疗基金会、主权财富基金、养老基金及家族基金等。

作为具有全球视野的长期价值投资者，高瓴资本始终坚持独立思考、深入研究，通过深刻理解行业和业务的发展规律，同时寻找具有伟大格局观的企业家，将长期资本投资于优质企业成长的关键阶段。投资之后，高瓴通过自身丰富的全球资源，协助企业不断提升战略及运营管理水平，从而帮助企业创造长期价值。

截至2016年底，高瓴资本的投资领域涵盖了生命健康、消费与零售、科技创新、金融、企业服务等行业。代表性的互联网和消费行业投资案例包括：腾讯、百度、京东、携程、Airbnb、Uber、美的、格力、百丽国际、普洛斯物流、中通快递、蓝月亮、滴滴出行、美团、蔚来汽车、孩子王、摩拜、Grabtaxi等。

生物医药和医疗健康领域始终是高瓴的重点战略投资方向。高瓴已经投资了一批国内外优质医药企业，其中包括：百济神州、药明康德、甘李药业、君实生物、信达生物、惠每医疗（梅奥在华合资公司）、Moderna等。

在创新药行业，高瓴立志成为全球优质企业的超长期合伙人，与被投资企业一起共担风险，共创价值。以百济神州为例子，高瓴在百济神州还未崭露头角的早期阶段就开始投资，参与了百济神州从成立以来的每一轮融资，是百济神州在中国唯一的全程投资人。从2014年的A轮，2015年的B轮，到2016年纳斯达克上市及之后的增发，高瓴是百济神州每一轮股权融资的主要投资人。并且，高瓴在投资之后将内部的研究和经验完全分享给百济神州，帮助公司在每一个关键时点做出最恰当的战略决策。

高瓴资本始终坚持长期价值投资理念，矢志不渝的为中国医药企业带来最优质的资本支持，并不遗余力地帮助企业家实现他们的梦想，共享成功！

Founded in 2005 by Mr. Zhang Lei, Hillhouse Capital Group is an investment firm focused on long-term opportunities backed by structural tailwinds. It is now one of the largest investment funds in Asia, with a global reputation and track record. The firm manages more than US$30 billion for long-sighted global institutional clients, including endowment funds for world-class universities, foundations, sovereign wealth funds, pensions and family offices.

As a value oriented investor with a global vision, Hillhouse relies on independent thinking and thorough research to pinpoint investable trends and look for entrepreneurs with strategic vision. We partner with and support good companies by channelling funds to where they are needed, when they are needed most. Drawing on the strengths of our global resources, proprietary research, and network of operating advisors, we also assist companies in creating long-term value by helping them optimize strategies and operations.

Hillhouse invests in areas such as healthcare, consumer, TMT, advanced manufacturing, financials and business services. As of mid-2017, Hillhouse has invested in many leading consumer and TMT companies. These include Tencent, Baidu, JD.com, Ctrip, Airbnb, Uber, Midea, Gree, Belle Int'l, GLP, ZTO, Blue Moon, Kidswant, Didi, Meituan, NIO, Mobike and Grabtaxi. In the healthcare and biotech sectors, a particular area of focus for Hillhouse, we have partnered with BeiGene, Wuxi AppTec, Ganlee, Junshi, Innovent, Huimei (JV with Mayo Clinic in China) and Moderna, amongst others.

In supporting industry-leading drug developers, Hillhouse is dedicated to sharing risks and creating value together with portfolio companies, with an aim of building long-term cooperative partnerships with exceptional entrepreneurs worldwide. In the case of BeiGene, a biopharmaceutical company focusing on immuno-oncology area, Hillhouse made its first investment to BeiGene well before it achieved industry-wide prominence, and provided it with steady capital support and resources throughout its entire journey. As a major investor in each and every one of BeiGene's funding rounds, Hillhouse participated in BeiGene's series A and series B funding in 2014 and 2015, its listing on the Nasdaq in 2016 and a follow up public placement. In addition to providing capital, Hillhouse also supports BeiGene by sharing its internal research insights and experiences to assist BeiGene with making crucial strategic decisions.

Adhering to the principles of long-term, value-oriented investment, Hillhouse is determined to bring the best funding support to pharmaceutical companies in China. We help entrepreneurs reach for their dreams and together travel the path to success.

上海醴泽投资管理有限公司

LYZZ Capital Advisors Management, Ltd.

上海醴泽投资管理有限公司（以下简称“醴泽资本”）是一家致力于中国医药健康产业投资的专业基金。由成功科学家、企业家等行业资深人士组成的投资团队，依靠企业管理经验和海内外行业资源为被投企业提供增值服务，力求通过中国医药创新为患者带来福音，同时努力让中国创新走向国际。

醴泽资本管理团队具有成功的人民币基金和外资基金管理经验，并拥有众多的优质项目投资和退出案例，成功投资过微芯生物、诺康生物、凯赛生物、天津赛诺、Neurelis，江苏晨泰等十余家医药行业创新型企业。同时通过增值服务，为企业引入行业优质资产和创新标的，从而实现共赢。

醴泽资本围绕中国市场对医药创新的渴求，在全球范围内选择优质标的，充分发挥投资与产业化的协同效应，并为投资标的提供多赢的退出方式。通过与国内外知名行业机构和企业合作，引进国际先进技术，结合国内实际情况进行开发，成为国际企业进中国和国内创新企业走出去的优选合作伙伴。同时拥有强大的海内外行业顾问团队参与被投企业的运营，从而为企业、投资人和基金创造价值，实现共赢。

LYZZ Capital Advisors is a leading healthcare-dedicated investment management group in China. The LYZZ management team is composed of highly experienced scientific and medical professionals who’ve been senior executives in pharmaceutical and biotech companies, and have worked together for many years. They take pride in their ability to add value to their portfolio companies with their operational experience and global network, helping their portfolios to develop innovative medicines for unmet medical conditions, and become internationally recognized innovators.

The LYZZ Capital team has successful managed several USD and RMB funds with a strong portfolio of invested companies and excellent returns. They search for talents, assets and technologies globally, with an emphasis on unmet medical needs and market potential in China. Their partners include some of the top global pharma companies, leading Chinese pharma companies, global top venture firms and many prominent professional organizations.

Notable investments by the LYZZ team in pharmaceutical innovation include Shenzhen Chipscreen, China Nuokang Biopharma, Cathay Industrial Biotech, Tianjin Sainuo, Neurelis, Alpha Biopharma, etc.

深圳市倚锋投资管理企业（有限合伙）

Shenzhen Efung Investment Management Enterprise

创立于20世纪末的倚锋，是我国第一批专业的创投机构。自2012年来专注于原创药及高端医疗器械的VC和PE投资业务。倚锋致力于以资本推动科技成果产业化，协助企业快速成长，并带给投资人丰厚回报。在逾十年的积累中，倚锋打造了专业的管理团队并建立了完备的风控策略，旨在用资本的力量带动并引领国内医疗健康产业，尤其是原创药及高端医疗器械领域的发展。

截止2017年7月，倚锋管理基金总规模逾10亿元，并于2017年5月获得了深圳市政府引导基金的注资。在团队的努力下，倚锋于2009年起连续获得了“深圳十佳创投机构”的称号。倚锋的创始合伙人、董事长朱晋桥先生，已根植医疗健康投资行业十余年，有着丰富的投资经验和精准的投资眼光。另一方面，倚锋的核心管理团队均由来自全球知名院校的医药、生物、化学等相关领域的博士组成，这也保证了倚锋在项目选择上的专业性。在精准的投资决策和专业的投资判断下，倚锋的管理团队曾投资了迈瑞医疗、和佳医疗、微芯生物、亚盛医药、前沿生物及Aridis Pharmaceuticals等国内外业界知名企业，创造了巨大的经济效益和社会影响力。

经过逾十年的积累，倚锋形成了“以创业者为中心，以价值创造者为本”的理念，并坚持投资、融资、风控、管理、服务的“五位一体”系统化运营，致力于用专业的经验和丰厚的资源与投资人一起参与和分享医疗健康行业的升级盛宴，并进一步打造以人为本、基业长青的卓越创投企业。

Founded by the end of the 20th century, Efung Capital is one of the pioneers in the professional investment industry. Efung Capital was established in 2007 and has been focusing on VC and PE investment of original drug and high-end medical device since 2012. Efung is committed to promote the industrialization of scientific and technological achievements by allocating the right capital at the right time. Our purpose is to help high-tech companies to grow rapidly and bring satisfactory returns to our investors. During more than a decade accumulation, Efung has created a professional management team, established a comprehensive risk management strategy, and intend to promote and lead the development of the domestic healthcare industry, especially in the original drug and high-end medical device area.

As of July 2017, Efung is managing a fund with more than one billion RMB, and qualifying for the Government guide fund of Shenzhen City in May 2017. Due to the team’s efforts, Efung was granted "top ten venture capital in Shenzhen" title continuously since 2007. Mr. Jinqiao Zhu, the founding partner and chairman of Efung, has been rooted in the medical and health investment industry for more than ten years; he has rich experience in investment and accurate investment insights. On the other hand, the core management team of Efung is composed of PhDs in medicine, biology, chemistry and related fields from globally well-known institutions, which also ensures the professionalism of the project selections. In the precise investment decision-making and professional investment judgment, Efung management team has invested prestigious domestic and international companies such as Mindray, Hokai, Chipscreen, Ascentage Pharma and Aridis Pharmaceuticals, etc, which has created huge economic benefits and social influence.

After more than ten years accumulation, Efung has formed a concept which called"entrepreneurs as the center, value creators as the base". Also, Efung keeps the faith on investment, financing, risk management, management, service “five in one" systematic operation, commits to participating and sharing the feast of health care industry upgrading with professional experience and rich resources, and this comcept will further build into a people-oriented and long lasting venture capital enterprise.

红杉资本股权投资管理（天津）有限公司

Sequoia Capital Equity Investment Management (Tianjin) Co., Ltd.

红杉是全球最高大的树种之一，以此命名的红杉资本自1972年在美国成立以来，作为第一家机构投资人投资了众多创新公司，包括苹果、思科、甲骨文、雅虎、谷歌产业潮流的领导者。红杉资本中国基金成立于2005年9月，始终视「创业者背后的创业者」为其企业精神，一直致力于发掘和培育产业界的参天大树——基业长青的伟大公司。十年来在中国投资了约300家具有鲜明技术和创新商业模式、具备高成长性和高回报潜力的成长型公司，包括阿里巴巴、唯品会、新浪网、滴滴出行、京东商城、掌趣科技、奇虎360、聚美优品、陌陌、光环新网、大众点评网、美团网、美丽说、今日头条、高德软件、赶集网、DJI大疆创新、文思创新、诺亚财富、万达院线、阿里影业、铂涛酒店集团、德邦物流、中通快递、贝达药业、新产业生物、华大基因、威高集团、鱼跃医疗等众多国内知名企业。红杉作为长期的价值投资者，我们最大的梦想是挖掘并培育出「百年老店」。

Sequoia Capital was founded in 1972 in Menlo Park, California, taking its name from one of the largest and longest-lived tree species in the world. In keeping with its motto “The Entrepreneurs Behind The Entrepreneurs”, and in keeping with its legendary namesake, Sequoia Capital has always been devoted to building great companies that stand the test of time. Formed in September 2005, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models. Particularly, in the healthcare sector, portfolio includes Beta Pharma, Snibe Diagnostic, BGI, Yuwell, WEGO, and Guahao.com.

启明维创创业投资管理（上海）有限公司

Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd.

启明创投成立于2006年，以其卓越的投资业绩在中国风险投资界享有盛誉。先后在上海、北京、苏州、香港和西雅图设有办公室。2016年，启明在美国募集了一支投资医疗健康的基金，并在西雅图成立了启明美国公司。目前，启明创投旗下管理五支美元基金，四支人民币基金，管理资产总额达27亿美金。

启明创投致力于成为中国优秀创业家们的首选投资伙伴。自成立至今，专注于投资互联网消费（Intersumer）、医疗健康（Healthcare）、信息技术（IT）以及清洁环保技术（Clean Technology）等行业早期和成长期的优秀企业。截止目前，启明已投资超过210家企业，其中有超过30家分别在美国纽交所、纳斯达克、香港联交所、台湾柜买中心、上交所A股及深交所上市或通过并购方式赢得投资回报。其中有大批知名企业包括：小米、大众点评、iTutorGroup、蘑菇街、美图公司、哔哩哔哩弹幕网、泰格医药、甘李药业、再鼎药业、微医集团、海博思创、Face++、优必选和摩拜单车等。就投资回报率而言，启明创投始终占据中国风险投资行业的领先位置。

启明创投始终秉持促进中国企业创新与成长，推动社会产业进步与发展为己任，凭借其投资团队丰富的行业经验和全球资源网络以及在业界卓越的声誉，不遗余力地帮助创业家和他们的企业突破自我、不断创新，与之共创事业，共享成功！

Founded in 2006, Qiming is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou and Hong Kong. In 2016, Qiming raised a US healthcare fund, and set up Qiming US office in Seattle. Currently Qiming manages five US Dollar funds and four RMB funds with US$2.7 billion assets under management.

Qiming strives to be the investor of choice for top entrepreneurs in China. Since our debut, we have backed over 210 young, fast-growing and innovative companies across China in the internet and consumer ("Intersumer"), healthcare, information technology and clean technology sectors. Over 30 of them are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, and Shenzhen Stock Exchange or achieved exit through M&A. Many of our portfolio companies are today's most influential brands in their respective sectors, including Xiaomi, Dianping, iTutorGroup, Mogujie, Meitu, Bilibili, Tigermed, Gan & Lee, Zai Lab, We Doctor Group, HyperStrong, Face++, UBTech and Mobike. Qiming consistently ranks among the top venture firms in terms of returns to its investors.

Qiming drives innovation and growth of business enterprises and promotes overall industry advancement and social development. With access to our partners' experience and global network as well as our excellent industry background, we spare no efforts in helping our entrepreneurs and their companies succeed!

元明资本
Yuanming Capital

元明资本由熟悉中美两国的企业家和资深金融医药投资专家创立，专注于对中美两国医药研发、创新医疗器械研制、高端医疗服务行业先进企业的投资，成立于2015年1月。

元明资本的创始合伙人为在中美商界拥有成功创办企业经历、丰富社会资源与卓越领导力的田源博士和姜明博士。

元明资本拥有优秀的管理团队，团队成员具有世界顶级学府的专业背景，国际知名医药研发机构的资深经历以及数十年行业耕耘的精专从业经验，在北美、中国及全球其他地区主导与参与过具有国际领先水平的新药研发与投资。

元明资本将国内外医药资源优势、资金优势与资本市场相结合，充分进行资源整合，在中美两国医药市场和资本市场的高度互动和交流中寻找战略性成长机会。

元明资本高度重视与医药及医疗产业具有国际化视野和一流专业水准的创始人及团队合作。元明资本关注具有发展前景和成长价值的医药和医疗项目，通过控股权收购、行业整合投资、夹层投资及其他法律法规允许的投资方式进行并购投资，通过对目标公司进行业务重组及改善，挖掘并提升企业价值，通过多层次的退出方式最终获取基金超额收益。

Yuanming Capital was founded in January 2015 by entrepreneurs and senior medical investment experts who are familiar with the market of China and America. This cross-border investment company seeks to invest in pharmaceutical research, creative medical instruments development and advanced medical service companies in China and America.

The partners of Yuanming Capital are Dr. Yuan Tian and Dr. Ming Jiang. They have wide network, prominent leadership and successful experience in starting business.

Yuanming Capital possesses an outstanding management team. The team members have strong academic background in top-class universities, extensive working experience in world-famous medical R&D institutes and profound expertise in pharmaceutical business. They have successfully led or participated in the research and investment of new medicine with international advanced level in North America, China and other areas around the globe.

Yuanming Capital combines domestic and foreign medical resource advantages and financial advantages with capital market, and seeks to find strategic growth opportunity through the highly interactive communication of China and America's medical and capital market.

Yuanming Capital pays high attention to cooperate with founders and teams with international vision and first-class professional standard in pharmaceutical and medical industry. The firm focuses on pharmaceutical and medical programs that have promising future and great potential growth value. Buyout is made through stake purchase, industrial consolidation investment, mezzanine investment and other investment ways within the scope allowed by relevant laws and regulations. The firm exploits and promotes the potential value of the target companies by business reconstructing and improvement. The firm applies multi-level exits of capital and achieves excess profits.

上海浦东科技投资有限公司

Shanghai Pudong Science and Technology Investment Co., Ltd.

上海浦东科技投资有限公司（以下简称“浦东科投”）成立于1999年，改革前是一家国有综合投资管理公司。

公司注册资本1.56亿元；投资了15个科技项目和6个科技服务平台，包括复旦张江、杏灵药业、透景医疗等高科技及医疗项目。

前期多元化投资业务为公司培养了一批投资领域的人才并积累了一批优质资产。利用境内境外资本市场估值落差，调动市场资源，围绕IC产业开展并购业务 。

注重并购与整合的联动；在与上海、北京、浙江等地发起设立多支投资基金；投资并购了一批优质项目；2015年下半年，公司作为发起人，联合相关方面，在北京设立规模8亿元的北京高精尖产业（健康诊疗）并购投资基金，并通过竞争性遴选，成为基金的管理公司。

为支持国家“双创”战略，积极布局一批具有发展潜力的中小微企业，公司正在发起设立首期规模20亿元的上海浦东小微企业成长基金（正在设立中）。

Shanghai Pudong Science and Technology Investment Co., Ltd (PDSTI), established in 1999, was a comprehensive state-owned investment management company prior to the reform.

Registered capital: RMB 156 million; invested in 15 projects in high technology and healthcare sector.

Adjusted investment strategy to shift the focus onto cross border M&A opportunities. Took advantage of valuation gap between domestic and foreign capital market in the IC industry.

Invested in and acquired some quality assets; Established a number of M&A investment funds in Shanghai, Beijing and Zhejiang; Invested in a listed company and became its largest shareholder.

In the second half of 2015, the company, acting as the promoter and together with the relevant parties, established the Beijing sophisticated industry (healthcare clinics) M&A investment fund with the size of RMB 8 million, and became the manager of the fund after a competitive selection.

In order to support the State’s “Entrepreneurship and Innovation” strategy by proactively establishing a batch of middle, small and mirco businesses with development potential, the company is promoting to establish the Shanghai small and micro businesses development fund with the initial size of RMB 2 billion, which is under the process of establishment.

高特佳投资集团
GTJA Investment Group

2001年高特佳投资集团在深圳成立，专注医疗健康产业投资，以战略性股权投资为主导，投资覆盖并购、PE、VC、天使等全阶段。拥有国内规模最大的专业医疗投资团队，构建医疗健康产业投资生态平台，致力成为具有全球影响力的医疗健康投资机构。

资产管理规模200亿元，医疗健康产业基金24支，先后投资130余家企业，其中医疗健康企业60余家，并推动了11家企业成功上市，其中控股投资国内血液制品龙头企业博雅生物，并助推其成功上市（股票代码：300294）。

集团业务立足中国，面向全球，在深圳、上海、北京、南京等地建立运营中心。

Founded in Shenzhen in 2001, GTJA Investment Group is centered on strategic equity investment with a focus on healthcare industry, covering all stages of investment including M&A, PE, VC, and angel investment. With the biggest and most professional team in healthcare investment, GIG has established an eco platform for healthcare investment, and is devoted to become a globally influential healthcare investment institution.

GIG, with an AUM of ￥20 B and 24 funds devoted to the healthcare industry, has invested in more than 130 companies, more than 60 of which in the healthcare sector. The group has taken more than 11 of these companies public, and amongst all, Boya Bio-Pharmaceutical (300294), still a holding company of GIG, is a domestic leader in blood products.

Operating in 8 offices including Shenzhen, Shanghai, Beijing and Nanjing, GIG has established a firm foothold in China, and is growing into an investment group with global vision and impact.

上海建信股权投资管理有限公司

Shanghai Jianxin Capital Management Co., Ltd.

上海建信股权投资管理有限公司是专注于生物医药行业的创业投资基金，致力于生物医药、诊断试剂、以及医疗器械等领域的投资。

公司聚焦于重大疾病和重大临床需求，开展深入研究，提前布局具有一流团队和技术平台的创业公司，并在产品管线、团队组建、申报注册、临床试验等方面提供专业的见解、经验和资源，推动其早日成为行业龙头企业。

公司成立至今，参与投资国内和海外的医药健康项目41个，其中已退出项目6个，先后投资的公司有：深圳微芯生物、北京东方百泰、中山康方生物、上海和誉生物、厦门力品药业、武汉海特生物（代码:300683）等。

Jianxin Capital is a venture capital firm focusing on the healthcare industry including biotech, IVD, medical device, etc.

The company focuses on the in-depth research in major diseases and unmet clinical needs , promoting the establishment of startups with first-tier teams and technology platforms. Jianxin also provides professional insights, experience, and resources in product pipelines, team formation, application for registration, and clinical trials, to promote the startups becoming an industry leader.

Since the establishment of the company, it has invested in 41 domestic and overseas deals in healthcare industry. Six deals have already successfully exited from the 41 deals. Jianxin has invested in Chipscreen, Eastern Biotech, Akeso Biopharma, Abbisko Therapeutics, LP Pharma, Wuhan Hiteck(code: 300683),etc.

北京德福悦安投资顾问有限公司

GL Capital Group

德福资本(GL Capital Group)是一家专注于中国医疗健康行业控股项目和成长期企业的投资公司。于2010年由原诺华中国区总裁李振福先生创立，目前管理数支美元和人民币基金，资产总额逾13亿美元，截至2017年已投公司超过40家。以“发现、投资、支持优秀的医疗健康企业，为投资人带来优异的回报，促进行业良性发展”为使命，德福投资致力于成为中国医疗健康行业最具影响力的投资机构及最受尊敬的合作伙伴。

德福资本重点关注处于成长期/成熟期、或有独特技术优势的创新型企业，投资类型多样，退出方式灵活。德福资本中国团队由具有丰富投资和管理经验、具备国际视野又了解中国市场的专业投资管理人士组成。拥有丰富的行业资源，能够为被投资企业提供专业性的增值服务。

GL Capital Group, an investment firm with a focus on buyout and growth-stage opportunities in China’s healthcare industry, was founded by former Novartis China President Jeffrey Li in 2010 and manages both USD and RMB funds, with over US$1.3 billion in aggregate AUM and over 40 portfolio companies as of 2017. With the mission of “Achieve superior returns for our investors by identifying, investing in and supporting exceptional healthcare companies that propel industry developments”, GL Capital is devoted to become the most influential investment institution and the most respected partner in China’s healthcare industry.

GL Capital has a strong brand in China’s healthcare investment industry for the proprietary resources, value-add and experience the Fund brings to portfolio companies. GL Capital team consists of investment and industry professionals with extensive China market experience. The team brings expertise from various backgrounds and is regarded by portfolio companies as a high value-add investor GL Capital invests in growth and late-stage companies and innovative enterprises with high growth and barrier to entry. GL Capital is flexible in both deal structuring and exit channels.

中投海外直接投资有限责任公司

CIC Capital Corporation

中投公司成立于2007年9月29日，是依照《中华人民共和国公司法》设立的国有独资公司，组建宗旨是实现国家外汇资金多元化投资，在可接受风险范围内实现股东权益最大化。公司总部设在北京，注册资本金为2,000亿美元。

中投公司下设三个子公司，分别是中投国际有限责任公司（以下简称“中投国际”）、中投海外直接投资有限责任公司（以下简称“中投海外”）和中央汇金投资有限责任公司（以下简称“中央汇金”）。

中投公司的境外投资和管理业务分别由中投国际和中投海外承担。中投国际和中投海外均坚持市场化、商业化、专业化和国际化的运作模式。

中投海外于2015年1月成立，是中投公司对外直接投资业务平台，开展直接投资和多双边基金管理。中投海外下设投资一部、投资二部和运营管理部门。其中，投资一部职责包括基础设施、矿业以及油气能源方面的直接投资；管理相关多双边平台基金以及项目跟投等；投资二部职责包括除投资一部三个行业以及农业以外行业的直接投资；管理相关多双边平台基金以及项目跟投等。

Headquartered in Beijing, China Investment Corporation (CIC) was founded on 29 September 2007 as a wholly state-owned company incorporated in accord with China's Company Law, with registered capital of $200 billion. The company was established as a vehicle to diversify China's foreign exchange holdings and seek maximum returns for its shareholder within acceptable risk tolerance.

CIC has three subsidiaries, CIC International Co., Ltd. (CIC International), CIC Capital Corporation (CIC Capital) and Central Huijin Investment Ltd. (Central Huijin).

The overseas investment and management activities of CIC are undertaken by CIC International and CIC Capital. Both CIC International and CIC Capital are market-oriented commercial entities with a specialized mandate and global reach.

CIC Capital was incorporated in January 2015 with a mandate to specialize in making direct investments to refine CIC's overall portfolio management and enhance investment on long-term assets. CIC Capital encompasses two investment departments and operational and management departments. Investment Department I is responsible for direct investments in infrastructure, mining, and energy (oil and gas) and for managing related bilateral, multilateral, and platform fund investments, and co-investments. Investment Department II is responsible for direct investments in sectors other than agriculture and the three sectors managed by Investment Department I and for managing related bilateral, multilateral, and platform fund investments, and co-investments.

平安银行医疗健康金融事业部

Finance SBU of Healthcare Industries of Ping An Bank

平安银行医疗健康金融事业部是平安银行贯彻平安集团“大医疗健康战略”成立的总行级医疗健康专营金融机构，于2015年8月成立。作为全国银行业首个总行级健康产业专营机构，事业部致力于打造“专业银行+垂直银行+综合银行”三位一体的行业银行，以“商行+投行+投资”的理念搭建行业化综合价值平台，作为平安集团大金融资产、大医疗健康产业布局（商业健康险、互联网医疗、线下诊所联盟、医保管理等）与医药行业战略客户的连接枢纽，以成为行业龙头的BD、财务、投资等一站式服务平台为愿景，从战略、资本、运营、财务、品牌等维度为企业创造价值。目前，事业部管理资产规模千亿元、人均创利过千万、实现医药行业龙头70%覆盖、与113家医药上市公司实现业务合作。

事业部汇聚顶尖名校金融、医学、法律等人才，具备商业银行、券商、国际投行、PE机构等各业精英，形成行业研究、产业开发、投资银行、交易银行、跨境金融、审批六大团队。事业部成功打造“平安医药通”服务品牌，以“做医药、更轻松”为理念，为行业客户提供“医药跨境通”、“医药交易通”、“医药投行通”三大解决方案，提供“全产业链+全生命周期+全流程”的综合化金融服务。

自2015年以来，事业部与药明康德、绿叶、迈瑞医疗、康哲、海王星辰、罗欣、人福、九州通、爱尔眼科、美年大健康、乐普医疗、老百姓、天士力等多家上市公司，在美股、港股私有化、跨境并购资金离岸、并购基金、产业基金等领域合作近30单有影响力的案例，业务涵盖A股40%医疗健康类上市公司，遍布美、英、法、澳等全球范围城市，参与跨境并购项目130亿元，私有化融资460亿元。凭借在跨境并购领域的出色表现，荣膺2016年中国并购公会“并购专项奖—年度最佳并购融资奖”。同时在交易银行产品、大股东、管理层需求方案等各层面服务客户，总交易金额达100亿美元!

事业部正联合医药产业领袖、全球金融巨头，共同发起成立“平安健康荟”——服务于行业资源整合和并购重组的专业化开放式平台，为医药企业提供集“并购标的推荐+并购融资设计+并购联合投资+并购顾问服务”一体的闭环解决方案，共同建立国内医药产融合作新生态。

Finance SBU of Healthcare Industries of Ping An Bank was established in according to the “Healthcare Strategy” of Ping An Group in August 2015, which is focus to the finance of healthcare industry specialized institutions of the head office level. As the first head office level healthcare industry specialized institution of the domestic banks, the SBU is committed to create a “professional bank + vertical bank + integrated bank” three-in-one industry bank. With the concept of “commercial bank + investment bank + invest”, building integrated industry value platform, the SBU connects Ping An Group great financial assets, great healthcare industry layout (commercial health insurance, internet medical, offline clinic alliance, etc.) and the pharmaceutical industry strategic customers. The aim of the SBU is to create value for the enterprise from the strategic, capital, operations, finance, and other dimensions. At present, the asset size of the SBU is 100 billion Yuan, per capital profit is over 10 million Yuan, coverage to the leading pharmaceutical companies is over 70%, and builds business cooperation with 113 listing pharmaceutical companies.

The SBU gathers finance, medicine and law elites from top schools, as well as elites from commercial bank, brokerage, and international investment bank, PE industry, who are divided into six groups of industry research, industry development, investment bank, trading bank, cross-border finance and approval.

With the concept of easier medical, the SBU successfully creates Ping An Medical Pass, which provides three solutions of medical cross-border pass, medical trading pass and medical investment pass, as well as integrated financial services of whole industry chain + whole life cycle + whole process.

Since 2015, the SBU has nearly 30 influencing financial cases in US/Hong Kong privatization, cross-border M&A, M&A funds, industries funds, etc. with listed companies such as Wuxi App Tec, Luye, Mindrey, CMS, Nepstar, Luoxin, Humanwell, Jointown, Aier Eye, Health-100, Lepu Medical, Lbx Drugs, Tasly, ect. The business of the SBU covers 40% healthcare listed companies of A shares , throughout the United States, Britain, France and Australia and other global city, involving in cross-border M&A 13 billion Yuan, private financing 46 billion Yuan.

With the outstanding performance in cross-border M&A, it won “M & A Award-the best M & A financing Award” in 2016 of CMAA. At the same time, the total transaction amount is of $10 billion Yuan in providing the transaction banking products and satisfying the needs of major shareholders and management level!

The SBU tries it best effort to co-found the professional open platform of Ping An healthy Club with the pharmaceutical industry leaders and global financial giants, which focuses on professional open platform of industry resource integration and M&A, providing solutions for pharmaceutical enterprises with M&A targets recommendation, M&A finance design, M&A joint investment, and M&A advisory, thus establish new ecological cooperation with the domestic pharmaceutical companies.

博信股权投资基金管理股份有限公司

Boxin Fund Management Co., Ltd.

博信股权投资基金管理股份有限公司（以下称“博信基金”）创立于2007年12月，是国内最早从事股权投资管理的专业机构之一，注册资本约10,028万元人民币。成立11年来，博信基金凭借丰富的行业经验、精湛的专业能力、广博的政府及社会人脉资源、庞大的企业信息数据库、严谨的风控决策流程、多元化的企业增值服务，跻身国内知名股权投资基金之列，并荣膺专业评测机构清科集团及投中集团评选的“2010年中国私募股权投资机构10强”、投中集团“2011年中国最佳新锐私募股权机构”、CLPA中国有限合伙人联盟2011-2012年度颁奖榜单“最具LP投资价值GP50强”、清科集团“2013年中国私募股权投资机构50强（本土）”、清科集团“2014年中国私募股权投资机构50强”等。2015年11月23日，博信基金成功登录新三板挂牌交易，股票代码为834395，股票简称为博信资产。

经过10年的发展，博信基金以严格的管理、优良的业绩和一流的服务，树立了良好的品牌形象，赢得了投资者和业界的广泛认可。

博信基金旗下人民币基金和美元基金规模合计近90亿元人民币，资管计划规模超过260亿元人民币。截至目前，累计近40个项目已通过上市、并购和股权转让等方式实现退出。博信基金所投项目退出回报率水平处于同行业前列。

Established in Dec. 2007 and with RMB 100.28 million of registered capital, Boxin Fund Management Co., Ltd. (“Boxin Fund”) is one of the first equity investment managers in China. In the past decade, Boxin Fund has evolved into one of the most prominent equity investment funds in China, thanks to its extensive industry experience, strong professional capabilities, broad government and social network, comprehensive sector database, prudent risk management protocols and diversified value-added services. Based on its professional excellence, Boxin Fund has won numerous awards including “2010 Top 10 Private Equity Investors in China” (Zero2IPO Group and ChinaVenture), “2011 Best New Private Equity Investor” (ChinaVenture), “2011-2012 Top 50 Domestic Private Equity Investors for LP Value Creation” (CLPA) and “2014 Top 50 Private Equity Investors in China” (Zero2IPO Group). On Nov 23rd, 2015, Boxin Fund (834395) became successfully listed on the National Equities Exchange and Quotations (NEEQ).

After 10 years of dedicated development, Boxin Fund has earned a stellar reputation among investors and peers through its stringent management schemes, strong performance profile and high-quality services.

Currently, Boxin Fund manages almost RMB 9 billion under its RMB and USD private equity funds and over RMB 260 billion of other asset management business. As of today, Boxin Fund has accumalatively exited near 40 companies through IPO, acquisition, and transfer of shares. Our exiting IRR ranks top tier in industry.

博远资本

BioTrack capital

博远资本是一家同时关注早期新产品、新技术和新模式的创业企业，以及中晚期与上市公司共同开展国内外并购和投资的专业医疗基金。基金投资行业主要是生物医药、医疗器械和设备、医疗服务,医疗IT,动物保健以及其他与医疗健康相关领域的企业进行股权投资。

BioTrack capital is a healthcare fund focusing on early stage innovative technology, product and business model and middle/late stage M&A fund collaborating with listed companies. BioTrack is mainly invest in biotech, medical device/diagnostics , medical service and medical IT.

第一创业证券股份有限公司

First Capital Securities Co., Ltd.

第一创业证券股份有限公司（以下简称“第一创业）是经中国证监会批准，由华熙昕宇、首创集团等多家实力雄厚的股东投资设立的全国性证券公司，前身是1993年4月成立的佛山证券公司。公司注册资本21.89亿元，总部设在深圳，员工总数超过2800人。2016年5月11日，公司首次公开发行股票并在深圳证券交易所上市交易，证券简称“第一创业”，证券代码“002797”。

齐全的业务牌照与资质

第一创业（含各子公司)拥有齐全的证券业务牌照，业务体系覆盖交易所、银行间等场内、场外市场，可为广大投资者和客户提供固定收益、投资银行、资产管理、证券经纪、研究咨询、直接投资、私募股权基金、公募基金、期货、另类投资等一站式综合金融服务。

网点覆盖全国主要城市

目前，第一创业在全国设有40余家营业部，并在北京、上海、深圳、河北设立了分公司；拥有3家全资子公司：第一创业期货有限责任公司、第一创业投资管理有限公司、深圳第一创业创新资本管理有限公司；控股第一创业摩根大通证券有限责任公司、创金合信基金管理有限公司；参股银华基金管理有限公司、证通股份有限公司、中证机构间报价系统股份有限公司；并与国家高端智库——国家金融与发展实验室联合发起设立了“深圳市第一创业债券研究院”。

致力于成为“有固定收益特色的业绩优良的”的上市证券公司

第一创业多年来一直坚持“追求可持续发展，努力打造具有独特经营模式、业绩优良、富有竞争力的一流投资银行”的公司愿景，以客户为中心，以创新为动力，致力于为客户提供专业的金融中介服务。经过20多年的发展，公司建立了完善的公司治理结构和稳定的核心管理团队，并形成了优秀的企业文化，在固定收益、资产管理、私募股权基金管理、投资银行、证券经纪等业务领域已形成了差异化竞争优势，实现了可持续发展。

First Capital Securities Co., Ltd. (hereinafter referred to as “First Capital”) is a nationwide securities company approved by the China Securities Regulatory Commission, and established by Huaxi Xinyu Investment Co, Beijing Capital Group and numerous other shareholders of great strength. Formerly known as Foshan Securities Company, it was incorporated in April 1993. The Company, headquartered in Shenzhen, has registered capital of RMB2,189 million, and more than 2,800 employees. The Company launched its initial public offering on May 11, 2016, and its shares are listed and traded on the Shenzhen Stock Exchange. Its securities abbreviation is “First Capital” and its stock code, “002797”.

A complete set of business licenses and qualifications

First Capital (including its subsidiaries) has a complete set of securities business licenses, and its scope of business encompasses exchange and interbank as well as other exchange-traded and over-the-counter markets, providing fixed income, investment banking, asset management, securities brokerage, research inquiry, direct investment, private equity funds, publicly offered funds, futures, alternative investments and other integrated one-stop financial services to all investors and our customers.

Nationwide network covers major cities

Currently, First Capital has more than 40 sales offices nationwide, and has set up branches in Beijing, Shanghai, Shenzhen and Hebei. It has three wholly-owned subsidiaries: First Capital Futures Co., Ltd., First Capital Investment Management Co., Ltd., and First Capital Innovative Management Corporation LTD.; controlling stakes in JP Morgan First Capital Securities Co., Ltd. and Truvalue Asset Management Co., Ltd..; equity stakes in Yinhua Fund Management Co., Ltd., E-Capital Transfer Co., Ltd., and China Securities Internet System Co., Ltd.. It has also teamed up with National Institution for Finance & Development, a top national-level think tank in China, to establish “Shenzhen First Capital Bond Research Institute”.

Committed to becoming a listed securities company “with fixed income characteristics that excels”

First Capital has always upheld its vision of the “pursuit of sustainable growth, diligently creating a competitive first class investment bank with a unique business model and excellent performance”. It is customer-oriented, innovation-driven, and committed to providing professional financial intermediary services to customers. Having developed for more than two decades, the Company has established good corporate governance, a stable core management team, as well as excellent corporate culture. It has created competitive differentiation advantages in fixed income, asset management, private equity fund management, investment banking, securities brokerage and other business areas, achieving sustainable growth.

中航信托股份有限公司

AVIC Trust Co., Ltd

中航信托股份有限公司是经中国银监会批准设立的股份制非银行金融机构，是经中国商务部核准的外商投资企业，由国内大型央企中国航空工业集团公司及境外战略投资者新加坡华侨银行等单位共同发起组建，于2009年12月底完成重新登记开业，注册地为南昌市红谷滩新区“中航广场”24-25楼，注册资本为465726.71万元。

公司设有信托业务中心、投资管理部、财富管理中心、风险管理部、计划财务部、办公室、稽核审计部、信息技术部等部门，在北京、上海、深圳、广州、重庆、昆明、沈阳、杭州、成都等全国主要大中城市共设有32个业务团队，现有员工500余人。

经中国银监会核准，公司主要业务分为信托业务与固有业务两大类。其中，主营业务信托业务发展迅速，取得了骄人的业绩。截至2017年末，存续信托项目超2000个，受托资产余额超6489亿元。主要经营指标如信托资产规模、信托报酬率、人均利润等已赶超行业平均水平，部分指标跻身行业前列。

作为中航工业集团公司下属成员单位，公司贯彻“高起点、高境界、可持续、快发展”的经营方针；倡导先进的经营理念和高效的经营机制，聘任了卓越的独立董事，率先建立了首席风险控制官岗位设置，导入了适用的管理工具，建立了适应竞争环境各级人才队伍，构造了IT化的管理规范；坚持走专业化、差异化发展道路，专注于具有行业优势和区域优势、能可持续发展、形成核心能力的产品和业务，致力于打造“细分市场资产管理核心能力，成为专业化的一流金融服务商”的战略愿景。

公司坚持以人为本，积极投身社会公益事业，先后投入资金兴建希望小学，持续做好对弱势群体的关心扶助，努力践行社会责任，凭借守土有责的大爱情怀和追求发展的雄心壮志获得社会的广泛认可，先后荣获“江西省十大爱心企业”、“中国最具成长性信托公司”、“中国优秀信托公司”等称号。

中航信托借助强大的股东背景，立足江西，依托航空，面向全国，力争创建一流公司、建设一流团队、创造一流业绩、实现一流管理、争做一流员工；与客户携手，畅想美好愿景，分享丰硕成果！

AVIC trust Co., Ltd is a joint-stock and non-bank financial intermediary approved by the China Banking Regulatory Commission (CBRC), and a foreign-investment enterprise authorized by Commerce Department. The company, jointly set up by the large-scale state-owned enterprise, Aviation Industry Corporation of China (AVIC), and overseas strategic investor, Oversea-Chinese Banking Corporation Ltd (OCBC), etc., completed the re-registration and started at the end of Dec, 2009. The registration place is 24-25/F AVIC Square, Honggutan New District, Nanchang, Jiangxi Prov. ,the registered capital is 4.6572671 billion Yuan.

The company is equipped with trust business center, investment management department, wealth management center, risk management department, financing plan department, office, audit department, information technology department and other departments, as well as 32 business teams in major cities throughout China, including, Beijing, Shanghai, Shenzhen, Guangzhou,Chongqing, Shenyang, Hangzhou, Chengdu, Xiamen, etc., with the number of 500 staffs.

Approved by CBRC, the company mainly engages in trust business and inherent business, among which the trust business develops rapidly and achieves impressive performance. By the end of 2017, it has more than 2000 surviving trust items, and AUM is 650 billion Yuan. The main business indicators, such as trust asset size, trust rate of return, profits per capita, etc. have caught up with and surpassed the average level of industry, and part of which has been the forefront of industry.

As a subordinate unit of the AVIC group, it implements the operating principles of “high starting point, high level, sustainable and rapid development"; it promotes advanced management concept and efficient operational mechanism, appointing excellent independent directors, taking the lead in establishing a post of Chief Risk Control Officer, importing the applicable management tools, establishing a personnel team at different levels to adapt environment of competition and constructing IT management standard; It persists in taking the specialized and differentiated road of development, and focusing on the core product and business which have industrial and regional advantages for sustainable development. It is committed to building a strategic vision of "segmenting market asset management core competencies to become a professional first-class financial service provider".

Adhering to the idea of people oriented, the company is actively engaged in public welfare undertakings, successively invests to build hope elementary school,. Continuously cares for and supports the vulnerable groups, makes efforts to carry out the social responsibility, and with love of territory and ambition to pursue development, it has been successively awarded the titles of "Jiangxi top ten caring enterprise", "China's most growing trust company" , "China excellent trust companies",and so on, getting a wider recognition of the society.

With the strong background of the shareholders, basing in Jiangxi, relying on the aviation, facing the whole nation, AVIC TRUST strives to create a first-class company, build a first-class team, create first-class achievements, implement first-class management and to be top-grade employees; it hands in hand with the customers, thinks fine visions and shares the great success!

宝石花医疗健康投资控股集团有限公司

Gem Flower Healthcare Investment Holding Group Co., Ltd.

2017年3月，中国石油通过海峡能源产业基金利用社会资本打造了宝石花医疗健康投资控股集团有限公司（以下简称宝石花医疗集团）这个专业化医疗产业平台。宝石花医疗注册资本100亿，致力于整合中石油集团核心医院资产，以及其他相关医院和医疗资源，打造中国乃至亚洲最大的医院管理集团之一。

中石油旗下拥有306家医院，其中10家三级医院，40家二级医院，50家一级医院和200家社区卫生服务站。2017年8月7日，作为第一家改革试点单位，中石油中心医院正式改制为宝石花医疗资产投资有限公司，标志着中石油医院社会化改革取得重要突破。紧接着，宝石花医疗集团先后完成了西南油气田总医院、东方物探中心医院、华北油田总医院、兰州石化总医院、辽阳石化总医院、辽河油田总医院等六家医院的改革方案获批和公司注册成立，到目前为止，已经形成了总医疗机构达到89家，实现管理床位数 7,296 张，在册职工 10,142 人，产值规模 34.54 亿元的大型医疗集团。

目前，宝石花医疗正按照中石油医院社会化工作“四个一批”部署，在“全面推动一批”的基础上，持续整合中石油旗下的其他医疗机构，实现“努力完成一批、扫尾清理一批、深化提高一批”的目标，到2018年年底前基本完成中石油医院社会化改制和移交工作。

宝石花医疗集团将以“整合全球资源，助力健康中国”为历史使命，通过统筹规划、投资、建设“非营利性医院集团”、“医疗+”、“医院+”三大业务板块，整合推进所属医院基本医疗服务、高端医疗服务、医养结合服务、健康养老服务、商业健康保险服务，加强集团集约化管理、专业化运营，实现资产和资本的强强联合，奋力打造千亿市值医疗集团。

On March 2017, China Petroleum (PetroChina), through the use of social capital from Strait Energy Industry Fund founded Gem Flower Healthcare Investment Holding Group Limited (hereinafter referred to as Gem Flower Healthcare Group). The business will be specialized medical industry platform.

Gem Flower Healthcare, with registered capital of 10 billion, is committed to the integration of CNPC Core hospital assets, as well as other hospitals and medical resources, to build the largest hospital management group in China and Asia at large. PetroChina has 306 hospitals, including 10 level-three hospitals, 40 level-two hospitals, 50 level-one hospitals, and 200 community health clinics and service stations.

On August 7, 2017, as the first reform pilot unit, PetroChina Central Hospital was formally transformed into Gem Flower Healthcare Asset Investment Co., Ltd., marking a major breakthrough in the socialization reform of China Petroleum Hospital. Subsequently, the Gem Flower Healthcare Group has completed the Southwest Oil and Gas field General Hospital, as well as the reform program of six hospitals, such as the Oriental Geophysical Center Hospital, Huabei Oilfield General Hospital, Lanzhou Petrochemical General Hospital, Liaoyang Petrochemical General Hospital, and Liaohe Oilfield Clinic, were approved and incorporated. So far, the total medical institutions have been formed to 89. As a medical group, the total number of beds is 7,296, with staff of 10,142 personnel and total revenue of 3.454 billion yuan. At present, Gem Flower Healthcare treatment is in accordance with the social work of PetroChina Hospital “four a batch of” deployment, in the “comprehensive promotion of a group of” on the basis of the continuous integration of the other medical institutions under the oil company, to achieve “efforts to complete a batch, clean up a batch, deepen a batch”.

By the end of 2018, the social restructuring and transfer of PetroChina hospitals will be basically completed. Gem Flower Healthcare Group will “integrate global resources to help create healthy China” for historical mission, through the overall planning, investment, construction of “non-profit hospital group”, “Medical +”, “Hospital +”, integrated to promote hospital basic medical services, high-end medical services, medical and nursing services and health pension services. The commercial health insurance service strengthens the group intensive management; the specialized operation realizes the asset; and the capital with powerful business model strives to build the hundred billion market valuation of Gem Flower Healthcare Group.

方圆基金管理（香港）有限公司

Prudence Investment Management (Hong Kong) Limited

方圆基金管理（香港）有限公司是一家成立于香港的资产管理公司，主要业务为基金管理和投资咨询。公司持有由香港证监会颁发的证券销售牌照（1号牌）、投资咨询牌照（4号牌）、基金管理牌照（9号牌）；并拥有由中国证监会批准的RQFII资质。公司现管理资产规模逾200亿港币，自2010年起每年均获得全球基金研究权威机构AsiaHedge及Eurekahedge对包括“最佳固定收益基金”、“最佳长期投资收益基金”等的多个奖项获奖及提名。

方圆基金长期以来关注医疗健康领域，尤其专注于创新药领域的投资，历年来投资了药明康德、昊海生物科技、三生制药、联邦制药、绿叶制药、中国中药等项目，致力于和所投资企业共同成长。为了迎接香港联交所的改革，亦与元明资本共同发起元明方圆医药产业基金，方圆愿通过联合医药上市公司和业内知名人士，共同推动创新类医药企业的上市与发展。方圆基金作为香港第一梯队基金管理公司，拥有丰富的基金管理经验和高效的资本市场对接能力，有利于协助投资项目早日上市，早日实现投资回报。方圆基金致力于为上市企业、控股股东和管理层提供一站式资产管理服务，成为彼此信赖的专业合作伙伴，谋求长期协同发展。

Prudence Investment management (Hong Kong) Limited is licensed to carry out Type 1 (dealing in securities), Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the Securities and Futures Ordinance (SFO), and also has RQFII qualification under authorization from China Securities Regulatory Commission (CSRC). Our main business focuses on fund management and investment advisory. Our domestic asset management platform possesses the license to conduct private equity investment, with products covering fixed income, equity, commodity derivative, and private equity investments. Also, closely connected with prestige world-class private banks, we assist our clients to set up and manage private banking accounts. Our assets under management exceed 20 billion HKD, and we are awarded as “Best Asian Fixed Income Fund” or “Long Term Performance Award” by AsiaHedge and EurokeHedge consecutively since 2010.

With close attention to healthcare sector, especially to innovative medicines, we have invested in WuXi AppTec, Haohai biological technology, 3SBIO INC, UNITED LABORATORIES, LUYE PHARMA, CHINA TCM and so on. To embrace the reform of Hong Kong Securities and Futures Commission, we have launched Yuanming and Prudence Medicine Industry Fund jointly with Yuanming Capital. We aim to promote the initial public offering and development of innovative medicine companies, with strong support from listed pharmaceutical companies and renowned professionals. As a top tier asset management company with abundant experience in fund management and strong capability to connect with capital markets in various aspects, Prudence have an edge on assisting potential companies to get listed and to achieve investment return early. Dedicated to provide one-stop asset management services for listed companies, shareholders and management team, we are more than happy to be reliable professional partner with them for long-term cooperative development.

苏州工业园区元禾原点创业投资管理有限公司

SIP Oriza Seed Fund Management Co., Ltd.

苏州工业园区元禾原点创业投资管理有限公司（下称“元禾原点”）是苏州元禾控股股份有限公司（下称“元禾控股”）的成员企业，是元禾控股专业化的早期股权投资管理平台，在中国证券投资基金业协会完成私募基金登记（证书号：P1000706），主要开展种子基金和成长基金的募集和投资管理工作。

元禾原点重点关注TMT和Healthcare两大领域内初创期和成长期创业企业的投资机会，目前在苏州、上海、杭州、广州、深圳、南京和北京等地设有子公司或者办公室，深入挖掘和培育这些城市和周边地区的优质项目。经过十多年的发展，元禾原点已总结出了一套针对早期项目的项目评价筛选、项目风险控制、项目培育和增值服务的管理体系，积累了丰富的产业和金融资源，并培养了一支经验丰富的专业投资团队。元禾原点目前已拥有专业团队成员42人，分为合伙人、投资业务团队和支持风控团队。

截至2017年6月底，元禾原点所管理的基金规模达人民币35亿元，在投项目180多个，投资金额为人民币18.58亿元。所投资的项目平均收益水平IRR超过30%（复利）。所投资和管理的项目中，按投资金额计算，在行业领域划分上，70%的投资项目属于TMT领域，30%的投资项目属于HC领域；在投资阶段划分上，67%的项目属于种子期，33%的投资项目属于成长期。

Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcare field. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.

礼来投资咨询（上海）有限公司

Lilly Asia Ventures

礼来亚洲基金（Lilly Asia Ventures）成立于2008年，专注于亚洲尤其是中国生物医药、生物技术、医疗器械、医疗服务和动物保健领域的股权投资，同时也是中国最早的由跨国制药公司投资设立的产业基金。

我们的团队由富有医疗健康领域投资、产品研发和市场销售成功经验的专业人士组成，通过独特的专业化投资策略发现并投资有潜力的公司。无论是处于初创期、成长期、或是成熟期（Pre-IPO）的公司，我们都致力于发掘并帮助其成长为细分领域内的行业标杆乃至全球具有影响力的伟大企业。与此同时，我们为员工和我们的投资人赢得丰厚的回报。

Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. Its investors include Eli Lilly & Co., a Fortune 500 company and one of the most globalized and innovative pharmaceutical companies in the world. As a leading biomedical venture fund in China, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.

北京枫海资本管理中心

Beijing Maplesea Capital Management Center

北京枫海资本管理中心（有限合伙）（简称枫海资本）于2015年3月成立，是专注于医疗健康产业的私募股权投资基金。枫海资本立足中国大陆，主要聚焦长三角、京津唐以及珠三角地区。一期基金规模5亿元，由健康产业上市公司独立出资。

枫海资本主要投资标的以未上市公司股权为主，关注的投资方向包括但不限于：1）以慢病和康复为主的综合医院、专科连锁医院、独立医疗中心；2）围绕医改形成的第三方外包服务企业；3）医疗器械、医疗信息化及可穿戴医疗设备的企业；4）新技术推动的生物药、新药开发和医学检测企业等。

枫海资本的核心管理团队来自弘毅、摩根士丹利、平安集团和中投公司，在医疗健康产业及投融资领域积累了多年经验，拥有深厚资源，对行业有深刻理解。公司管理科学、规范，具有严谨的投资操作流程和完善的风险控制体系。同时，具有很强的产业整合能力，投资人后续出资实力雄厚，未来项目退出渠道顺畅。

枫海资本希望通过资本和管理的帮助，促进医疗健康产业中优质企业的创新与成长。

Beijing Maplesea Capital Management Center (referred to as Maplesea Capital), established in March 2015, is a private equity investment fund specializing in the health industry investment. Maplesea Capital is based in mainland China and mainly focuses on the Yangtze River Delta, Beijing-Tianjin-Tangshan and Pearl River Delta regions. The first phase of the fund is RMB 500 million, which is independently funded by a listed company in the health industry.

Maplesea Capital's main investment targets are the equity of unlisted companies. The investment directions include, but are not limited to: 1) General hospital, specialized chain hospital and independent medical center focusing on chronic diseases and rehabilitation; 2) Third-party outsourcing service enterprise formed around medical reforms; 3) Enterprise of medical equipment, medical informatization and wearable medical equipment; 4) New technology-driven biopharmaceuticals, new drug development and medical testing companies.

Maplesea Capital's core management team is from Hony Capital, Morgan Stanley, Ping An Group and China Investment Corporation. The core team has accumulated years of experience in the medical and health industry and investment and financing fields, has profound resources and has deep understanding of the industry. The company's management is scientific and standardized. It has rigorous investment operation procedures and a complete risk control system. At the same time, Maplesea Capital has a strong industrial integration capability, and investors have strong follow-up funding and the exit channel is smooth in the future.

Maplesea Capital hopes to promote the innovation and growth of high-quality companies in the health industry through the help of capital and management.

鼎晖投资
CDH Investments

鼎晖投资成立于2002年，是专注于投资中国市场的最大的私募基金管理机构之一，旗下拥有私募股权投资、创新与成长投资、夹层及信用投资、地产投资、固定收益等业务板块，截至2017年9月30日管理资产总规模超过1,127亿元人民币。

鼎晖投资的前身是中国第一家中外合资投资银行——中国国际金融有限公司（以下简称“中金公司”）的直接投资部。遵照证监会2001年的政策要求，2002年8月中金公司中外两个股东联合瑞士保险资本投资，分拆成立了鼎晖投资。自成立以来，鼎晖投资已累计投资企业200余家，截至目前，60余家企业已成功上市，代表项目包括美的集团、百丽集团、万洲国际、达利食品、恒阳集团、晨光文具、南孚电池、康弘药业、绿叶制药、慈铭体检、新世纪医疗、张江生物、口碑、商汤科技等，为投资者带来了优秀的投资回报。

鼎晖投资得到了诸多专业投资人的认可和支持。目前，共有逾150家国内外著名投资人投资于鼎晖投资，包括：新加坡政府投资公司、加拿大退休金计划投资局、荷兰养老基金、斯坦福大学校园捐赠基金、阿拉伯阿布扎比投资局、LGT、Towers Waston、鲲行投资、全国社会保障基金、国际金融公司、中投保公司、国科控股、国创开元母基金、海通国际等。

基于中国经济增长模式，鼎晖始终保持价值趋向型的投资理念，投资策略上始终关注于中国最具吸引力的资产。不同的业务板块具有统一的文化及价值理念，共享鼎晖大平台的资源。

Founded in 2002, CDH Investment is one of the largest private equity fund management institutions focused on investing in the Chinese market. It owns private equity investment, venture and growth investment, mezzanine and credit investment, real estate investment, fixed income and other business sectors. The total assets under management on September 30, 2017 exceeded RMB 112.7 billion.

The predecessor of CDH Investments is the direct investment department of China International Capital Corporation Limited (hereinafter referred to as “CICC”), the first Sino-foreign joint venture investment bank in China. In compliance with the policy requirements of the China SEC in 2001, the two shareholders of China International Capital Corporation and Swiss Securities Capital Investment Co., Ltd. merged and established CDH Investments in August 2002. Since its inception, CDH Investment has invested more than 200 companies. Till now, more than 60 companies have been listed successfully. Representative projects include Midea, Belle, WH Group, Dali, Hengyang, M&G, Nanfu, Kang Hong Pharmaceutical, Luye Pharmaceuticals, Ciming, New Century Medical, Mabtech, Koubei, SenseTime, etc., have brought investors excellent return.

CDH Investment has been recognized and supported by many professional investors. At present, there are more than 150 well-known domestic and foreign investors investing in CDH Investments, including: Singapore Government Investment Corporation, Canada Pension Plan Investment Agency, Dutch Pension Fund, Stanford University Campus Endowment Fund, Arab Abu Dhabi Investment Authority, LGT, Towers Waston, Minhang Investment, National Social Security Fund, International Finance Corporation, China Insurance Investment Corporation, Guoke Holdings, Guochuang Kaiyuan Fund, Haitong International, etc.

Based on China's economic growth model, CDH investments has always maintained a value-oriented investment philosophy. Its investment strategy has always focused on China's most attractive assets. Different business sections have a unified culture and value concept and share the resources of the CDH platform.

宁波弘晖股权投资合伙企业（有限合伙）

HighLight Capital

弘晖资本是中国最优秀的健康产业投资平台。弘晖资本管理着美元和人民币双币种基金，资产总额达62亿人民币。我们的投资专注于医疗服务、医疗IT、医疗器械（包括影像设备、诊断试剂和医疗耗材）、生物医药（化学药、生物药以及生物制剂）等。

目前已成功投资包括：鱼跃医疗 (002223)、合全药业 （832159）、药明康德（WUXI）、林华医疗(835637)、开拓药业(839419)、康龙化成、迈瑞医疗、中和药业、马泷齿科、趣医网、崔玉涛儿童健康管理中心、京颐股份、凯因科技、润东医药等一批优质项目。

弘晖资本秉持“专业、稳健、创新”精神，致力于服务健康行业的企业家和创业者，共同打造属于全体医疗健康产业创业者和投资人共享的产业投资平台。

HighLight Capital is striving to be the best healthcare investment fund in China. HighLight Capital is dedicated to support healthcare companies to generate robust and sustained growth prospect in China and to partner with entrepreneurs with dedication and highest standard.

HighLight Capital currently manages both RMB & USD fund with total AUM of over US$600 million. We invest in subsectors such as health service, medical device and biotech (chemical drug, biological drug and biological reagent)etc. Since inception in 2014, we have closed over 40 deals including Yuwell (002223), Syn The All Pharmaceutical (832159), Wuxi(WUXI), Linhwa (835637), Kintor (839419), Phamaron, Mindray, Zhonghe, Malo Clinic, Kyee Group.

交银国际控股有限公司

BOCOM International Holdings Co., Ltd.

交银国际控股有限公司为国有股份制商业银行交通银行于香港仅有的知名证券及与证券相关的金融服务综合平台。我们成立于1998年，是香港最早具中资背景的持牌证券公司之一，经历多次经济及行业周期与监管改革的考验。我们的目标是为客户提供一站式证券及金融服务，扩展全球业务。凭借交通银行于香港及中国内地长期建立的客户基础、广泛的品牌知名度及行业专长，我们能够利用竞争优势提高客户忠诚度，并为客户与股东创造价值。

我们相信向客户提供全方位综合证券及金融产品及服务的能力是我们核心竞争优势之一。我们主要业务为：

证券经纪及保证金融资

我们代客户买卖股票、债券、期货、期权及其他有价证券并提供保证金融资服务，为客户的证券交易提供杠杆。

企业融资及承销

我们向公司客户提供一站式企业融资及承销方案，包括首次公开发售保荐及财务顾问、承销（股权及债券）及配售服务。

投资及贷款

我们自行投资股权、固定收益证券及其他金融产品。此外，我们会向客户提供结构性融资及贷款，以满足彼等各种融资需求。另外，我们亦自行投资私营企业股权。

资产管理及顾问

我们向客户提供全面的资产管理及顾问服务，包括互惠基金管理、专项资产管理、私募股权基金管理及投资顾问。

与交通银行集团的关系

交通银行是本公司的最终控股股东。交通银行始建于1908年，是中国第一家全国性的国有股份制商业银行。交通银行的H股及A股先后于2005年及2007年在联交所（股份代号：3328）及上海证券交易所（股份代号：601328）上市。交通银行是中国主要的金融服务供货商，本身及透过全资附属公司、非全资附属公司及联营公司提供丰富的企业及零售银行产品及服务。业务范围涵盖企业银行、个人银行、资金业务及其他业务。

BOCOM International Holdings Company Limited is a well-established and the only integrated platform for securities and related financial services of BOCOM in Hong Kong, one of the State-Owned Joint Stock Commercial Banks. Founded in 1998, we were one of the earliest licensed securities firms with a PRC background in Hong Kong and have weathered many economic and industry cycles as well as regulatory reforms. Our objectives are to offer one-stop securities and financial services for our clients and to expand our international operations. Leveraging BOCOM's long established client base in Hong Kong and the PRC, wide brand recognition and industry expertise, we have been able to capitalise on our competitive strengths to increase client adhesion and create value for our clients and shareholders.

We believe that one of our core competitive strengths is our ability to offer comprehensive and integrated securities and financial products and services to our clients. Our principal business lines are:

Securities Brokerage and Margin Financing

We execute trades on behalf of our clients in stocks, bonds, futures, options and other tradable securities and offer margin financing services to provide
leverage to clients' securities transactions.

Corporate Finance and Underwriting

We provide one-stop corporate finance and underwriting solutions to our corporate clients, including IPO sponsorship, financial advisory, as well as underwriting (equity and debt) and placing services.

Investment and Loans

We invest in equity and fixed income securities and other financial products for our own account. In addition, we may extend structured financing and loans to our clients to meet their various financing needs. Furthermore, we also invest in equity of private companies for our own account.

Asset Management and Advisory

We provide comprehensive asset management and advisory services to our clients, comprising mutual fund management, specialised asset management, private equity fund management and investment advisory.

RELATIONSHIP WITH THE BOCOM GROUP

BOCOM is the ultimate controlling shareholder of the Company. BOCOM was founded in 1908 and is the first nationwide state-owned joint stock commercial bank in the PRC. The H shares and A shares of BOCOM have been listed on the Stock Exchange (stock code: 3328) and the Shanghai Stock Exchange (stock code: 601328) since 2005 and 2007, respectively. BOCOM is a major financial services provider in the PRC and provides a broad range of corporate and retail banking products and services on its own account and through its wholly-owned subsidiaries, non wholly-owned subsidiaries and associates. Its scope of business comprises corporate banking, personal banking, treasury business and other businesses.

招商局海通贸易有限公司

China Merchants Hoi Tung Trading Co., Ltd.

招商局集团(简称“招商局”)是中央直接管理的国有重要骨干企业，经营总部设于香港，亦被列为香港四大中资企业之一。2017年，招商局集团各项经济指标再创新高：实现营业收入5844亿元，同比增长18%；利润总额1271亿元，同比增长14.3%，在央企中排名第二；截至2017年底，集团总资产7.3万亿元，同比增长7.8%，规模在央企中排名第一。招商局集团成为8家连续十三年荣获国务院国资委经营业绩考核A级的央企之一和连续四个任期“业绩优秀企业”。

招商局海通贸易有限公司（简称“招商海通”），其前身为香港海通有限公司，1972年成立于香港，是招商局集团旗下专门从事专业性贸易业务的二级企业。2016年6月29日，正式更名为招商局海通贸易有限公司。现已发展成为集海事、食品、船贸及大宗贸易为一体的综合性贸易集团。

China Merchants Group (CMG) is a leading state-owned enterprise based in Hong Kong, under direct supervision of State-owned Assets Supervision and Administration Commission of the State Council. The business performance hit record high in 2017, with 584.4 billion RMB revenue, 18% up year-on-year, and 127.7 billion RMB total profit, 14.3% up year-on-year, raking No.2 among all the SOEs. By the end of 2017, the company had the total assets of 7.3 trillion RMB, 7.8% up year-on-year, ranking No.1 among all the SOEs. It has been recognized as one of the eight Level-A SOE for thirteen consecutive years and the High Performance Enterprise for four consecutive years.

Merchants Hoi Tung Trading Company Limited (For short Merchants Hoi Tung), its predecessor was Hong Kong Hoitung Co., LTD., which was founded in 1972. It’s a secondary subsidiary of China Merchants Group specializing in professional trading business. Since June 29th, 2016, it officially changed the name to Merchants Hoi Tung Trading Company Limited. Now it has develop into a comprehensive trade group , business includes of marine trading, food trading, shipping trading and commodities trading.

北京大数长胜资产管理有限公司

Beijing Great Numbers Asset Management Co., Ltd.

北京大数长胜资产管理有限公司总部位于北京，是一家致力于实现资本长期稳定增值的传承基金。公司实力雄厚，涉及地产、医疗、教育、高端制造等行业投资和实业运作。公司始终坚持独立深入思考，通过专业化、精细化投研操作，实现管理资产过百亿人民币；股权、证券投资回报均领先于市场。

公司医药领域在投项目包括药明康德、药明生物、亚盛医疗、小净透析、中生方政等，其中药明生物2017年6月于港交所上市，当前总市值已超千亿港币；中生方政2016年4月于新三板挂牌上市，亚盛医药在全新作用机制抗肿瘤创新药物开发领域内拥有多项核心技术，特别是在蛋白-蛋白相互作用靶点领域内的药物设计技术处于全球领先地位。在医药领域之外，公司还投资了宁德时代、拉卡拉、澜起科技、豪威科技等高端制造及互联网大消费领域项目。

生物医药行业是公司大举投资的产业领域，公司坚持研究发现价值，金融服务实体产业的投资理念，公司与元明资本、高林资本、通和毓承等专注于医疗健康领域的投资基金及相关上市公司深入开展交流合作，积极探索医药领域的成长机会，促进新品种、新机会的研究与开发，使更多优秀的医疗技术资源共享。让资本助力中国医药创新升级，与国民健康携手同行，是大数长胜不变的使命与追求。

Beijing Great Numbers Asset Management Company Limited, headquartered in Beijing, is a family fund dedicated to the long-term and stable growth of assets. Backed by strong financial resources, the company has been carrying out investments in a broad variety of sectors such as the real estate, healthcare, education, high-end manufacturing etc.. The company upholds the independent proprietary research, which is also the key to our investment process. By taking advantage of a professional and well-managed research and investment team, we have managed assets of billions RMB. The investment return on private equity and security far exceeds the market.

In the healthcare sector, the investment portfolio companies are WuXi AppTec, WuXi Biologics, Ascentage Pharma, Jing Dialysis Center and National Bio-Founder Biotech. WuXi Biologics, a HK-listed company, is a global leading biologics services provider that offers comprehensive, integrated and highly customized services. The total market value has surpassed 100 billion HKD within half a year of listing. The National Bio-Founder Biotech was listed on the National Equities Exchange and Quotations in April, 2016, a provider of diagnostic kit for cervical cancer. Ascentage Pharma is a leader in the design of small molecule therapeutics that target protein-protein interactions.

Additionally, the company also invests in high-end manufacturing and TMT sectors such as CATl, Lakala Payment, Montage Technology Group and OmniVision.

The healthcare sector has always been a focus of our investment. We have put unprecedented efforts in the study and research on this field. The company also aims to develop good relationships with medical institutions, organizations and associations. We would like to contribute our share to the development of the whole industry. What is more, we have conducted a series of cooperation with renowned investment funds, which are dedicated to the biomedical field, such as YuanMing Capital, Gaolin Capital, 6 Dimensions Capital, and other listed companies. We are now sparing no efforts to explore the investment opportunities to promote the industrial development. It is our great will to work with more institutions to boost the research and development of new varieties. The company is also eager to see that more excellent medical technology resources can be shared. In the next few years, the company will dedicate itself to making full use of the capital to help upgrade China's pharmaceutical innovation. It is also our mission to make more contributions to the national healthcare development.

浩悦资本有限公司

HaoYue Capital

浩悦资本创立于2013年，致力于成为嫁接中国医疗事业与资本的桥梁。浩悦资本的研究领域和交易范围覆盖医疗服务、移动医疗、制药、高值耗材和医用器械等多个细分领域。浩悦资本团队由深耕中国医疗健康领域多年的资深投资银行家组成，在创立浩悦资本前已完成数十起私募融资及并购重组项目，项目总规模超过5亿美金。

从2013年创立到2018年4月，浩悦资本已成功完成超过57起私募融资和并购项目，交易总金额达15亿美金以上，不但交易数量多年稳居国内头把交椅，在完成交易的复杂程度和难度上亦领先于行业水平。浩悦资本的客户均来自于覆盖医疗健康细分领域前三。其中，浩悦资本为其近一半的客户提供超过两轮以上的融资顾问服务，持续致力于协助企业完成在融资过程中遇到的资产重组、股权重组业务改进、人才招募等多项挑战。

浩悦资本长期密切追踪医疗健康投资市场动态和投资趋势，每周发布医疗行业周报和整理医疗大事件，从资本角度解读新政策和新前沿。此外，浩悦资本打造的中国医疗健康投资“卓悦榜”品牌，每年发布中国医疗行业资本年度趋势，并邀请数百家投资机构参与实名票选年度投资案例等权威奖项。浩悦资本期待未来持续见证和关注中国医疗健康行业的发展。

Established in 2013, HaoYue Capital is dedicated to bridge the gap between healthcare industry and capital in China. Our research and deals experience cover several healthcare sectors including medical services, mobile healthcare, pharmaceuticals, high-value medical consumables and medical devices. As a Top healthcare investment bank in China, HaoYue Capital was founded by experienced healthcare investment bankers, who have completed dozens of VC, PE and M&A deals with total amount exceeding 500 million USD.

By April 2018, HaoYue Capital has successfully provided financial advisory services for 57 VC, PE and M&A deals, the total amount of which is over $1.5billion. Since its establishment, HaoYue Capital has always ranked first in Chinese healthcare financial advisory industry in terms of both number and complexity of the deals. Our clients are all among the Top 3 from their specific segments. Half of our clients have requested our financial advisory services for more than twice, so as to be better assisted in asset restructuring, improvement of equity restructuring and recruitment of talents during the financing process.

HaoYue Capital has been closely following the trend of healthcare investment market for a long period of time. We publish weekly reports and industry analysis to interpret new government policies and the latest healthcare investment from the perspective of capital. In addition, HaoYue Capital created “Zhuoyuebang”, an annual event where hundreds of investors are invited to vote for annual awards such as “Investment Cases of the Year”. We will continuously devote ourselves to the development of China's healthcare industry in the future.

珠海夏尔巴股权投资管理有限公司

Sherpa Venture Capital

夏尔巴（Sherpa），在藏语里即为东方人，是居住在喜马拉雅山脉两侧的民族，以“珠穆朗玛向导”著称，夏尔巴人以丰富的登山经验和极强的体力、耐力为众多攀登珠峰的挑战者们服务，充当着探路导向、架设绳索、保驾护航的幕后英雄。

夏尔巴投资（Sherpa Venture Capital）的创始团队认为，创业者就如攀登珠峰的人，夏尔巴投资作为专业的医疗健康基金，为创业者们提供的正是创业的经验、行业的资源、稳定的资金支持和全方位的增值服务，夏尔巴投资希望能够协助创业者们共同见证雪山之巅的绝景。

夏尔巴资本是一只专注医疗行业投资的，成熟稳定且有丰富投资管理经验的创业团队。核心投资团队都有14年以上的医疗产业投资运营管理经验，价值观一致，经历风雨且长期合作，相互信任又能力互补。

公司核心管理团队于合作超过7年，累计投资近70个医疗项目，管理资金总额近7亿美 元; 历史投资项目已有4个项目退出或部分退出，多个项目在退出渠道中; 曾经管理过5只综合基金中的医疗专业投资，及2只医疗专业基金，具备完整的基金组合构建经验; 已在医疗服务、医药、生物技术、医疗器械等细分领域内投资并管理过细分行业龙头企业，形成项目源、投后增值服务、退出等全方面资源优势。

核心创始团队与同期医疗行业专注基金相比，实现了位居前列的投资业绩，且投出了如贝瑞基因、信达生物、亚心医院等细分领域的明星项目。团队一起见证了众多企业的兴衰成败，更具前瞻性发展眼光和全局性看问题的能力; 多年共历风雨，经历各种考验使得创始团队之间建立了深度的了解和互信。核心团队之间对行业认知既有高度共识，又分别在不同细分行业中有深度的积累和优势，保证对细分方向的全面覆盖；更加灵活和具有主动性的创业机制，确保团队生产力的完全释放，是公司长远发展的有利保障。

The Sherpa people, living amongst the Himalayan mountains, serve as guides at the extreme altitudes of Mount Everest. Sherpas are the guides of dreams, who are renowned in mountaineering for their wisdom, expertise, bravery and strength.

The founding team of Sherpa Venture Capital believes that the entrepreneurs, much like the climbers of Mount Everest, will reach the world pinnacle of wellness through the support and guidance of Sherpa, providing them with experiences, industrial resources, financial support and a full range of value-added services.

Sherpa Venture Capital is a leading venture capital firm in China’s Health and Life-science Industry. Sherpa Venture Capital is built by an exceptionally experienced team of entrepreneurs, focused on the investment and cultivation of the Pharmaceutical and Biotech industry.

Sherpa Venture Capital specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where we have established robust portfolio sources, lasting value-adding collaborations and relationships, as well as, mature all-cycle services with key resources. Our core team has more than 15 years of healthcare investment operation and management experience, with aligned values, deep mutual trust, and critically complimentary expertise.

We, at Sherpa Venture Capital, strive to become one of China's foremost investment institutions in healthcare and life-science, providing indispensable services throughout value chains. We, at Sherpa Venture Capital, aspire to be the backbone of China's future in health.

博裕投资顾问有限公司

Boyu Capital

成立于2011年，博裕资本是专注于中国的私募股权投资基金。我们致力于投资高速增长行业的优秀企业，通过少数股权或相对控股等投资方式，为企业增长转型以及国有企业改制提供资本和管理支持。

投资团队：创始合伙人是本土一流私募基金投资人，拥有全球500强企业的高管背景。投资团队成员拥有丰富的投资和管理经验，能够执行复杂多样的投融资交易，并致力于投资高速增长行业的优秀龙头企业，协助公司打造业界领袖。

投资策略: 专注于四大朝阳产业，消费品和零售、金融服务、医疗健康以及科技/媒体/商业服务; 积极创造独有投资机会，坚持挖掘最有投资价值的公司；精心设计最优交易结构，把握最佳投资机会，稳中求胜。

增值服务：致力提供全面增值服务，帮助提升企业价值，锦上添花。凭借着团队主要成员丰富的企业发展、运营及管理经验，博裕资本自成立初始便明确了以提供企业全方位的增值服务及业务转型升级平台的投资理念，致力于协助被投资企业制定战略规划、有效提升运营效率、进一步完善治理结构等，并凭借我们专业的收购兼并和融资经验，引导被投资企业向资本市场发展。我们坚信如此的投资理念将会赢得企业家和国有企业高管们的共鸣，从而促使被投资企业快速发展壮大。

基金优势：企业运营和管理水平在业界享有至高声誉；本土经验与全球视野的完美结合。

Founded in 2011, Boyu Capital is a China-focused investment firm. Our mission is to deliver long-term risk-adjusted returns for the Fund's investors through a systematic and tailor-made investment approach. Boyu Capital provides growth and transformational capital for fast-growing businesses in Greater China, as well as participating in the restructuring of state-owned enterprises.

Investment Team: The founding team are world-class business operators and experienced China investors. Our investment professionals came from top-tier global private equity firms, investment banks, and other professional institutions.

Investment Strategy: Focus on Consumer/Retail, TMT/Business Services, Healthcare, Financial Services; proactive and theme-based deal sourcing thanks to deep domain knowledge in focused sectors; optimal transaction structures for either minority stakes or control, growth and transformational capital (including expansion stage deals, shareholder recaps, PIPE deals).

Value-added services: With our founding members' extensive experience in building businesses and managing business operations, Boyu has been designed from its inception as a business-transforming platform and will always seek to add concrete value to its portfolio companies in such critical areas as strategic planning, operational improvements, corporate governance, mergers and acquisitions and corporate finance. We strongly believe that our well-defined value-added investment philosophy will resonate with entrepreneurs and SOE executives alike and will achieve favorable results for our portfolio companies.

Advantage: Unparalleled corporate leadership and operating experience; strong investment track record, China insights with global perspectives.

泰福资本
TF Capital

泰福资本成立于2014年，聚焦于生命科学领域的风险投资,主要投资有潜力的早期及成长期企业。通过多元化、战略性布局，选择优质的合作伙伴，期望在中国生命科学的快速发展中把握机会。投资团队在这些领域有多年经验及行业资源，希望与被投资企业共同快速成长。

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

国泰君安证券股份有限公司

Guotai Junan Securities Co., Ltd.

国泰君安，中国证券行业长期、持续、全面领先的综合金融服务商。国泰君安跨越了中国资本市场发展的全部历程和多个周期，始终以客户为中心，深耕中国市场，为个人和机构客户提供各类金融服务，确立了全方位的行业领先地位。从2007到2016年的十年里，国泰君安的营业收入有八年名列行业前三，在致力于实现高质量增长、规模领先的同时，注重盈利能力和风险管理。自2008年以来，国泰君安连续十年获得中国证监会授予的A类AA级监管评级，该评级是迄今为止中国证券公司获得的最高评级。

在二十余年创新发展过程中，国泰君安逐渐形成了风控为本、追求卓越的企业文化，成为中国资本市场全方位的领导者以及中国证券行业科技和创新的引领者。这样的成绩源自于全体国泰君安人的共识：客户至上、统筹兼顾的利益观，风控为本、追求卓越的业务观，以人为本、协同协作的人才观，创新超越、珍惜声誉的处世观；源自于对共识的高度认同和持续实践。

基于在中国本土强大的竞争优势，未来，国泰君安将主动满足客户跨境需求，务实推进国际化，建立覆盖全球的业务网络和执行能力，为客户提供综合金融服务，努力成为根植本土、覆盖全球、有重要影响力的综合金融服务商。

GTJA, a comprehensive financial provider with a long-term, sustainable and overall leading position in the Chinese securities industry, has gone through the whole course of multiple periods of the development of Chinese capital markets. While GTJA is always client-oriented and firmly based in the Chinese market and provides various financial services for individuals and institutional clients, it has established itself as a leader in the industry in an all-round manner. From 2007 to 2016, GTJA has occupied the top three places in terms of operating revenue for eight years. While GTJA is committed to realizing the high-quality growth and a leading position in scale, it also lays emphasis on its profitability and risk management. Since 2008, GTJA has been rated as A level of AA class for ten consecutive years by CSRC, which is the highest rating for Chinese securities companies so far.

Based on strong competitive advantages in China, GTJA will positively satisfy the cross-border demands of clients, practically promote the process of internationalization, develop a business network covering the world and executive capacity, provide comprehensive financial services for clients and strive to become a comprehensive financial service provider of significant influence based in China and expanding to the world.

Over the past two decades of innovative development, GTJA has gradually formed a culture of “striving for excellence on the basis of risk management” and developed into a leader in all aspects in Chinese capital markets and a leader in science, technology and innovation in the Chinese securities industry. Such achievements are derived from the consensus among all staff of GTJA on an interest outlook of client orientation and overall consideration, a business outlook of striving for excellence on the basis of risk management, a talent outlook of people first and joint cooperation and the living outlook of innovation and reputation cherishing, as well as the high identification and continuous practice of the consensus.

国寿股权投资有限公司

China Life Private Equity Investment Co., Ltd.

中国人寿是国内最大的商业保险集团，累计保单客户超过5亿人，基本医保项目400多个，为6,800多万人次提供医疗保障服务；承办260多个大病保险项目，覆盖4.2亿人；与此同时，作为最大的国有商业保险集团，中国人寿与各级地方政府进行着良好而深入的合作，与29个省市级政府建立了战略合作伙伴关系。通过对接中国人寿庞大的客户资源和丰富的保险资源，能够为被投资企业提供客户资源和保险产品对接解决方案，推动被投资企业或机构快速发展、做大做强。

国寿股权投资有限公司（简称“国寿股权”）为中国人寿旗下开展私募股权投资业务的专业化平台。由国寿股权作为管理人的国寿大健康基金成立于2016年，是国内目前规模最大的旗舰型大健康产业股权投资基金，总规模500亿元人民币。该基金亦是保监会相关政策颁布后，首支获批成立的保险资金私募股权投资基金，过往3年著名投资案例包括：全球领先的制药及医疗器械研发开放式能力和技术平台公司——药明康德、国内领先的生物制药企业之一——信达生物、全球领先的高科技医疗设备研发制造企业——迈瑞医疗、国内领先的高端医疗设备企业——联影医疗等。

China Life Insurance is the largest commercial insurance group in China, with more than 500 million cumulative insurance policy customers, more than 400 basic medical insurance projects, providing medical insurance services for more than 68 million people. Undertaking more than 260 major disease insurance projects, China Life Insurance covers 420 million people. By connecting the huge customer resources and abundant insurance resources of China Life, it can provide the invested enterprises with customer resources and insurance solutions and promote the rapid development of the invested enterprises and institutions.

China Life Private Equity Investment Company Limited is the fund manager for China Life Healthcare Fund,which is the first flagship healthcare private equity fund of China Life. As the major investment platform of healthcare investments for China Life, it is also the largest domestic healthcare private equity investment fund in China, with the total AuM of RMB 50 Billion. So far, China Life Investment has successfully invested in multiple leading companies in healthcare sector, and established good strategic partnership with several domestic and overseas top-tier medical institutions.

上海东富龙科技股份有限公司

Shanghai Tofflon Science and Technology Co., Ltd.

上海东富龙科技股份有限公司（中文简称：东富龙；外文简称：Tofflon）是一家为全球制药企业提供制药工艺、核心设备、系统工程整体解决方案的综合化制药装备供应商，产品广泛应用于无菌注射剂、固体制剂、化学原料药、生物工程、中药提取等药物制造科学领域。东富龙成立于1993年，经过20载艰苦奋斗，锐意进取，东富龙已有超过8000多台制药设备和制药系统服务于全球40多个国家和地区的2000家知名制药企业，并已成功进入到西欧、北美等高法规市场，2011年2月1日，东富龙正式在深圳证券交易所创业板上市（股票名称：东富龙；股票代码：300171）。

今天东富龙专注于药物制造科学和药机制造科学的研究，践行制药装备与制药工艺的融合、创新，致力于智慧药厂的开发与建设。汇聚全球技术，在上海总部建立了综合研究所，逐步在欧洲、美国、印度建立全球设计所和技术中心，与美国、欧洲、日本合作伙伴成立合资企业和开展技术合作，拥有具有全球竞争力的五大现代化的制药装备生产基地，先后通过了德国TUV ISO9001、ISO14001、OHSAS 18001、CE、UL、PED、ASME等国际认证，拥有中外员工2000多名，对接各国制药标准（USFDA / MHRA / WHO / TGA / MCC等），提供具有全球竞争力的注射剂解决方案、固体制剂解决方案、原料药解决方案、生物工程解决方案、中药解决方案、检查包装解决方案等，致力于成长为全球制药装备整体解决方案的主流供应商。

未来东富龙秉承“专业技术服务于制药工业”的使命，聚焦制药工业关注的挑战和压力，从药物创新、制药工艺、核心设备、系统工程方面提供系统整体解决方案，成为智慧药厂的交付者，服务于全球制药工业。从“中国的东富龙成长为世界的东富龙”，从“单一设备供应商成长为系统方案解决者”。在做强制药主业的同时，积极布局和发展医疗器械和食品工程，为实现社会、客户、股东、员工及其家庭幸福的最大化而不懈努力，为服务于人类大健康事业做出新的贡献！

Shanghai Tofflon Science and Technology Co. Ltd. (Short for “Tofflon”, Stock Code: SZ 300171) was founded in 1993. It is a comprehensive pharmaceutical equipment supplier to provide process support, core equipments, integrated system and pharma engineering for the pharma and biotech industry in the world. Since its foundation, Tofflon has supplied more than 8000 equipments and systems for 2000 pharmaceutical companies across over 40 countries and regions in the world which have been widely applied in the fields of liquid and lyo injectables, chemical API, bio engineering and pharma packaging, etc.

Today Tofflon focuses on studying drug manufacture science and process equipment manufacture science, practices drug process knowledge integration with pharma equipment knowledge. Taking “Synergy Global Advanced Technologies” strategy, Tofflon builds comprehensive development institute in Shanghai headquarters, is building design houses and technical centers in USA, Europe and India, establishes joint ventures and technology collaboration with the technical partners from USA, Europe and Japan. Furthermore Tofflon has built five modern pharmaceutical equipments manufacturing bases with global competitiveness. It has been approved with all the international regulatory certifications like German TUV ISO9001, ISO14001, OHSAS 18001, CE, UL, PED, ASME, etc. Thanks to 2000 Chinese and foreign employees professional works, it can provide competitive pharmaceutical equipment and system solutions valuable for today and future’s competence improvement of the pharma and biotech companies.

In the future to commit to its mission “Expertise in Pharmaceutical Industry”, Tofflon will continuously work with pharmaceutical industry to face and meet the challenges and pressures in the industry through developing “innovative drug manufacturing science” and building “advanced drug manufacturing platform”. In the following years, Tofflon will dedicate itself to grow from “China Tofflon to Global Tofflon”, from “Equipment Supplier to Solution Provider” so as to grow up to a total solution provider of pharmaceutical manufacturing systems and engineering for the global pharma and biotech industry to contribute to the maximum benefits and welfare of its served society, customers, stockholders, employees and their families.

北京科信必成医药科技发展有限公司

CoSci Med-Tech Co., Ltd.

北京科信必成医药科技发展有限公司总部位于北京中关村国家自主示范区海淀核心区，成立于2003 年，是一家拥有多项国内外自主知识产权的国家高新技术企业，是“中关村国家自主创新示范区创新型企业”，北京G20高端服务企业，北京市自然科学基金项目承担企业，全国企事业知识产权试点单位，国家技术转移示范机构，北京市专利示范单位，中关村20 周年突出贡献企业， 2010 年~2012 年连续三年获得德勤高科技、高成长中国50 强及亚太500 强。

科信必成先后承担了国家“十一五”、“十二五”、“十三五”重大新药创制项目，多项国际化合作项目列入中关村科技园区海淀园专项发展资金。研发中心建立可达到FDA、EMA 药物制剂标准的化学药物速释、缓释、控释口服固体制剂技术平台。开发品种涵盖老年慢病领域、改良型创新儿童药、儿童罕见病用药系列产品，同时涵盖心脑血管、呼吸系统、神经系统、退行性疾病、解热镇痛、等多个领域，在每个领域均有系列产品满足不同治疗时期的需求。科信必成拥有13 项具有独立自主知识产权可产业化的围绕控缓释共性关键技术平台，主要包括掩味颗粒技术、精准给药系统微片技术、渗透泵控释片给药系统技术、群控释放渗透泵控释片技术、固体分散物工业化制备技术、醋酸纤维素水分散体微囊包合技术、水为润湿剂制备凝胶骨架片技术、蜡质骨架材料双层缓释片制备技术等，截至目前申请药物制剂国家发明专利171 项，获得84 项授权；申请国际PCT 专利7 项，1 项已获得美国和欧洲13 国授权。

科信必成是专注于口服固体制剂产业化的药品研发机构，已为国内60 多家制药企业提供服务，其中包括50 家上市公司以及2016 年度中国医药工业百强榜前100 强中的27家。近年公司加大与国际制药企业的合作力度，将最先进的创新理念和制剂技术引进，并消化吸收再创新，推进国内制药技术研发与工业化水平的进步，从而真正的打造具有国际先进水平的药物制剂技术平台，实现口服药物速、缓、控释等制剂技术和产品达到国际水平，助推中国医药产业实现国际化。

CoSci Med-Tech Co.,Ltd, is an technology driven innovative pharmaceutical service enterprise located in Beijing Zhongguancun Science and Technology Park. Its focus is the R&D and industrialization of oral solid modified-release formulations, with its own patented innovative Drug Delivery Technologies.

During the last 15 successful business years, CoSci has filed 171 patent applications and granted 84 by the Chinese Office of Intellectual Properties. We’ve also filed 7 international PCT applications and 1 was approved by EU Office and US office.

CoSci’s 13 technology platforms were positively assessed by domestic and global partners:

·Milti-Porous Osmotic Pump Controlled-Release Tablet
·Complete Dissolution of Drug Content From Osmotic Pump Formulations
·Enteric-Coated Pellet
·Tablet Matrix Using Water as Wetting-Agent
·Double-Layer Wex-based Matrix
·Sustained-Release Pellet
·Industrial Production of Solid Dispersions
·Microencapsulation of Cellulose Acetate Dispersables
·Extended-Release Drug Delivery System Oral Dipersable Pellets
·Mirco-Tablet
·Colon-Release Formulations
·Multi-Unit Sustained-&Controlled-Release Formulations (Mirco-Pellet Compression)

Well accepted is also the philosophy of CoSci: we realize products rather than technology, which lead to marketing value of our partners. Currently we have 118 valuable products in our pipeline.

方恩（天津）医药发展有限公司

Fountain Medical (TIANJIN) Co., Ltd.

方恩（天津）医药发展有限公司是一家能够提供全方位与国际标准接轨的临床开发服务的CRO（合同研究组织）公司。方恩以天津为中心分别在美国、北京、上海、南京、广州、成都、香港、台湾、韩国、亚美尼亚及日本建立了分支机构。方恩现有员工1200 多位，中国大陆的临床运营团队分布在全国36 个城市，目前还在不断的发展壮大中，致力于为国内外生物制药或医疗器械客户提供高质量低成本的全方位的临床研究服务。

方恩自成立以来，参与并承担了“十一、五”及“十二、五”重大新药创制项目，通过了国内外大中型制药企业的数十次稽查，为许多国内外领先的医药企业及全球一些非盈利机构和一些新兴的生物医药公司提供临床研究服务。至今为止，方恩已支持提交国内外15 个新药证书并有11 个已经批准； 承接了200 多项临床试验项目包括多个治疗领域下的入组10000 例的上市后研究；与亚洲300 多家临床试验机构保持着良好的合作关系；目前已经为分布于中国大陆、香港、台湾和韩国的各阶段临床试验入组了近60000 例受试者。

相信丰富的临床经验、对合作需求的敏锐触觉、顺应合作伙伴需求及对细节的专注性将成为方恩成功发展的基石。

Fountain Medical Development Ltd. (FMD) is a Contract Research Organization (CRO) offering a full range of ICH GCP compliant clinical research services, these services target multinational pharmaceutical and medical device companies looking to establish their medical product(s) in the US, Europe, and parts of East Asia (including China, Hong Kong, Taiwan, and South Korea; Japan).Our extensive global experience in multiple therapeutic areas, is comprehensive and transcends other local and global CRO’s.

Our competitive costs and rich clinical experience allow us to pass significant savings onto our clients. Our extensive clinical experience and high sensitivity for cooperation not only satisfies the detail oriented requirements of our partners, but also establishes a solid foundation for FMD to thrive. In the course of our steady growth and expansion, we have successfully completed more than 200 clinical trial projects and enrolled more than 60,000 patients in clinical trials; in addition, we have maintained stable partnerships with more than 300 sites in Asia. As a global CRO, FMD has completed many pivotal international studies, the results of which can be used in FDA and EMA applications, ensuring that FMD is your trustworthy CRO of choice.

无锡药明康德新药开发股份有限公司

WuXi AppTec Co., Ltd.

药明康德（股票代码：603259）是国际领先的开放式能力与技术平台公司，为全球制药及医疗器械等领域提供从药物发现、开发到市场化的全方位一体化的实验室研发和生产服务。本着以研究为首任，以客户为中心的宗旨，药明康德通过高性价比、高效率的服务平台帮助全球客户缩短药物及医疗器械研发周期、降低研发成本。药明康德平台涵括小分子药物研发及生产、细胞疗法与基因疗法研发生产、医疗器械测试等，正承载着来自全球30多个国家的3000多家创新合作伙伴的数千个研发创新项目，致力于将最新和最好的医药和健康产品带给全球病患，实现“让天下没有难做的药，难治的病”的梦想。

WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."

药渡经纬信息科技（北京）有限公司

Pharmacodia (Beijing) Co., Ltd.

药渡经纬信息科技（北京）有限公司（以下简称“药渡”）成立于2013年，中国首家药物垂直领域研发大数据公司。药渡秉承促进全球医药行业持续发展理念，以“助力药物创新，加速药物研发”为企业使命，成功打造以大数据驱动的生物医药垂直领域综合信息服务平台。结合药渡结构化大数据深度分析医药研发生态圈需求，通过大数据处理技术和专业数据分析模型与算法，将“数据技术”与“药物研发”深度结合，提供数据支撑、药物资讯、研发资源对接、药渡学院等一体化服务，成为中国医药信息行业的“领跑者”。

全球领先结构化药物研发大数据平台，也是中国唯一聚焦药物研发生态圈的“一站式服务”信息平台。药渡通过先进的药物数据信息分析方法和药物领域数据清洗处理技术及应用产品成为以“数据驱动的生物医药垂直领域”国内药物信息第一家；并成功打造以“药物数据”为核心的药渡数据、药渡资讯、药渡咨询、药渡金融、药渡专著等众多业务，为生物医药行业提供富有价值的创新产品和专业服务。

药渡产品用户已覆盖140多个国家，广泛服务于政府专业机构、高校科研院所、药物研发企业、投融资机构等。2015年、2016年获评“中关村医药研发大数据平台”、“国家高新技术企业”。2017年与国家食药监局药审中心、中关村管委会、北大药学院等多家政府单位和院校开展合作，提供数据支撑与专业服务。

Founded in 2013, Pharmacodia (Beijing) Co., Ltd. (“Pharmacodia”) is China’s first pharmaceutical R&D big data company. Pharmacodia has successfully created a comprehensive information service platform in the biomedicine field. Based on in depth analysis of pharmaceutical R&D Data, the company provides service including database support, drug news, R&D resources. Pharmacodia has become the "Leader" of China's pharmaceutical information provider.

Pharmacodia products have covered more than 140 countries and are widely used in government agencies, university research institutes, drug research and development companies, investment and financing institutions. Pharmacodia was awarded "ZHONGGUANCUN Pharmaceutical R&D Big-Data Platform" and "National High-tech Enterprise" in 2015 and 2016 respectively.

缔脉生物医药科技（上海）有限公司

dMed Biopharmaceutical Company Limited

缔脉生物医药科技（上海）有限公司是一家临床合同研究组织（CRO），旨在为中国及全球生物医药公司和医疗器械公司提供高水准全方位的服务，包括为客户就临床开发的各个方面以及产品注册申报出谋划策，也提供与临床试验相关的各种支持。致力于提高研发产品的成功率。

服务对象及主营业务

服务于中国生物医药和医疗器械公司，以及在中国开展临床研究的国外中小型生物医药 和医疗器械公司：临床试验设计及执行，试验数据分析及报告，注册文件及提交，系统 支持，功能性服务， 以及咨询服务（临床研发及注册策略咨询，技术咨询，国外开展临 床试验及注册的咨询）

服务于跨国生物医药和医疗器械公司 (立足于中国，服务于全球临床试验)： 生物统计，临床试验数据管理，临床编程，医学报告撰写，药物不良反应事件评估及风险管理，注册文件支持及运作，质量监控及稽查

合作模式

战略合作 – 提供长期、多维度、跨地区的服务与战略合作伙伴关系

业务流程服务外包 -- 提供高效率的、有成本优势的、灵活方便的业务流程外包服务

咨询服务 -- 依照客户需求，提供各种灵活快捷的科学和战略方面的咨询性服务

质量监督--代表客户或者与客户紧密合作，使用高质量的系统和关键评价指标，确保其他供应商为客户提供的服务是高质量的和有一致性的

风险共担–与客户携手共同投资和开发，共同承担风险

dMed Biopharmaceutical Company Limited is a clinical Contract Research Organization (CRO), providing high-end services to innovative biopharmaceutical and medical device companies. dMed is committed to increasing the probability of success of R&D products. Its services include scientific, strategic, regulatory and quality assurance related consultation for clinical development and product registration; clinical trial design and execution; clinical data management, statistical analysis, medical writing; pharmacovigilance and risk management; and clinical trial quality system and assurance.

Our Clients and Services

Provide service for domestic biopharmaceutical and medical device companies and small and medium-sized biopharmaceutical and medical device companies interested in China market End-to-End Services including Clinical Trial design and conduct, clinical trial data Analysis and Report, Regulatory submission, Systems support, Functional Services, comprehensive Consultation Services (clinical development plan and regulatory strategies, scientific consultation, international facilitation for clinical trial execution and registration)

Provide service for multinational biopharmaceutical and medical device companies (In China for China & In China for Global), such as Statistics, Data Management, Programming, Medical Writing, Pharmacovigilance and Risk Management, Regulatory documentation support and operations, Quality Assurance & Audit

Our Solutions

Strategic partnership – a mid to long term relationship in broad spectrum of services, processes or geographic scopes

Full Service – provide holistic solution and services from development planning to regulatory submission as well as post-marketing support

Functional Service – Business process outsource with cost-effectiveness, or strategic resource flexibility

Consulting Service – Scientific and strategic consultation in flexible way upon client needs

Oversight – Partner with or act on behalf of client to ensure consistency with quality system and key metrics

Risk Sharing partnership – Co-invest in drug development process and share risks

零氪科技（北京）有限公司

LinkDoc Co., Ltd.

零氪科技于2014年11月成立，作为全球领先的人工智能与医疗大数据平台，拥有国内最大规模和体量的医疗大数据资源库和最具优势的技术支撑服务体系，目前已在全国范围内为政府部门、各级医疗机构、国内外医疗器械厂商、药企等提供高质量的临床与科研数据整体解决方案。

零氪科技凭借在医疗大数据整合、处理和分析上的核心技术优势，依托先进的医疗人工智能工具，致力于为社会和行业提供大数据辅助决策（辅助管理、辅助科研、辅助临床诊疗）、医院舆情监控及品牌建设、药械研发、保险控费、患者全流程管理等一体化服务。

公司创始人团队来自腾讯、百度、麦肯锡、阿斯利康等五百强企业高管以及政府和行业协会，具有多年行业从业经验。公司总人数已达800人，其中，有200人的技术团队专注人工智能及大数据技术的开发，专业涵盖：人工智能、技术架构、产品设计、数据安全、数据挖掘、系统工程、计算机视觉、临床医学等多个领域。同时在全国31个省市及自治区拥有专业医学临床服务团队300余人，服务全国近500家三甲医院。

Founded in November of 2014, as a world leading AI and medical big data platform, LinkDoc has processed the largest scale and volume medical data and provided the most advantageous technical solutions in China. LinkDoc has been providing solutions integrated with high quality clinic and scientific research data to governments, various levels of medical institutions, domestic and foreign medical device manufacturers, pharmaceutical companies, etc. throughout the country.

With the advantages of core technologies in medical big data integration, processing and analysis, and advanced medical AI tools, LinkDoc is committed to providing integrated service as big data aided decision-making (management, scientific research, clinical diagnosis and treatment), hospital media coverage monitoring and brand building, medical device research and development, insurance cost control, patient whole-process management, etc.

The founders of the company are experienced entrepreneurs and professionals from top 500 enterprises such as Tencent, Baidu, McKinsey, AstraZeneca as well as government and industry associations, with years of experience in the field. The total number of staff has reached 800, including a team of 200 technicians focusing on AI and big data technology development in such fields as artificial intelligence, technical architecture, product design, data security, data mining, system engineering, computer vision and clinical medicine. In addition, the company has a clinical service team of more than 300 professionals in 31 provinces and municipalities around China, which servers nearly 500 top hospitals in China.

凯莱英医药集团（天津）股份有限公司

Asymchem Laboratories (Tianjin) Co., Ltd.

凯莱英医药集团（股票代码：002821.SZ）作为中国医药研发生产服务外包（CDMO）领军企业，致力于制药工艺的技术创新和商业化应用，为全球制药企业提供临床研究阶段新药和新上市药物原料药及cGMP标准中间体的研究开发、工艺优化和规模化生产等CMC一体化服务。凭借在技术方面长期前瞻性投入，凯莱英在绿色化学创新技术开发及应用方面位于全球最前沿。目前集团拥有八家研发生产基地（其中一家在建）及多家销售公司，截至2017年12月31日，全球员工总数近2700人，其中国家“千人计划”专家1名，天津市“千人计划”专家2名，具有跨国制药企业10年以上工作经验的权威专家和管理人才30余名，申请国际国内专利120余项，先后荣获“国家级企业技术中心”、“国家工信部首批绿色制造体系示范单位—绿色工厂”、“中国十大CMO企业”、“天津市科技小巨人领军企业”、“2016/2015/2014年度天津开发区百强企业”、“首批天津科技领军企业”等诸多荣誉。多年来，公司依托先进的技术优势、高科技人才团队和良好的创新模式，成为多家大型国际制药公司长期战略合作伙伴及全球首选供应商之一。依靠自身完整质量体系，旗下四家子公司先后多次通过美国FDA、澳大利亚TGA及韩国MFDS审查。

Asymchem, (SHE: 002821 listed on the Shenzhen Stock Exchange), is one of the world's leading global outsourcing companies with over 20 years' history, serving the pharmaceutical and biotech industries at all stages of drug development chain. Asymchem's technical capabilities span the development and manufacture of enzymes for use in bio-catalysis, to developing practical continuous flow technologies for commercialization, to developing and manufacturing of common potent compounds (such as cytotoxic, beta lactams) , just to name a few. Asymchem has applied over 120 patents, and was recognized as the “State-certified Enterprise Technology Center”, “Green Factory with Green Manufacturing System”, “The Top 10 CMOs in China”, “Tianjin Little High-Tech Giant Leader Enterprise”, “Top 100 Enterprises in TEDA” in 2017/2016/2015/2014, and the “2017 Tianjin Binhai New Area (“TBNA”) Leading Landmark Enterprise”, etc. With a workforce of over 2700 well-trained professionals and some of the most modern facilities in the world, Asymchem has supported many companies, large and small, at all stages of the pharmaceutical research and development chain. Asymchem's integrated services model eliminates the need for handoffs, ensuring that customers' projects are completed on schedule and on budget at the demanded quality. Four of Asymchem's manufacturing sites have successively passed the inspections by the USFDA, Australian TGA, and Korean MFDS several times.

上海立迪生物技术股份有限公司

Shanghai LIDE Biotech Co., Ltd.

上海立迪生物技术股份有限公司（以下简称“上海立迪”），致力于从事肿瘤转化医学及精准医疗研究，以帮助和指导医生进行临床用药，为患者个体化精准治疗方案的选择提供理论依据和指导。公司拥有AAALAC国际认证的SPF级实验动物中心及世界一流的仪器设备。旗下有两家全资子公司“西安立迪生物技术有限公司”和“上海立闻医学检验所”（以下简称“上海立闻”），两家子公司均具有临床医学检验所资质。上海立迪于2016年8月“新三板”挂牌（证券代码：838848）。

上海立闻致力于肿瘤个体化诊断及精准医学的第三方检验单位，可提供分子检测、病理及伴随诊断等相关服务。公司实验室严格按照国家生物安全II级标准建设，并已顺利通过美国病理学家协会（CAP）病理实验室认证。上海立闻-普洛麦格联合实验室由上海立闻与美国普洛麦格公司共同创办，致力于热点肿瘤标志物（MSI、dMMR等）的研究和开发应用。

西安立迪拥有AAALAC国际认证的SPF级实验动物中心，同时也是西安高新区转化医学公共服务平台。

Shanghai LIDE Biotechnology Co., Ltd. ("Shanghai LIDE"), is committed to translational medicine and precision medical research of cancer, provide drug treatment guides to physicians, and proposing personalized treatment plans.

The company owns AAALAC accredited SPF level animal centers and world-class equipment. Shanghai LIDE has two wholly-owned subsidiaries, "Xi'an LIDE Biotechnology Co., Ltd." and "Shanghai LIWEN Diagnostics" (hereinafter referred to as "Shanghai LIWEN") both with qualification of clinical testing laboratory. Shanghai LIDE was listed on the "New OTC Market" in August 2016 (stock code: 838848),

Shanghai LIWEN is a third-party medical institution for individual diagnosis and precision medicine. It can provides services such as molecular testing, pathology and companion diagnosis. The company owns safety level 2 laboratories and is certified for molecular tests from Shanghai Centre for Clinical Laboratory (SCCL) and for anatomical pathology and molecular pathology tests from College of American Pathology (CAP).

Additionally, Shanghai LIWEN - Promega joint laboratory co-founded by Shanghai LIWEN and Promega, is dedicated to the research, development and application of hotspot tumor markers (MSI, dMMR, etc.), and provides services for the tests of hotspot tumor markers and companion diagnosis in accordance with CAP standards.

As the public service platform for translational medicine of Xi'an Hi-tech industries development zone, Xi'an LIDE also owns a SPF-level laboratorial animal center with the certification of AAALAC.

浙江九洲药业股份有限公司

Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

浙江九洲药业股份有限公司（股票代码：603456）成立于1998年，是一家以特色原料药为主营业务，并为国际大型制药公司提供新药CDMO一站式服务的上市制药企业，是全球卡马西平、奥卡西平、酮洛芬和格列齐特原料药的主要生产商，国际市场占有率均位居全球前列。公司先后获得全国医药行业百强企业、国家原料药出口龙头企业、国家高新技术企业、国家技术创新示范企业等荣誉。

公司产品保持海外市场竞争实力。通过了美国FDA、欧盟EDQM等国际官方认证，目前已形成中枢神经类、非甾体类、抗感染类、降糖类药物以及抗病毒、肿瘤治疗、心血管药物等多种类别药物并举的产品格局，为公司未来发展注入新的活力。

公司拥有较为完善的生产、研发体系，在浙江台州、江苏盐城拥有五大生产基地。公司研发拥有国家认定企业技术中心、国家级博士后科研工作站、省级院士专家工作站、浙江省重点企业研究院等创新平台。在上海、杭州、台州及美国设有研发机构。拥有一支涵盖多面的高层次、专业型、国际化的研发团队。九洲研发在研究开发和创新水平等方面处于行业领先地位，尤其在高端氟化学、不对称手性合成、糖苷及生物酶技术领域拥有核心技术，体现了高水平的技术研发实力。

“九洲，与世界同步”。九洲药业始终秉承“关爱生命，维护健康”的企业使命，在保持公司传统产品稳定增长的同时，大力发展新药CDMO业务，着力推进特色制剂和生物医药的产业布局，将九洲药业打造成为国内一流、国际有影响力的“面向患者的制药公司”，为人类健康事业作出更大贡献。

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, (Stock code 603456), which was established in 1998, is a publicly listed company focusing on the production of characteristic APIs and providing one-stop services of CDMO to international large-scale pharmaceutical companies. Jiuzhou is the main manufacturer and supplier of API Carbamazepine, Oxcarbazepine, Ketoprofen and Gliclazidein globally.

Jiuzhou has successively won various honorary titles, such as “Top 100 Chinese Pharmaceutical Industry ”, “China's Leading Exporter of APIs ”, “National High-tech Enterprise”, “National Technology Innovation Demonstration Enterprises”, etc..

Jiuzhou’s API fills with competitiveness in overseas markets. It has been successfully certified by different Regulatory Authorities such as FDA and EDQM.

Presently, Jiuzhou has formed a variety of active API pipelines comprising Central Nervous System, non-steroidal, anti-infective, hypoglycemic and antiviral, oncological treatment, and cardiovascular drugs, injecting new vitality into the future development of the company.

Jiuzhou has a comparatively complete manufacture and R&D system, and five production sites in Taizhou, Zhejiang and Yancheng, Jiangsu. There are R&D centers in Shanghai, Hangzhou, Taizhou and the United States, with a high-level, professional, and international team. Jiuzhou’s R&D innovation platform was awarded national certified enterprise technology center, national post-doctoral scientific research workstation, provincial academician expert workstation, and Research Institute of key enterprises in Zhejiang. Furthermore, Jiuzhou’s R&D is at the forefront of innovation, especially in the fields of high-end fluorochemicals, asymmetric chiral syntheses, glycosides, and bio-enzymes technologies, demonstrating a high level of technological R&D capabilities.

“Jiuzhou, in sync. with the world". Adhering to the mission of "Care Life, Care Health", Jiuzhou steadily keeps the growth of traditional API, simultaneously, vigorously develops new drug CDMO business and focuses on promoting the industrial layout of characteristic formulation and biomedicine. Jiuzhou is aimed to be a domestic first-class and internationally influential “patient oriented pharmaceutical company", and make greater contributions to human health.

北京春天医药科技发展有限公司

Proswell Medical Co., Ltd.

北京春天医药（Proswell）科技发展有限公司，成立于2004年，致力于推动中国健康事业的发展，创建本土CRO的国际品牌，为药品研发评价提供系列优质服务。

春天医药14年来，本着“专业、高效、坦诚、快乐、承担责任、分享荣誉、双赢互惠、持续发展”的服务理念，为制药企业提供专业服务，为人类健康保驾护航，引领CRO行业健康蓬勃发展。

春天重视研究质量，2010年1月公司质量管理体系通过ISO9001:2008标准的现场核查，并获得由中国质量认证中心（CQC）颁发的国际认可注册证书，成为国内首家获此证书的CRO。2018年1月春天Proswell顺利通过CQC现场审核，并获得最新《质量管理体系认证证书》（颁发日期2018年1月30日/证书编号：00116Q31463R2M/1100）。这标志着春天会为合作伙伴提供更为优质高效的临床研究服务，该体系持续稳健运行，至今已近十余年。

春天医药公司愿景：聚焦创新药CRO全产业链，深耕肿瘤医学、神经医学等优势细分领域，提供可信服的ALCOA+全球CRO领先服务。

Proswell Medical Company, established in 2004, provides a wide range of world-class services for clinical trial and pharmaceutical development for domestic and oversea customers . Proswell takes on the responsibility for creating an international brand by local clinical Contracted Reasearch Organization (CRO) and promoting the development of China CRO Industry. Proswell successfully passed ISO 9001:2008 Quality Management System Certification in January 2010 and became the first local certified CRO in China. This achievement represents Proswell’s sincerity, dedication, professionality and commitment to its partners and customers to provide clinical trial service with supreme-quality and balanced-efficiency!

中国药科大学

China Pharmaceutical University

中国药科大学是一所历史悠久、在药学界享有盛誉的教育部直属“211工程”重点建设的大学，坐落于历史文化名城古都南京。前身为始建于1936年的国立药学专科学校（四年制），是我国历史上第一所由国家创办的高等药学学府。

学校学科涵盖理学、医学、工学、经济学、管理学、文学、法学7个学科门类。药学一级学科为国家重点学科。2015年，学校药理与毒理学、化学以及临床医学三个学科领域的ESI排名进入全球前1%。药理与毒理学学科发文量居国内高校之首。学校现有25个本科专业、5个专科（高职）专业、 药学、中药学2个一级学科博士点、24个二级学科博士点、5个一级学科硕士点、36个二级学科硕士点，5个专业学位授权点；药学、中药学2个博士后流动站。23个学科专业可招收博士后研究人员。

学校是全国医药院校中唯一一所连续三次获得国家级教学成果一等奖殊荣的高校。2014年，学校推荐申报的3项教学成果全部荣获第七届国家级教学成果二等奖，囊括该届国家级药学教育类教学成果奖所有奖项。学校就业率一直位列教育部直属高校及江苏省高校前茅。2014届本科毕业生就业率位列教育部直属高校第一名。

学校推进科研创新，研发普惠良药。建有“天然药物活性组分与药效”国家重点实验室和省部级重点实验室、工程技术中心、创新平台18个。与海外40多个国家和地区的院校及科研机构建有学术联系。“十二五”以来，获国家“重大新药创制”科技重大专项课题26项，经费资助达1.78亿元，获批项目数、经费数均居全国高校之首。获国家科技进步二等奖2项，获国家新药证书2本、新药临床批文6个、授权发明专利410件；发表SCI论文3919篇。

截止2015年底，学校全日制在校生15000余人，其中：研究生3600余人，本专科生近12000人。专任教师910人，其中：中国工程院院士2人、德国科学院院士1人、“国家杰出青年科学基金”获得者5人、“长江学者”6人、“千人计划”入选者2人、“万人计划”入选者3人。学校现有玄武门、江宁2个校区，占地近2100亩。

今天的中国药科大学，正朝着建设国际知名的高水平研究型大学的目标努力迈进。

China Pharmaceutical University (CPU), situated in the historical and cultural city of Nanjing, is one of the “211 Project” key universities affiliated to the Ministry of Education (MOE) of China. It has been known for its long history and high reputation in China’s pharmaceutical field. CPU was founded in 1936 as China’s first independent four-year National College of Pharmacy and the first public institution for higher pharmaceutical education in the country.

CPU provides a wide variety of disciplines in sciences, medicine, engineering, economics, management, arts and law. Its first-level discipline of pharmacy is enlisted as the National Key Discipline. In 2015’s ESI ranking, its pharmacology and toxicology, chemistry as well as clinical medicine entered the world’s Top 1%. Its publications in pharmacology and toxicology ranked top among all universities in China. CPU offers 25 bachelor’s degree programs, 5 associate (polytechnic) programs, 24 research-oriented doctoral degree programs under the two first-level disciplines of pharmacy and traditional Chinese pharmacy, 36 research-oriented master’s degree programs under its 5 first-level disciplines, 23 post-doctoral research programs under its two first-level disciplines of pharmacy and traditional Chinese pharmacy as well as 5 professional degree programs at the master’s level.

CPU is the only one among all medical and pharmaceutical colleges & universities that has won first prizes of the National Outstanding Teaching Achievements for three times consecutively. In 2014, all its three recommended projects for the National Outstanding Teaching Achievement Awards won the second prizes, covering all the awards for pharmaceutical education. The employment rate for its graduates has always been ranking on the top among all universities affiliated to MOE and all the local colleges and universities in Jiangsu Province. In the Year 2014, its undergraduate employment rate ranked No. 1 among all universities directly under MOE.

The University promotes innovation in research and aims to develop effective medicines for public health. It has 18 key laboratories, engineering centers and innovation platforms, including the State Key Laboratory of Natural Medicines. The university has established academic collaboration with universities and institutions in over 40 countries and regions. In China’s National Key High-Tech Innovation Project for the R&D of Novel Drugs, the university has undertaken 26 major projects with a total fund of 178 million RMB, No.1 among all universities in China in terms of either the total number of projects or the total amount of funds. Our researchers won two second prizes of the National Science & Technology Progress Award and obtained 2 new drug certificates, the approval documents for clinical trials of 6 new drugs as well as 410 authorized patents. We published 3919 papers in SCI-indexed journals.

By the end of Year 2015, CPU hosts more than 15,000 full-time students, including around 12,000 undergraduates and over 3,600 postgraduates. It has 910 full-time faculty, including 2 members of the Chinese Academy of Engineering, 1 member of the German Academy of Sciences, 5 winners of research funds for the “National Outstanding Youths”, 6 “Changjiang Scholars”, 2 scholars in China’s “Two Thousand Talents Program" for returned high-level talents from overseas and 3 scholars in China’s “Ten Thousand Talents Program". The University is composed of two campuses, namely the Xuanwumen Campus and the Jiangning Campus, which cover a total area of about 2100 mu (or 140 hectares).

Today, CPU is striving forward to build itself into a world-famous, high-level and research-oriented university.

沈阳药科大学

Shenyang Pharmaceutical University

沈阳药科大学是一所具有光荣革命传统的学校，前身为1931年诞生于江西瑞金的中国工农红军卫生学校，是我国历史最悠久的综合性药科大学。学校总占地面积143.45万平方米，总建筑面积70.4万平方米。

学校目前已发展成为多学科、多层次、多形式教育的高等药学学府，设有药学院、制药工程学院、中药学院、生命科学与生物制药学院、工商管理学院、医疗器械学院、功能食品与葡萄酒学院、社科与文体学院、继续教育学院和亦弘商学院10个学院。在1154名教职工中，专任教师657名，其中教授114名，副教授228名。现有中国工程院院士1人，长江学者特聘教授1人，中组部“千人计划”国家特聘专家1人，国务院药学学科评议组成员1人，新世纪百千万人才工程国家级人选3人，现有在校研究生2419名（博士443、硕士1976）、本科生8522名、成人函授生4985名。

学校始终以医药及相关行业发展需求为导向，围绕学校办学定位、突出药学学科优势、坚持药学教育主线，适度拓展本科专业布局，持续优化本科专业结构，逐步形成了以药为主，跨医、工、理、管、经5个学科门类10个专业类的本科专业结构布局。共设置20个本科专业，其中国家级特色专业5个。学校是国家批准有权授予博士学位、硕士学位和招收港、澳、台地区学员及外国留学生、国内高中保送生的院校。现有博士后流动站2个（药学、中药学），一级学科博士学位授权点2个，二级学科博士学位授权点19个，一级学科硕士授权点7个，二级学科硕士授权点51个，硕士专业学位授权点4个。药剂学科为国家级重点学科，中药分析学为国家中医药管理局“十二五”中医药重点学科，药学和中药学为辽宁省高等学校一流特色学科。“十一五”以来，学校共主持承担国家、省、市等各级各类课题945项，其中国家“863”、“973”、国家重大科技专项、国家科技支撑计划、国家自然科学基金等国家级课题288项，经费到款4.26亿元。与企业签订技术贸易合同、协议1733份，成交额4.49亿元，到款额1.95亿元。

学校积极开展国内外学术交流与合作，与美国、日本、英国、俄罗斯等19个国家和地区的63所高等院校及科研机构建立了合作关系。

面向未来，学校坚持“团结、勤奋、求实、创新”的校训精神，并在“立足药学，突出特色，注重质量，创新发展”的理念指导下，持续提升学校的核心竞争力和国际化办学水平，加快建设成为药学教育领域特色鲜明、国内一流、国际知名的高水平大学。

Shenyang Pharmaceutical University is a school has a glorious revolutionary tradition, the predecessor was born in 1931 in Jiangxi Ruijin Chinese Red Army of Workers and Peasants Health School, is the oldest comprehensive pharmaceutical university in our country. The school covers an area of 1.4345 million square meters, with a total construction area of 704,000 square meters.

The university now has developed into a multi-disciplinary, multi-level, multi-forms of education in higher medicine university. It contains 10 schools,including school of pharmacy, school of pharmaceutical engineering, school of traditional Chinese medicine, school of life science and biological pharmaceutical, school of industrial and commercial management, school of medical apparatus and instruments, school of functional food and wine, school of social sciences and literary style, school of continuing education, and also Hong Business school. In 1154 faculty members, there are 657 full-time teachers including 114 professors, 228 associate professors.Existing Chinese Academy of Engineering 1, the Yangtze River scholar Professor 1, the Central Organization Department, "thousands of plans," National Distinguished experts, the State Council pharmacy disciplines 1, New Century Talents Project national candidates 3, existing school graduate 2419 (443 Doctoral, Master 1976), undergraduates 8522, adult students of correspondence 4985.

School has always been guided by the demands of pharmaceutical and related industries development, around the school running orientation, prominent medicine discipline advantage, adhere to the pharmacy education the main line, moderately expand the undergraduate professional layout, continuous optimization of the structure of undergraduate majors, gradually formed is given priority to with medicine, across the medical, engineering, science, management, the five disciplines ten undergraduate professional class structure layout. A total set up 20 undergraduate programs, including five national professional characteristics. School is the national approval shall have the right to grant doctorate, master's degree and recruit students in Hong Kong, Macao, and Taiwan and foreign students, high school unripe domestic colleges and universities. Existing post-doctoral flow station 2 (Pharmacy and Traditional Chinese medicine), first level discipline doctorate authorization 2, the second level discipline doctorate authorization 19, level discipline master's degree authorization point 7, secondary discipline master's degree authorization points 51, authorized professional master degree 4. Pharmacy disciplines as national key disciplines, medicine analytics for the State Administration of Traditional "second five" key disciplines in medicine, pharmacy and Traditional Chinese medicine Liaoning Province Academic Discipline class characteristics. "Eleventh Five-Year", the school presided over the commitment to national, provincial and municipal levels of 945 and other topics, including the national "863", "973", a major national scientific and technological projects, the State Science and Technology Support Program, the National Natural Science Foundation 288 national issues, funding models to 426 million yuan. And technology trade enterprises signed contracts, agreements parts 1733, and turnover of 449 million yuan, to the amount of 195 million yuan.

The University actively carries out academic exchanges and cooperation with 63 universities and research institutions. The areas containthe United States, Japan, Britain, Russia and other 19 countries.

For the future, the school adhere to the "unity, diligence, truth-seeking, innovative" spirit of school motto, and "based on medicine, prominent characteristics, pay attention to quality, innovation and development", under the guidance of the concept of core competitiveness and continued ascension school education internationalization level, speed up the construction become a pharmaceutical education field characteristic, high level of domestic first-class, internationally renowned university.

北京大学药学院

Peking University School of Pharmaceutical Sciences

北京大学药学院始建于1941年，是国家重点药学院之一，在学科建设、师资培养、教学、科研等方面做出了重要贡献，为我国培养了大量药学高级人才。

药学院由六系（化学生物学系，药物化学系，天然药物学系，药剂学系，分子与细胞药理学系，药事管理与临床药学系）、一室（天然药物及仿生药物国家重点实验室）、一所（应用药物研究所）、一中心（药学实验教学中心）组成。北京大学药学学科于2007年被认定为国家一级重点学科，在教育部2012年学科评估中排名第一。

学院的科学研究主要集中于心脑血管疾病、肿瘤、老年病等重大疾病，以天然药物及仿生药物国家重点实验室为核心，药物化学、生药学、药理学等重点学科为依托，在核酸药物、糖类药物、中药及天然药物等领域积累了较雄厚的基础，取得了国内领先、国际上有影响的成绩，有些研究成果已达到国际先进水平。学院承担国家自然科学基金、“973”、“863”、国家科技支撑计划、国家科技重大专项等国家级及省部级重要科研项目，参与北京大学“211”及“985”工程建设。学院获得国家自然科学二等奖4项，省部级奖励45项；近五年获得发明专利135项，发表研究论文1824篇（其中SCI收录1236篇）。2009年以来，药学院积极面向国家重大需求，承担了国家“重大新药创制”科技重大专项课题“北京大学综合性创新药物研究开发技术大平台的建设”，构建了完整的创新药物发现与研发体系，新药研发自主创新能力明显加强，目前有1个抗肿瘤一类新药被SFDA批准进入II期临床研究，另外2个一类新药进入临床研究。

药学院与国内外知名大学、科研机构、制药企业有着广泛的合作与交流，促进了国际学术影响力与科研水平的稳步提升。

北京大学药学院今后几年的奋斗目标是：逐步发展为一所学科齐全、具有国际一流水平的药学院。

Peking University School of Pharmaceutical Sciences (SPS), established in 1941, is a national key pharmaceutical school. In the past decades, SPS has made great achievements in discipline construction, faculty training, teaching, and scientific research, and has nurtured a large number of high-level pharmaceutical scientists and professionals.

SPS is composed of six academic departments (Chemical Biology, Medicinal Chemistry, Natural Medicine, Pharmaceutics, Molecular and Cellular Pharmacology, Pharmacy Administration and Clinical Pharmacy), one key laboratory (State Key Laboratory of Natural and Biomimetic Drugs), one institute (Institute of Applied Pharmaceutical Research), and one center (Pharmaceutical Teaching Laboratory Center). The pharmaceutical science discipline of Peking University became an accredited national key discipline in 2007, and was ranked the first in discipline evaluation by Chinese Ministry of Education in 2012.

The scientific research of SPS is mainly focused on major diseases including cardiovascular and cerebrovascular diseases, tumor, and senile diseases. With the State Key Laboratory of Natural and Biomimetic Drugs as the core, and with the support from key disciplines (Medicinal Chemistry, Pharmacognosy, and Pharmacology), SPS has built up a solid foundation in the scientific research of nucleic acid drugs, saccharide drugs, and natural medicines (including traditional Chinese medicines). Some research achievements have reached international top level. SPS undertakes national key research programs, including projects from National Natural Science Foundation of China (NSFC), “973” and “863” projects, and National Key Technologies R&D Programs, as well as provincial and ministerial research projects. SPS also participates in the “211” and “985” project of Peking University. SPS has won 4 National Natural Science Award (class two), and 45 awards at provincial and ministerial levels. In the past five years, SPS has obtained 135 issued patents, and has published 1824 research papers (1236 cited by SCI). To meet the primary demands of the nation, SPS has been establishing the Peking University Comprehensive Center for Drug Discovery and Development (CCDDD) since 2009, which is supported by the Primary Drug Innovation Program of National Science and Technology Mega Projects. Thus far, SPS has built up an integrated research and technology system for the discovery and development of innovative drugs. One class I anti-tumor innovative drug (IND) has entered phase II clinical trial, and two other class I INDs have been approved for clinical trial by SFDA.

SPS has extensive cooperations and communications with top universities, research institutes, and pharmaceutical enterprises at home and abroad. The international impact and academic strength of the School has been increasing in the past years.

In the coming years, Peking University School of Pharmaceutical Sciences aims to develop into a comprehensive and international top-level pharmaceutical school.

复旦大学药学院

School of Pharmacy Fudan University

复旦大学药学院创建于1936 年，是我国最具影响力的五所高等药学院校之一。现有教职员工131人，其中：正高职称37人，副高职称45人；博士生导师37名，硕士生导师67名。拥有国家“千人计划”特聘教授3名、国家“青年千人计划”人才1名、入选上海市“千人计划”特聘教授2名、973项目首席科学家2名、国家“杰出青年基金获得者”3名和“优秀青年基金获得者”1名、教育部“长江学者”特聘教授1名、教育部新世纪优秀人才10名、上海市领军人才1名、上海市优秀学术和技术带头人6名等。

药学院下设药物化学、药剂学、药理学和临床药学四大学科群，按药学一级学科专业招收本科生，分为药学和临床药学方向。2012年以来，已培养本科生639名、硕士生314余名、博士生84余名，受到了社会和用人单位普遍欢迎。在列年培养的学生中，有6人成为中国科学院和中国工程院院士、1人成为美国科学院院士。目前在读研究生405名、本科生（含留学生）384余名。获得国家精品课程1项（药理学）、全国百篇优秀博士学位论文2篇（药剂学）。

学院以药学基础及应用基础研究为主，兼顾新药开发，侧重于抗感染药物、抗肿瘤药物、心脑血管药物的新理论、新技术、新方法、新产品等研究。拥有智能化递药教育部和全军重点实验室、上海药物创制产业化开发中心、上海市小分子药物重点实验室、国家中医药管理局三级实验室（中药制剂、中药生药分析）等。设有仪器分析测试、计算机辅助药物设计、动物实验、药物筛选与药效评价、分子影像与示踪、药物制剂中试等多个技术支撑平台。

2012年以来，承担国家重大科学研究计划（973）、国家重大创制新药技术专项、863计划项目、国家自然科学基金等国家及省部级项目162项，到位科研经费约达1.5亿元；授权专利113项；年均发表SCI论文150篇以上；获得国家科技进步奖二等奖2项（第二和第三完成人）、教育部自然科学奖二等奖（第二完成人）和上海市科技进步二等奖（第五完成人）各1项等。

Founded in 1936, School of Pharmacy Fudan University (SPFDU) has a long history and now is one of five most influential pharmacy schools in China.The SPFDU has 131 faculties, with 37 professors and 45 associate professors,which include 37 doctoral supervisors and 67 master supervisors. There are 3“Thousand Person Plan” distinguished professors from the national project and 1 “Thousand Youth Person Plan” professor, 2 elected “Thousand Person Plan” distinguished professors from Shanghai project, 2 chief scientists of national key scientific research project (973), 1 Yangtze Distinguished Professor recognized by the Ministry of Education, 3 National Outstanding Youth Foundation Winners, 1 National Excellent Youth Foundation Winner and other 10 cross-century talents recognized by the Ministry of Education, 1 leading figure in Shanghai,and 6 outstanding academic leaders in Shanghai.

SPFDU is organized into four main academic departments: PharmaceuticalChemistry, pharmaceutics, Pharmacology and Clinical Pharmacy.SPFDU has undergraduates majored in pharmacy and clinical pharmacy.Since 2012, about639 undergraduate students, 314 masters and 84 PhD have graduated from SPFDU.6 of the undergraduate students have been awarded as national Academicians. Currently students of SPFDU consist of almost 405 graduate students and over 384 undergraduates including foreign students. Besides,Pharmacology was awarded as national excellent course and 2 theses about pharmaceutics were selected as the national excellent Ph.D. Thesis.

Based on pharmaceutical basic research and applied basic research, and taking account into the development of new medicine, SPFDU focuses on research about the new theories new technologies, new methods and new products of anti-infective drugs, antineoplastic drugs and cardiovascular drugs. The School has Smart Drug Delivery laboratory, Key Laboratory of Ministry, Moleculesand Three-level laboratories of Traditional Chinese Medicine (TCM) and the TCM crude drug analysis of the State Traditional Chinese Medicine Administration. It also includes several supporting technical platforms: Specialized Integrated Platform of National New Drugs Development, Screening and Efficacy Evaluation Platform for Antivirals, Technology Platform for the development of New Formulation and New Drug Delivery System, GLP Laboratory Animal Center, Instrument Test Center.

Since 2012, SPFDU has accomplished national key scientific researches (973), major projects of national development of new drugs,863 and national and provincial projects of the national natural science foundation162 terms. Also, SPFDU achieved funding about 1.5 billion, 113 patents, over 150 publications on SCI annually and 2 second national prize of science and technology progress, 2 first prize of natural science from the Ministry of Education, 1first prize of science and technology progress from the Ministry of Education, 1 second prize of natural science from the Ministry of Education and 1 second prize of science and technology progress from shanghai government.

中国人民解放军军事医学科学院毒物药物研究所

Institute of Pharmacology and Toxicology Academy of Military Medical Sciences

毒物药物研究所是1958年5月由军事医学科学院毒物、化学、药理三系合并而成。成立以来，研究所牢记使命，始终围绕国家和军队重大需求，走过了辉煌的历程。

历经几代科学家50多年的奋斗，针对外军装备的6类14种制式化学战剂，我所建立了完备的防化医学体系，带领我国防化医学实现了从无到有，从弱到强的历史性转变。目前全军装备的14种防化药品全部由我所研制，特别是抗神经性毒剂特效药是我国药物发展史上结构全新药物研发的典范。以抗神经性毒剂防治药物研究作为重要组成部分的“战时特种武器防害医学防护”获得了医药卫生领域迄今为止唯一的国家科技进步特等奖。

21世纪以来，我国生物安全形势面临严峻考验。2005年，我国各地禽流感频发，有演变为当年SARS危机可能。时任国务院总理温家宝亲临我所召开应急防控会议，要求尽快研制抗流感特效药。我所临危受命，在短时间内突破国外技术壁垒，创新建立了磷酸奥司他韦生产工艺按时完成国家战储任务。2011年，全球最大磷酸奥司他韦原料药生产线通过国家验收，标志我国流感防控药物生产和储备不再依赖国外。

我所建立以来，共获得国家和军队新药证书73个，其中国家一类新药证书7个，形成了以抗毒、抗神经精神疾病、抗病毒及超级菌研究为优势特色的创新药物研发体系。研究所目前拥有国家重点实验室、国家工程技术研究中心、国家战略药品研发基地、国家药品安全评价和食品安全风险评估等五个国家级创新药物研发平台，是我国创新药物研究的一支重要力量。

Institute of Pharmacology and Toxicology, Academic Military Medical Sciences established in 1958, is a comprehensive institute composed of a good variety of disciplines, including pharmaceutical chemistry, pharmaceutical analysis, pharmaceutics, drug metabolism, pharmacology, hygienic toxicology, experimental pathology and biochemistry.

Orienting to the studies of novel medications, BIPT has advanced instruments and facilities as well as the advanced means and techniques in all the fields of research and development (R & D) of new drugs, and it has been able to complete independently the whole process of preclinical researches concerning the development of a new drug. It usually involves the drug design, synthesis, pharmacological evaluation, safety evaluation and supply of preparations for clinical trials. Several new drugs involved in antihypertensive, analgesics, diabetes mellitus, antiviral, has been developed successfully.

中国医学科学院北京协和医学院医药生物技术研究所

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College

中国医学科学院北京协和医学院医药生物技术研究所（原名抗生素研究所）成立于1958 年，是我国抗感染药物的主要研发单位，也是我国第一支青霉素的诞生地，为我国抗生素的研发、人才培养及工业化生产起到了奠基的作用，在我国重大疾病、尤其是传染性疾病的防控中作出了突出贡献。随着生物学理论与技术进步和社会的发展，药物研究的范围扩展至肿瘤、代谢、心血管、免疫调节等领域，1986 年研究所更名为医药生物技术研究所。

研究所现有在职人员约260人，包括中国工程院院士，国家（部）级突出贡献专家，长江学者特聘教授，国家自然基金委创新群体、杰出青年和优秀青年基金获得者，万人计划领军人才，科技部重点领域创新团队与中青年领军人才，协和学者，协和讲座教授等。现有博士生导师26人、硕士生导师40人，在读博士、硕士学位研究生150余人。

“十三五”以来，研究所在抗生素和抗感染药物研发传统优势的基础上，以应对病原耐药和重大突发传染性疾病为重点，加强新机制新结构抗感染创新药物研究、以合成生物学和化学生物学及细菌基因组学为代表的现代生物技术研究、以及关键技术和资源支撑平台建设，努力打造我国微生物和抗感染药物研究和技术转化、研究生教学和人才培养的核心基地。

The Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, was founded in 1958 as the Institute of Antibiotics, a national key institute for developing drugs to combat infectious diseases in China. As the place of giving birth to the first ampule of penicillin in China, the institute laid a solid foundation for discovery and development of antibiotics, nurturing professional talents and industrial production of antibiotics. The institute has also made great contribution to the prevention of cancer, metabolic disease, cardio-vascular system disease and immune system disease, etc. In 1986, the institute was changed name as Institute of Medicinal Biotechnology.

Today, there are about 260 employees in the institute including Academicians of the Chinese Academy of Engineering, National Outstanding Scientists, Cheung-Kong Scholars, Creative Research Groups of the National Natural Science Foundation of China (NSFC), Distinguished Young Scholars and Excellent Young Scientists of NSFC, Leading Scientists of Ten thousand talent program, Key innovation team of the Ministry of Science and Technology, Scholars of Peking Union Medical College, etc. There are 26 doctoral tutors and 40 master tutors, and more than 150 doctoral degree and master degree candidates.

Now, based on the traditional advantage areas of research and development of antibiotics and anti-infectious drugs, the institute will be focusing on the strategy study of deal with pathogen resistance and major infectious diseases, strengthened to develop new anti-infectious drugs with new mechanisms and new structures. The research of modern frontier technology, such as synthetic biology, chemical biology and bacteria genomics, will be strengthened at the same time. It is our goal that the institute will be constructed as the core base of microbiological and anti-infective drug research.

首都医科大学附属北京天坛医院

Beijing Tiantan Hospital, Capital Medical University

首都医科大学附属北京天坛医院始建于1956年，是一所以神经外科为先导，神经科学为特色，集医、教、研、防为一体的大型现代化三级甲等综合教学性医院。经过半个多世纪的艰苦创业和奋发努力，医院实现了跨越式发展，医疗技术水平以及医院的知名度跻身于国内一流医院的行列。

目前医院现有床位1150张，设有30余个临床科室和11个医技科室，年门诊量达百万以上、年住院病人近3万人次，拥有各类先进的医疗设备。

Founded in 1956, Beijing Tiantan Hospital affiliated to the capital medical university, a quaternity consisting of medical treatment, scientific research, medical education and disease especially associated with neurosurgery serving as a precursor. Through hard work and strenuous efforts for more than half a century, the hospital has already achieved leap-and-bound development and ascended into the top-level hospitals in China in terms of medical technology and hospital fame.There are 1150 beds over 30 clinical departments and 11 adjunct departments at present in hospital equipped with various advanced medical equipments, and furthermore, patient visits steadily increased tallying up to over 1,000,000 outpatient visits per year and 30,000 inpatient admissions per year.

北京市纳微化结构药物工程技术研究中心

Beijing Nanostructured Drug Engineering & Technology Center

北京市纳微化结构药物工程技术研究中心依托北京化工大学有机无机复合材料国家重点实验室和北京万生药业有限公司，利用具有自主知识产权的超重力技术和理论，完成难溶性药物及靶向药物的纳微化制备，进而形成新药研发产业化级技术，实现纳米药物产业化规模，增强生物医药领域创新能力，提升新药开发水平和制药行业的产业技术进步。

中心通过药物纳微化关键技术的研究，突破了纳米药物产业化技术的瓶颈，创制了高性能低成本的纳微结构药物颗粒的超重力制备新方法，并实现了工业示范生产，与华药集团倍达制药有限公司、浙江新和成股份有限公司合作，分别开发建成了40吨/年的纳米头孢呋辛酯和5000吨/年纳微结构维生素A颗粒超重力法制备工业生产线，成为国际上首次实现超重力过程强化技术在生物药物材料领域应用的工业化事例，产生了良好的经济和社会效益。

中心自成立以来，以市场需求为导向，已取得突破性进展，研制的纳米降血脂药物非诺贝特完成全部临床前研究工作，2015年获得SFDA临床批件（2015L06032）。目前中心正与多个世界著名前十强制药大公司合作，进行药物颗粒纳米化技术的研究和开发。纳微结构药物颗粒超重力法制备新工艺获得2008年教育部技术发明一等奖。

Beijing Nanostructured Drug Engineering & Technology Center was established backed by State Key Laboratory of organic-inorganic composites of BUCT and Beijing Wansheng Pharmaceutical Co., Ltd. The center aims to complete the nanofabrication of poorly water-soluble drugs and targeted drugs by utilizing the independent intellectual property rights of HIGEE technology and theory, in order to format the industrialized technology of new drugs' research, to achieve the scale of industrialization of nano-drugs, to enhance the ability of innovation in the field of biomedical drug, to promote the level of new drug development and the progress of industrial technology in pharmaceutical industry.

The center has conquered the bottleneck of nano-drug industrialization technology and created a new method of HIGEE for high-performance and low-cost nanostructured drug particles and successfully brought industrial demonstration production into reality in the process of solving crucial technology of nano-drug fabrication. Through the cooperation with North China Pharmaceutical Group Beta Pharmaceutical Co., Ltd. and Zhejiang NHU Company Ltd., a 40 tons/year of nano-CEFUROXIME AXETIL production line and a 5000 tons/year of nanostructured vitamins A particles production line were developed by HIGEE technology, respectively. The production lines have become the first industrialized case in the world to be applied in pharmaceutical materials by using the technology of HIGEE, additionally good economic and social benefits has emerged.

The center has made some breakthroughs by following the market demands since its establishment. A lipid-lowering drug, Fenofibrate Nanotablets, all it's preclinical research has been completed and SFDA clinical approval (No.2015L06032) was obtained in 2015. The center is currently working in conjunction with a number of the world's top-10 pharmaceutical companies in research and development of drug nanoparticle. The New HIGEE Technology for Nanostructured Drug won the first prize of the Technological Invention Award of the Ministry of Education in 2008.

北京协和医院

Peking Union Medical College Hospital

北京协和医院是集医疗、教学、科研于一体的大型三级甲等综合医院，是国家卫生计生委指定的全国疑难重症诊治指导中心，也是最早承担高干保健和外宾医疗任务的医院之一，以学科齐全、技术力量雄厚、特色专科突出、多学科综合优势强大享誉海内外。在2009-2016年度复旦大学医院管理研究所公布的“中国最佳医院排行榜”中连续八年名列榜首。

北京协和医院临床药理研究中心（简称“中心”）成立于1995年，经国家食品药品监督管理局（SFDA）批准，目前包括I期临床试验研究室及36个临床专业组，专业组数量居全国第一。多年来，中心一直负责全院药物及医疗器械临床试验的组织、管理、协调、质量监督等工作，还组织了多次多种形式的GCP培训。有国家级专家数名直接参与国家GCP讲学、全国新药及临床试验机构评审。此外，“中心”拥有国内最大规模、完成临床研究项目最多的I期临床试验研究室。

医院另设药物临床试验伦理委员会，组建于1996年，负责审核I - IV期药物及医疗器械临床试验，是为药物临床试验专设的独立工作机构。伦理委员会一贯秉承严格审查、独立判断的准则，在业内享有盛誉。

自上个世纪以来，中心一直承担“1035项目，国家科技支撑计划”、“十一五”、“十二五”等科技重大专项项目，多个专业组曾多次通过国内外（包括FDA、EMEA等）权威机构的核查。无论是在药物临床试验数量、质量还是科学研究水平方面，中心在国内外均具有很高的知名度。

Peking Union Medical College Hospital (PUMCH) is a Class A tertiary comprehensive hospital committed to delivering state-of-the-art clinical care, innovative scientific research and rigorous medical education. It is designated by the National Health and Family Planning Commission as one of the national referral centers offering diagnostic and therapeutic care of complex and rare disorders, as well as one of the earliest Chinese hospitals offering medical care to senior leaders and foreign patients. PUMCH enjoys high reputation for its full range of disciplines, cutting-edge technologies and outstanding specialties. From 2009 to 2015, PUMCH has consecutively topped the “Best Hospital Ranking in China”, which was published by the Hospital Management Institute, Fudan University.

Clinical Pharmacology Research Center (CPRC) was founded in 1995. Approved by SFDA, CPRC has one phase I unit and 36 specialized groups which has the largest number of specialized groups in China by now. Clinical trials of new drug or device conducted in PUMCH are organized, managed, coordinated and controlled by CPRC. All kinds of GCP trainings are also organized by CPRC. There are several national-level experts in CPRC that take part in the national GCP training, new drug application review and clinical trial institution inspection. Moreover, In the Phase I Unit, which is in the leading domestic level and international famous, the study team is well trained and experienced.

The independent ethics committee of in drug clinical trials in PUMCH (PUMCH-IEC), established in 1996, applies research ethics from stage I to IV including drug and medical instrument, with strict review and independent judgment. These excellent credits helped the unit build a confident interaction with sponsors and patients.

256 Standard Operation Procedures (SOPs) are running in CPRC to secure that high quantity trials conducted here with high quality. Several projects of the Major National Science and Technology Specific Project of “10th, 11th and 12th five-year plan” and projects of the National Science and Technology Support Program were undertaken. Many specialized groups were inspected by regulatory authority and/or audited by sponsor favourably. CPRC of PUMCH is becoming one of the best in China.

中国药促会大事记（2017年11月–2018年9月）

2017年

11月4日 由中国药促会和贝达药业股份有限公司联合主办的“凯美纳上市6周年学术峰会”在广州隆重举行。

11月22日 受人社部委托，中国药促会开展医保动态调整机制研究，并在北京召开“建立我国基本医保药品目录动态调整机制研讨会”。

11月28日 中国药促会代表团参加了由国家药品监督管理局国际交流中心、日本大阪府主办，中国药促会、大阪医药品协会协办的“第九届中日制药交流会”。双方就中日药品监管体系动态改革现状进行交流讨论，并达成诸多共识。

12月4日 中国药促会执行会长宋瑞霖会见了安全网上药店联盟全球董事会成员代表团，双方就互联网药品销售安全及监管、打击线上非法制售药品等行为进行了深入交流和讨论。

12月6日 中国药促会作为支持单位率团参加“2017亚太生技投资论坛”。执行会长宋瑞霖围绕《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》作主旨报告。

12月7日 由中国药促会、台湾-生技医疗产业策进会、香港生物医药创新协会、澳门国际中药质量研究会和香港交易及结算所共同主办的“第一届中华生物医药创新与投资大会”在台北举行。中国药促会代表团参加第一届“中华医药创新与投资大会”及台湾医疗科技展，大会开幕式上，两岸暨港澳生物医药创新合作平台正式成立。

12月18日 中国药促会向人社部提交在我国建立医保药品目录动态调整机制的建议。

12月25日 中国药促会与国家药品监督管理局南方医药经济研究所在北京签订了战略合作协议。此次签订战略合作协议，将有利于双方互取所长、形成资源整合优势，通过开展以医药信息大数据为支撑的深度医药政策研究，为药品监管改革建言献策。

2018年

1月5日 中国药促会在北京召开了“2018年会长会议扩大会议”。会议总结了十届会员大会第四次会议以来的主要工作、审议通过了2018年重点工作安排，与会代表围绕医保药品目录动态调整机制、ICH的相关工作等热门问题展开激烈讨论。

1月5日 经2018年会长会议扩大会议审议通过，中国医学科学院北京协和医院、上海安翰医疗技术有限公司、中天（上海）生物科技有限公司正式加入中国药促会。

1月10日 中国药促会执行会长宋瑞霖出席在美国旧金山举行的第36届J.P.摩根健康产业大会，并在亚洲论坛举行的午餐会上应邀发表了题为《2017中国药品监管重大变革》的演讲。

1月20日 中国药促会在《Nature》发表的展示中国医药创新重大成果系列文章获评“2017年度中国十大医学科技新闻”。

1月30日 中国药促会执行会长宋瑞霖、投资专委会候任主委元明资本创始合伙人田源在中国药促会会见了香港交易所行政总裁李小加一行，双方就港交所即将设立的创新板和双方如何在医药创新资本市场展开全面合作进行了深入讨论，并达成诸多共识。

3月7日 中国药促会执行会长宋瑞霖会见了香港招商局集团总经理助理、招商局海通贸易公司董事长李亚东和招商局集团健康产业事业部部长余世新一行，双方就如何在医药创新及资本市场开展合作进行了深入探讨，并达成诸多共识。

3月17日 由中国药促会主办的“ICH药物警戒相关二级指导原则研讨会”在北京召开。会议围绕ICH E2A、M1、E2B的概念与应用角度，展示了我国实施ICH相关二级指导原则的监管要求、应用策略与企业操作实践。国家药品监督管理局ICH工作办公室主任周思源、中国药促会执行会长宋瑞霖和药品审评中心、药品评价中心、信息中心、中国药学会、中国药促会等有关部门领导、工作人员以及全国各地从事药物警戒和创新药物研发相关工作的100多家企业的300余名代表参加会议。

3月17日 中国药促会创新研发服务专业委员会成立大会在北京召开。会议选举缔脉生物医药科技（上海）有限公司董事长兼CEO谭凌实博士为专委会第一届主任委员并研究部署了专委会的重点工作。

3月21日 中国药促会执行会长宋瑞霖率团到访香港招商局集团总部与招商局集团健康产业事业部签订了合作备忘录。双方就中国医药产业现状及招商局集团布局大健康板块等内容进行了深入的探讨。

3月22日 中国药促会组团赴港参加由香港交易所主办的“2018香港生物科技峰会”。执行会长宋瑞霖结合《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》作主旨报告，并应邀组织“内地生物医药创新进展及发展趋势”小组讨论。

3月22日 中国药促会与香港交易所在“2018香港生物科技峰会”上签订了合作备忘录。双方确认建立更加紧密的合作关系，建立高级行政人员之间定期会面或其他沟通形式的机制；设立研究课题，合办研讨会及专业行业培训；双方在进一步完善生物科技企业香港上市规则和相关管理办法方面持续交流意见；双方特别确认，将在双方能力范围内，支持、鼓励、协助生物科技企业到香港上市。

4月4日 中国药促会“关于药品管理法知识产权保护相关条款的研究”结题会在北京召开。

4月9日 由中国药促会、荷兰王国驻华大使馆、中国医药保健品进出口商会、中国医疗器械行业协会、北京生物技术和新医药产业促进中心共同主办的“荷兰生命科学和健康领域商务路演”在北京成功举办。来自中国药促会会员单位及荷兰医药界的近百位专家学者、企业高管参加了本次活动。本次活动促进了中荷两国在生命科学、医疗卫生及健康领域的交流与合作。

4月10日-12日 应 JPMA 邀请，中国药促会执行会长宋瑞霖率团出席在日本东京召开的第七届亚洲制药组织合作会议（APAC）。期间，代表团还访问日本制药工业协会（JPMA），与 JPMA 知识产权委员会就日本药品知识产权保护制度和医药监管政策等开展调研。

4月13日 由中国药促会、消除癌症计划（ECI）与美国癌症研究基金会（NFCR）主办的“中国脑癌攻关圆桌会工作组会议”在北京天坛医院新院召开。全球医药、科学届的领军人物及专注医药领域投资的合伙人将携手组建包括基础研究、临床试验、标本库与大数据处理、投资开发等脑瘤攻关工作组。中国药促会与美国癌症研究基金会将共同在首都医科大学附属北京天坛医院建立脑瘤临床药物研发平台。

4月23日 四川九章生物科技有限公司、博雅生物制药集团股份有限公司、中航信托股份有限公司、宝石花医疗健康投资控股集团有限公司、方圆基金管理（香港）有限公司、苏州工业园区元禾原点创业投资管理有限公司、礼来投资咨询（上海）有限公司、北京枫海资本管理中心（有限合伙）、鼎晖投资、宁波弘晖股权投资合伙企业（有限合伙）、凯莱英医药集团（天津）股份有限公司、上海立迪生物技术股份有限公司和浙江九洲药业股份有限公司正式加入中国药促会。

5月7日 上海复宏汉霖生物技术股份有限公司、上海君实生物医药科技股份有限公司、上海泽生科技开发股份有限公司、交银国际控股有限公司、招商局海通贸易有限公司、北京大数长胜资产管理有限公司、浩悦资本有限公司和珠海夏尔巴股权投资管理有限公司正式加入中国药促会。

5月18日 中国药促会医药创新投资专业委员会换届大会暨第二届第一次工作会议在北京顺利召开。会议总结了第一届专委会的工作成果并研究探讨了第二届重点工作安排；选举产生了第二届投资专委会委员、副主任委员和主任委员。投资专委会第二届主任委员田源博士、副主任委员、委员及业界相关人士共 90 余人出席了会议。

5月18日 中国药促会医药创新投资专业委员会创办的首届“中国生物医药创新投资人论坛”在北京胜利召开。投资专委会第二届主任委员田源博士、副主任委员和香港生物医药创新协会、香港交易所以及礼来亚洲基金、平安创投等 20 多家知名机构以及 130 多位来自医药创新企业及相关领域专业投资人参加了会议。

5月23日 中国药促会药物临床研究专委会第二届第二次工作会议在杭州召开。会议研究部署了临床专委会即将开展的重点工作。会议还增补了副主任委员 3 人、委员 5 人。

5月24日 由中国药促会、中国心血管健康联盟、中国抗血栓药物治疗联盟、杭州市投资促进局和杭州经济技术开发区管委会共同主办的第三届“中国临床研究质量管理（GCP）暨 ICH 大会”在浙江省杭州市召开。大会围绕我国药品监管改革和实施 ICH 相关指南对临床试验管理的新要求，以及新药研发企业与临床研究机构面临的热点与难点问题展开深入讨论。来自医学、临床研究机构及药物研究领域的众多专家，以及国内医药企业及临床研究机构相关工作人员共计 300 余人参加会议。

6月8日、15日 中国药促会在北京召开 2018 年度会员单位联络秘书工作会议。

6月12日 香港交易及结算所有限公司全资附属公司香港联合交易所有限公司宣布，聘任中国药促会执行会长宋瑞霖和中国药促会医药创新投资专业委员会主任委员田源为联交所生物科技咨询小组成员。

6月26日 中国药促会“我国创新药医保准入路径研究”结题会在北京召开。

7月3日 中国药促会“基层医疗机构慢性病治疗药物管理制度研究”结题会在北京召开。

7月6日 由中国药促会与苏州工业园区管委会主办的“中美肿瘤专家圆桌会议”在苏州举行。主办方代表、美国 FDA 肿瘤专家代表团及国内创新企业的领军人物共 30 多位代表参加会议。与会代表围绕国际肿瘤药研发趋势、新药审批及国内企业最新研发进展等相关议题展开讨论。

7月20日 由中国药促会、中国药师协会、中国医院协会和北京大学人民医院共同主办的以“中国医院改革和医院药学政策”为主题的第九届“中国医院药学政策论坛”在北京顺利召开。国家卫健委医政医管局、部分省市医保基金管理处 / 医保结算中心、部分省市卫计委药政处 / 医政处等单位相关领导及药学相关领域的代表共计 400 余人参加会议。

7月24日 上海仁会生物制药有限公司、广东天普生化医药股份有限公司、厦门艾德生物医药科技股份有限公司、东曜药业有限公司、杭州阿诺生物医药科技有限公司、长风药业股份有限公司、合肥天麦生物科技发展有限公司、博裕投资顾问有限公司和上海泰甫创业投资管理有限公司正式加入中国药促会。

8月21日 中国药促会“新形势下我国药品医保目录动态调整机制研究”课题开题会在北京召开。

9月7日-8日 由中国药学会、中国药促会和烟台市政府共同主办的以“创新、合作、投资、共赢”为主题的 2018 医药创新与发展国际会议在烟台隆重召开。共有约 800 名来自国内外政府机构、科研院所、有关企业的代表和专家学者出席会议。

9月17日 中国药促会第十届会员大会第五次会议在江苏省苏州市召开。大会听取并审议了年度工作报告、会费收支情况报告、发展会员单位的议案、医药企业伦理准则、成立换届选举筹备工作组的议案，并以无记名投票的方式表决通过了《关于追认会费标准的议案》。会议还审议通过了天境生物科技（上海）有限公司、北京春天医药科技发展有限公司、国泰君安证券股份有限公司和国寿股权投资有限公司共 4 家单位的入会申请。中国药促会 124 家会员单位 250 多位代表参加了会议。

9月18日-20日 由中国药促会联合中国医疗器械行业协会、中国医院协会、香港交易所共同主办的第三届“中国医药创新与投资大会”在苏州工业园区召开。大会设置了包括临床数据首发、上市 / 非上市公司路演、医疗器械项目路演、国际路演、人工智能（AI）路演、罕见病路演、投资人经验分享论坛和跨境并购论坛及两场闭门会（香港交易所与创新企业闭门座谈会和国际顶级科学家座谈会）在内逾 21 场特色活动。

2018“独墅湖杯”医药创新品牌评选系列活动

4月3日 召开第一次工作会议，成立了项目推荐与评审专家委员会，初步确定了评选活动管理办法、评选标准等。

8月10日 复审会议当场决出各项目提名奖入围名单，并对外公示。

9月17日 终审会议采取无记名投票方式，评选结果现场封存。

9月17日 颁奖典礼在苏州文化艺术中心隆重举行。知名专家、学者、企业家等近 700 位嘉宾出席了典礼。

Remarkable Events of PhIRDA (November, 2017 - September, 2018)

2017

November 4 — PhIRDA and Betta Pharmaceuticals Co., Ltd. co-hosted the 6th Debut Anniversary Academic Summit of Conmana in Guangzhou.

November 22 — Commissioned by the Ministry of Human Resources and Social Security of the People's Republic of China (MOHRSS), PhIRDA conducted the research on dynamic adjustment mechanism of medical insurance and hosted seminar on how to establish the dynamic adjustment mechanism for NRDL in Beijing.

November 28 — PhIRDA delegation participated in the 9th Sino-Japan Pharmaceutical Exchanges Conference, which was co-hosted by CCFDIE and Osaka Prefecture of Japan and co-organized by PhIRDA and Osaka Pharmaceutical Industries Association. Participants had a fruitful discussion on the dynamic reforms drug regulatory system in China and Japan and reached a lot of consensus.

December 4 — PhIRDA Executive President Song Ruilin met with the ASOP Global Delegation, and had a fruitful discussion on topics of the safety and regulatory of online drug stores and combat illegal internet drug sales etc.

December 6 — PhIRDA participated in 2017 Asia Pacific Biotech Investment Forum as the supporter. PhIRDA Executive President Song Ruilin made a keynote speech on the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation.

December 7 — Co-hosted by PhIRDA, Institute for Biotechnology and Medicine Industry (IBMI), HK Bio-Med Innotech Association (HKBMIA), International Association of Quality Research in Chinese Medicine and Hong Kong Exchanges and Clearing Limited (HKEX), the 1st BioMed Innovation and Investment Conference was successfully held in Chinese Taipei. PhIRDA delegation participated in the event and the Healthcare Expo. In the opening ceremony, Pharmaceutical Cooperation Platform among China Mainland, Chinese Taipei, Hong Kong and Macau was officially established.

December 18 — PhIRDA submitted suggestions on establishing dynamic adjustment mechanism for NRDL to the Ministry of Human Resources and Social Security of the People's Republic of China (MOHRSS).

December 25 — PhIRDA and Southern Medicine Economic Research Institute of National Medical Products Administration signed agreement of strategic cooperation in Beijing, which was helpful for both sides to learn from each other, integrate resource, facilitate to conduct deep researches on pharmaceutical policies supported by big data, making great contributions to the drug regulation reform in China.

2018

January 5 — 2018 PhIRDA President Board Meeting was held in Beijing. The meeting summarized the main works after the Forth Meeting of 10th PhIRDA General Assembly, and reviewed and approved key work arrangements for 2018. All attendees discussed and made recommendations on the dynamic adjustment mechanism of NRDL and ICH related work etc.

January 5 — Reviewed by 2018 PhIRDA President Board Meeting, Peking Union Medical College Hospital, Shanghai Ankon Medical Technologies Co., Ltd. and Microbio (Shanghai) Biotechnology Co., Ltd. officially joined PhIRDA.

January 10 — PhIRDA Executive President Song Ruilin attended the 36th Annual J.P. Morgan Healthcare Conference and delivered a speech on the Significant Reforms in 2017 China Pharmaceutical Administration in Asia Forum.

January 20 — PhIRDA's series of articles, *From Imitator to Innovator*, published on *Nature* were awarded the 2017 China's Top 10 News of Medical Science and Technology.

January 30 — PhIRDA Executive President Song Ruilin and Tian Yuan, PhIRDA Pharmaceutical Innovation Investment Specialty Committee Chairman-elect and Founding Partner of Shenzhen Qianhai YuanMing Asset Management Co., Ltd., met with Charles Li, Chief Executive of Hong Kong Exchanges and Clearing Limited in PhIRDA office, having a discussion on the upcoming New Board in HKEX and how to develop deep cooperation in pharmaceutical innovation and investment industry.

March 7 — PhIRDA Executive President Song Ruilin met with Li Yadong, Assistant to General Manager of China Merchants Group and Chairman of China Merchants Hoi Tung Trading Company Limited and Yu Shixin, General Manager of CMG Healthcare & Pharmaceutical Industry Development Department, having a fruitful discussion and reached consensus on the topics of pharmaceutical innovation and cooperation in capital market.

March 17 — PhIRDA held the Seminar on ICH Related Pharmacovigilance Secondary Guidelines in Beijing. The seminar discussed the definitions and application of ICH E2A, M1 and E2B, presenting the regulatory requirements, strategies and operations on implementation ICH related secondary guidelines in China. Zhou Siyuan, Director of ICH Working Office in CFDA, PhIRDA Executive President Song Ruilin and 300 representatives from CDE, CDR, CFDAIC, Chinese Pharmaceutical Association, relevant departments and over 100 pharmaceutical industries specializing on pharmacovigilance and innovation R&D attended the event.

March 17 — PhIRDA Innovation R&D Services Specialty Committee Inaugural Meeting was held in Beijing. Tan Lingshi, Chairman of the Board & CEO of dMed Biopharmaceutical Company Limited was elected as the chairman, arranged the main work for the committee.

March 21 — PhIRDA Delegation, led by Executive President Song Ruilin, visited China Merchants Group (CMG) and signed Memorandum of Understanding with CMG Healthcare & Pharmaceutical Industry Development Department, and made a fruitful discussion on pharmaceutical industry in China and CMG's investment strategy in healthcare sector.

March 22 — PhIRDA delegation attended 2018 HKEX Biotech Summit. PhIRDA Executive President Song Ruilin made a keynote speech on the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation and organized panel discussion on the development and trends of biopharmaceutical innovation in China.

March 22 — PhIRDA and Hong Kong Exchanges and Clearing Limited (HKEX) signed Memorandum of Understanding at the 2018 HKEX Biotech Summit. Both sides decided to build a closer collaboration through holding regular meetings among the senior administrative staff and seminars for research projects; continue to exchange ideas on further improving the regulations on biotech companies to be listed in Hong Kong and related administrations; support and encourage biotech companies with all efforts to be listed in Hong Kong.

April 4 — Seminar on "Research on Drug Administration Law Concerning Intellectual Property Protection Related Items" was held in Beijing by PhIRDA.

April 9 — Co-hosted by PhIRDA, Embassy of the Kingdom of the Netherlands, CCCMHPIE, CAMDI and BPBC, Roadshow for the Dutch Life Science and Health was successfully held in Beijing. More than 100 representatives, experts, and senior management from PhIRDA members and Dutch life science industry and pharmaceutical companies participated in the roadshow. The roadshow was a strong basis for the cooperation between China and Netherlands, promoting the bilateral communication on life science and health sector and provided a platform for pharmaceutical enterprises.

April 10 -12 — Invited by JPMA, PhIRDA delegation, led by Executive President Song Ruilin, attended the 7th Asia Partnership Conference of Pharmaceutical Associations (APAC) in Tokyo, Japan. During the conference, PhIRDA delegation paid a visit to Japan Pharmaceutical Manufacturers Association (JPMA) and conducted investigation and research on Japanese pharmaceutical intellectual property protection system and drug regulatory policies with JPMA Intellectual Property Committee.

April 13 — Co-hosted by PhIRDA, Eliminate Cancer Initiative (ECI), National Foundation for Cancer Research (NFCR), China Brain Cancer Mission-- Working Group Meeting was successfully held in the new headquarter of Beijing Tian Tan Hospital. Global leaders of pharmaceutical and scientific researches and clinical experts of domestic brain cancer research institutions would bring joint efforts to set up working groups that focus on fundamental research, clinical trials, Biobank and big data process and funding. PhIRDA and NFCR would cooperate to establish a clinical drugs research platform for brain cancer in Beijing Tian Tan Hospital of Capital Medical University.

April 23 — PhIRDA formally accepted Sichuan Jiuzhang Biological Science and Technology Co., Ltd., Boya Bio-pharmaceutical Group Co., Ltd., Biomobie (Shanghai) Regenerative Medicine Co., Ltd., AVIC Trust Co., Ltd., Gem Flower Healthcare Investment Holding Group Co., Ltd., Prudence Investment Management (Hong Kong) Limited, SIP Oriza Seed Fund Management Co., Ltd., Lilly Asia Ventures, Beijing Maplesea Capital Management Center, CDH Investments, HighLight Capital, Asymchem Laboratories (Tianjin) Co., Ltd., Shanghai LIDE Biotech Co., Ltd. and Zhejiang Jiuzhou Pharmaceutical Co., Ltd. officially joined PhIRDA.

May 7 — Shanghai Henlius Biotech, Inc., Shanghai Junshi Biosciences Co., Ltd., Zensun (Shanghai) Sci & Tech Co., Ltd., BOCOM International Holdings Co., Ltd., China Merchants Hoi Tung Trading Co., Ltd., Beijing Great Numbers Asset Management Co., Ltd., HaoYue Capital Ltd. and Sherpa Venture Capital officially joined PhIRDA.

May 18 — The General Election and the First Meeting of the 2nd PhIRDA Pharmaceutical Innovation Investment Specialty Committee was successfully held in Beijing.The meeting reviewed the achievement of the 1st session and arranged missions for the 2nd session. The 2nd Pharmaceutical Innovation Investment Specialty Committee was elected, including the chairman, vice-chairman and members. Tian Yuan, chairman of specialty committee, vice-chairmen and members, more than 90 representatives attended the meeting.

May 18 — The First China BioMed Innovation Investors Forum was successfully held by PhIRDA Pharmaceutical Innovation Investment Specialty Committee in Beijing. The chairman of the 2nd Pharmaceutical Innovation Investment Specialty Committee Tian Yuan, vice-chairman and 130 representatives from HKBMIA, HKEX, Lily Asia Ventures, Ping An Bank and other 20 famous investment institutions attended the forum.

May 23 — The 2nd working meeting of the 2nd PhIRDA Drug R&D Specialty Committee was successfully held in Beijing. The meeting arranged the mission for future work. 3 vice-chairmen and 5 members were approved to take part in the committee.

May 24 — The 3rd China Cardiovascular Disease Clinical Research Quality Management Standard (GCP) Conference and ICH Conference was co-hosted by PhIRDA, China Cardiovascular Association, China Anti-thrombotic Drug Treatment Alliance, Hangzhou Investment Promotion Bureau and Hangzhou Economic-Technological Development Area in Hangzhou, Zhejiang Province. The conference held discussion on the reform of domestic pharmaceutical review and approval system, new demands for conducting ICH guidelines and hot issues for the enterprises and clinical trial institutions specialized in pharmaceutical innovation R&D. More than 300 people attended this conference, including experts from medical and clinical institutions, representatives from pharmaceutical companies and R&D institutions.

June 8 & 15 — The 2018 PhIRDA Contact Representative Meeting was held in Beijing by PhIRDA.

June 12 — HKEX announced that SONG Ruilin, Executive President of PhIRDA, and Tian Yuan, Chairman of PhIRDA Pharmaceutical Innovation Investment Specialty Committee were appointed as the Biotech Advisory Panel Member for the Stock Exchange of Hong Kong Limited.

June 26 — Closing seminar on “Research on the Access for Medical Insurance of Innovative Drugs in China” was held in Beijing by PhIRDA.

July 3 — Closing seminar on “Research on Chronic Disease Treatment Drug Management System of Primary Medical Institutes in China” was held in Beijing by PhIRDA.

July 6 — Co-hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Suzhou Industrial Park Administrative Office (SIPAC), SINO-U.S. Oncology Experts Roundtable was successfully held in Suzhou. Participants from the hosts, U.S. oncology experts from FDA and senior managers from top leading innovative enterprises in China, more than 30 representatives attended in this event. Participants had a fruitful discussion on the global trend of oncology drugs R&D, approval system for new drug and the latest pharmaceutical R&D status in China.

July 20 — The 9th China Hospital Pharmacy Policy Forum, co-hosted by PhIRDA, Chinese Pharmacists Association, Chinese Hospital Association, and Peking University People’ s Hospital, was successfully held in Beijing on July 20th, 2018. More than 400 representatives attended the meeting, including leaders from the National Health Commission of the People’ s Republic of China, provincial and municipal Medical Insurance Management Centers, and representatives from pharmaceutical related fields.

July 24 — Shanghai Benemae Pharmaceutical Co., Ltd., Techpool Bio-Pharma Co., Ltd., Amoy Diagnostics Co., Ltd., TOT Biopharma Co., Ltd, Adlai Nortye Biopharma Co., Ltd., CF Pharm Tech, Inc., Hefei Tianmai Biotechnology Development Co., Ltd, BOYU Capital Advisory Co., Ltd. and Shanghai TF Venture Capital Management Co. Ltd. officially joined PhIRDA.

August 21 — Opening seminar on "Research on Dynamic Adjustment Mechanism of NRDL in China under the New Situation" was held in Beijing by PhIRDA.

September 7-8 — Co-hosted by CPA, PhIRDA and Yantai Municipal Government, 2018 International Pharmaceutical Innovation Conference themed "Innovation, Cooperation, Investment and Win-win" was held in Yantai. Over 800 domestic and foreign representatives and experts from government, scientific research institutes and enterprises attended this event.

September 17 — The Fifth Meeting of 10th PhIRDA General Assembly was held in Suzhou, Jiangsu Province. The meeting approved *PhIRDA Annual Work Report, PhIRDA's Annual Financial Report for Year 2017-2018, the Proposal on Recruiting Members of PhIRDA, PhIRDA Code of Ethics and Proposal on Establishing Preparation Working Group for General Election*. *The Proposal on Revising the Membership Fees Standard* was passed by secret ballot. Approved at the meeting, four new members officially joined PhIRDA, including I-Mab Biopharma Co., Ltd., Proswell Medical Co., Ltd., Guotai Junan Securities Co., Ltd. and China Life Private Equity Investment Co., Ltd. More than 250 representatives from 124 PhIRDA members attended this event.

September 18-20 — Co-hosted by PhIRDA, CAMDI, CHA and HKEX, 2018 China BioMed Innovation and Investment Conference was held in Suzhou Industrial Park. Over 21 special events, including Clinical-Trial Data Release of Innovative Drugs, Listed/Non-Listed Company Roadshow, Medical Devices Roadshow, International Roadshow, Artificial Intelligence Roadshow, Rare Diseases and Orphan Drugs Roadshow, Investors' Experience Sharing Forum, Cross-Border M&A Forum and other two closed meetings (HKEX & Innovative Pharmaceutical Companies Forum and Top Leading Scientists Meeting), were arranged in this event.

2018 "Dushu Lake Prize" Selection Activities of China Pharmaceutical Innovation Brand

April 3 — The first working meeting was held. Establishing the Expert Recommendation and Review Committee and the standard of regulation of management and criteria of the selection was decided on the meeting.

August 10 — The review meeting determined and released the list of candidate projects.

September 17 — The final review meeting casted a secret ballot and sealed the result on the spot.

September 17 — The awards ceremony was held in Suzhou Culture and Arts Center. Nearly 700 participants, including famous experts, scholars and entrepreneurs, attended in this event.